PDF bestand Page 1. VUmc Cancer Center Amsterdam VUmc CCA

Comments

Transcription

PDF bestand Page 1. VUmc Cancer Center Amsterdam VUmc CCA
VUmc Cancer Center Amsterdam
VUmc CCA
Annual Report 2012
Appendices
Address
VUmc Cancer Center Amsterdam (VUmc CCA)
VU University Medical Center
PK 7 Z 182
De Boelelaan 1117
1081 HV Amsterdam
The Netherlands
phone: (31)20 4443113
e-mail: [email protected]
website : www.vumc.nl/afdelingen/CCA-V-ICI
Appendix Annual Report 2012 VUmc CCA - 1
List of contents
Appendices
1. Organization
3
2. Scientific input
7
3. Newly started PhD projects
18
4. Scientific output
20
5. Indicators of esteem
62
6. Societal impact
108
7. Ongoing projects
113
8. International collaboration
145
9. Scientific Research Committee
153
10. Evening lectures
164
Appendix Annual Report 2012 VUmc CCA – List of contents - 2
Appendix 1. Organization
Management Board
Management Board (MB) members:
- P.C. Huijgens, oncology research, director of VUmc CCA
- G. Kraal, immunology research, deputy director of VUmc CCA
- H.J. Bonjer, regionalisation
- G.C.P.M. Hoskens, manager finances division I
- C.R. Leemans, education, chairman of internal advisory board
- G.A. Meijer, infrastructure
- B.J. Slotman, regionalisation
- H.M.W.Verheul, patient care/fundraising, member
Supportive staff
J. van Diemen (board assistant)
- Y.M. Duiker (board assistant)
- E. van Kessel (project manager)
- M.A.J. Koelink (senior secretary)
- G.K. Kuipers (senior board assistant)
- H. Loeffen (communication advisor)
- E.M. Ruhé-Hoogervorst (senior board assistant)
- E. Takkenberg (fundraiser)
- B. Volman (project controller)
- J. Zweers (project controller)
Executive Board
The Executive Board (EB) of VUmc CCA consists of the program leaders. The EB meets every 2
months together with the MB, chaired by one of the MB directors. The EB advises the MB about:
- research projects
- long-term policy with respect to personnel and materials
- first money stream graduate students
Appendix Annual Report 2012 VUmc CCA – Organization - 3
-
allocation of equipment for research of > € 12.000
patient care projects
clinical and translational research
education
fundraising for cancer research, care and education
early diagnostics
all matters concerning VUMC CCA whether on request or not.
The complete EB convenes regularly to discuss the long term policy of VUmc CCA.
Executive Board members:
Program 1: Oncogenesis:
- R.H. Brakenhoff
- P.J.F. Snijders
- J. de Winter
Program 2: Immunopathogenesis:
- R.H.J. Beelen
- T.D. de Gruijl
- E. Hooijberg
- Y. van Kooyk
- R. Mebius
Program 3: Disease profiling:
- G.A.M.S. van Dongen
- O.S. Hoekstra
- C. Jimenez
- C.L. Verweij
- T. Würdinger
Program 4: Innovative therapy:
- R. de Bree
- J. Janssen
- G.J. Peters
- S. Senan
- H. van der Vliet
Program 5: Quality of Life
- J. Dekker
- G.J.L. Kaspers
- B.D. Onwuteaka-Philipsen
- I.M. Verdonck-de Leeuw
- O. Visser
Internal Advisory Board
The members of the internal advisory board consist of 5 to 10 heads of departments involved in
cancer and immunology within the VUmc. The chairman is member of the MB. The board meets
twice a year.
Internal Advisory Board members:
- C.R. Leemans (Chair)
- M.A. Blankenstein
- J. Bonjer
- C.D. Dijkstra
- J.J. Heimans
- O.S. Hoekstra
- G.C.P.M. Hoskens
- P.C. Huijgens
- G.G. Kenter
Appendix Annual Report 2012 VUmc CCA – Organization - 4
-
G. Kraal
D. de Kruif
G.A. Meijer
H. Meijers-Heijboer
C.J.J. Mulder
B. Slotman
E.F. Smit
H.M.W. Verheul
A. Voskuyl
Scientific Research Committee (CWO)
The CWO is divided into a section that advises merely animal related protocols and a section that
advises patient related protocols and other project proposals.
The CWO advises about the research policy and about the feasibility of new research projects upon
request of the MB. The CWO advises the MB specifically about the quality and the feasibility of all
research proposals that need permission of the ethical committees for patient related or animal
related research before they can be realized.
Research proposals made on behalf of (inter)nationally recognized joint ventures (EORTC, HOVON,
SIOP, SKION) and multi-center studies in which the VUMC is not the main judging committee, are
judged only marginally on local feasibility.
The CWO also advises on other research proposals for which judgment by the CWO is desired. The
CWO gives asked and unasked advice to the MB about the quality of research within VUMC CCA. The
CWO section for patient related protocols meets twice a month, the CWO section for animal related
protocols meets once a month.
The VUMC Management Regulations stipulate that the VUmc CCA CWO section for patients related
protocols is composed of 5 to 9 members. In view of the institute’s size and in order to have
sufficient expertise in the different research fields, the CWO has been extended to a maximum of 15
members.
Scientific Research Committee (CWO) members - Section for patient related protocols:
- A.A. van der Loosdrecht (chair)
- A.A. van Bodegraven
- B.J.M. Braakhuis
- A.J.M. van den Eertwegh
- M. van Egmond
- T.D. de Gruijl (till July 2012)
- N. Haasbeek (from August 2012)
- N.H. Hendrikse
- D. de Jong (from August 2012)
- M. Klein (from February 2012)
- G.K. Kuipers (secretary)
- R.D.M. Steenbergen (from August 2012)
- F.B.J.M. Thunnissen (till April 2012)
- W.J.J. Unger (from August 2012)
- Q. Waisfisz
Scientific Research Committee (CWO) members - Section for animal related protocols:
- R. Scheper (chair)
- B.J. Appelmelk
- V. van Beusechem
- G. Kraal
- G.K. Kuipers (secretary till September 2012)
- Y.M. Duiker (secretary from September 2012)
Appendix Annual Report 2012 VUmc CCA – Organization - 5
Committee for Education & Training
This committee supervises and advices about all training and education activities within VUmc CCA.
The graduate training is organized within the Oncology Graduate School Amsterdam (OOA) and the
Leiden Amsterdam Institute for Immunology (ALIFI).
More in detail, by means of subgroups, this committee organizes and advises about training in the
framework of the:
- oncology profile
- immunology profile
- masters education in oncology
- masters education in immunology
- graduate students education
- postgraduate education
- SMBWO (Foundation for the Training of Biomedical Scientists)
- NVVI (Dutch Society for Immunology)
- all other types of education within VUmc CCA.
Each of these subgroups is composed of the main teachers within the education involved. The
committee gives asked and unasked advice about the quality and quality maintenance of education
within VUmc CCA. The committee meets at least six times a year.
Members of the Committee for Education & Training:
- C.R Leemans (chair)
- R.H.J. Beelen
- M.M. van Duist
- G.A. Meijer
- E.M. Ruhé-Hoogervorst (secretary)
Subgroups:
Oncology profile committee members:
- B.J.M. Braakhuis
- E. Boven
- A.A. van de Loosdrecht
- N.C.T. van Grieken
- F.B.J.M Thunnissen
- E.M. Ruhé-Hoogervorst (profile coordinator)
Immunology and Infection committee members:
- B.J. Appelmelk
- I.E.M. Bultink
- K.A. Gelderman
- I.M.W. van Hoogstraten
- M.B.E. von Blomberg
- G.K. Kuipers (profile coordinator)
Directorate OOA (Oncology Graduate School Amsterdam)
- A.W. Griffioen from September
- G.A. Meijer till September
- E.M. Ruhé-Hoogervorst, secretary (VUmc)
- T. Sixma (NKI)
- M. Spaargaren (AMC)
Funding by Stichting VUmc CCA
The Stichting VUmc CCA supports VUmc and VUmc CCA in their cancer research and care for
patients with cancer.
Appendix Annual Report 2012 VUmc CCA – Organization - 6
Appendix 2. Scientific input
Program 1: Oncogenesis
Department
Full professor
Oudejans CBM
Meijers-Heijboer HE
te Riele H
Kenter GG
Bloemena E
Schulten EAJM
van der Waal I
Brakenhoff RH
Leemans CR
Meijer CJLM
Meijer GA
Middeldorp JM
Mooi WJ
Peeper DS
Snijders PJF
Associate professor
Berkhof J
van de Wiel MA
de Winter JP
Dorsman JC
Braakhuis BJM
Heideman DAM
Steenbergen RDM
van Kemenade F
Assistent professor
Menko FH
van Hest LP
Waisfisz Q
Karagozoglu KH
Bleeker MCG
Carvalho B
Cillessen SAGM
de Jong D
Hooijberg E
Pegtel M
Rozendaal L
van Criekinge WMR
van Hattum AH
Other tenured staff
Gille JJP
Heins YM
Holstege H
Poddighe J
Oudgenoeg G
Bremmer JF
Rekers N
Scheffer GL
Thunnissen FBJM
Total tenured staff
Non tenured staff
Ameziane N
de Lange J
de Wit M
Funding
FTE
Clinical Chemistry
Clinical Genetics
Clinical Genetics
Obstetrics and Gynaecology
Oral and Maxillofacial Surgery and Pathology
Oral and Maxillofacial Surgery and Pathology
Oral and Maxillofacial Surgery and Pathology
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
1
1
1
1
1
1
1
1
1
3
1
1
1
1
1
0,05
0,20
0,00
0,33
0,20
0,10
0,20
0,85
0,05
0,17
0,10
0,50
0,10
0,00
0,60
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Clinical Genetics
Clinical Genetics
Otolaryngology/Head and Neck Surgery
Pathology
Pathology
Pathology
1
2
1
1
1
1
1
1
1,00
0,50
1,00
1,00
0,85
0,50
0,50
0,10
Clinical Genetics
Clinical Genetics
Clinical Genetics
Oral and Maxillofacial Surgery and Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
1
1
1
1
1
2
3
1
3
3
1
2
1
0,20
0,10
0,80
0,10
0,20
0,61
0,90
0,15
0,50
0,83
0,10
0,11
0,04
Clinical Genetics
Clinical Genetics
Clinical Genetics
Clinical Genetics
Laboratory Medical Oncology
Otolaryngology/Head and Neck Surgery
Pathology
Pathology
Pathology
1
1
1
1
1
4
3
3
1
0,10
0,10
0,50
0,10
1,00
0,23
0,38
0,25
0,10
16,30
Clinical Genetics
Clinical Genetics
Laboratory Medical Oncology
1
3
1
1,00
1,00
0,75
Appendix Annual Report 2012 VUmc CCA – Scientific input - 7
Pham TV
van Beynum JR
Schaaij-Visser BM
Jordanova ES
Nagel R
Stoepker C
Hesselink AT
Lalic D
Wilting SM
PhD students
Adank M
Bakker JL
Corbin M
Dommering CJ
Faramarz A
Haitjema A
Kooi EI
Massink M
Mol BM
Roohollahi K
Stoepker C
de Leeuw DC
Neerincx M
Paulis YWJ
Heusschen R
Ferns D
Dekker H
Dekker H
Matse JH
Ramawadh RS
de Boer DV
Graveland APJ
Martens-de Kemp SR
Rietbergen MM
van der Plas M
Bierkens M
Bosch LJW
Cordes M
de Strooper LMA
Hiemstra AC
Hubers J
Luttmer R
Miok V
Mollers M
Novalic Z
Ramayanti O
Scherpenisse M
Schütze DM
Snellenberg S
van Boerdonk R
Verweij FJ
Haloua JP
Total non tenured staff
Total research staff
Laboratory Medical Oncology
Laboratory Medical Oncology
Medical Oncology
Obstetrics and Gynaecology
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Pathology
Pathology
Pathology
3
3
1
1
2
1
3
3
3
1,00
1,00
0,33
0,70
1,00
0,50
1,00
0,24
1,00
Clinical Genetics
Clinical Genetics
Clinical Genetics
Clinical Genetics
Clinical Genetics
Clinical Genetics
Clinical Genetics
Clinical Genetics
Clinical Genetics
Clinical Genetics
Clinical Genetics
Laboratory Hematology
Laboratory Medical Oncology
Laboratory Medical Oncology
Medical Oncology
Obstetrics and Gynaecology
Oral and Maxillofacial Surgery and Pathology
Oral and Maxillofacial Surgery and Pathology
Oral and Maxillofacial Surgery and Pathology
Oral and Maxillofacial Surgery and Pathology
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Surgery
1
1
2
1
2
3
3
2
3
1
1
3
3
3
3
1
1
3
1
1
3
1
3
3
4
3
2
3
3
1
3
3
3
3
3
3
3
3
3
3
3
3
0,20
0,75
0,75
0,10
0,75
0,75
0,75
0,75
0,69
0,00
0,53
0,37
0,75
0,75
0,38
0,75
0,20
0,25
0,40
0,30
0,50
0,05
0,19
0,75
0,75
0,00
0,50
0,34
0,75
0,75
1,00
1,00
0,75
0,75
0,75
0,75
0,75
0,75
0,75
0,75
0,75
0,75
33,77
50,07
Appendix Annual Report 2012 VUmc CCA – Scientific input - 8
Program 2: Immunopathogenesis
Department
Full professor
de Rie MA
Gibbs S
Starink TM
Mulder CJJ
Bitter W
Vandenbroucke-Grauls CMJE
Beelen RHJ
Dijkstra CD
Kraal G
Mebius RE
van Kooyk Y
Scheper RJ
van den Elsen PJ
Verweij CL
Verweij CL
Associate professor
Stoof TJ
de Gruijl TD
Appelmelk BJ
van Die IM
van Egmond M
von Blomberg BME
van Egmond M
Assistent professor
Franken SM
Kirtschig G
Rustemeyer T
van Montfrans C
Felt-Bersma RJF
van Bodegraven AA
van Nieuwkerk CMJ
Ang W
van der Sar AM
van den Eertwegh AJM
den Haan JMM
Unger WWJ
Douma CE
Farhat K
Nurmohamed SA
Mulder MF
van der Plas RN
Other tenured staff
Boks MA
van Rooijen N
van Vliet SJ
Ouburg S
Scheffer GL
van Hoogstraten IMW
Total tenured staff
Non tenured staff
Reinders J
Santegoets SJAM
Geurtsen J
Houben E
Ambrosini M
Bakema JE
Funding
FTE
Dermatology
Dermatology
Dermatology
Gastroenterology
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Pathology
Pathology
Pathology
Pathology
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
0,20
0,25
0,10
0,06
0,35
0,12
0,50
0,05
0,60
0,80
0,60
0,01
0,10
0,20
0,30
Dermatology
Laboratory Medical Oncology
Medical Microbiology and Infection Control
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Pathology
Surgery
1
1
1
1
1
1
1
0,08
1,00
0,70
0,60
0,10
0,09
0,90
Dermatology
Dermatology
Dermatology
Dermatology
Gastroenterology
Gastroenterology
Gastroenterology
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Medical Oncology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Nefrology
Nefrology
Nefrology
Paediatrics
Paediatrics
1
1
1
1
1
1
1
1
1
1
2
2
3
1
1
1
1
0,30
0,05
0,30
0,20
0,20
0,20
0,20
0,05
0,55
0,05
0,60
0,69
0,20
0,15
0,15
0,10
0,00
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Pathology
Pathology
Pathology
2
1
2
3
3
1
0,58
0,00
1,00
0,17
0,25
0,10
13,80
Dermatology
Laboratory Medical Oncology
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
2
3
2
1
3
2
0,50
1,00
0,63
0,70
1,00
0,89
Appendix Annual Report 2012 VUmc CCA – Scientific input - 9
da Silva Aresta Belo van Wijk AI
Garcia-Vallejo JJ
Gul N
Ilarregui JM
Koning JJ
Koning N
Kuijk LM
Lenos KJ
Papadopoulos P
Tefsen B
Unger WWJ
van de Pavert SA
Veninga H
Broers CJM
van der Kuip M
Bontkes HJ
Gelderman KA
Greijer AE
Oostlander AE
PhD students
Kosten IJ
Ates LS
Boot H
Stoop EJM
van de Weerd R
van der Woude AD
Weerdenburg EM
Lam SW
Bar-Ephraim J
Beijer MR
Bloem K
Braster R
da Silva Aresta Belo van Wijk AI
Fehres CM
Ferrantelli E
Foster TL
Galama SM
Goverse G
Grewal SK
Hiemstra IH
Klaver EJ
Perdicchio M
Pires da Silva Baptista A
Stavenuiter AWD
van der Steen LPE
van Hout MWM
Walraven M
van den Dungen FAM
de Jong T
Gross S
Lubbers J
Ozturk S
Turksma A
Vosslamber S
Total non tenured staff
Total research staff
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Paediatrics
Paediatrics
Pathology
Pathology
Pathology
Pathology
4
2
3
3
2
4
3
3
2
2
2
2
3
1
1
1
1
3
2
0,83
1,00
0,73
1,00
1,00
0,75
1,00
1,00
0,33
0,67
0,03
1,00
1,00
0,20
0,02
0,10
0,10
0,41
0,21
Dermatology
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Medical Oncology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Molecular Celbiology and Immunology
Neonatology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
1
1
3
3
2
1
1
3
1
1
4
1
4
3
2
2
2
2
2
1
1
2
2
3
2
2
3
2
3
3
2
3
3
3
0,75
0,75
0,19
0,25
0,75
0,31
0,75
0,75
0,37
0,75
0,53
0,75
0,63
0,75
0,44
0,44
0,25
0,75
0,75
0,63
0,75
0,50
0,75
0,75
0,56
0,13
0,75
0,20
0,75
0,75
0,75
0,44
0,31
0,75
35,78
49,58
Appendix Annual Report 2012 VUmc CCA – Scientific input - 10
Program 3: Disease profiling
Department
Funding
FTE
Clinical Chemistry
Gastroenterology
Hematology
1
1
1
0,05
0,06
0,10
Kluytmans J
Medical Microbiology and Infection Control
1
0,10
Savelkoul PHM
Vandenbroucke-Grauls CMJE
Dijkstra CD
Heimans JJ
Boellaard R
Comans EFI
Hoekstra OS
Lammertsma AA
de Bree R
Leemans CR
van Dongen GAMS
Bloemena E
Meijer CJLM
Meijer GA
Pena AS
Verweij CL
Wesseling P
Postmus PE
Smit EF
Castelijns JA
Lems WF
Bonjer HJ
Kazemier G
Associate professor
van de Wiel MA
Jimenez CR
van Beusechem VW
Herscheid JDM
Molthoff CFM
Windhorst AD
Ylstra B
van der Horst-Bruinsma IE
Assistent professor
Zijlstra JM
Hekker TAM
Ossenkopp YJ
Smit AM
van der Pouw-Kraan CTM
le Poole CY
Postma TJ
Reijneveld JC
Raijmakers PG
van Schie A
Visser GWM
Wang S
Beliën JAM
Carvalho B
Fijneman RJA
van Criekinge WMR
van Grieken NCT
Becker A
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Molecular Celbiology and Immunology
Neurology
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pulmonology
Pulmonology
Radiology
Rheumatology
Surgery
Surgery
1
1
1
1
1
1
1
1
1
1
1
1
3
1
1
1
1
1
1
1
1
1
1
0,15
0,13
0,05
0,06
0,30
0,20
0,30
0,15
0,10
0,05
0,85
0,20
0,18
0,10
0,00
0,10
0,15
0,20
0,20
0,20
0,10
0,20
0,30
Clinical Epidemiology and Biostatistics
Laboratory Medical Oncology
Laboratory Medical Oncology
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Pathology
Rheumatology
2
1
1
1
1
1
1
1
0,50
1,00
0,50
0,17
0,30
0,15
0,40
0,40
Hematology
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Molecular Celbiology and Immunology
Nefrology
Neurology
Neurology
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Pathology
Pathology
Pathology
Pathology
Pathology
Pulmonology
1
1
1
1
1
1
1
1
1
3
1
4
2
2
2
2
1
1
0,30
0,01
0,01
0,01
0,90
0,10
0,10
0,10
0,05
0,10
0,10
1,00
0,80
0,31
0,90
0,11
0,20
0,20
Full professor
Blankenstein MA
Mulder CJJ
Huijgens PC
Appendix Annual Report 2012 VUmc CCA – Scientific input - 11
Daniels JMA
Hashemi SMS
Sutedja TG
Bultink IEM
van der Laken CJ
van Schaardenburg D
Voskuyl AE
Paul MA
te Velde EA
Other tenured staff
Kaiser AM
Pettersson Fernholm AM
van de Laar TJW
Huisman MC
Verbeek J
Yaqub MM
Waalboer DCJ
Parlayan
Scheffer GL
Sie DLS
Hendrikse NH
Total tenured staff
Non tenured staff
Terhaar sive Droste JS
Verwer E
Vugts D
Poot AJ
Vugts D
van der Velde AG
PhD students
van der Meijde E
Vink A
Wubulikasimu A
Wubulikasimu A
Bakker SF
Ben Larbi I
Nijeboer P
Radersma M
Seinen ML
van Wanrooij RLJ
Budding A
Schepens MLM
Roemer MGM
Koekkoek J
Sizoo E
van Dellen E
Cheebsumon P
Frings V
Hoyng LL
Makris N
Nissen IA
Oprea D
Rizvi SN
Flach GB
Heuveling D
van der Putten L
Vosjan MJWD
van Elsland S
Blits M
Bosch LJW
Pulmonology
Pulmonology
Pulmonology
Rheumatology
Rheumatology
Rheumatology
Rheumatology
Surgery
Surgery
1
1
1
1
4
1
1
1
1
0,20
0,20
0,20
0,10
0,20
0,05
0,10
0,10
0,20
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Otolaryngology/Head and Neck Surgery
Pathology
Pathology
Pathology
Pharmacy
1
1
1
1
2
1
4
2
3
1
1
0,05
0,01
0,10
0,20
0,03
0,30
0,67
1,00
0,50
0,60
0,30
18,41
Gastroenterology
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Pathology
3
3
4
2
4
3
0,40
1,00
0,92
1,00
0,08
0,58
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Gastroenterology
Gastroenterology
Gastroenterology
Gastroenterology
Gastroenterology
Gastroenterology
Medical Microbiology and Infection Control
Medical Microbiology and Infection Control
Medical Oncology
Neurology
Neurology
Neurology
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Nuclear Medicine and PET Research
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Paediatrics
Pathology
Pathology
1
3
2
1
2
2
2
3
3
2
3
2
3
4
3
4
2
2
2
4
3
4
4
1
3
1
2
4
2
2
0,19
0,75
0,38
0,37
0,75
0,38
0,44
0,50
0,50
0,75
0,40
0,69
0,50
0,10
0,12
0,32
0,13
0,75
0,75
0,75
0,75
0,40
0,40
0,02
0,75
0,10
0,12
0,75
0,63
0,25
Appendix Annual Report 2012 VUmc CCA – Scientific input - 12
de Groen FLM
de Ridder A
Goos JACM
Krijgsman O
Scheinin AI
Sillars-Hardebol AH
Timmer LM
van den Broek E
van Thuijl HF
Voorham QJM
de Langen AJ
Johannesma PC
Kuiper JL
Mellema WW
Paff T
Schook R
Siebring-van Olst E
Rodjan F
Abis GSA
Abis GSA
de Cuba E
Total non tenured staff
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pathology
Pulmonology
Pulmonology
Pulmonology
Pulmonology
Pulmonology
Pulmonology
Pulmonology
Radiology
Surgery
Surgery
Surgery
1
2
2
1
2
2
3
1
3
3
1
2
3
3
3
3
1
3
1
3
1
Total research staff
0,75
0,75
0,75
0,75
0,75
0,12
0,75
0,75
0,75
0,75
0,02
0,44
0,75
0,75
0,75
0,15
0,75
0,25
0,37
0,38
0,75
29,90
48,31
Program 4: Innovative therapy
Department
Full professor
Zuurmond WWA
Boers M
Uyl-de Groot CA
Mulder CJJ
Huijgens PC
Ossenkoppele GJ
van de Loosdrecht AA
Griffioen AW
Peters GJ
Boven E
Gerritsen WR
Verheul H
Heimans JJ
Vandertop WP
Smit TH
de Bree R
Leemans CR
Kaspers GJL
van Furth AM
Scheper RJ
Senan S
Slotman BJ
Lems WF
Cuesta MA
Rauwerda JA
van Leeuwen PAM
Wisselink W
Anesthesiology
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Gastroenterology
Hematology
Hematology
Hematology
Laboratory Medical Oncology
Laboratory Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Neurology
Neurosurgery
Orthopaedics
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Paediatric Oncology
Paediatrics
Pathology
Radiation Oncology
Radiation Oncology
Rheumatology
Surgery
Surgery
Surgery
Surgery
Funding
FTE
1
1
3
1
1
1
1
1
1
1
1
1
1
1
4
1
1
1
1
1
1
1
1
1
1
1
1
0,20
0,30
0,00
0,06
0,10
0,30
0,30
0,80
0,80
0,25
0,25
0,20
0,06
0,10
0,15
0,10
0,05
0,20
0,30
0,02
0,20
0,20
0,10
0,09
0,05
0,10
0,15
Appendix Annual Report 2012 VUmc CCA – Scientific input - 13
van Moorselaar RJA
Associate professor
Perez RSGM
van Agtmael MA
Schuurhuis GJ
van Beusechem VW
Wurdinger T
Assistent professor
Coupe VMH
Xavier de Menezes R
Chamuleau MED
Issa DE
Janssen JJWM
Thielen N
Visser O
Zweegman S
Cloos J
Broxterman HJ
Giovannetti E
Buter J
van den Eertwegh AJM
van der Houven van Oordt CW
van der Vliet JJ
van der Vorst MJDL
van Linde ME
Voortman J
Postma TJ
Reijneveld JC
Baayen JC
de Witt Hamer PC
Feller RE
Noske DP
Peerdeman SM
Moll AC
Eerenstein SEJ
van Weert S
de Haas V
Oeij NA
Dahele MR
Doornaert P
Griffioen GHMJ
Haasbeek CJ
Lafleur MVM
Lagerwaard FJ
Sminia P
Bultink IEM
van Schaardenburg D
Voskuyl AE
Hartemink KJ
Meijerink WJ
Oosterhuis JW
van den Tol MP
van der Peet DL
Geldof AA
ter Haar R
Vis A
Other tenured staff
Bogaards JA
Irandoust M
Urology
1
0,10
Anesthesiology
Internal Medicine
Laboratory Hematology
Laboratory Medical Oncology
Neurosurgery
1
1
1
1
1
0,10
0,20
0,75
0,50
0,30
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Hematology
Hematology
Hematology
Hematology
Hematology
Hematology
Laboratory Hematology
Laboratory Medical Oncology
Laboratory Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Neurology
Neurology
Neurosurgery
Neurosurgery
Neurosurgery
Neurosurgery
Neurosurgery
Opthalmonology
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Paediatric Oncology
Paediatric Oncology
Radiation Oncology
Radiation Oncology
Radiation Oncology
Radiation Oncology
Radiation Oncology
Radiation Oncology
Radiation Oncology
Rheumatology
Rheumatology
Rheumatology
Surgery
Surgery
Surgery
Surgery
Surgery
Urology
Urology
Urology
1
1
1
4
1
4
1
1
4
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1,00
0,58
0,30
0,40
0,30
0,40
0,30
0,30
0,69
1,00
1,00
0,10
0,05
0,09
0,20
0,17
0,20
0,20
0,10
0,10
0,05
0,30
0,00
0,30
0,10
0,05
0,02
0,02
0,00
0,00
0,05
0,05
0,10
0,05
0,00
0,05
0,40
0,10
0,05
0,10
0,40
0,20
0,10
0,20
0,30
0,30
0,10
0,10
Clinical Epidemiology and Biostatistics
Laboratory Hematology
3
3
0,50
0,08
Appendix Annual Report 2012 VUmc CCA – Scientific input - 14
van Oostveen JW
Dong W
Labots M
Piersma SR
van der Veer MS
Rovithi MN
Froklage F
Berenguer de Felipe J
Langius JAE
Wierdsma NJ
Abbink F
Senthi S
Thijssen VLJL
van Sörnsen de Koste JR
Al MCM
Jansen G
ter Wee MM
Bundel EM
van Ginkel TC
Total tenured staff
Non tenured staff
Demirel E
Peeters CFW
Veldhuijzen IK
Noordhuis P
Honeywell R
van der Stoop PM
Hulleman E
Mahdavian Delawary B
van Tuyl L
Bijnsdorp IV
PhD students
Bongers ML
Chaturvedi N
Greuter MJ
de Boer YS
Regelink JC
van Luijn M
Wondergem MJ
Sikkens JJ
Alhan C
Bachas C
de Leeuw DC
Kerkhoff N
Niewerth D
Ruben JM
van Alphen C
Verhagen HJMP
Wojtuszkiewicz A
Wouters R
Zeijlemaker W
Avan A
Azijli K
de Bruin R
El-Naggar M
Galvani E
Gotink KJ
Hodzic J
Koster BD
Kuipers-de Wilt LHAM
Laboratory Hematology
Laboratory Medical Oncology
Laboratory Medical Oncology
Laboratory Medical Oncology
Laboratory Medical Oncology
Medical Oncology
Neurology
Neurosurgery
Nutricion and dietics
Nutricion and dietics
Paediatric Oncology
Radiation Oncology
Radiation Oncology
Radiation Oncology
Rheumatology
Rheumatology
Rheumatology
Urology
Urology
1
4
3
3
3
3
2
2
3
1
1
1
3
1
1
1
4
4
3
0,05
0,33
0,10
1,00
0,92
1,00
0,75
1,00
1,00
0,22
0,00
0,20
0,60
0,20
1,00
1,00
1,00
0,50
0,80
30,60
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Hematology
Laboratory Medical Oncology
Neurosurgery
Paediatric Oncology
Plastic, reconstructive and handsurgery
Rheumatology
Urology
3
3
3
4
1
2
3
2
3
3
1,00
0,69
0,79
0,60
1,00
0,80
0,80
0,50
0,66
1,00
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Clinical Epidemiology and Biostatistics
Gastroenterology
Hematology
Hematology
Hematology
Internal Medicine
Laboratory Hematology
Laboratory Hematology
Laboratory Hematology
Laboratory Hematology
Laboratory Hematology
Laboratory Hematology
Laboratory Hematology
Laboratory Hematology
Laboratory Hematology
Laboratory Hematology
Laboratory Hematology
Laboratory Medical Oncology
Laboratory Medical Oncology
Laboratory Medical Oncology
Laboratory Medical Oncology
Laboratory Medical Oncology
Laboratory Medical Oncology
Laboratory Medical Oncology
Laboratory Medical Oncology
Laboratory Medical Oncology
3
3
3
2
4
3
1
1
4
4
3
1
3
3
3
3
1
3
3
4
3
3
4
4
3
3
3
3
0,75
0,75
0,50
0,25
0,40
0,50
0,30
0,20
0,38
0,69
0,38
0,63
0,75
0,75
0,50
0,75
0,75
0,75
0,75
0,12
0,00
0,75
0,13
0,44
0,62
0,75
0,56
0,06
Appendix Annual Report 2012 VUmc CCA – Scientific input - 15
Schulkens I
van der Mijn JC
Huijts L
Neefjes ECW
Offringa R
Schneiders FL
Versteeg KS
Wentink MQ
van Dijk J
Koekkoek J
Sizoo E
van Dellen E
Caretti V
Hiddingh L
van Rijn S
Buskermolen S
Mourits DL
Klumpers DD
Posthuma de Boer J
Schmitz MS
Cohen R
Schouten CS
Slobbe P
Vosjan MJWD
Blufpand HN
Gordijn MS
Jansen MHA
Kors WA
Sewing ACP
van Vuurden DG
Veldhuijzen van Zanten SEM
Wilhelm AJ
Kleibeuker EA
Narayan RS
Ong CL
Ong CL
Tol J
de Jong MC
Scheffer HJ
Bruijnen STG
den Uyl D
Gent YYJ
Konijn NPC
Rasch LA
Verbrugge CSE
Weijers K
Ankersmit M
Buijs N
Nielsen K
van Dam DA
van der Sluis TM
Total non tenured staff
Total research staff
Laboratory Medical Oncology
Laboratory Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Medical Oncology
Medical Psychology
Neurology
Neurology
Neurology
Neurosurgery
Neurosurgery
Neurosurgery
Nutricion and dietics
Opthalmonology
Orthopaedics
Orthopaedics
Orthopaedics
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Paediatric Oncology
Paediatric Oncology
Paediatric Oncology
Paediatric Oncology
Paediatric Oncology
Paediatric Oncology
Paediatric Oncology
Pharmacy
Radiation Oncology
Radiation Oncology
Radiation Oncology
Radiation Oncology
Radiation Oncology
Radiology
Radiology
Rheumatology
Rheumatology
Rheumatology
Rheumatology
Rheumatology
Rheumatology
Rheumatology
Surgery
Surgery
Surgery
Surgery
Urology
3
4
4
3
4
1
3
4
3
4
3
4
3
3
3
3
3
4
4
4
2
2
3
2
4
3
3
1
3
1
3
1
3
3
1
3
2
3
1
4
3
3
1
4
1
3
3
3
3
3
3
0,75
0,75
0,75
0,75
0,19
0,75
0,50
0,50
0,40
0,10
0,13
0,33
0,44
0,75
0,75
0,75
0,19
0,62
0,25
0,75
0,69
0,40
0,75
0,13
0,75
0,75
0,75
0,00
0,45
0,40
0,50
0,10
0,60
0,30
0,30
0,30
0,19
0,50
0,31
0,75
0,12
0,75
0,30
0,19
0,25
0,75
0,75
0,75
0,75
0,75
1,00
47,68
78,28
Appendix Annual Report 2012 VUmc CCA – Scientific input - 16
Program 5: Quality of life
Department
Full professor
Heimans JJ
Festen JM
Leemans CR
Verdonck-de Leeuw IM
Kaspers GJL
Dekker J
Assistent professor
Reijneveld JC
Rinkel RNPM
Israels T
Other tenured staff
van Dijk EM
Lubberding S
van Uden-Kraan CF
van den Berg MH
van Litsenburg R
Total tenured staff
Non tenured staff
Mostert SM
van Dulmen-den Broeder E
PhD students
Boele F
Sizoo E
Cnossen IC
de Bruijn M
Krebber AMH
van Gogh CDL
van Nieuwenhuizen AJ
Braam KI
Overbeek A
van Litsenburg R
Total non tenured staff
Total research staff
Funding
FTE
Neurology
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Paediatric Oncology
Rehabilitation Medicine
1
1
1
1
1
1
0,06
0,05
0,05
0,60
0,20
0,10
Neurology
Otolaryngology/Head and Neck Surgery
Paediatric Oncology
1
1
4
0,10
0,05
0,20
Medical Psychology
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Paediatrics
Paediatrics
3
2
3
3
1
0,30
0,57
0,44
0,60
0,83
4,15
Paediatric Oncology
Paediatric Oncology
4
4
0,60
0,80
Medical Psychology
Neurology
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Otolaryngology/Head and Neck Surgery
Paediatrics
Paediatrics
Paediatrics
3
3
4
3
2
1
3
3
3
1
0,75
0,13
0,67
0,12
0,75
0,05
0,75
0,50
0,25
0,13
5,50
9,65
Appendix Annual Report 2012 VUmc CCA – Scientific input - 17
Appendix 3. Newly started PhD projects
PhD student
Project leader
Department
Project
Program
Avan A
Peters GJ
Medical Oncology
Genetic and molecular mechanisms underlying
Pancreatic Ductal Adenocarcinoma aggressive
behaviour and chemoresistance
4
Bar-Ephraim J
Mebius R
Molecular Celbiology
and Immunology
The influence of vitamin A metabolism on
immune cell differentiation in the gut
2
Cordes M
Meijer GA
Pathology
Molecular biomarkers for the stratification of
metastatic colorectal cancer patients
1
de Boer DV
Brakenhoff RH
Otolaryngology/Head
and Neck Surgery
Targeted therapy of precancerous fields in
head and neck mucosa
1
de Jong MC
de Graaf P
Radiology
Radiogenomics in retinoblastoma patients
3
de Jong MC
Moll A
Radiology
Trilateral retinoblastoma: meta-analysis and
cost-effectiveness of brain screening
3
de Jong MC
Castelijns JA
Radiology
Multicenter implementation of MR imaging
studies in children with retinoblastoma for
assessment of response to chemotherapy and
early detection of pineoblastoma and craniofacial second primary malignancies
3
Ferrantelli E
Beelen RHJ
Molecular Celbiology
and Immunology
European training and research in peritoneal
dialyses
2
Foster TL
Beelen RHJ
Molecular Celbiology
and Immunology
European training and research in peritoneal
dialyses
2
Kerkhoff N
Ossenkoppele GJ
Hemotology
Role of immune responses focussing on DC in
the pathogenesis of low risk and high risk
myelodysplastic syndromes: implications for
immunotherapy
2
Konijn NPC
Lens WF
Rheumatology
COBRA-light vier jaar extensieonderzoek
4
Koster BD
de Gruijl TD
Surgery
Immunomodulation of the sentinel lymph node
4
Miok V
Snijders PJF
Pathology
Comprehensive molecular characterisation of a
longitudinal in vitro model of high-risk HPVmediated transformation
1
Mourits DL
Moll AC
Opthalmology
Complications, functional, and cosmetic
results in patients treated for retinoblastoma
in the Netherlands
5
Offringa T
Verheul HMW
Medical Oncology
Chemotherapy and maximal tumor debulking
of multi-organ colorectal cancer metastases
4
Ozturk S
Verweij CL
Pathology
B cells in the preclinical phase of rheumatoid
arthritis
3
Roemer MGM
de Jong D
Medical Oncology
Characterizing genetic alterations in diffuse
lage B-cell lymphomas occuring in immune
provileged sites
3
Scheffer HJ
van Kuijk C
Radiology
Evidence based interventional oncology: from
last resort to potent alternative or additional
treatment
4
Appendix Annual Report 2012 VUmc CCA – Newly started PhD projects - 18
Schouten CS
de Bree R
Otolaryngology/Head
and Neck Surgery
Response evaluation after chemoradiation for
advanced oropharyngeal cancer using PET-CT
and MRI
3
van Alphen C
Jimenez CR
Medical Oncology
Unravelling protein expression changes during
HPV-induced transformation using a label-free
proteomics approach
3
Veldhuijzen van
Zanten SEM
Kaspers GJL
Paediatrics
Drug distribution and local drug delivery in
diffuse intrinsic pontine glioma
4
Versteeg KS
Verheul HMW
Medical Oncology
Optimalization of systemic treatment
strategies in elderly patients with advanced
solid malignancies
5
Wouters R
Cloos J
Paediatric Oncology
Improvement of prognosis of pediatric AML by
identification and characterization of (stem)
cells responsible for development of relapse
4
Wouters R
Cloos J
Paediatric Oncology
Clonal evolution of acute myeloid leukemia
stem cells
4
Appendix Annual Report 2012 VUmc CCA – Newly started PhD projects - 19
Appendix 4. Scientific output
Abbreviations:
(x /y):
1:
2:
3:
4:
5:
(Cat.A):
(Cat.B):
(Cat.C):
(Cat.D):
After publications, x: quartile score (1-5), y: Impact Factor of journal
Quartile score: SCI journal from lowest quarter, publications in peer-reviewed journals without an Impact Factor
Quartile score: SCI journal from the second quarter (>25th and < 50th percentile)
Quartile score: SCI journal from the third quarter (>50th and < 75th percentile)
Quartile score: SCI journal belonging to the highest quarter 75th-90th percentile
Quartile score: SCI journal belonging to > 90th percentile
Dissertations prepared and defended at VUmc
Dissertations prepared elsewhere and defended at VUmc
Dissertations prepared at VUmc and defended elsewhere
Dissertations prepared and defended elsewhere
Program 1: Oncogenesis
Scientific papers refereed
1.
Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, Tan IB, Middeldorp JM. Nasopharyngeal
carcinoma in Indonesia: epidemiology, incidence,signs, and symptoms at presentation. Chinese Journal of Cancer 2012;
31: 185-196 (1 / 0.182)
2. Ameziane N, Sie DLS, Dentro S, Ariyurek Y, Kerkhoven L, Joenje H, Dorsman JC, Ylstra B, Gille JJP, Sistermans EA, de
Winter JP. Diagnosis of fanconi anemia: mutation analysis by next-generation sequencing. Anemia 2012; 2012: 132856
(0 / 0)
3. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen XQ, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM,
Caligo MA, Loman N, Harbst K, Lindblom A, Arver B, Rosenquist R, Karlsson P, Nathanson K, Domchek S, Rebbeck T,
Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowowcka-Perlowska E, Osorio A, Duran M, Andres R, Benitez J, Hamann
U, Hogervorst FB, van Os TA, Verhoef S, Meijers-Heijboer HEJ, Wijnen J, Garcia EBG, Ligtenberg MJ, Kriege M, Collee M,
Ausems MGEM, Oosterwijk JC, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R,
Adlard J, Davidson R, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Rogers MT,
Donaldson A, Dorkins H, Godwin AK, Bove B, Stoppa-Lyonnet D, Houdayer C, Buecher B, de Pauw A, Mazoyer S, Calender
A, Leone M, Bressac-de Paillerets B, Caron O, Sobol H, Frenay M, Prieur F, Ferrer SF, Mortemousque I, Buys S, Daly M,
Miron A, Terry MB, Hopper JL, John EM, Southey M, Goldgar D, Singer CF, Fink-Retter A, Tea MK, Kaulich DG, Hansen TVO,
Nielsen FC, Barkardottir RB, Gaudet M, Kirchhoff T, Joseph V, Dutra-Clarke A, Offit K, Piedmonte M, Kirk J, Cohn D,
Hurteau J, Byron J, Fiorica J, Toland AE, Montagna M, Oliani C, Imyanitov E, Isaacs C, Tihomirova L, Blanco I, Lazaro C,
Teule A, Del Valle J, Gayther SA, Odunsi K, Gross J, Karlan BY, Olah E, Teo SH, Ganz PA, Beattie MS, Dorfling CM, van
Rensburg EJ, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S,
Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schafer D,
Caldes T, de la Hoya M, Nevanlinna H, Muranen TA, Lesperance B, Spurdle AB, Neuhausen SL, Ding YC, Wang XS,
Fredericksen Z, Pankratz VS, Lindor NM, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti
R, Papi L, Ottini L, Radice P, Greene MH, Loud JT, Andrulis IL, Ozcelik H, Mulligan AM, Glendon G, Thomassen M, Gerdes
AM, Jensen UB, Skytte AB, Kruse TA, Chenevix-Trench G, Couch FJ, Simard J, Easton DF. Common variants at 12p11,
12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.
Breast Cancer Research 2012; 14: (4 / 5.245)
4. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30: F88-F99
(4 / 3.766)
5. Aruhuri B, Tarivonda L, Tenet V, Sinha R, Snijders PJF, Clifford G, Pang J, McAdam M, Meijer CJLM, Frazer IH, Franceschi S.
Prevalence of Cervical Human Papillomavirus (HPV) Infection in Vanuatu. Cancer Prevention Research 2012; 5: 746-753 (4
/ 4.908)
6. Backes DM, Bleeker MCG, Meijer CJLM, Hudgens MG, Agot K, Bailey RC, Ndinya-Achola JO, Hayombe J, Hogewoning CJA,
Moses S, Snijders PJF, Smith JS. Male circumcision is associated with a lower prevalence of human papillomavirusassociated penile lesions among Kenyan men. International Journal of Cancer 2012; 130: 1888-1897 (4 / 5.444)
7. Bakker JL, de Winter JP. A Role for ATM in Hereditary Pancreatic Cancer. Cancer Discovery 2012; 2: 14-15 (0 / 0)
8. Bakker ST, van de Vrugt HJ, Visser JA, zenne-Goette E, van der Wal A, Berns MAD, van de Ven M, Oostra AB, de Vries S,
Kramer P, Arwert F, van der Valk M, de Winter JP, Riele HT. Fancf-deficient mice are prone to develop ovarian tumours.
Journal of Pathology 2012; 226: 28-39 (5 / 6.318)
9. Bierkens M, Wilting SM, van Wieringen WN, van de Wiel MA, Ylstra B, Meijer CJLM, Snijders PJF, Steenbergen RDM. HPV
type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. BMC Cancer 2012; 12: 36 (4 / 3.011)
10. Bierkens M, Wilting SM, van Wieringen WN, van Kemenade FJ, Bleeker MCG, Jordanova ES, Bekker-Lettink M, van de Wiel
MA, Ylstra B, Meijer CJLM, Snijders PJF, Steenbergen RDM. Chromosomal profiles of high-grade cervical intraepithelial
neoplasia relate to duration of preceding high-risk human papillomavirus infection. International Journal of Cancer 2012;
131: E579-E585 (4 / 5.444)
11. Braakhuis BJM, Brakenhoff RH, Leemans CR. Treatment choice for locally advanced head and neck cancers on the basis of
risk factors: biological risk factors. Annals of Oncology 2012; 23: 173-177 (5 / 6.425)
12. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human
papillomavirus-related disease in developed countries. Vaccine 2012; 30: F157-F167 (4 / 3.766)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 20
13. Capelle LG, den Hoed CM, de Vries AC, Biermann K, Casparie MK, Meijer GA, Kuipers EJ. Premalignant gastric lesions in
patients with gastric mucosa-associated lymphoid tissue lymphoma and metachronous gastric adenocarcinoma: a casecontrol study. European Journal of Gastroenterology & Hepatology 2012; 24: 42-47 (2 / 1.757)
14. Carvalho B, Sillars-Hardebol AH, Postma C, Mongera S, Droste JTS, Obulkasim A, van de Wiel M, van Criekinge W, Ylstra B,
Fijneman RJA, Meijer GA. Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression
associated with ageing, chromosomal instability, and fatty acid metabolism. Cell Oncol 2012; 35: 53-63 (4 / 3.105)
15. Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado B, Grabsch H, Santos MAS, Meijer GA,
Seruca R, Carvalho B, Oliveira C. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 upregulation in intestinal gastric cancer. Journal of Pathology 2012; 228: 31-44 (5 / 6.318)
16. Castellsague X, Diaz M, Vaccarella S, de Sanjose S, Munoz N, Herrero R, Franeschi S, Meijer CJLM, Bosch FX. Intrauterine
Device Use, Cervical Infection With Human Papillomavirus, and Risk of Cervical Cancer: A Pooled Analysis of 26
Epidemiological Studies. Obstetrical & Gynecological Survey 2012; 67: 353-355 (4 / 2.514)
17. Cong SY, Pepers BA, Zhou TT, Kerkdijk H, Roos RA, van Ommen GJ, Dorsman JC. Huntingtin with an expanded
polyglutamine repeat affects the Jab1-p27(Kip1) pathway. Neurobiology of Disease 2012; 46: 673-681 (4 / 5.403)
18. Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS, Tommasino M, Clifford GM, Snijders PJF. Human
Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR. Journal of Virology 2012;
86: 6855-6861 (4 / 5.402)
19. Corver WE, Ruano D, Weijers K, den Hartog WCE, van Nieuwenhuizen MP, de Miranda N, van Eijk R, Middeldorp A,
Jordanova ES, Oosting J, Kapiteijn E, Hovens G, Smit J, van Wezel T, Morreau H. Genome Haploidisation with Chromosome
7 Retention in Oncocytic Follicular Thyroid Carcinoma. PloS one 2012; 7: (4 / 4.092)
20. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen XQ, Wang XS, Kirchhoff T,
McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL, Ozcelik H, Mulligan AM, Thomassen M, Gerdes
AM, Jensen UB, Skytte AB, Kruse TA, Caligo MA, Von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona
H, Karlsson P, Nathanson KL, Rebbeck TR, Domchek SM, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E,
Huzarski T, Byrski T, Gronwald J, Cybulski C, Gorski B, Osorio A, Duran M, Tejada MI, Benitez J, Hamann U, Hogervorst
FBL, van Os TA, van Leeuwen FE, Meijers-Heijboer HEJ, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems
MGEM, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles RA, Adlard J, Davidson R, Eccles DM,
Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson SV, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE,
Bove B, Godwin AK, Stoppa-Lyonnet D, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Leone M, Boutry-Kryza N,
Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch HT, Snyder CL, Buys SS, Daly MB, Terry M,
Chung WK, John EM, Miron A, Southey MC, Hopper JL, Goldgar DE, Singer CF, Rappaport C, Tea MKM, Fink-Retter A,
Hansen TVO, Nielsen FC, Arason A, Vijai J, Shah S, Sarrel K, Robson ME, Piedmonte M, Phillips K, Basil J, Rubinstein WS,
Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I,
Feliubadalo L, Brunet J, Gayther SA, Pharoah PPD, Odunsi KO, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS,
van Rensburg EJ, Dorfling CM, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold
N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K,
Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen TA, Nevanlinna H, Tischkowitz M, Spurdle AB, Neuhausen SL, Ding
YC, Lindor NM, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel A,
Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G, Offit K, Simard J. Common Variants at
the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and
BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention 2012; 21: 645-657 (5 / 4.123)
21. Coupe VM, Gonzalez-Barreiro L, Gutierrez-Berzal J, Melian-Boveda AL, Lopez-Rodriguez O, Alba-Dominguez J, Alba-Losada
J. Transcriptional analysis of human papillomavirus type 16 in histological sections of cervical dysplasia by in situ
hybridisation. Journal of Clinical Pathology 2012; 65: 164-170 (3 / 2.306)
22. Coupe VMH, Bogaards JA, Meijer CJLM, Berkhof J. Impact of vaccine protection against multiple HPV types on the costeffectiveness of cervical screening. Vaccine 2012; 30: 1813-1822 (4 / 3.766)
23. de Vries Y, Lwiwski N, Levitus M, Kuyt B, Israels SJ, Arwert F, Zwaan M, Greenberg CR, Alter BP, Joenje H, Meijers-Heijboer
H. A Dutch Fanconi Anemia FANCC Founder Mutation in Canadian Manitoba Mennonites. Anemia 2012; 2012: 865170 (0
/ 0)
24. De Vuyst H, Mugo NR, Chung MH, McKenzie KP, Nyongesa-Malava E, Tenet V, Njoroge JW, Sakr SR, Meijer CJLM, Snijders
PJF, Rana FS, Franceschi S. Prevalence and determinants of human papillomavirus infection and cervical lesions in HIVpositive women in Kenya. Br J Cancer 2012; 107: 1624-1630 (4 / 5.042)
25. De Vuyst H, Ndirangu G, Moodley M, Tenet V, Estambale B, Meijer CJLM, Snijders PJF, Clifford G, Franceschi S. Prevalence
of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa.
International Journal of Cancer 2012; 131: 949-955 (4 / 5.444)
26. de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AHC, Stegeman I, Kraaijenhagen RA,
Fockens P, van Leerdam ME, Dekker E, Kuipers EJ. Immunochemical Fecal Occult Blood Testing Is Equally Sensitive for
Proximal and Distal Advanced Neoplasia. American Journal of Gastroenterology 2012; 107: 1570-1578 (5 / 7.282)
27. de Wit M, Jimenez CR, Carvalho B, Belien JAM, is-van Diemen PM, Mongera S, Piersma SR, Vikas M, Navani S, Ponten F,
Meijer GA, Fijneman RJA. Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate
biomarkers for colorectal adenoma-to-carcinoma progression. Gut 2012; 61: 855-864 (5 / 10.111)
28. Del Pino M, Bleeker MCG, Quint WG, Snijders PJF, Meijer CJLM, Steenbergen RDM. Comprehensive analysis of human
papillomavirus prevalence and the potential role of low-risk types in verrucous carcinoma. Modern Pathology 2012; 25:
1354-1363 (4 / 4.792)
29. Dijkstra MG, Heideman DAM, van Kemenade FJ, Hogewoning KJA, Hesselink AT, Verkuijten MCGT, van Baal WM,
Nieuwenhuyzen-de Boer GM, Snijders PJF, Meijer CJLM. Brush-based self-sampling in combination with GP5+/6+-PCRbased hrHPV testing: High concordance with physician-taken cervical scrapes for HPV genotyping and detection of highgrade CIN. Journal of Clinical Virology 2012; 54: 147-151 (3 / 3.969)
30. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Shani PS, Kaufman B, Liljegren A, Lindblom A, Olsson H,
Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J,
Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Cajal TR, Stavropoulou AV, Benitez J,
Hamann U, Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HEJ, Oosterwijk JC, van Asperen CJ, Garcia EBG,
Hoogerbrugge N, Jager A, van der Luijt RB, Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F,
Izatt L, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H, StoppaLyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Leone M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 21
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys S, Daly M, Miron A, Terry MB, Chung W, John
EM, Southey M, Goldgar D, Singer CF, Tea MKM, Gschwantler-Kaulich D, Fink-Retter A, Hansen TVO, Ejlertsen B,
Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, Demars LR,
DiSilvestro P, Rodriguez G, Toland AE, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I,
Ramus SJ, Sucheston L, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N,
Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H,
Aittomaki K, Simard J, Spurdle AB, Beesley J, Chen XQ, Tomlinson GE, Weitzel J, Garber JE, Olopade OI, Rubinstein WS,
Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor N, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo
P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H, Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo
MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SL. A Nonsynonymous Polymorphism in IRS1 Modifies Risk of
Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology
Biomarkers & Prevention 2012; 21: 1362-1370 (5 / 4.123)
Draht MXG, Riedl RR, Niessen H, Carvalho B, Meijer GA, Herman JG, van Engeland M, Melotte V, Smits KM. Promoter CpG
island methylation markers in colorectal cancer: the road ahead. Epigenomics 2012; 4: 179-194 (2 / 2.375)
Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, Doeberitz MV, Goecke
TO, Schmiegel W, Buettner R, Moeslein G, Letteboer TGW, Garcia EG, Hes FJ, Hoogerbrugge N, Menko FH, Van Os TAM,
Sijmons RH, Wagner A, Kluijt I, Propping P, Vasen HFA. Risks of Less Common Cancers in Proven Mutation Carriers With
Lynch Syndrome. J Clin Oncol 2012; 30: 4409-4415 (5 / 18.372)
Fijneman RJA, Anderson RA, Richards E, Liu JM, Tijssen M, Meijer GA, Anderson J, Rod A, O'Sullivan MG, Scott PM,
Cormier RT. Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract. Cancer Science 2012; 103: 593-599
(3 / 3.325)
Fijneman RJA, de Wit M, Pourghiasian M, Piersma SR, Pham TV, Warmoes MO, Lavaei M, Piso C, Smit F, is-van Diemen PM,
van Turenhout ST, Droste JSTS, Mulder CJJ, Blankenstein MA, Robanus-Maandag EC, Smits R, Fodde R, van Hinsbergh
VWM, Meijer GA, Jimenez CR. Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early
Diagnosis of Human Colorectal Cancer. Clin Cancer Res 2012; 18: 2613-2624 (5 / 7.742)
Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, Dennis J, Wang Q, Humphreys MK, Luccarini C,
Baynes C, Conroy D, Maranian M, Ahmed S, Driver K, Johnson N, Orr N, Silva ID, Waisfisz Q, Meijers-Heijboer H,
Uitterlinden AG, Rivadeneira F, Hall P, Czene K, Irwanto A, Liu JJ, Nevanlinna H, Aittomaki K, Blomqvist C, Meindl A,
Schmutzler RK, Muller-Myhsok B, Lichtner P, Chang-Claude J, Hein R, Nickels S, Flesch-Janys D, Tsimiklis H, Makalic E,
Schmidt D, Bui M, Hopper JL, Apicella C, Park DJ, Southey M, Hunter DJ, Chanock SJ, Broeks A, Verhoef S, Hogervorst FBL,
Fasching PA, Lux MP, Beckmann MW, Ekici AB, Sawyer E, Tomlinson I, Kerin M, Marme F, Schneeweiss A, Sohn C,
Burwinkel B, Guenal P, Truong T, Cordina-Duverger E, Menegaux F, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H,
Milne RL, Alonso MR, Gonzalez-Neira A, Benitez J, nton-Culver H, Ziogas A, Bernstein L, Dur CC, Brenner H, Muller H,
Arndt V, Stegmaier C, Justenhoven C, Brauch H, Bruning T, Wang-Gohrke S, Eilber U, Dork T, Schurmann P, Bremer M,
Hillemanns P, Bogdanova NV, Antonenkova NN, Rogov YI, Karstens JH, Bermisheva M, Prokofieva D, Khusnutdinova E,
Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Lambrechts D, Yesilyurt BT, Floris G, Leunen
K, Manoukian S, Bonanni B, Fortuzzi S, Peterlongo P, Couch FJ, Wang XS, Stevens K, Lee A, Giles GG, Baglietto L, Severi G,
McLean C, Alnaes GG, Kristensen V, Borrensen-Dale AL, John EM, Miron A, Winqvist R, Pylkas K, Jukkola-Vuorinen A,
Kauppila S, Andrulis IL, Glendon G, Mulligan AM, Devilee P, van Asperen CJ, Tollenaar RAEM, Seynaeve C, Figueroa JD,
Garcia-Closas M, Brinton L, Lissowska J, Hooning MJ, Hollestelle A, Oldenburg RA, van den Ouweland AMW, Cox A, Reed
MWR, Shah M, Jakubowska A, Lubinski J, Jaworska K, Durda K, Jones M, Schoemaker M, Ashworth A, Swerdlow A, Beesley
J, Chen XQ, Muir KR, Lophatananon A, Rattanamongkongul S, Chaiwerawattana A, Kang D, Yoo KY, Noh DY, Shen CY, Yu
JC, Wu PE, Hsiung CN, Perkins A, Swann R, Velentzis L, Eccles DM, Tapper WJ, Gerty SM, Graham NJ, Ponder BAJ,
Chenevix-Trench G, Pharoah PDP, Lathrop M, Dunning AM, Rahman N, Peto J, Easton DF. Genome-wide association
analysis identifies three new breast cancer susceptibility loci. Nature Genetics 2012; 44: 312-U120 (5 / 35.532)
Gille JJP, Floor K, Kerkhoven L, Ameziane N, Joenje H, de Winter JP. Diagnosis of Fanconi Anemia: Mutation Analysis by
Multiplex Ligation-Dependent Probe Amplification and PCR-Based Sanger Sequencing. Anemia 2012; 2012: 603253 (0 /
0)
Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, Castellsague X. Human papillomavirus and
diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; : F34-F54 (4 / 3.766)
Goede J, Weijerman ME, Broers CJM, de Winter JP, van der Voort-Doedens L, Hack WWM. Testicular Volume and Testicular
Microlithiasis in Boys With Down Syndrome. Journal of Urology 2012; 187: 1012-1017 (4 / 3.746)
Gok M, Heideman DAM, van Kemenade FJ, de Vries ALM, Berkhof J, Rozendaal L, Belien JAM, Overbeek L, Babovic M,
Snijders PJF, Meijer CJLM. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical
screening programme: Characteristics of the responders. European Journal of Cancer 2012; 48: 1799-1808 (4 / 5.536)
Gok M, van Kemenade FJ, Heideman DAM, Berkhof J, Rozendaal L, Spruyt JWM, Belien JAM, Babovic M, Snijders PJF, Meijer
CJLM. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of
the cervical screening program. International Journal of Cancer 2012; 130: 1128-1135 (4 / 5.444)
Graveland AP, Braakhuis BJM, Eerenstein SEJ, de Bree R, Bloemena E, de Maaker M, van den Brekel MWM, Dijk F, Mesker
WE, Tanke HJ, Leemans CR, Brakenhoff RH. Molecular diagnosis of minimal residual disease in head and neck cancer
patients. Cell Oncol 2012; 35: 367-375 (4 / 3.105)
Gudlaugsson E, Skaland I, Janssen EAM, Smaaland R, Shao ZM, Malpica A, Voorhorst F, Baak JPA. Comparison of the effect
of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in
breast cancer. Histopathology 2012; 61: 1134-1144 (4 / 3.082)
Heideman DAM, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, Snijders PJF, Thunnissen E, Zwarthoff EC. KRAS
and BRAF Mutation Analysis in Routine Molecular Diagnostics: Comparison of Three Testing Methods on Formalin-Fixed,
Paraffin-Embedded Tumor-Derived DNA. Journal of Molecular Diagnostics 2012; 14: 247-255 (4 / 3.576)
Henken FE, De-Castro Arce J, Rosl F, Bosch L, Meijer CJLM, Snijders PJF, Steenbergen RDM. The functional role of Notch
signaling in HPV-mediated transformation is dose-dependent and linked to AP-1 alterations. Cell Oncol 2012; 35: 77-84
(4 / 3.105)
Henken FE, Oosterhuis K, Ohlschlager P, Bosch L, Hooijberg E, Haanen JBAG, Steenbergen RDM. Preclinical safety
evaluation of DNA vaccines encoding modified HPV16 E6 and E7. Vaccine 2012; 30: 4259-4266 (4 / 3.766)
Hensen EF, van Duinen N, Jansen JC, Corssmit EPM, Tops CMJ, Romijn JA, Vriendsd AHJT, van der Mey AGL, Cornelisse CJ,
Devilee P, Bayley JP. High prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands.
Clinical Genetics 2012; 81: 284-288 (3 / 3.128)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 22
47. Hoebe EK, Le Large TYS, Tarbouriech N, Oosterhoff D, de Gruijl TD, Middeldorp JM, Greijer AE. Epstein-Barr VirusEncoded BARF1 Protein is a Decoy Receptor for Macrophage Colony Stimulating Factor and Interferes with Macrophage
Differentiation and Activation. Viral Immunology 2012; 25: 461-470 (2 / 1.966)
48. Hoebe EK, Wille C, Hopmans ES, Robinson AR, Middeldorp JM, Kenney SC, Greijer AE. Epstein-Barr Virus Transcription
Activator R Upregulates BARF1 Expression by Direct Binding to Its Promoter, Independent of Methylation. Journal of
Virology 2012; 86: 11322-11332 (4 / 5.402)
49. Hubers AJ, Heideman DAM, Herder GJM, Burgers SA, Sterk PJ, Kunst PW, Smit HJ, Postmus PE, Witte BI, Duin S, Snijders
PJF, Smit EF, Thunnissen E. Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis
for lung cancer. Journal of Clinical Pathology 2012; 65: 541-545 (3 / 2.306)
50. Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F,
Flugelman A, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Paligo M, Aretini P, Kantala J, Aroer B, Von Wachenfeldt A,
Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Nathanson KL,
Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Cajal TR, Tsitlaidou M,
Benitez J, Gilbert M, Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HEJ, Oosterwijk JC, van Asperen
CJ, Blok MJ, Nelen MR, van den Ouweland AMW, Seynaeve C, van der Luijt RB, Devilee P, Easton DF, Peock S, Frost D,
Platte R, Ellis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin
A, Bove B, Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P,
Coupier I, Peyrat JP, Vennin P, Muller D, Fricker JP, Venat-Bouvet L, Johannsson O, Isaacs C, Schmutzler R, Wappenschmidt
B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Preisler-Adams S, Simard J, Soucy P,
Durocher F, Chenevix-Trench G, Beesley J, Chen X, Rebbeck T, Couch F, Wang X, Lindor N, Fredericksen Z, Pankratz VS,
Peterlongo P, Bonanni B, Fortuzzi S, Peissel B, Szabo C, Mai PL, Loud JT, Lubinski J. Association of PHB 1630 C > T and
MTHFR 677 C > T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a
multicenter study. Br J Cancer 2012; 106: 2016-2024 (4 / 5.042)
51. Khodakarami N, Clifford GM, Yavari P, Farzaneh F, Salehpour S, Broutet N, Bathija H, Heideman DAM, van Kemenade FJ,
Meijer CJLM, Hosseini SJ, Franceschi S. Human papillomavirus infection in women with and without cervical cancer in
Tehran, Iran. International Journal of Cancer 2012; 131: E156-E161 (4 / 5.444)
52. Kirchhoff T, Gaudet MM, Antoniou AC, McGuffog L, Humphreys MK, Dunning AM, Bojesen SE, Nordestgaard BG, Flyger H,
Kang D, Yoo KY, Noh DY, Ahn SH, Dork T, Schurmann P, Karstens JH, Hillemanns P, Couch FJ, Olson J, Vachon C, Wang
XS, Cox A, Brock I, Elliott G, Reed MWR, Burwinkel B, Meindl A, Brauch H, Hamann U, Ko YD, Broeks A, Schmidt MK, van 't
Veer LJ, Braaf LM, Johnson N, Fletcher O, Gibson L, Peto J, Turnbull C, Seal S, Renwick A, Rahman N, Wu PE, Yu JC, Hsiung
CN, Shen CY, Southey MC, Hopper JL, Hammet F, Van Dorpe T, Dieudonne AS, Hatse S, Lambrechts D, Andrulis IL,
Bogdanova N, Antonenkova N, Rogov JI, Prokofieva D, Bermisheva M, Khusnutdinova E, van Asperen CJ, Tollenaar RAEM,
Hooning MJ, Devilee P, Margolin S, Lindblom A, Milne RL, Arias JI, Zamora MP, Benitez J, Severi G, Baglietto L, Giles GG,
Spurdle AB, Beesley J, Chen XQ, Holland H, Healey S, Wang-Gohrke S, Chang-Claude J, Mannermaa A, Kosma VM,
Kauppinen J, Kataja V, Agnarsson BA, Caligo MA, Godwin AK, Nevanlinna H, Heikkinen T, Fredericksen Z, Lindor N,
Nathanson KL, Domchek SM, Loman N, Karlsson P, Askmalm MS, Melin B, Von Wachenfeldt A, Hogervorst FBL, Verheus M,
Rookus MA, Seynaeve C, Oldenburg RA, Ligtenberg MJ, Ausems MGEM, Aalfs CM, Gille HJP, Wijnen JT, Garcia EBG, Peock
S, Cook M, Oliver CT, Frost D, Luccarini C, Pichert G, Davidson R, Chu C, Eccles D, Ong KR, Cook J, Douglas F, Hodgson S,
Evans DG, Eeles R, Gold B, Pharoah PDP, Offit K, Chenevix-Trench G, Easton DF. Breast Cancer Risk and 6q22.33:
Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.
PloS one 2012; 7: (4 / 4.092)
53. Knies K, Schuster B, Ameziane N, Rooimans M, Bettecken T, de Winter J, Schindler D. Genotyping of fanconi anemia
patients by whole exome sequencing: advantages and challenges. PloS one 2012; 7: e52648 (4 / 4.092)
54. Kocken M, Berkhof J, van Kemenade FJ, Louwers JA, Zaal A, Nobbenhuis MAE, Kenter G, Snijders PJF, Meijer CJLM,
Helmerhorst TJM. Long-term CIN3+risk in women with abnormal cytology; role of hrHPV testing. Br J Cancer 2012; 106:
817-825 (4 / 5.042)
55. Kocken M, Uijterwaal MH, de Vries ALM, Berkhof J, Ket JCF, Helmerhorst TJM, Meijer CJLM. High-risk human
papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical
disease: A systematic review and meta-analysis. Gynecol Oncol 2012; 125: 500-507 (5 / 3.888)
56. Krijgsman O, Israeli D, Haan JC, van Essen HF, Smeets SJ, Eijk PP, Steenbergen RDM, Kok K, Tejpar S, Meijer GA, Ylstra B.
CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material. Genes Chromosomes & Cancer
2012; 51: 344-352 (3 / 3.306)
57. Linde N, Lederle W, Depner S, Van Rooijen N, Gutschalk CM, Mueller MM. Vascular endothelial growth factor-induced skin
carcinogenesis depends on recruitment and alternative activation of macrophages. Journal of Pathology 2012; 227: 1728 (5 / 6.318)
58. Louwers JA, Berkhof J, Zaal A, Kocken M, Rozendaal L, Heideman DAM, van Baal WM, Snijders PJF, Verheijen RHM, Meijer
CJLM. HrHPV-testing in a university hospital gynecology outpatient clinic: Recommendations for clinical practice. Gynecol
Oncol 2012; 124: 518-524 (5 / 3.888)
59. Meijer CJLM, Berkhof J. Screening: Cervical cancer-should we abandon cytology for screening?. Nature Reviews Clinical
Oncology 2012; 9: 558-559 (5 / 11.963)
60. Moll AC, Dommering CJ, Bosscha MI, de Graaf P, Kors WA, van Leeuwen FE. Risk Factors for the Incidence of Second
Cancers in Survivors of Retinoblastoma With a Family History. J Clin Oncol 2012; 30: 3028 (5 / 18.372)
61. Mollers M, Scherpenisse M, van der Klis FRM, King AJ, van Rossum TGJ, van Logchem EM, Feltkamp MC, Meijer CJLM,
Snijders PJF, Boot HJ, de Melker HE. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to
vaccination. Cancer Epidemiology 2012; 36: 519-524 (3 / 2.01)
62. Morris AR, Bos A, Diosdado B, Rooijers K, Elkon R, Bolijn AS, Carvalho B, Meijer GA, Agami R. Alternative Cleavage and
Polyadenylation during Colorectal Cancer Development. Clin Cancer Res 2012; 18: 5256-5266 (5 / 7.742)
63. Munk AC, Gudlaugsson E, Malpica A, Fiane B, Lovslett KI, Kruse AJ, Ovestad IT, Voorhorst F, Janssen EAM, Baak JPA.
Consistent Condom Use Increases the Regression Rate of Cervical Intraepithelial Neoplasia 2-3. PloS one 2012; 7: (4 /
4.092)
64. Nagel JHA, Peeters JK, Smid M, Sieuwerts AM, Wasielewski M, de Weerd V, Trapman-Jansen AMAC, van den Ouweland A,
Bruggenwirth H, van IJcken WFJ, Klijn JGM, van der Spek PJ, Foekens JA, Martens JWM, Schutte M, Meijers-Heijboer H. Gene
expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. Breast Cancer Research
and Treatment 2012; 132: 439-448 (4 / 4.431)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 23
65. Oostra AB, Nieuwint AWM, Joenje H, de Winter JP. Diagnosis of fanconi anemia: chromosomal breakage analysis. Anemia
2012; 2012: 238731 (0 / 0)
66. Out AA, Wasielewski M, Huijts PEA, van Minderhout IJHM, Houwing-Duistermaat JJ, Tops CMJ, Nielsen M, Seynaeve C,
Wijnen JT, Breuning MH, van Asperen CJ, Schutte M, Hes FJ, Devilee P. MUTYH gene variants and breast cancer in a Dutch
case-control study. Breast Cancer Research and Treatment 2012; 134: 219-227 (4 / 4.431)
67. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R,
Koker M, Dahmen I, Muller C, Di Cerbo V, Schildhaus HU, Altmuller J, Baessmann I, Becker C, de Wilde B, Vandesompele J,
Bohm D, Ansen S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS,
Rauh D, Grutter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C,
Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma
H, Thunnissen E, Smit EF, Heideman DAM, Snijders PJF, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun
OT, Lund-Iversen M, Sanger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B,
Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J,
Schneider R, Buttner R, Wolf J, Nurnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK. Integrative genome
analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics 2012; 44: 1104-1110 (5 /
35.532)
68. Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Nogues C, Gauthier-Villars M, Lasset C, Fricker JP, Peock S, Frost
D, Evans DG, Eeles RA, Paterson J, Manders P, van Asperen CJ, Ausems MGEM, Meijers-Heijboer H, Thierry-Chef I,
Hauptmann M, Goldgar D, Rookus MA, van Leeuwen FE. Exposure to diagnostic radiation and risk of breast cancer
among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). British Medical Journal 2012; 345: (5
/ 14.093)
69. Posthuma de Boer J, van Egmond PW, Helder MN, de Menezes RX, Cleton-Jansen AM, Belien JAM, Verheul HMW, van Royen
BJ, Kaspers GJJL, van Beusechem VW. Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin.
Oncotarget 2012; 3: 1169-1181 (4 / 4.784)
70. Rachmadi L, Jordanova ES, Kolkman-Uljee S, van der Linden-Narain I, Purwoto G, Siregar B, Fleuren GJ, Cornain S, Veselic
M. Cytomorphological Analysis of Uterine Cervical Pap Smears in Relation to Human Papillomavirus Infection in
Indonesian Women. Acta Cytologica 2012; 56: 171-176 (1 / 0.488)
71. Rahner N, Brockschmidt FF, Steinke V, Kahl P, Becker T, Vasen HF, Wijnen JT, Tops CJ, Holinski-Feder E, Ligtenberg MJ,
Spruijt L, Goergens H, Stemmler S, Kloor M, Dietmaier W, Schumacher J, Noethen MM, Propping P. Mutation and
association analyses of the candidate genes ESR1, ESR2, MAX, PCNA, and KAT2A in patients with unexplained MSH2deficient tumors. Familial Cancer 2012; 11: 19-26 (1 / 1.302)
72. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NWJ, Heideman DAM, Kenter GG, Cuzick J, Snijders PJF,
Meijer CJLM. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer:
final results of the POBASCAM randomised controlled trial. Lancet Oncology 2012; 13: 78-88 (5 / 22.589)
73. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VMH, Hesselink AT, Rozendaal L, Heideman DAM, Verheijen RH, Bulk S,
Verweij WM, Snijders PJF, Meijer CJLM. Evaluation of 14 triage strategies for HPV DNA-positive women in populationbased cervical screening. International Journal of Cancer 2012; 130: 602-610 (4 / 5.444)
74. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VMH, Rozendaal L, Heideman DAM, Verheijen RHM, Bulk S, Verweij W,
Snijders PJF, Meijer CJLM. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and
implications. Br J Cancer 2012; 106: 975-981 (4 / 5.042)
75. Rijkaart DC, Heideman DAM, Coupe VMH, Brink AATP, Verheijen RHM, Skomedal H, Karlsen F, Morland E, Snijders PJF,
Meijer CJLM. High-Risk Human Papillomavirus (hrHPV) E6/E7 mRNA Testing by PreTect HPV-Proofer for Detection of
Cervical High-Grade Intraepithelial Neoplasia and Cancer among hrHPV DNA-Positive Women with Normal Cytology.
Journal of Clinical Microbiology 2012; 50: 2390-2396 (4 / 4.153)
76. Rodrigo JP, Garcia-Pedrero JM, Suarez C, Takes RP, Thompson LDR, Slootweg PJ, Woolgar JA, Westra WH, Brakenhoff RH,
Rinaldo A, Devaney KO, Williams MD, Gnepp DR, Ferlito A. Biomarkers predicting malignant progression of laryngeal
epithelial precursor lesions: a systematic review. European Archives of Oto-Rhino-Laryngology 2012; 269: 1073-1083 (3 /
1.287)
77. Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo
C, Carozzi F, Gillio Tos A, Arbyn M, Meijer CJLM, Snijders PJF, Cuzick J, Giorgi Rossi P. Health Technology assessment
Report: Ricerca del dna di papillomavirus umano (HPV) come test primario per lo screening dei precursori del cancro del
collo dell'utero.. Epidemiologia e Prevenzione 2012; 36: 1-72 (1 / 0,651)
78. Ronco G, Meijer CJ, Cuzick J, Giorgi-Rossi P, Peto J, Segnan N, Dillner J. Screening for Cervical Cancer. Annals of Internal
Medicine 2012; 156: 604-605 (5 / 16.733)
79. Rositch AF, Hudgens MG, Backes DM, Moses S, Agot K, Nyagaya E, Snijders PJF, Meijer CJLM, Bailey RC, Smith JS. VaccineRelevant Human Papillomavirus (HPV) Infections and Future Acquisition of High-Risk HPV Types in Men. Journal of
Infectious Diseases 2012; 206: 669-677 (5 / 6.41)
80. Rositch AF, Poole C, Hudgens MG, Agot K, Nyagaya E, Moses S, Snijders PJF, Meijer CJLM, Bailey RC, Smith JS. Multiple
Human Papillomavirus Infections and Type Competition in Men. J Infect Dis 2012; 205: 72-81 (5 / 6.41)
81. Saeland E, Belo AI, Mongera S, van Die I, Meijer GA, van Kooyk Y. Differential glycosylation of MUC1 and CEACAM5
between normal mucosa and tumour tissue of colon cancer patients. International Journal of Cancer 2012; 131: 117-128
(4 / 5.444)
82. Sanduleanu S, Masclee AM, Meijer GA. Interval cancers after colonoscopy-insights and recommendations. Nature Reviews
Gastroenterology & Hepatology 2012; 9: 550-554 (5 / 8.102)
83. Scherpenisse M, Mollers M, Schepp RM, Boot HJ, de Melker HE, Meijer CJLM, Berbers GAM, van der Klis FRM.
Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine 2012; 30: 6686-6693 (4 / 3.766)
84. Scherpenisse M, Mollers M, Schepp RM, Boot HJ, Meijer CJLM, Berbers GAM, van der Klis FRM, de Melker HE. Changes in
Antibody Seroprevalence of Seven High-Risk HPV Types between Nationwide Surveillance Studies from 1995-96 and
2006-07 in The Netherlands. PloS one 2012; 7: e48807 (4 / 4.092)
85. Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK,
Ambrosone CB, Aittomaki K, Amiano P, Apicella C, Baglietto L, Bandera EV, Beckmann MW, Berg CD, Bernstein L,
Blomqvist C, Brauch H, Brinton L, Bui QM, Buring JE, Buys SS, Campa D, Carpenter JE, Chasman DI, Chang-Claude J, Chen
C, Clavel-Chapelon F, Cox A, Cross SS, Czene K, Deming SL, Diasio RB, Diver WR, Dunning AM, Durcan L, Ekici AB,
Fasching PA, Feigelson HS, Fejerman L, Figueroa JD, Fletcher O, Flesch-Janys D, Gaudet MM, Gerty SM, Rodriguez-Gil JL,
Giles GG, van Gils CH, Godwin AK, Graham N, Greco D, Hall P, Hankinson SE, Hartmann A, Hein R, Heinz J, Hoover RN,
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 24
Hopper JL, Hu JJ, Huntsman S, Ingles SA, Irwanto A, Isaacs C, Jacobs KB, John EM, Justenhoven C, Kaaks R, Kolonel LN,
Coetzee GA, Lathrop M, Marchand L, Lee AM, Lee IM, Lesnick T, Lichtner P, Liu JJ, Lund E, Makalic E, Martin NG, Mclean
CA, Meijers-Heijboer H, Meindl A, Miron P, Monroe KR, Montgomery GW, Muller-Myhsok B, Nickels S, Nyante SJ, Olswold
C, Overvad K, Palli D, Park DJ, Palmer JR, Pathak H, Peto J, Pharoah P, Rahman N, Rivadeneira F, Schmidt DF, Schmutzler
RK, Slager S, Southey MC, Stevens KN, Sinn HP, Press MF, Ross E, Riboli E, Ridker PM, Schumacher FR, Severi G, Silva ID,
Stone J, Sund M, Tapper WJ, Thun MJ, Travis RC, Turnbull C, Uitterlinden AG, Waisfisz Q, Wang XS, Wang ZM, Weaver J,
Schulz-Wendtland R, Wilkens LR, Van Den Berg D, Zheng W, Ziegler RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ,
Henderson BE, Chanock SJ, Garcia-Closas M, Kraft P, Haiman CA, Vachon CM. A meta-analysis of genome-wide
association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular
Genetics 2012; 21: 5373-5384 (5 / 7.636)
86. Sillars-Hardebol AH, Carvalho B, Belien JA, de Wit M, is-van Diemen PM, Tijssen M, van de Wiel MA, Ponten F, Fijneman
RJA, Meijer GA. BCL2L1 has a functional role in colorectal cancer and its protein expression is associated with
chromosome 20q gain. Journal of Pathology 2012; 226: 442-450 (5 / 6.318)
87. Sillars-Hardebol AH, Carvalho B, Belien JAM, de Wit M, Delis-van Diemen PM, Tijssen M, van de Wiel MA, Ponten F, Meijer
GA, Fijneman RJA. CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression. Cell Oncol 2012; 35: 293300 (4 / 3.105)
88. Sillars-Hardebol AH, Carvalho B, Tijssen M, Belien JAM, de Wit M, is-van Diemen PM, Ponten F, van de Wiel MA, Fijneman
RJA, Meijer GA. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut 2012;
61: 1568-1575 (5 / 10.111)
89. Sillars-Hardebol AH, Carvalho B, van Engeland M, Fijneman RJA, Meijer GA. The adenoma hunt in colorectal cancer
screening: defining the target. Journal of Pathology 2012; 226: 1-6 (5 / 6.318)
90. Sivachandran N, Dawson CW, Young LS, Liu FF, Middeldorp J, Frappier L. Contributions of the Epstein-Barr Virus EBNA1
Protein to Gastric Carcinoma. Journal of Virology 2012; 86: 60-68 (4 / 5.402)
91. Smetsers S, Muter J, Bristow C, Patel L, Chandler K, Bonney D, Wynn RF, Whetton AD, Will AM, Rockx D, Joenje H,
Strathdee G, Shanks J, Klopocki E, Gille JJP, Dorsman J, Meyer S. Heterozygote FANCD2 mutations associated with
childhood T Cell ALL and testicular seminoma. Familial Cancer 2012; 11: 661-665 (1 / 1.302)
92. Smits AJJ, Kummer JA, Hinrichs JWJ, Herder GJM, Scheidel-Jacobse KC, Jiwa NM, Ruijter TEG, Nooijen PTGA, LooijenSalamon MG, Ligtenberg MJL, Thunnissen FB, Heideman DAM, de Weger RA, Vink A. EGFR and KRAS mutations in lung
carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung
adenocarcinoma. Cell Oncol 2012; 35: 189-196 (4 / 3.105)
93. Smits M, Wurdinger T, van het Hof B, Drexhage JAR, Geerts D, Wesseling P, Noske DP, Vandertop WP, de Vries HE,
Reijerkerk A. Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced
angiogenesis in glioblastoma. Faseb Journal 2012; 26: 2639-2647 (5 / 5.712)
94. Snellenberg S, De Strooper LMA, Hesselink AT, Meijer CJLM, Snijders PJF, Heideman DAM, Steenbergen RDM.
Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical
scrape. BMC Cancer 2012; 12: (4 / 3.011)
95. Snellenberg S, Schutze DM, Claassen-Kramer D, Meijer CJLM, Snijders PJF, Steenbergen RDM. Methylation status of the E2
binding sites of HPV16 in cervical lesions determined with the Luminex (R) xMAP (TM) system. Virology 2012; 422: 357365 (3 / 3.351)
96. Starink TM, Houweling AC, van Doom MB, Leter EM, Jaspars EH, van Moorselaar R, Postmus PE, Johannesma PC, van
Waesberghe JH, Ploeger MH, Kramer MT, Gille JJ, Waisfisz Q, Menko FH. Familial multiple discoid fibromas: A look-alike of
Birt-Hogg-Dube syndrome not linked to the FLCN locus. Journal of the American Academy of Dermatology 2012; 66: 259263 (5 / 3.991)
97. Terhaar sive Droste JS, van Turenhout ST, Oort FA, van der Hulst RWM, Steeman VA, Coblijn U, van der Eem L, Duijkers R,
Bouman AA, Meijer GA, Depla ACTM, Scholten P, Loffeld RJLF, Coupe VMH, Mulder CJJ. Faecal immunochemical test
accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study. BMC Gastroenterology 2012; 12:
94 (3 / 2.422)
98. Thas O, Clement L, Rayner JCW, Carvalho B, van Criekinge W. An Omnibus Consistent Adaptive Percentile Modified
Wilcoxon Rank Sum Test with Applications in Gene Expression Studies. Biometrics 2012; 68: 446-454 (3 / 2.215)
99. Thuijs NB, Uitdehaag BMJ, Van Ouwerkerk WJR, van der Valk P, Vandertop WP, Peerdeman SM. Pediatric meningiomas in
The Netherlands 1974-2010: a descriptive epidemiological case study. Childs Nervous System 2012; 28: 1009-1015 (3 /
1.542)
100. Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chirieac LR, Dacic S, Flieder D, Gazdar A, Geisinger K, Hasleton P,
Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Motoi N, Nicholson AG, Noguchi M, Nonaka D, Pelosi
G, Petersen I, Rekhtman N, Roggli V, Travis WD, Tsao MS, Wistuba I, Xu HD, Yatabe Y, Zakowski M, Witte B, Kuik DJ.
Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver
study. Modern Pathology 2012; 25: 1574-1583 (4 / 4.792)
101. Thunnissen E, Boers E, Heideman DAM, Grunberg K, Kuik DJ, Noorduin A, van Oosterhout M, Pronk D, Seldenrijk C,
Sietsma H, Smit EF, van Suylen R, von der Thusen J, Vrugt B, Wiersma A, Witte BI, den Bakker M. Correlation of
immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in
non small cell lung carcinoma. Virchows Archiv 2012; 461: 629-638 (3 / 2.491)
102. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca
F, Rossi G. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Archiv
2012; 461: 245-257 (3 / 2.491)
103. Thunnissen E, Kerr KM, Herth FJF, Lantuejoul S, Papotti M, Rintoul RC, Rossi G, Skov BG, Weynand B, Bubendorf L, Katrien
G, Johansson L, Lopez-Rios F, Ninane V, Olszewski W, Popper H, Jaume S, Schnabel P, Thiberville L, Laenger F. The
challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung
Cancer 2012; 76: 1-18 (4 / 3.434)
104. Thunnissen F, Prinsen C, Hol B, Van der Drift M, Vesin A, Brambilla C, Montuenga L, Field J. Smoking history and lung
carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development. Lung Cancer 2012; 75: 156-160 (4 /
3.434)
105. Tracy SI, Kakalacheva K, Luenemann JD, Luzuriaga K, Middeldorp JM, Thorley-Lawson DA. Persistence of Epstein-Barr
Virus in Self-Reactive Memory B Cells. Journal of Virology 2012; 86: 12330-12340 (4 / 5.402)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 25
106. Tsang CM, Yip YL, Lo KW, Deng W, To KF, Hau PM, Lau VMY, Takada K, Lui VWY, Lung ML, Chen H, Zeng M, Middeldorp
JM, Cheung ALM, Tsao SW. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells.
Proceedings of the National Academy of Sciences of the United States of America 2012; 109: E3473-E3482 (5 / 9.681)
107. van der Drift MA, Prinsen CFM, Knuiman GJ, Janssen JP, Dekhuijzen PNR, Thunnissen FBJM. Diagnosing Peripheral Lung
Cancer: The Additional Value of the Ras-Association Domain Family 1A Gene Methylation and Kirsten Rat Sarcoma 2 Viral
Oncogene Homolog Mutation Analyses in Washings in Nondiagnostic Bronchoscopy. Chest 2012; 141: 169-175 (5 / 5.25)
108. van Essen HF, Ylstra B. High-resolution copy number profiling by array CGH using DNA isolated from formalin-fixed,
paraffin-embedded tissues. Methods in Molecular Biology 2012; 838: 329-341 (0 / 0)
109. van Liempt SWJD, van Rheenen-Flach LE, van Waesberghe JHTM, Bleeker MCG, Piek JMJ, Lambalk CB. Solely inhibin B
producing ovarian tumour as a cause of secondary amenorrhoea with hot flushes: case report and review of literature.
Human Reproduction 2012; 27: 1144-1148 (5 / 4.475)
110. van Monsjou H, van Velthuysen M, van den Brekel M, Jordanova E, Melief C, Balm A. Human papillomavirus status in
young patients with head and neck squamous cell carcinoma. International Journal of Cancer 2012; 130: 1806-1812 (4 /
5.444)
111. van Riel S, Thunnissen E, Heideman D, Smit EF, Biesma B. A patient with simultaneously appearing adenocarcinoma and
small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation. Annals of Oncology 2012; 23: 3188-3189 (5 /
6.425)
112. van Steenwijk PJD, Ramwadhdoebe TH, Lowik MJG, van der Minne CE, Berends-van der Meer D, Fathers LM, Valentijn
ARPM, Oostendorp J, Fleuren GJ, Hellebrekers BWJ, Welters MJP, van Poelgeest MI, Melief CJM, Kenter GG, van der Burg
SH. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical
squamous intraepithelial lesions. Cancer Immunology Immunotherapy 2012; 61: 1485-1492 (3 / 3.701)
113. van Turenhout ST, Oort FA, Droste JSTS, Coupe VMH, van der Hulst RW, Loffeld RJ, Scholten P, Depla ACTM, Bouman AA,
Meijer GA, Mulder CJJ, van Rossum LGM. Hemorrhoids detected at colonoscopy: an infrequent cause of false-positive
fecal immunochemical test results. Gastrointestinal Endoscopy 2012; 76: 136-143 (4 / 4.878)
114. van Turenhout ST, Terhaar Sive Droste JS, Meijer GA, Masclee AA, Mulder CJJ. Anticipating implementation of colorectal
cancer screening in The Netherlands: a nation wide survey on endoscopic supply and demand. BMC Cancer 2012; 12: 46
(4 / 3.011)
115. van Turenhout ST, van Rossum LGM, Oort FA, Laheij RJF, van Rijn AF, Droste JSTS, Fockens P, van der Hulst RWM,
Bouman AA, Jansen JBMJ, Meijer GA, Dekker E, Mulder CJJ. Similar fecal immunochemical test results in screening and
referral colorectal cancer. World Journal of Gastroenterology 2012; 18: 5397-5403 (3 / 2.471)
116. van Wieringen WN, Unger K, Leday GGR, Krijgsman O, Xavier de Menezes R, Ylstra B, van de Wiel MA. Matching of array
CGH and gene expression microarray features for the purpose of integrative genomic analyses. BMC Bioinformatics
2012; 13: 80 (4 / 2.751)
117. van't Westeinde SC, Horeweg N, Vernhout RM, Groen HJM, Lammers JWJ, Weenink C, Nackaerts K, Oudkerk M, Mali W,
Thunnissen FB, de Koning HJ, van Klaveren RJ. The Role of Conventional Bronchoscopy in the Workup of Suspicious CT
Scan Screen-Detected Pulmonary Nodules. Chest 2012; 142: 377-384 (5 / 5.25)
118. Verweij FJ, Middeldorp JM, Pegtel DM. Intracellular signaling controlled by the endosomal-exosomal pathway.
Communicative & Integrative Biology 2012; 5: 88-93 (0 / 0)
119. Voorham QJM, Carvalho B, Spiertz AJ, Claes B, Mongera S, van Grieken NCT, Grabsch H, Kliment M, Rembacken B, van de
Wiel MA, Quirke P, Mulder CJJ, Lambrechts D, van Engeland M, Meijer GA. Comprehensive Mutation Analysis in Colorectal
Flat Adenomas. PloS one 2012; 7: (4 / 4.092)
120. Voorham QJM, Carvalho B, Spiertz AJ, van Grieken NCT, Mongera S, Rondagh EJA, van de Wiel MA, Jordanova ES, Ylstra B,
Kliment M, Grabsch H, Rembacken BJ, Arai T, de Bruine AP, Sanduleanu S, Quirke P, Mulder CJJ, van Engeland M, Meijer
GA. Chromosome 5q Loss in Colorectal Flat Adenomas. Clin Cancer Res 2012; 18: 4560-4569 (5 / 7.742)
121. Vredeveld LCW, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon
M, Mooi WJ, Peeper DS. Abrogation of BRAF(V600E)-induced senescence by PI3K pathway activation contributes to
melanomagenesis. Genes & Development 2012; 26: 1055-1069 (5 / 11.659)
122. Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MPG, Waisfisz Q, Rottenberg S, Boven E, Jonkers J,
Jimenez CR. Proteomics of Mouse BRCA1-deficient Mammary Tumors Identifies DNA Repair Proteins with Potential
Diagnostic and Prognostic Value in Human Breast Cancer. Molecular & Cellular Proteomics 2012; 11: (5 / 7.398)
123. White RE, Raemer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, Savoldo B, Coutinho R, Boedoer C, ribben J, brahim
HA, ower M, ourse JP, andhi MK, iddeldorp J, ader FZ, urray P, uenz C, llday MJ. EBNA3B-deficient EBV promotes B cell
lymphomagenesis in humanized mice and is found in human tumors. Journal of Clinical Investigation 2012; 122: 14871502 (5 / 13.069)
124. Wu YL, Sommers JA, Khan I, de Winter JP, Brosh RM. Biochemical Characterization of Warsaw Breakage Syndrome
Helicase. Journal of Biological Chemistry 2012; 287: 1007-1021 (4 / 4.773)
125. Yan ZJ, Guo R, Paramasivam M, Shen WP, Ling C, Fox D, Wang YC, Oostra AB, Kuehl J, Lee DY, Takata M, Hoatlin ME,
Schindler D, Joenje H, de Winter JP, Li L, Seidman MM, Wang WD. A Ubiquitin-Binding Protein, FAAP20, Links RNF8Mediated Ubiquitination to the Fanconi Anemia DNA Repair Network. Molecular Cell 2012; 47: 61-75 (5 / 14.178)
126. Zaal A, Louwers JA, Berkhof J, Kocken M, ter Harmsel WA, Graziosi GCM, Spruijt JWM, Balas C, Papagiannakis E, Snijders
PJF, Meijer CJLM, van Kemenade FJ, Verheijen RHM. Agreement between colposcopic impression and histological
diagnosis among human papillomavirus type 16-positive women: a clinical trial using dynamic spectral imaging
colposcopy. BJOG-An International Journal of Obstetrics and Gynaecology 2012; 119: 537-544 (4 / 3.407)
127. Zaal A, Peyrot WJ, Berns PMJJ, van der Burg MEL, Veerbeek JHW, Trimbos JB, Cadron I, van Diest PJ, van Wieringen WN,
Krijgsman O, Meijer GA, Piek JMJ, Timmers PJ, Vergote I, Verheijen RHM, Ylstra B, Zweemer RP. Genomic aberrations
relate early and advanced stage ovarian cancer. Cell Oncol 2012; 35: 181-188 (4 / 3.105)
128. Zhang Z, Sun D, Hutajulu SH, Nawaz I, Nguyen Van D, Huang G, Haryana SM, Middeldorp JM, Ernberg I, Hu LF.
Development of a Non-Invasive Method, Multiplex Methylation Specific PCR (MMSP), for Early Diagnosis of
Nasopharyngeal Carcinoma. PloS one 2012; 7: e45908 (4 / 4.092)
129. Zijlmans HJMA, Punt S, Fleuren GJ, Trimbos JB, Kenter GG, Gorter A. Role of IL-12p40 in cervical carcinoma. Br J Cancer
2012; 107: 1956-1962 (4 / 5.042)
130. Zurolo E, de Groot M, Iyer A, Anink J, van Vliet EA, Heimans JJ, Reijneveld JC, Gorter JA, Aronica E. Regulation of Kir4.1
expression in astrocytes and astrocytic tumors: a role for interleukin-1 beta. Journal of Neuroinflammation 2012; 9: 280
(3 / 3.827)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 26
Scientific papers non-refereed
1.
Allison J, Meijer GA. Colonic Polyps: The Harm of Overdiagnosis. Practical Gastroenterology 2012; 36: 25-38
Scientific publications (Books, book chapters, proceedings)
1.
2.
Bleeker MCG, Heideman DAM, Snijders PJF, Horenblas S, Meijer CJLM. Epidemiology and Etiology of Penile Cancer; in
Muneer A, Arya M, Horenblas S, (eds): Textbook of Penile Cancer. Springer. 2012; : 1-11
Heideman DAM, Bleeker MCG, Ahmed HU, Horenblas S, Snijders PJF, Meijer CJLM. Molecular biology of penile cancer; in
Muneer A, Arya M, Horenblas S, (eds): Textbook of penile cancer. Springer. 2012
Professional publications
1.
2.
3.
4.
Iskender SY, Eekhoff EMW, van der Waal I. Bisfosfonaatgerelateerde osteonecrose van de kaak. Nederlands Tijdschrift
voor Tandheelkunde 2012119: 206-211
Nolte JW, Baart JA, van der Waal I. Een gingivahyperplasie op basis van neurofibromatose. Nederlands Tijdschrift voor
Tandheelkunde 2012119: 173-174
van de Vijfeijken SECM, Karagozoglu KH, Rietveld DHF, Meester MMC, van der Waal I. Osteoradionecrose van de
mandibula, vermoedelijk veroorzaakt door een frameprothese. Nederlands Tijdschrift voor Tandheelkunde 2012119:
413-414
Wijs RW, Meleti M, Bloemena E, van der Waal I. Een niet-gepigmenteerde naevus als ongewone gingivazwelling.
Nederlands Tijdschrift voor Tandheelkunde 2012119: 283-284
Dissertations
1.
2.
3.
4.
5.
Gok M. HPV Testing on self-collected cervico-vaginal material: a new way of woman friendly cervical screening.. Vrije
Universiteit Amsterdam, 5/15/2012. (Co-)promotores: C.J.L.M. Meijer, P.J.F. Snijders, D.A.M. Heideman, F.J. van
Kemenade (cat A)
Louwers JA. The role of digitaal colposcopy, the human papillomavirus and biomarkers. Vrije Universiteit Amsterdam,
4/12/2012. (Co-)promotores: R.H.M. Verheijen, C.J.L.M. Meijer, P.J.F. Snijders, W.A. ter Harmsel (cat A)
Sillars-Hardebol AH. Chromosome 20q genes in the pathogenesis of colorectal cancer. Vrije Universiteit Amsterdam,
3/12/2012. (Co-)promotores: G.A. Meijer, B. Carvalho, R.J.A. Fijneman (cat A)
van der Drift MA. Epidemiologic and molecular aspects of lung cancer. Vrije Universiteit Amstedam, 5/12/2012. (Co-)
promotores: P.N.R. Dekhuijzen, F.B.J.M. Thunnissen (cat D)
Weijers M. Oral squamous cell carcinoma; some epidemiological and clinicopathological aspects. Vrije Universiteit
Amsterdam, 10/29/2012. (Co-)promotores: I. van der Waal (cat A)
Program 2: Immunopathogenesis
Scientific papers refereed
1.
Abdallah AM, Rashid M, Adroub SA, Arnoux M, Ali S, van Soolingen D, Bitter W, Pain A. Complete Genome Sequence of
Mycobacterium phlei Type Strain RIVM601174. Journal of Bacteriology 2012; 194: 3284-3285 (3 / 3.825)
2. Abdallah AM, Rashid M, Adroub SA, Elabdalaoui H, Ali S, van Soolingen D, Bitter W, Pain A. Complete Genome Sequence
of Mycobacterium xenopi Type Strain RIVM700367. Journal of Bacteriology 2012; 194: 3282-3283 (3 / 3.825)
3. Anderson AL, Zheng Y, Song DC, LaRosa D, Van Rooijen N, Kierstein G, Kierstein S, Haczku A, Levinson AI. The B-cell
superantigen Finegoldia magna protein L causes pulmonary inflammation by a mechanism dependent on MyD88 but not
B cells or immunoglobulins. Inflammation Research 2012; 61: 161-169 (2 / 2.109)
4. Arnes JB, Stefansson IM, Straume O, Baak JPA, Lonning PE, Foulkes WD, Akslen LA. Vascular proliferation is a prognostic
factor in breast cancer. Breast Cancer Research and Treatment 2012; 133: 501-510 (4 / 4.431)
5. Barral P, Sanchez-Nino MD, Van Rooijen N, Cerundolo V, Batista FD. The location of splenic NKT cells favours their rapid
activation by blood-borne antigen. EMBO Journal 2012; 31: 2378-2390 (5 / 9.205)
6. Benard EL, van der Sar AM, Ellett F, Lieschke GJ, Spaink HP, Meijer AH. Infection of zebrafish embryos with intracellular
bacterial pathogens. Journal of Visualized Experiments 2012; 15: 61 (0 / 0)
7. Bode LGM, van Wunnik P, Vaessen N, Savelkoul PHM, Smeets LC. Rapid detection of methicillin-resistant Staphylococcus
aureus in screening samples by relative quantification between the mecA gene and the SA442 gene. Journal of
Microbiological Methods 2012; 89: 129-132 (2 / 2.086)
8. Boettcher S, Ziegler P, Schmid MA, Takizawa H, Van Rooijen N, Kopf M, Heikenwalder M, Manz MG. Cutting Edge: LPSInduced Emergency Myelopoiesis Depends on TLR4-Expressing Nonhematopoietic Cells. J Immunol 2012; 188: 58245828 (4 / 5.788)
9. Bogels M, Braster R, Nijland PG, Gul N, van de Luijtgaarden W, Fijneman RJ, Meijer GA, Jimenez CR, Beelen RH, van
Egmond M. Carcinoma origin dictates differential skewing of monocyte function. Oncoimmunology 2012; 1: 798-809 (0 /
0)
10. Bontkes HJ, Ruben JM, Alhan C, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Azacitidine differentially affects
CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes. Leukemia Research 2012; 36:
921-930 (3 / 2.923)
11. Boonstra K, van Erpecum KJ, van Nieuwkerk KMJ, Drenth JPH, Poen AC, Witteman BJM, Tuynman HARE, Beuers U, Ponsioen
CY. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflammatory
Bowel Diseases 2012; 18: 2270-2276 (4 / 4.855)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 27
12. Bossini-Castillo L, Martin JE, Broen J, Gorlova O, Simeon CP, Beretta L, Vonk MC, Callejas JL, Castellvi I, Carreira P, GarciaHernandez FJ, Castro MF, Coenen MJH, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Distler JHW, Koeleman BP,
Voskuyl AE, Schuerwegh AJ, Palm O, Hesselstrand R, Nordin A, Airo P, Lunardi C, Scorza R, Shiels P, van Laar JM, Herrick
A, Worthington J, Denton C, Tan FK, Arnett FC, Agarwal SK, Assassi S, Fonseca C, Mayes MD, Radstake TRDJ, Martin J. A
GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations.
Human Molecular Genetics 2012; 21: 926-933 (5 / 7.636)
13. Bottai D, Di Luca M, Majlessi L, Frigui W, Simeone R, Sayes F, Bitter W, Brennan MJ, Leclerc C, Batoni G, Campa M, Brosch
R, Esin S. Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction
of cell wall integrity and strong attenuation. Molecular Microbiology 2012; 83: 1195-1209 (4 / 5.01)
14. Boulter L, Govaere O, Bird TG, Radulescu S, Ramachandran P, Pellicoro A, Ridgway RA, Seo SS, Spee B, Van Rooijen N,
Sansom OJ, Iredale JP, Lowell S, Roskams T, Forbes SJ. Macrophage-derived Wnt opposes Notch signaling to specify
hepatic progenitor cell fate in chronic liver disease. Nature Medicine 2012; 18: 572-579 (5 / 22.462)
15. Bradshaw AC, Coughlan L, Miller AM, Alba R, Van Rooijen N, Nicklin SA, Baker AH. Biodistribution and inflammatory
profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. Journal of Controlled Release 2012; 164:
394-402 (5 / 5.732)
16. Bratton DJ, Nunn AJ, Wojnarowska F, Kirtschig G, Sandell A, Williams HC. The value of the pragmatic-explanatory
continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study. Trials
2012; 13: (3 / 2.496)
17. Broers CJM, Gemke RJBJ, Weijerman ME, Kuik DJ, van Hoogstraten IMW, van Furth AM. Frequency of lower respiratory tract
infections in relation to adaptive immunity in children with Down syndrome compared to their healthy siblings. Acta
Paediatrica 2012; 101: 862-867 (3 / 2.073)
18. Broers CJM, Gemke RJBJ, Weijerman ME, van der Sluijs KF, van Furth AM. Increased Pro-inflammatory Cytokine Production
in Down syndrome Children Upon Stimulation with Live Influenza A Virus. Journal of Clinical Immunology 2012; 32: 323329 (3 / 3.077)
19. Bronkhorst IHG, Vu THK, Jordanova ES, Luyten GPM, van der Burg SH, Jager MJ. Different Subsets of Tumor-Infiltrating
Lymphocytes Correlate with Macrophage Influx and Monosomy 3 in Uveal Melanoma. Investigative Ophthalmology &
Visual Science 2012; 53: 5370-5378 (4 / 3.597)
20. Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, Cherrington NJ. Altered arsenic
disposition in experimental nonalcoholic Fatty liver disease. Drug Metabolism and Disposition 2012; 40: 1817-1824 (4 /
3.733)
21. Celie JWAM, Katta KK, Adepu S, Melenhorst WBWH, Reijmers RM, Slot EM, Beelen RHJ, Spaargaren M, Ploeg RJ, Navis G,
van der Heide JJH, van Dijk MCRF, van Goor H, van den Born J. Tubular epithelial syndecan-1 maintains renal function in
murine ischemia/reperfusion and human transplantation. Kidney International 2012; 81: 651-661 (5 / 6.606)
22. Chen F, Liu ZG, Wu WH, Rozo C, Bowdridge S, Millman A, Van Rooijen N, Urban JF, Wynn TA, Gause WC. An essential role
for T(H)2-type responses in limiting acute tissue damage during experimental helminth infection. Nature Medicine 2012;
18: 260-266 (5 / 22.462)
23. Choundry N, Petry F, Van Rooijen N, McDonald VK. A Protective Role for Interleukin 18 in Interferon gamma-Mediated
Innate Immunity to Cryptosporidium parvum That Is Independent of Natural Killer Cells. J Infect Dis 2012; 206: 117-124
(5 / 6.41)
24. Christerson L, Bom RJM, Bruisten SM, Yass R, Hardick J, Bratt G, Gaydos CA, Morre SA, Herrmann B. Chlamydia
trachomatis Strains Show Specific Clustering for Men Who Have Sex with Men Compared to Heterosexual Populations in
Sweden, the Netherlands, and the United States. Journal of Clinical Microbiology 2012; 50: 3548-3555 (4 / 4.153)
25. Coombes JL, Han SJ, Van Rooijen N, Raulet DH, Robey EA. Infection-Induced Regulation of Natural Killer Cells by
Macrophages and Collagen at the Lymph Node Subcapsular Sinus. Cell Reports 2012; 2: 124-135 (0 / 0)
26. Coughlan L, Bradshaw AC, Parker AL, Robinson H, White K, Custers J, Goudsmit J, Van Rooijen N, Barouch DH, Nicklin SA,
Baker AH. Ad5:Ad48 Hexon Hypervariable Region Substitutions Lead to Toxicity and Increased Inflammatory Responses
Following Intravenous Delivery. Molecular Therapy 2012; 20: 2268-2281 (5 / 6.873)
27. Coughlan L, Vallath S, Gros A, Gimenez-Alejandre M, Van Rooijen N, Thomas GJ, Baker AH, Cascallo M, Alemany R, Hart
IR. Combined Fiber Modifications Both to Target alpha(v)beta(6) and Detarget the Coxsackievirus-Adenovirus Receptor
Improve Virus Toxicity Profiles In Vivo but Fail to Improve Antitumoral Efficacy Relative to Adenovirus Serotype 5. Human
Gene Therapy 2012; 23: 960-979 (4 / 4.218)
28. Daleke MH, Ummels R, Bawono P, Heringa J, Vandenbroucke-Grauls CMJE, Luirink J, Bitter W. General secretion signal for
the mycobacterial type VII secretion pathway. Proceedings of the National Academy of Sciences of the United States of
America 2012; 109: 11342-11347 (5 / 9.681)
29. Daleke MH, van der Woude AD, Parret AHA, Ummels R, Groot AM, Watson D, Piersma SR, Jimenez CR, Luirink J, Bitter W,
Houben ENG. Specific Chaperones for the Type VII Protein Secretion Pathway. Journal of Biological Chemistry 2012; 287:
31939-31947 (4 / 4.773)
30. Dashty M, Akbarkhanzadeh V, Zeebregts CJ, Spek CA, Sijbrands EJ, Peppelenbosch MP, Rezaee F. Characterization of
coagulation factor synthesis in nine human primary cell types. Scientific Reports 2012; 2: (0 / 0)
31. de Bruin RC, Schneiders FL, Santegoets SJ, Verheul HM, de Gruijl TD, van der Vliet HJ. Bulldozing Beta-linked glycolipids
for recognition by invariant NKT cells. Immunotherapy 2012; 4: 20 (1 / 1.854)
32. de Bruin RCG, Schneiders FL, Santegoets SJAM, Verheul HMW, de Gruijl TD, van der Vliet HJ. Gram-positive bacteria: a
major microbial 'turn-on' for invariant NKT cells. Immunotherapy 2012; 4: 19 (1 / 1.854)
33. de Bruin RCG, Schneiders FL, Santegoets SJAM, Verheul HMW, De Gruijl TD, Van der Vliet HJ. An alpha-galactosylceramide
nose job shapes up iNKT cells. Immunotherapy 2012; 4: 20-21 (1 / 1.854)
34. de Crom SCM, Obihara CC, van Loon AM, rgilagos-Alvarez AA, Peeters MF, van Furth AM, Rossen JWA. Detection of
enterovirus RNA in cerebrospinal fluid: Comparison of two molecular assays. Journal of Virological Methods 2012; 179:
104-107 (2 / 2.011)
35. de Gruijl TD. Dendritic Cell Subsets In Human Skin and Their Role In T-Cell Activation. Experimental Dermatology 2012;
21: 802-804 (4 / 3.543)
36. de Kivit S, Saeland E, Kraneveld AD, van de Kant HJG, Schouten B, van Esch BCAM, Knol J, Sprikkelman AB, van der Aa LB,
Knippels LMJ, Garssen J, van Kooyk Y, Willemsen LEM. Galectin-9 induced by dietary synbiotics is involved in suppression
of allergic symptoms in mice and humans. Allergy 2012; 67: 343-352 (5 / 6.271)
37. den Haan JM, Mebius RE, Kraal G. Stromal cells of the mouse spleen. Frontiers in Immunology 2012; 3: 201 (0 / 0)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 28
38. den Haan JMM, Kraal G. Innate Immune Functions of Macrophage Subpopulations in the Spleen. Journal of Innate
Immunity 2012; 4: 437-445 (4 / 4.209)
39. Dhaliwal K, Scholefield E, Ferenbach D, Gibbons M, Duffin R, Dorward DA, Morris AC, Humphries D, MacKinnon A,
Wilkinson TS, Wallace WAH, Van Rooijen N, Mack M, Rossi AG, Davidson DJ, Hirani N, Hughes J, Haslett C, Simpson AJ.
Monocytes Control Second-Phase Neutrophil Emigration in Established Lipopolysaccharide-induced Murine Lung Injury.
Am J Respir Crit Care Med 2012; 186: 514-524 (5 / 11.08)
40. Drabek T, Janata A, Jackson EK, End B, Stezoski J, Vagni VA, Janesko-Feldman K, Wilson CD, Van Rooijen N, Tisherman SA,
Kochanek PM. Microglial depletion using intrahippocampal injection of liposome-encapsulated clodronate in prolonged
hypothermic cardiac arrest in rats. Resuscitation 2012; 83: 517-526 (5 / 3.601)
41. Driessen NN, Boshoff HIM, Maaskant JJ, Gilissen SAC, Vink S, van der Sar AM, Vandenbroucke-Grauls CMJE, Bewley CA,
Appelmelk BJ, Geurtsen J. Cyanovirin-N Inhibits Mannose-Dependent Mycobacterium-C-Type Lectin Interactions but Does
Not Protect against Murine Tuberculosis. J Immunol 2012; 189: 3585-3592 (4 / 5.788)
42. Duffy D, Perrin H, Abadie V, Benhabiles N, Boissonnas A, Liard C, Descours B, Reboulleau D, Bonduelle O, Verrier B, Van
Rooijen N, Combadiere C, Combadiere B. Neutrophils Transport Antigen from the Dermis to the Bone Marrow, Initiating a
Source of Memory CD8(+) T Cells. Immunity 2012; 37: 917-929 (5 / 21.637)
43. Elvington M, Huang YX, Morgan BP, Qiao F, Van Rooijen N, Atkinson C, Tomlinson S. Atargeted complement-dependent
strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood
2012; 119: 6043-6051 (5 / 9.898)
44. Etzrodt M, Cortez-Retamozo V, Newton A, Zhao J, Ng A, Wildgruber M, Romero P, Wurdinger T, Xavier R, Geissmann F,
Meylan E, Nahrendorf M, Swirski FK, Baltimore D, Weissleder R, Pittet MJ. Regulation of Monocyte Functional
Heterogeneity by miR-146a and Relb. Cell Reports 2012; 1: 317-324 (0 / 0)
45. Feingold BJ, Silbergeld EK, Curriero FC, van Cleef BA, Heck ME, Kluytmans JA. Livestock density as risk factor for
livestock-associated methicillin-resistant Staphylococcus aureus, the Netherlands. Emerg Infect Dis 2012; 18: 1841-1849
(5 / 6.169)
46. Frank S, van Die I, Geyer R. Structural characterization of Schistosoma mansoni adult worm glycosphingolipids reveals
pronounced differences with those of cercariae. Glycobiology 2012; 22: 676-695 (3 / 3.58)
47. Franzke CW, Cobzaru C, Triantafyllopoulou A, Loffek S, Horiuchi K, Threadgill DW, Kurz T, Van Rooijen N, BrucknerTuderman L, Blobel CP. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal
keratinocyte differentiation. Journal of Experimental Medicine 2012; 209: 1105-1119 (5 / 13.853)
48. Garaude J, Kent A, Van Rooijen N, Blander JM. Simultaneous Targeting of Toll- and Nod-Like Receptors Induces Effective
Tumor-Specific Immune Responses. Science Translational Medicine 2012; 4: (5 / 7.804)
49. Garcia Z, Lemaitre F, Van Rooijen N, Albert ML, Levy Y, Schwartz O, Bousso P. Subcapsular sinus macrophages promote
NK cell accumulation and activation in response to lymph-borne viral particles. Blood 2012; 120: 4744-4750 (5 / 9.898)
50. Gautier EL, Chow A, Spanbroek R, Marcelin G, Greter M, Jakubzick C, Bogunovic M, Leboeuf M, Van Rooijen N, Habenicht
AJ, Merad M, Randolph GJ. Systemic Analysis of PPAR gamma in Mouse Macrophage Populations Reveals Marked Diversity
in Expression with Critical Roles in Resolution of Inflammation and Airway Immunity. J Immunol 2012; 189: 2614-2624
(4 / 5.788)
51. Gliem M, Hermsen D, Van Rooijen N, Hartung HP, Jander S. Secondary Intracerebral Hemorrhage Due to Early Initiation of
Oral Anticoagulation After Ischemic Stroke An Experimental Study in Mice. Stroke 2012; 43: 3352-3357 (5 / 5.729)
52. Gliem M, Mausberg AK, Lee JI, Simiantonakis I, Van Rooijen N, Hartung HP, Jander S. Macrophages prevent hemorrhagic
infarct transformation in murine stroke models. Ann Neurol 2012; 71: 743-752 (5 / 11.089)
53. Gonzalez IT, Barrientos G, Freitag N, Otto T, Thijssen VLJL, Moschansky P, von Kwiatkowski P, Klapp BF, Winterhager E,
Bauersachs S, Blois SM. Uterine NK Cells Are Critical in Shaping DC Immunogenic Functions Compatible with Pregnancy
Progression. PloS one 2012; 7: (4 / 4.092)
54. Green NK, Hale A, Cawood R, Illingworth S, Herbert C, Hermiston T, Subr V, Ulbrich K, Van Rooijen N, Seymour LW, Fisher
KD. Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves
virotherapy of cancer. Nanomedicine 2012; 7: 1683-1695 (4 / 5.055)
55. Greijer AE, Stevens SJ, Verkuijlen SA, Juwana H, Fleig SC, Verschuuren EA, Hepkema BG, Cornelissen JJ, Brooimans RA,
Verdonck LF, Middeldorp JM. Variable EBV DNA Load Distributions and Heterogeneous EBV mRNA Expression Patterns in
the Circulation of Solid Organ versus Stem Cell Transplant Recipients. Clinical & Developmental Immunology 2012; : (2 /
1.838)
56. Grugan KD, Mccabe FL, Kinder M, Greenplate AR, Harman BC, Ekert JE, Van Rooijen N, Anderson GM, Nemeth JA, Strohl
WR, Jordan RE, Brezski RJ. Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor
Function. J Immunol 2012; 189: 5457-5466 (4 / 5.788)
57. Gul N, Grewal S, Bogels M, van der Bij GJ, Koppes MM, Oosterling SJ, Fluitsma DM, Hoeben KA, Beelen RH, van Egmond M.
Macrophages mediate colon carcinoma cell adhesion in the rat liver after exposure to lipopolysaccharide.
Oncoimmunology 2012; 1: 1517-1526 (0 / 0)
58. Halaby T, Reuland AE, al Naiemi N, Potron A, Savelkoul PHM, Vandenbroucke-Grauls CMJE, Nordmann P. A Case of New
Delhi Metallo-beta-Lactamase 1 (NDM-1)-Producing Klebsiella pneumoniae with Putative Secondary Transmission from the
Balkan Region in the Netherlands. Antimicrobial Agents and Chemotherapy 2012; 56: 2790-2791 (5 / 4.841)
59. Harris SR, Clarke IN, Seth-Smith HMB, Solomon AW, Cutcliffe LT, Marsh P, Skilton RJ, Holland MJ, Mabey D, Peeling RW,
Lewis DA, Spratt BG, Unemo M, Persson K, Bjartling C, Brunham R, de Vries HJC, Morre SA, Speksnijder A, Bebear CM,
Clerc M, de Barbeyrac B, Parkhill J, Thomson NR. Whole-genome analysis of diverse Chlamydia trachomatis strains
identifies phylogenetic relationships masked by current clinical typing. Nature Genetics 2012; 44: 413-U221 (5 / 35.532)
60. Hess DLJ, Pettersson Fernholm AM, Rijnsburger MC, Herbrink P, van den Berg HP, Ang CW. Gastroenteritis caused by
Campylobacter concisus. Journal of Medical Microbiology 2012; 61: 746-749 (3 / 2.502)
61. Hiemstra IH, Bouma G, Geerts D, Kraal G, den Haan JMM. Nod2 improves barrier function of intestinal epithelial cells via
enhancement of TLR responses. Molecular Immunology 2012; 52: 264-272 (3 / 2.897)
62. Ho YS, Adroub SA, Abadi M, Al Alwan B, Alkhateeb R, Gao G, Ragab A, Ali S, van Soolingen D, Bitter W, Pain A, Abdallah
AM. Complete Genome Sequence of Mycobacterium vaccae Type Strain ATCC 25954. Journal of Bacteriology 2012; 194:
6339-6340 (3 / 3.825)
63. Ho YS, Adroub SA, Aleisa F, Mahmood H, Othoum G, Rashid F, Zaher M, Ali S, Bitter W, Pain A, Abdallah AM. Complete
Genome Sequence of Mycobacterium fortuitum subsp fortuitum Type Strain DSM46621. Journal of Bacteriology 2012;
194: 6337-6338 (3 / 3.825)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 29
64. Hoefsloot W, Boeree MJ, van Nieuwkoop C, Bernards AT, Savelkoul PHM, van Ingen J, van Soolingen D. No human
transmission of Mycobacterium malmoense in a perfect storm setting. European Respiratory Journal 2012; 40: 15761578 (5 / 5.895)
65. Hoentjen F, Hanauer SB, de Boer NK, Rubin DT. Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis
Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction. Digestive Diseases and Sciences 2012; 57:
250-253 (2 / 2.117)
66. Hoentjen F, Rubin DT. Infectious Proctitis: When to Suspect It Is Not Inflammatory Bowel Disease. Digestive Diseases and
Sciences 2012; 57: 269-273 (2 / 2.117)
67. Holz LE, Benseler V, Vo M, McGuffog C, Van Rooijen N, McCaughan GW, Bowen DG, Bertolino P. Naive CD8 T cell
activation by liver bone marrow-derived cells leads to a "neglected" IL-2(low) Bim(high) phenotype, poor CTL function and
cell death. Journal of Hepatology 2012; 57: 830-836 (5 / 9.264)
68. Houben D, Demangel C, van Ingen J, Perez J, Baldeon L, Abdallah AM, Caleechurn L, Bottai D, van Zon M, de Punder K,
van der Laan T, Kant A, Bossers-de Vries R, Willemsen P, Bitter W, van Soolingen D, Brosch R, van der Wel N, Peters PJ.
ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. Cellular Microbiology 2012; 14: 12871298 (4 / 5.458)
69. Houben ENG, Bestebroer J, Ummels R, Wilson L, Piersma SR, Jimenez CR, Ottenhoff THM, Luirink J, Bitter W. Composition
of the type VII secretion system membrane complex. Molecular Microbiology 2012; 86: 472-484 (4 / 5.01)
70. Huizinga R, van der Star BJ, Kipp M, Jong R, Gerritsen W, Clarner T, Puentes F, Dijkstra CD, van der Valk P, Amor S.
Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis. Glia 2012; 60:
422-431 (4 / 4.82)
71. Hutajulu SH, Ng N, Jati BR, Fachiroh J, Herdini C, Hariwiyanto B, Haryana SM, Middeldorp JM. Seroreactivity against
Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
Journal of Medical Virology 2012; 84: 768-776 (2 / 2.82)
72. Ingersoll MA, Potteaux S, Alvarez D, Hutchison SB, Van Rooijen N, Randolph GJ. Niacin inhibits skin dendritic cell
mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
Immunobiology 2012; 217: 548-557 (3 / 3.205)
73. Jharap B, Koudstaal LG, Neefjes-Borst EA, Van Weyenberg SJB. Colonic telangiectasias in progressive systemic sclerosis.
Endoscopy 2012; 44: E42-E43 (5 / 5.21)
74. Jiang J, Karimi O, Ouburg S, Champion CI, Khurana A, Liu GC, Freed A, Pleijster J, Rozengurt N, Land JA, Surcel HM,
Tiitinen A, Paavonen J, Kronenberg M, Morre SA, Kelly KA. Interruption of CXCL13-CXCR5 Axis Increases Upper Genital
Tract Pathology and Activation of NKT Cells following Chlamydial Genital Infection. PloS one 2012; 7: (4 / 4.092)
75. Jonsdottir K, Janssen SR, Da Rosa FC, Gudlaugsson E, Skaland I, Baak JPA, Janssen EAM. Validation of Expression Patterns
for Nine miRNAs in 204 Lymph-Node Negative Breast Cancers. PloS one 2012; 7: (4 / 4.092)
76. Jonsdottir K, Zhang H, Jhagroe D, Skaland I, Slewa A, Bjorkblom B, Coffey ET, Gudlaugsson E, Smaaland R, Janssen EAM,
Baak JPA. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer. Breast Cancer Research and
Treatment 2012; 135: 381-390 (4 / 4.431)
77. Jonsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, Van Rooijen N, Shimizu T, Schwartz LB, Daeron M, Bruhns
P. Human Fc gamma RIIA induces anaphylactic and allergic reactions. Blood 2012; 119: 2533-2544 (5 / 9.898)
78. Joseph SJ, Didelot X, Rothschild J, de Vries HJC, Morre SA, Read TD, Dean D. Population Genomics of Chlamydia
trachomatis: Insights on Drift, Selection, Recombination, and Population Structure. Molecular Biology and Evolution
2012; 29: 3933-3946 (5 / 5.55)
79. Joshi MD, Unger WJ, Storm G, van Kooyk Y, Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate
carriers. Journal of Controlled Release 2012; 161: 25-37 (5 / 5.732)
80. Kasza I, Varady G, Andrikovics H, Koszarska M, Tordai A, Scheffer GL, Nemeth A, Szakacs G, Sarkadi B. Expression Levels
of the ABCG2 Multidrug Transporter in Human Erythrocytes Correspond to Pharmacologically Relevant Genetic
Variations. PloS one 2012; 7: e48423 (4 / 4.092)
81. Kluytmans-van den Bergh M, Kluytmans JAJW. Control of Multidrug-Resistant Microorganisms: Beyond the Hospital.
Clinical Infectious Diseases 2012; 55: 1512-1514 (5 / 9.154)
82. Kneepkens CMF, von Blomberg BME. Clinical practice Coeliac disease. European Journal of Pediatrics 2012; 171: 10111021 (3 / 1.879)
83. Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses. Nature Reviews
Immunology 2012; 12: 813-820 (5 / 33.287)
84. Koning JJ, Mebius RE. Interdependence of stromal and immune cells for lymph node function. Trends in Immunology
2012; 33: 264-270 (5 / 10.403)
85. Kraan CTMV, Baggen JM, van Bodegraven AA, Mulder CJJ, Zwiers A, Geerts D, Kraal G, Horrevoets AJ, Bouma G. Defective
IL-1A expression in patients with Crohn's disease is related to attenuated MAP3K4 signaling. Human Immunology 2012;
73: 912-919 (2 / 2.837)
86. Kroeze KL, Boink MA, Sampat-Sardjoepersad SC, Waaijman T, Scheper RJ, Gibbs S. Autocrine Regulation of ReEpithelialization After Wounding by Chemokine Receptors CCR1, CCR10, CXCR1, CXCR2, and CXCR3. Journal of
Investigative Dermatology 2012; 132: 216-225 (5 / 6.314)
87. Kroeze KL, Vink L, de Boer EM, Scheper RJ, van Montfrans C, Gibbs S. Simple wound exudate collection method identifies
bioactive cytokines and chemokines in (arterio) venous ulcers. Wound Repair and Regeneration 2012; 20: 294-303 (4 /
2.911)
88. Kuijk LM, Klaver EJ, Kooij G, van der Pol SMA, Heijnen P, Bruijns SCM, Kringel H, Pinelli E, Kraal G, de Vries HE, Dijkstra
CD, Bouma G, van Die I. Soluble helminth products suppress clinical signs in murine experimental autoimmune
encephalomyelitis and differentially modulate human dendritic cell activation. Molecular Immunology 2012; 51: 210-218
(3 / 2.897)
89. Kumamaru H, Saiwai H, Kobayakawa K, Kubota K, Van Rooijen N, Inoue K, Iwamoto Y, Okada S. Liposomal clodronate
selectively eliminates microglia from primary astrocyte cultures. Journal of Neuroinflammation 2012; 9: (3 / 3.827)
90. Landoni VI, Chiarella P, Martire-Greco D, Schierloh P, Van Rooijen N, Rearte B, Palermo MS, Isturiz MA, Fernandez GC.
Tolerance to lipopolysaccharide promotes an enhanced neutrophil extracellular traps formation leading to a more
efficient bacterial clearance in mice. Clin Exp Immunol 2012; 168: 153-163 (3 / 3.36)
91. le Poole CY, Welten AGA, ter Wee PM, Paauw NJ, Djorai AN, Valentijn RM, Beelen RHJ, van den Born J, van Ittersum FJ. A
Peritoneal Dialysis Regimen Low in Glucose and Glucose Degradation Products Results in Increased Cancer Antigen 125
and Peritoneal Activation. Peritoneal Dialysis International 2012; 32: 305-315 (3 / 2.097)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 30
92. Mac Aogain M, Kulah C, Rijnsburger M, Celebi G, Savelkoul PHM, O'Gara F, Mooij MJ. Characterization of imipenem
resistance mechanisms in Pseudomonas aeruginosa isolates from Turkey. Clinical Microbiology and Infection 2012; 18:
E262-E265 (4 / 4.54)
93. Markov PV, van de Laar TJ, Thomas XV, Aronson SJ, Weegink CJ, van den Berk GE, Prins M, Pybus OG, Schinkel J. Colonial
History and Contemporary Transmission Shape the Genetic Diversity of Hepatitis C Virus Genotype 2 in Amsterdam.
Journal of Virology 2012; 86: 7677-7687 (4 / 5.402)
94. Martens HA, Nienhuis HLA, Gross S, van der Steege G, Brouwer E, Berden JHM, de Sevaux RGL, Derksen RHWM, Voskuyl
AE, Berger SP, Navis GJ, Nolte IM, Kallenberg CGM, Bijl M. Receptor for advanced glycation end products (RAGE)
polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus 2012;
21: 959-968 (2 / 2.337)
95. Maruyama K, Nakazawa T, Cursiefen C, Maruyama Y, Van Rooijen N, D'Amore PA, Kinoshita S. The Maintenance of
Lymphatic Vessels in the Cornea Is Dependent on the Presence of Macrophages. Invest Ophth Vis Sci 2012; 53: 31453153 (4 / 3.597)
96. Mawhinney LA, Thawer SG, Lu WY, Van Rooijen N, Weaver LC, Brown A, Dekaban GA. Differential Detection and
Distribution of Microglial and Hematogenous Macrophage Populations in the Injured Spinal Cord of lys-EGFP-ki
Transgenic Mice. Journal of Neuropathology and Experimental Neurology 2012; 71: 180-197 (4 / 4.258)
97. Meevissen MHJ, Driessen NN, Smits HH, Versteegh R, van Vliet SJ, van Kooyk Y, Schramm G, Deelder AM, Haas H,
Yazdanbakhsh M, Hokke CH. Specific glycan elements determine differential binding of individual egg glycoproteins of
the human parasite Schistosoma mansoni by host C-type lectin receptors. International Journal for Parasitology 2012; 42:
269-277 (4 / 3.393)
98. Meissner TB, Liu YJ, Lee KH, Li A, Biswas A, van Eggermond MC, van den Elsen PJ, Kobayashi KS. NLRC5 Cooperates with
the RFX Transcription Factor Complex To Induce MHC Class I Gene Expression. J Immunol 2012; 188: 4951-4958 (4 /
5.788)
99. Melief J, Koning N, Schuurman KG, van de Garde MDB, Smolders J, Hoek RM, van Eijk M, Hamann J, Huitinga I.
Phenotyping primary human microglia: Tight regulation of LPS responsiveness. Glia 2012; 60: 1506-1517 (4 / 4.82)
100. Mi RJ, Song LN, Wang YC, Ding XK, Zeng JW, Lehoux S, Aryal RP, Wang JM, Crew VK, van Die I, Chapman AB, Cummings
RD, Ju TZ. Epigenetic Silencing of the Chaperone Cosmc in Human Leukocytes Expressing Tn Antigen. Journal of
Biological Chemistry 2012; 287: 41523-41533 (4 / 4.773)
101. Mishra AK, Alves JE, Krumbach K, Nigou J, Castro AG, Geurtsen J, Eggeling L, Saraiva M, Besra GS. Differential Arabinan
Capping of Lipoarabinomannan Modulates Innate Immune Responses and Impacts T Helper Cell Differentiation. Journal
of Biological Chemistry 2012; 287: 44173-44183 (4 / 4.773)
102. Miura K, Yang L, Van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic
steatohepatitis through CCR2. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012; 302: G1310G1321 (4 / 3.431)
103. Miyairi I, Ziebarth J, Laxton JD, Wang XF, Van Rooijen N, Williams RW, Lu L, Byrne GI, Cui Y. Host Genetics and Chlamydia
Disease: Prediction and Validation of Disease Severity Mechanisms. PloS one 2012; 7: (4 / 4.092)
104. Muris J, Feilzer AJ, Kleverlaan CJ, Rustemeyer T, van Hoogstraten IMW, Scheper RJ, von Blomberg BME. Palladium-induced
Th2 cytokine responses reflect skin test reactivity. Allergy 2012; 67: 1605-1608 (5 / 6.271)
105. Muris J, Kleverlaan CJ, Rustemeyer T, von Blomberg ME, van Hoogstraten IMW, Feilzer AJ, Scheper RJ. Sodium
tetrachloropalladate for diagnosing palladium sensitization. Contact Dermatitis 2012; 67: 94-100 (4 / 3.509)
106. Muthupalani S, Ge ZM, Feng Y, Rickman B, Mobley M, McCabe A, Van Rooijen N, Fox JG. Systemic Macrophage Depletion
Inhibits Helicobacter bilis-Induced Proinflammatory Cytokine-Mediated Typhlocolitis and Impairs Bacterial Colonization
Dynamics in a BALB/c Rag2(-/-) Mouse Model of Inflammatory Bowel Disease. Infection and Immunity 2012; 80: 43884397 (4 / 4.165)
107. Naessens T, Vander Beken S, van Bogaert P, Van Rooijen N, Lienenklaus S, Weiss S, de Koker S, Grooten J. Innate
Imprinting of Murine Resident Alveolar Macrophages by Allergic Bronchial Inflammation Causes a Switch from
Hypoinflammatory to Hyperinflammatory Reactivity. American Journal of Pathology 2012; 181: 174-184 (5 / 4.89)
108. Nutt SL, Mebius RE. Lymphocyte activation and effector functions. Current Opinion in Immunology 2012; 24: 253-254 (5
/ 9.522)
109. Oostlander AE, Everts V, Schoenmaker T, Bravenboer N, van Vliet SJ, van Bodegraven AA, Lips P, De Vries TJ. T cellmediated increased osteoclast formation from peripheral blood as a mechanism for crohn's disease-associated bone
loss. Journal of Cellular Biochemistry 2012; 113: 260-268 (3 / 2.868)
110. Otten MA, Bakema JE, Tuk CW, Glennie MJ, Tutt AL, Beelen RH, van de Winkel JGJ, van Egmond M. Enhanced Fc alpha RImediated neutrophil migration towards tumour colonies in the presence of endothelial cells. European Journal of
Immunology 2012; 42: 1815-1821 (4 / 5.103)
111. Ouwehand K, Spiekstra SW, Waaijman T, Breetveld M, Scheper RJ, de Gruijl TD, Gibbs S. CCL5 and CCL20 mediate
immigration of Langerhans cells into the epidermis of full thickness human skin equivalents. European Journal of Cell
Biology 2012; 91: 765-773 (2 / 2.806)
112. Overdevest ITMA, Heck M, van der Zwaluw K, Willemsen I, van de Ven J, Verhulst C, Kluytmans JAJW. Comparison of
SpectraCell RA Typing and Multilocus Sequence Typing for Extended-Spectrum-beta-Lactamase-Producing Escherichia
coli. Journal of Clinical Microbiology 2012; 50: 3999-4001 (4 / 4.153)
113. Pascal V, Laffleur B, Debin A, Cuvillier A, van Egmond M, Drocourt D, Imbertie L, Pangault C, Tarte K, Tiraby G, Cogne M.
Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic
effector recruitment on CD20 target cells. Haematologica-The Hematology Journal 2012; 97: 1686-1694 (5 / 6.424)
114. Piao XH, Komazawa-Sakon S, Nishina T, Koike M, Piao JH, Ehlken H, Kurihara H, Hara M, Van Rooijen N, Schutz G,
Ohmuraya M, Uchiyama Y, Yagita H, Okumura K, He YW, Nakano H. c-FLIP Maintains Tissue Homeostasis by Preventing
Apoptosis and Programmed Necrosis. Science Signaling 2012; 5: (4 / 7.499)
115. Qiu HY, KuoLee R, Harris G, Van Rooijen N, Patel GB, Chen WX. Role of Macrophages in Early Host Resistance to
Respiratory Acinetobacter baumannii Infection. PloS one 2012; 7: e40019 (4 / 4.092)
116. Rabinovich GA, van Kooyk Y, Cobb BA. Glycobiology of immune responses. Glycobiology of the Immune Response 2012;
1253: 1-15 (0 / 0)
117. Raghwani J, Thomas XV, Koekkoek SM, Schinkel J, Molenkamp R, van de Laar TJ, Takebe Y, Tanaka Y, Mizokami M,
Rambaut A, Pybus OG. Origin and Evolution of the Unique Hepatitis C Virus Circulating Recombinant Form 2k/1b. Journal
of Virology 2012; 86: 2212-2220 (4 / 5.402)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 31
118. Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, Felder MAR, Yang RK, Kalogriopoulos NA, Koslov DS, Van Rooijen N,
Sondel PM. Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer
Immunology Immunotherapy 2012; 61: 1683-1697 (3 / 3.701)
119. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel MA, Dijkmans BAC, Verweij
CL, Voskuyl AE. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis
patients. Arthritis Research & Therapy 2012; 14: R95 (4 / 4.445)
120. Recher M, Burns SO, de la Fuente MA, Volpi S, Dahlberg C, Walter JE, Moffitt K, Mathew D, Honke N, Lang PA, Patrizi L,
Falet H, Keszei M, Mizui M, Csizmadia E, Candotti F, Nadeau K, Bouma G, Delmonte OM, Frugoni F, Fomin AB, Buchbinder
D, Lundequist EM, Massaad MJ, Tsokos GC, Hartwig J, Manis J, Terhorst C, Geha RS, Snapper S, Lang KS, Malley R,
Westerberg L, Thrasher AJ, Notarangelo LD. B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp)
causes severe abnormalities of the peripheral B-cell compartment in mice. Blood 2012; 119: 2819-2828 (5 / 9.898)
121. Ribeiro-Viana R, Garcia-Vallejo JJ, Collado D, Perez-Inestrosa E, Bloern K, van Kooyk Y, Rojo J. BODIPY-Labeled DC-SIGNTargeting Glycodendrons Efficiently Internalize and Route to Lysosomes in Human Dendritic Cells. Biomacromolecules
2012; 13: 3209-3219 (5 / 5.479)
122. Robbins CS, Chudnovskiy A, Rauch PJ, Figueiredo JL, Iwamoto Y, Gorbatov R, Etzrodt M, Weber GF, Ueno T, Van Rooijen
N, Mulligan-Kehoe MJ, Libby P, Nahrendorf M, Pittet MJ, Weissleder R, Swirski FK. Extramedullary Hematopoiesis
Generates Ly-6C(high) Monocytes That Infiltrate Atherosclerotic Lesions. Circulation 2012; 125: 364-U415 (5 / 14.739)
123. Rosetti F, Tsuboi N, Chen K, Nishi H, Ernandez T, Sethi S, Croce K, Stavrakis G, cocer-Varela J, Gomez-Martin D, Van
Rooijen N, Kyttaris VC, Lichtman AH, Tsokos GC, Mayadas TN. Human Lupus Serum Induces Neutrophil-Mediated Organ
Damage in Mice That Is Enabled by Mac-1 Deficiency. J Immunol 2012; 189: 3714-3723 (4 / 5.788)
124. Rygiel TP, Karnam G, Goverse G, van der Marel APJ, Greuter MJ, van Schaarenburg RA, Visser WF, Brenkman AB, Molenaar
R, Hoek RM, Mebius RE, Meyaard L. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200
expression on the tumor. Oncogene 2012; 31: 2979-2988 (5 / 6.373)
125. Sanders MS, van Well GTJ, Ouburg S, Morre SA, van Furth AM. Toll-like receptor 9 polymorphisms are associated with
severity variables in a cohort of meningococcal meningitis survivors. BMC Infectious Diseases 2012; 12: (3 / 3.118)
126. Schiopu A, Nadig SN, Cotoi OS, Hester J, Van Rooijen N, Wood KJ. Inflammatory Ly-6C(hi) monocytes play an important
role in the development of severe transplant arteriosclerosis in hyperlipidemic recipients. Atherosclerosis 2012; 223:
291-298 (4 / 3.794)
127. Schneiders FL, de Bruin RCG, Santegoets SJAM, Bonneville M, Scotet E, Scheper RJ, Verheul HMW, de Gruijl TD, van der
Vliet HJ. Activated iNKT cells promote V gamma 9V delta 2-T cell anti-tumor effector functions through the production of
TNF-alpha. Clinical Immunology 2012; 142: 194-200 (3 / 4.046)
128. Schuitemaker A, van der Doef TF, Boellaard R, van der Flier WM, Yaqub M, Windhorst AD, Barkhof F, Jonker C, Kloet RW,
Lammertsma AA, Scheltens P, van Berckel BNM. Microglial activation in healthy aging. Neurobiology of Aging 2012; 33:
1067-1072 (5 / 6.189)
129. Schwandt T, Schumak B, Gielen GH, Jungerkes F, Schmidbauer P, Klocke K, Staratschek-Jox A, Van Rooijen N, Kraal G,
Ludwig-Portugall I, Franken L, Wehner S, Kalff JC, Weber O, Kirschning C, Coch C, Kalinke U, Wenzel J, Kurts C, Zawatzky
R, Holzmann B, Layland L, Schultze JL, Burgdorf S, den Haan JMM, Knolle PA, Limmer A. Expression of type I interferon by
splenic macrophages suppresses adaptive immunity during sepsis. EMBO Journal 2012; 31: 201-213 (5 / 9.205)
130. Siemerink MJ, Klaassen I, Vogels IMC, Griffioen AW, Van Noorden CJF, Schlingemann RO. CD34 marks angiogenic tip cells
in human vascular endothelial cell cultures. Angiogenesis 2012; 15: 151-163 (5 / 6.063)
131. Silva SL, Vaz AR, Diogenes MJ, Van Rooijen N, Sebastiao AM, Fernandes A, Silva RFM, Brites D. Neuritic growth
impairment and cell death by unconjugated bilirubin is mediated by NO and glutamate, modulated by microglia, and
prevented by glycoursodeoxycholic acid and interleukin-10. Neuropharmacology 2012; 62: 2398-2408 (5 / 4.814)
132. Simeone R, Bobard A, Lippmann J, Bitter W, Majlessi L, Brosch R, Enninga J. Phagosomal Rupture by Mycobacterium
tuberculosis Results in Toxicity and Host Cell Death. Plos Pathogens 2012; 8: (5 / 9.127)
133. Stoop EJM, Bitter W, van der Sar AM. Tubercle bacilli rely on a type VII army for pathogenicity. Trends in Immunology
2012; 20: 477-484 (5 / 10.403)
134. Stormer M, Arroyo A, Brachert J, Carrero H, Devine D, Epstein JS, Gabriel C, Gelber C, Goodrich R, Hanschmann KM, Heath
DG, Jacobs MR, Keil S, de Korte D, Lambrecht B, Lee CK, Marcelis J, Marschner S, McDonald C, McGuane S, Mckee M,
Muller TH, Muthivhi T, Pettersson A, Radziwon P, Ramirez-Arcos S, Reesink HW, Rojo J, Rood I, Schmidt M, Schneider CK,
Seifried E, Sicker U, Wendel S, Wood EM, Yomtovian RA, Montag T. Establishment of the first International Repository for
Transfusion-Relevant Bacteria Reference Strains: ISBT Working Party Transfusion-Transmitted Infectious Diseases (WPTTID), Subgroup on Bacteria. Vox Sanguinis 2012; 102: 22-31 (3 / 2.856)
135. Sundara YT, Jordanova ES, Hernowo BS, Gandamihardja S, Fleuren GJ. Decidual infiltration of FoxP3(+) regulatory T cells,
CD3(+) T cells, CD56(+) decidual natural killer cells and Ki-67 trophoblast cells in hydatidiform mole compared to normal
and ectopic pregnancies. Molecular Medicine Reports 2012; 5: 275-281 (1 / 0.418)
136. Suwannalai P, van de Stadt L, Radner H, Steiner G, El-Gabalawy H, Jol-van der Zijde C, van Tol M, van Schaardenburg D,
Huizinga T, Toes R, Trouw L. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis
and Rheumatism 2012; 64: 1323-1328 (4 / 7.866)
137. Tack GJ, van Wanrooij RLJ, Langerak AW, Tjon JML, von Blomberg BME, Heideman DAM, van Bergen J, Koning F, Bouma G,
Mulder CJJ, Schreurs MWJ. Origin and immunophenotype of aberrant IEL in RCDII patients. Molecular Immunology 2012;
50: 262-270 (3 / 2.897)
138. Tefsen B, Lagendijk EL, Park J, Akeroyd M, Schachtschabel D, Winkler R, van Die I, Ram AFJ. Fungal alphaarabinofuranosidases of glycosyl hydrolase families 51 and 54 show a dual arabinofuranosyl- and galactofuranosylhydrolyzing activity. Biological Chemistry 2012; 393: 767-775 (3 / 2.965)
139. Tefsen B, Ram AFJ, van Die I, Routier FH. Galactofuranose in eukaryotes: aspects of biosynthesis and functional impact.
Glycobiology 2012; 22: 456-469 (3 / 3.58)
140. Teruel M, Simeon CP, Broen J, Vonk MC, Carreira P, Camps MT, Garcia-Portales R, gado-Frias E, Gallego M, Espinosa G,
Beretta L, Airo P, Lunardi C, Riemekasten G, Witte T, Krieg T, Kreuter A, Distler JHW, Hunzelmann N, Koeleman BP,
Voskuyl AE, Schuerwegh AJ, Gonzalez-Gay MA, Radstake TRDJ, Martin J. Analysis of the association between CD40 and
CD40 ligand polymorphisms and systemic sclerosis. Arthritis Research & Therapy 2012; 14: R154 (4 / 4.445)
141. Teunis P, van Eijkeren J, Ang C, van Duynhoven Y, Simonsen J, Strid M, van Pelt W. Biomarker dynamics: estimating
infection rates from serological data. Statistics in Medicine 2012; 31: 2240-2248 (4 / 1.877)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 32
142. Theocharides APA, Jin LQ, Cheng PY, Prasolava TK, Malko AV, Ho JM, Poeppl AG, Van Rooijen N, Minden MD, Danska JS,
Dick J, Wang JCY. Disruption of SIRP alpha signaling in macrophages eliminates human acute myeloid leukemia stem cells
in xenografts. Journal of Experimental Medicine 2012; 209: 1883-1899 (5 / 13.853)
143. Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, Meager A, Elia A, Middeldorp JM, Clemens M,
Farrell PJ, Giovannoni G, Meier UC. Association of innate immune activation with latent Epstein-Barr virus in active MS
lesions. Neurology 2012; 78: 15-23 (5 / 8.312)
144. Unger WWJ, Pearson T, Abreu JRF, Laban S, van der Slik AR, Mulder-van der Kracht S, Kester MGD, Serreze DV, Shultz LD,
Griffioen M, Drijfhout JW, Greiner DL, Roep BO. Islet-Specific CTL Cloned from a Type 1 Diabetes Patient Cause Beta-Cell
Destruction after Engraftment into HLAA2 Transgenic NOD/SCID/IL2RG Null Mice. PloS one 2012; 7: (4 / 4.092)
145. Unger WWJ, van Beelen AJ, Bruijns SC, Joshi M, Fehres CM, van Bloois L, Verstege MI, Ambrosini M, Kalay H, Nazmi K,
Bolscher JG, Hooijberg E, de Gruijl TD, Storm G, van Kooyk Y. Glycan-modified liposomes boost CD4(+) and CD8(+) T-cell
responses by targeting DC-SIGN on dendritic cells. Journal of Controlled Release 2012; 160: 88-95 (5 / 5.732)
146. van Beek EM, Zarate JA, van Bruggen R, Schornagel K, Tool ATJ, Matozaki T, Kraal G, Roos D, van den Berg TK. SIRPalpha
controls the activity of the phagocyte NADPH oxidase by restricting the expression of gp91(phox). Cell Reports 2012; 2:
748-755 (0 / 0)
147. van Cleef BA, van Rijen MML, Ferket M, Kluytmans JA. Self-sampling is appropriate for detection of Staphylococcus
aureus: a validation study. Antimicrob Resist Infect Control 2012; 1: 34 (0 / 0)
148. van Cleef BAGL, Kluytmans JAJW, van Benthem BHB, Haenen A, Monen J, niels-Haardt I, Jurke A, Friedrich AW. Cross
Border Comparison of MRSA Bacteraemia between The Netherlands and North Rhine-Westphalia (Germany): A CrossSectional Study. PloS one 2012; 7: (4 / 4.092)
149. van de Ven R, Lindenberg JJ, Reurs AW, Scheper RJ, Scheffer GL, de Gruijl TD. Preferential Langerhans cell differentiation
from CD34(+) precursors upon introduction of ABCG2 (BCRP). Immunology and Cell Biology 2012; 90: 206-215 (3 /
3.661)
150. van de Ven R, Reurs AW, Wijnands PGJT, van Wetering S, Kruisbeek AM, Hooijberg E, Scheffer GL, Scheper RJ, de Gruijl
TD. Exposure of CD34(+) precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation:
implications for cancer immunotherapy. Cancer Immunology Immunotherapy 2012; 61: 181-191 (3 / 3.701)
151. van den Broek LJ, Niessen FB, Scheper RJ, Gibbs S. Development, validation and testing of a human tissue engineered
hypertrophic scar model. Altex 2012; 29: 389-402 (0 / 0)
152. van den Hout MFCM, Koster BD, Sluijter BJR, van Leeuwen PAM, Meijer S, van den Tol MP, van den Eertwegh AJM, Scheper
RJ, van de Ven R, de Gruijl TD. Response Breslow thickness and excision interval affect the activation state of Langerhans
cells in melanoma sentinel lymph nodes. Blood 2012; 119: 4809-4810 (5 / 9.898)
153. van der Does AM, Hensbergen PJ, Bogaards SJ, Cansoy M, Deelder AM, van Leeuwen HC, Drijfhout JW, van Dissel JT,
Nibbering PH. The Human Lactoferrin-Derived Peptide hLF1-11 Exerts Immunomodulatory Effects by Specific Inhibition of
Myeloperoxidase Activity. J Immunol 2012; 188: 5012-5019 (4 / 5.788)
154. van der Does AM, Joosten SA, Vroomans E, Bogaards SJP, van Meijgaarden KE, Ottenhoff THM, van Dissel JT, Nibbering
PH. The Antimicrobial Peptide hLF1-11 Drives Monocyte-Dendritic Cell Differentiation toward Dendritic Cells That
Promote Antifungal Responses and Enhance Th17 Polarization. Journal of Innate Immunity 2012; 4: 284-292 (4 / 4.209)
155. van der Helm JJ, Sabajo LOA, Grunberg AW, Morre SA, Speksnijder AGCL, de Vries HJC. Point-of-Care Test for Detection of
Urogenital Chlamydia in Women Shows Low Sensitivity. A Performance Evaluation Study in Two Clinics in Suriname. PloS
one 2012; 7: (4 / 4.092)
156. van der Kolk JH, van Putten LA, Mulder CJ, Grinwis GCM, Reijm M, Butler CM, von Blomberg BME. Gluten-dependent
antibodies in horses with inflammatory small bowel disease (ISBD). Veterinary Quarterly 2012; 32: 3-11 (3 / 1.667)
157. van der Laan AM, Schirmer SH, de Vries MR, Koning JJ, Volger OL, Fledderus JO, Bastiaansen AJNM, Hollander MR, Baggen
JM, Koch KT, Baan J, Henriques JP, van der Schaaf RJ, Vis MM, Mebius RE, Kraan TCV, Quax PH, Piek JJ, Horrevoets AJ, van
Royen N. Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis.
European Heart Journal 2012; 33: 1076-1084 (5 / 10.478)
158. van der Pouw Kraan T, Baggen JM, van Bodegraven AA, Mulder CJJ, Zwiers A, Geerts D, Kraal G, Horrevoets AJG, Bouma G.
Defective IL-1A expression in patients with Crohn's disease is related to attenuated MAP3K4 signaling. Human
Immunology 2012; 73: 912-919 (2 / 2.837)
159. van der Steen LP, Bakema JE, Sesarman A, Florea F, Tuk CW, Kirtschig G, Hage JJ, Sitaru C, van Egmond M. Blocking Fc
alpha Receptor I on Granulocytes Prevents Tissue Damage Induced by IgA Autoantibodies. J Immunol 2012; 189: 15941601 (4 / 5.788)
160. van der Woude AD, Sarkar D, Bhatt A, Sparrius M, Raadsen SA, Boon L, Geurtsen J, van der Sar AM, Luirink J, Houben ENG,
Besra GS, Bitter W. Unexpected Link between Lipooligosaccharide Biosynthesis and Surface Protein Release in
Mycobacterium marinum. Journal of Biological Chemistry 2012; 287: 20417-20429 (4 / 4.773)
161. van der Zouwen B, Kruisselbrink AB, Jordanova ES, Rutten CE, Borne PA, Falkenburg J, Jedema I. Alloreactive Effector T
Cells Require the Local Formation of a Proinflammatory Environment to Allow Crosstalk and High Avidity Interaction with
Nonhematopoietic Tissues to Induce GVHD Reactivity. Biology of Blood and Marrow Transplantation 2012; 18: 13531367 (4 / 3.873)
162. van Geenen EM, Sachar DB. Infliximab in Crohn's Disease-associated Toxic Megacolon. Journal of Clinical
Gastroenterology 2012; 46: 321-323 (3 / 3.159)
163. van Lent PLEM, Blom AB, Schelbergen RFP, Sloetjes A, Lafeber FPJG, Lems WF, Cats H, Vogl T, Roth J, van den Berg WB.
Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during
mouse and human osteoarthritis. Arthritis and Rheumatism 2012; 64: 1466-1476 (4 / 7.866)
164. van Luijn MM, Chamuleau MED, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM. Tumor immune escape in acute
myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation..
Oncoimmunology 2012; 1: 211-213 (0 / 0)
165. van Luijn MM, de Loosdrecht AAV, Lampen MH, van Veelen PA, Zevenbergen A, Kester MGD, De Ru AH, Ossenkoppele GJ,
van Hall T, van Ham SM. Promiscuous Binding of Invariant Chain-Derived CLIP Peptide to Distinct HLA-I Molecules
Revealed in Leukemic Cells. PloS one 2012; 7: (4 / 4.092)
166. van Wanrooij RLJ, Zwiers A, Kraal G, Bouma G. Genetic variations in interleukin-12 related genes in immune-mediated
diseases. Journal of Autoimmunity 2012; 39: 359-368 (5 / 7.368)
167. van Well GTJ, Sanders MS, Ouburg S, van Furth AM, Morre SA. Polymorphisms in Toll-Like Receptors 2, 4, and 9 Are
Highly Associated with Hearing Loss in Survivors of Bacterial Meningitis. PloS one 2012; 7: (4 / 4.092)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 33
168. Vanderkelen L, van der Sar A, Goddeeris BM, Michiels CW. Are bacterial lysozyme inhibitors important in bacteria-host
interactions?. Communications in Agricultural and Applied Biological Sciences 2012; 77: 61-65 (0 / 0)
169. Veenemans J, Mouton J, Kluytmans J, Donnely R, Verhulst C, van Keulen P. Effect of Manganese in Test Media on In Vitro
Susceptibility of Enterobacteriaceae and Acinetobacter baumannii to Tigecycline. Journal of Clinical Microbiology 2012;
50: 3077-3079 (4 / 4.153)
170. Verheul RJ, Hagenaars N, van Es T, van Gaal EVB, De Jong PHJL, Bruijns S, Mastrobattista E, Slutter B, Que I, Heldens JGM,
van den Bosch H, Glansbeek HL, Hennink WE, Jiskoot W. A step-by-step approach to study the influence of N-acetylation
on the adjuvanticity of N,N,N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine. European
Journal of Pharmaceutical Sciences 2012; 45: 467-474 (3 / 3.212)
171. Verkade E, Bergmans AMC, Budding AE, van Belkum A, Savelkoul P, Buiting AG, Kluytmans J. Recent Emergence of
Staphylococcus aureus Clonal Complex 398 in Human Blood Cultures. PloS one 2012; 7: (4 / 4.092)
172. Verweij CL. Clinical relevance of the type I interferon signature in multiple sclerosis. Pharmacogenomics 2012; 13: 18831884 (4 / 3.974)
173. Verweij SP, Ouburg S, de Vries H, Morre SA, van Ginkel CJW, Bos H, Sebens FW. The first case record of a female patient
with bubonic lymphogranuloma venereum (LGV), serovariant L2b. Sexually Transmitted Infections 2012; 88: 346-347 (3 /
2.854)
174. Vinet J, van Weering HRJ, Heinrich A, Kalin RE, Wegner A, Brouwer N, Heppner FL, Van Rooijen N, Boddeke HWGM, Biber
K. Neuroprotective function for ramified microglia in hippocampal excitotoxicity. Journal of Neuroinflammation 2012; 9:
(3 / 3.827)
175. von Moltke J, Trinidad NJ, Moayeri M, Kintzer AF, Wang SB, Van Rooijen N, Brown CR, Krantz BA, Leppla SH, Gronert K,
Vance RE. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 2012; 490: 107-111 (5 /
36.28)
176. Vriend HJ, Op de Coul ELM, van de Laar TJW, Urbanus AT, van der Klis FRM, Boot HJ. Hepatitis C virus seroprevalence in
The Netherlands. European Journal of Public Health 2012; 22: 819-821 (4 / 2.728)
177. Weber S, Tian HJ, Van Rooijen N, Pirofski LA. A Serotype 3 Pneumococcal Capsular Polysaccharide-Specific Monoclonal
Antibody Requires Fc gamma Receptor III and Macrophages To Mediate Protection against Pneumococcal Pneumonia in
Mice. Infection and Immunity 2012; 80: 1314-1322 (4 / 4.165)
178. Weerdenburg EM, Abdallah AM, Mitra S, de Punder K, van der Wel NN, Bird S, Appelmelk BJ, Bitter W, van der Sar AM. ESX5-deficient Mycobacterium marinum is hypervirulent in adult zebrafish. Cellular Microbiology 2012; 14: 728-739 (4 /
5.458)
179. Weisser SB, Van Rooijen N, Sly LM. Depletion and reconstitution of macrophages in mice. Journal of Visualized
Experiments 2012; 1: (0 / 0)
180. Wohlleber D, Kashkar H, Gartner K, Frings MK, Odenthal M, Hegenbarth S, Borner C, Arnold B, Hammerling G, Nieswandt
B, Van Rooijen N, Limmer A, Cederbrant K, Heikenwalder M, Pasparakis M, Protzer U, Dienes HP, Kurts C, Kronke M,
Knolle PA. TNF-Induced Target Cell Killing by CTL Activated through Cross-Presentation. Cell Reports 2012; 2: 478-487 (0
/ 0)
181. Xiang S, Dong HH, Liang HF, He SQ, Zhang W, Li CH, Zhang BX, Zhang BH, Jing K, Tomlinson S, Van Rooijen N, Jiang L,
Cianflone K, Chen XP. Oval Cell Response Is Attenuated by Depletion of Liver Resident Macrophages in the 2-AAF/Partial
Hepatectomy Rat. PloS one 2012; 7: (4 / 4.092)
182. Zhou D, Chen YT, Chen FL, Gallup M, Vijmasi T, Bahrami AF, Noble LB, Van Rooijen N, McNamara NA. Critical Involvement
of Macrophage Infiltration in the Development of Sjogren's Syndrome-Associated Dry Eye. American Journal of Pathology
2012; 181: 753-760 (5 / 4.89)
183. Zwiers A, Kraal L, Kraan TC, Wurdinger T, Bouma G, Kraal G. Cutting Edge: A Variant of the IL-23R Gene Associated with
Inflammatory Bowel Disease Induces Loss of MicroRNA Regulation and Enhanced Protein Production. J Immunol 2012;
188: 1573-1577 (4 / 5.788)
Scientific publications (books, book chapters, proceedings)
1.
Hoentjen F, Sakuraba A, Hanauer SB. Biologic Therapy of Crohn's Disease: Infliximab; in Baumgart DC, (ed): Crohn's
Disease and Ulcerative Colitis. Springer. 2012: 413-432.
Professional publications
1.
2.
Kraag DE, Serrarens J, Rustemeyer T. Een nieuwe bedreiging: allergie voor drakenfruit?. Nederlands Tijdschrift voor
Allergie en Astma 201212: 180-183
van Wanrooij RLJ, Neefjes-Borst EA, von Blomberg BM, Mulder CJJ, Bouma G. Als coeliakie niet beter wordt. Nederlands
Tijdschrift voor Geneeskunde 2012156: A4843
Dissertations
1.
2.
3.
4.
5.
6.
7.
Bögels M. Macrophages as therapeutic target in colon carcinoma. Vrije Universiteit Amsterdam, 11/9/2012. (Co-)
promotores: R.H.J. Beelen, H.J. Bonjer, M. van Egmond (cat A)
Daleke MH. Tail(or)-made protein secretion in pathogenic mycabacteria. Vrije Universiteit Amsterdam, 11/22/2012. (Co-)
promotores: W. Bitter, C.M.J.E. Vandenbroucke-Grauls, J. Luirink (cat A)
Gül N. Surgery-induced liver metastasis: how it begins and how to end it. Vrije Universiteit Amsterdam, 9/27/2012. (Co-)
promotores: R.H.J. Beelen, M. van Egmond (cat A)
Kroeze K. Towards Therapeutic control in cutaneous wound healing. Vrije Universiteit Amsterdam, 31/05/2012. (Co-)
promotores: S. Gibbs, R.J. Scheper (cat. A)
Streng-Ouwehand I. Sweet modulation of the immune respons. Vrije Universiteit Amsterdam, 2/3/2012. (Co-)promotores:
Y. Kooyk, W.W.J. Unger (cat A)
van Geenen EJM. Clinical and Pathological aspects of Pancreatitis. Vrije Universiteit Amsterdam, 12/4/2012. (Co-)
promotores: C.J.J. Mulder, M.J. Bruno, D.L. van der Peet (cat B)
van Well GThJ. Innate immune responses in (myco)bacterial meningitis. Vrije Universiteit Amsterdam, 6/18/2012. (Co-)
promotores: A.M. van Furth, J.J. Roord, S.A. Morré (cat A)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 34
Program 3: Disease profiling
Scientific papers refereed
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Al Hussainy R, Verbeek J, van der Born D, Molthoff C, Booij J, Herscheid JDM. Synthesis, biodistribution and PET studies in
rats of F-18-Labeled bridgehead fluoromethyl analogues of WAY-100635. Nuclear Medicine and Biology 2012; 39: 10681076 (4 / 3.023)
Alexiusdottir KK, Moller PH, Snaebjornsson P, Jonasson L, Olafsdottir EJ, Bjornsson ES, Tryggvadottir L, Jonasson JG.
Association of symptoms of colon cancer patients with tumor location and TNM tumor stage. Scandinavian Journal of
Gastroenterology 2012; 47: 795-801 (2 / 2.019)
Asselin MC, O'Connor JPB, Boellaard R, Thacker NA, Jackson A. Quantifying heterogeneity in human tumours using MRI
and PET. European Journal of Cancer 2012; 48: 447-455 (4 / 5.536)
Atak ZK, De Keersmaecker K, Gianfelici V, Geerdens E, Vandepoel R, Pauwels D, Porcu M, Lahortiga I, Brys V, Dirks WG,
Quentmeier H, Cloos J, Cuppens H, Uyttebroeck A, Vandenberghe P, Cools J, Aerts S. High Accuracy Mutation Detection
in Leukemia on a Selected Panel of Cancer Genes. PloS one 2012; 7: (4 / 4.092)
Baan B, Dihal AA, Hoff E, Bos CL, Voorneveld PW, Koelink PJ, Wildenberg ME, Muncan V, Heijmans J, Verspaget HW, Richel
DJ, Hardwick JCH, Hommes DW, Peppelenbosch MP, van den Brink GR. 5-aminosalicylic acid inhibits cell cycle progression
in a phospholipase D dependent manner in colorectal cancer. Gut 2012; 61: 1708-1715 (5 / 10.111)
Beekman R, Valkhof MG, Sanders MA, van Strien PMH, Haanstra JR, Broeders L, Geertsma-Kleinekoort WM, Veerman AJP,
Valk PJM, Verhaak RG, Lowenberg B, Touw IP. Sequential gain of mutations in severe congenital neutropenia progressing
to acute myeloid leukemia. Blood 2012; 119: 5071-5077 (5 / 9.898)
Belt EJT, Brosens RPM, Delis-van Diemen PM, Bril H, Tijssen M, van Essen DF, Heymans MW, Belien JAM, Stockmann HBAC,
Meijer S, Meijer GA. Cell Cycle Proteins Predict Recurrence in Stage II and III Colon Cancer. Annals of Surgical Oncology
2012; : 682-692 (5 / 4.166)
Belt EJT, Stockmann HBAC, Abis GSA, de Boer JM, de Lange-de Klerk ESM, van Egmond M, Meijer GA, Oosterling SJ. PeriOperative Bowel Perforation in Early Stage Colon Cancer is Associated with an Adverse Oncological Outcome. Journal of
Gastrointestinal Surgery 2012; 16: 2260-2266 (4 / 2.826)
Belt EJT, Velde EAT, Krijgsman O, Brosens RPM, Tijssen M, van Essen HF, Stockmann HBAC, Bril H, Carvalho B, Ylstra B,
Bonjer HJ, Meijer GA. High Lymph Node Yield is Related to Microsatellite Instability in Colon Cancer. Annals of Surgical
Oncology 2012; 19: 1222-1230 (5 / 4.166)
Bernet L, Benaclocha MM, Castera C, Munoz RC, Sevilla F, Alba J, Barranco JD, Cordoba A, Garcia-Caballero T, Hardisson
D, Hernandez JMD, Lazaro JM, Polo L, Riu F, Rezola R, Rojo F, Ruiz I, Hernandiz A, de las Heras JMD, Coupe VM. mRNA In
Situ Hybridization (HistoSonda): A New Diagnostic Tool for HER2-Status in Breast Cancer-A Multicentric Spanish Study.
Diagnostic Molecular Pathology 2012; 21: 84-92 (3 / 2.257)
Bijnsdorp IV, Rozendaal L, van Moorselaar RJA, Geldof AA. A predictive role for noncancerous prostate cells: low
connexin-26 expression in radical prostatectomy tissues predicts metastasis. Br J Cancer 2012; 107: 1963-1968 (4 /
5.042)
Bipat S, Niekel MC, Comans EFI, Nio CY, Bemelman WA, Verhoef C, Stoker J. Imaging modalities for the staging of
patients with colorectal cancer. Netherlands Journal of Medicine 2012; 70: 26-34 (4 / 2.072)
Boellaard R. Mutatis Mutandis: Harmonize the Standard!. Journal of Nuclear Medicine 2012; 53: 1-3 (5 / 6.381)
Bosch LJW, Mongera S, Terhaar Sive Droste JS, Oort FA, van Turenhout ST, Penning MT, Louwagie J, Mulder CJJ, van
Engeland M, Carvalho B, Meijer GA. Analytical sensitivity and stability of DNA methylation testing in stool samples for
colorectal cancer detection. Cell Oncol 2012; 35: 309-315 (4 / 3.105)
Bosch LJW, Oort FA, Neerincx M, Khalid-de Bakker CAJ, Droste JSTS, Melotte V, Jonkers DMAE, Masclee AAM, Mongera S,
Grooteclaes M, Louwagie J, van Criekinge W, Coupe VMH, Mulder CJ, van Engeland M, Carvalho B, Meijer GA. DNA
Methylation of Phosphatase and Actin Regulator 3 Detects Colorectal Cancer in Stool and Complements FIT. Cancer
Prevention Research 2012; 5: 464-472 (4 / 4.908)
Brouns EREA, Bloemena E, Belien JAM, Broeckaert MAM, Aartman IHA, van der Waal I. DNA ploidy measurement in oral
leukoplakia: Different results between flow and image cytometry. Oral Oncology 2012; 48: 636-640 (5 / 2.857)
Bruijnen STG, van der Weijden MAC, Klein JP, Hoekstra OS, Boellaard R, van Denderen JC, Dijkmans BAC, Voskuyl AE, van
der Horst-Bruinsma I, van der Laken CJ. Bone formation rather than inflammation reflects Ankylosing Spondylitis activity
on PET-CT: a pilot study. Arthritis Research & Therapy 2012; 14: (4 / 4.445)
Buffart TE, Carvalho B, van Grieken NCT, van Wieringen AN, Tijssen M, Kranenbarg EMK, Verheul HMW, Grabsch HI, Ylstra
B, van de Velde CJH, Meijer GA. Losses of Chromosome 5q and 14q Are Associated with Favorable Clinical Outcome of
Patients with Gastric Cancer. Oncologist 2012; 17: 653-662 (3 / 3.91)
Buis DR, van der Valk P, de Witt Hamer PC. Subcutaneous tumor seeding after biopsy in gliomatosis cerebri. Journal of
Neuro-Oncology 2012; 106: 431-435 (3 / 3.214)
Bultink IEM. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care & Research 2012; 64: 2-8 (4 /
4.851)
Busard MPH, Mijatovic V, L³chinger AM, Bleeker MCG, van den Pieters-van den Bos, Schats R, Van Kuijk C, Hompes PGA,
van Waesberghe JHTM. MR imaging of bladder endometriosis and its relationship with the anterior uterine wall:
Experience in a tertiary referral centre. European Journal of Radiology 2012; 81: 2106-2111 (3 / 2.606)
Busard MPH, Pieters-van den Bos I, Mijatovic V, Van Kuijk C, Bleeker MCG, van Waesberghe JHTM. Evaluation of MR
diffusion-weighted imaging in differentiating endometriosis infiltrating the bowel from colorectal carcinoma. European
Journal of Radiology 2012; 81: 1376-1380 (3 / 2.606)
Busard MPH, van der Houwen LEE, Bleeker MCG, van den Bos ICP, Cuesta MA, Van Kuijk C, Mijatovic V, Hompes PGA, van
Waesberghe JHTM. Deep infiltrating endometriosis of the bowel: MR imaging as a method to predict muscular invasion.
Abdominal Imaging 2012; 37: 549-557 (3 / 1.725)
Cardillo G, Rea F, Lucchi M, Paul MA, Margaritora S, Carleo F, Marulli G, Mussi A, Granone P, Graziano P. Primary
Neuroendocrine Tumors of the Thymus: A Multicenter Experience of 35 Patients. Annals of Thoracic Surgery 2012; 94:
241-246 (5 / 3.741)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 35
25. Cheebsumon P, Boellaard R, de Ruysscher D, van Elmpt W, van Baardwijk A, Yaqub M, Hoekstra OS, Comans EF,
Lammertsma AA, van Velden FH. Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods
compared to pathology. Eur J Nucl Med Mol Imaging 2012; 2: 56 (5 / 4.991)
26. Cibula D, bu-Rustum NR, Dusek L, Slama J, Zikan M, Zaal A, Sevcik L, Kenter G, Querleu D, Jach R, Bats AS, Dyduch G,
Graf P, Klat J, Meijer CJLM, Mery E, Verheijen RHM, Zweemer RP. Bilateral ultrastaging of sentinel lymph node in cervical
cancer: Lowering the false-negative rate and improving the detection of micrometastasis. Gynecol Oncol 2012; 127: 462466 (5 / 3.888)
27. Cibula D, bu-Rustum NR, Dusek L, Zikan M, Zaal A, Sevcik L, Kenter GG, Querleu D, Jach R, Bats AS, Dyduch G, Graf P,
Klat J, Lacheta J, Meijer CJLM, Mery E, Verheijen R, Zweemer RP. Prognostic significance of low volume sentinel lymph
node disease in early-stage cervical cancer. Gynecol Oncol 2012; 124: 496-501 (5 / 3.888)
28. Coenen EA, Driessen EMC, Zwaan CM, Stary J, Baruchel A, de Haas V, De Bont ESJM, Reinhardt D, Kaspers GJL, rentsenPeters STCJ, Meyer C, Marschalek R, Pieters R, Stam RW, van den Heuvel-Eibrink M. CBL mutations do not frequently occur
in paediatric acute myeloid leukaemia. British Journal of Haematology 2012; 159: 577-584 (4 / 4.941)
29. Collin P, Rondonotti E, Lundin KEA, Spada C, Keuchel M, Kaukinen K, Franchis RDE, Jacobs MAJM, Villa F, Mulder CJJ.
Video capsule endoscopy in celiac disease: Current clinical practice. Journal of Digestive Diseases 2012; 13: 94-99 (2 /
1.589)
30. Cornel MC, Gille JJP, Loeber JG, Langen AMMV, nkert-Roelse J, Bolhuis PA. Improving test properties for neonatal cystic
fibrosis screening in the Netherlands before the nationwide start by May 1st 2011. Journal of Inherited Metabolic Disease
2012; 35: 635-640 (3 / 3.577)
31. Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, Maertens J, Beverloo H, Kooy MvM, Wijermans
PW, Biemond BJ, Vellenga E, Verdonck LF, Ossenkoppele GJ, Lowenberg B. Comparative Analysis of the Value of
Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other
Cytogenetic Risk Categories. J Clin Oncol 2012; 30: 2140-2146 (5 / 18.372)
32. de Cuba EMV, Kwakman R, van Egmond M, Bosch LJW, Bonjer HJ, Meijer GA, te Velde EA. Understanding molecular
mechanisms in peritoneal dissemination of colorectal cancer. Virchows Archiv 2012; 461: 231-243 (3 / 2.491)
33. de Goede B, Klitsie PJ, Lange JF, Metselaar HJ, Kazemier G. Morbidity and mortality related to non-hepatic surgery in
patients with liver cirrhosis; A systematic review. Best Pract Res Clin Gastroenterol 2012; 26: 47-59 (3 / 2.456)
34. de Graaf P, Goricke S, Rodjan F, Galluzzi P, Maeder P, Castelijns JA, Brisse HJ. Guidelines for imaging retinoblastoma:
imaging principles and MRI standardization. Pediatric Radiology 2012; 42: 2-14 (3 / 1.674)
35. de Graaf P, Pouwels PJW, Rodjan F, Moll AC, Imhof SM, Knol DL, Sanchez E, van der Valk P, Castelijns JA. Single-Shot
Turbo Spin-Echo Diffusion-Weighted Imaging for Retinoblastoma: Initial Experience. American Journal of Neuroradiology
2012; 33: 110-118 (4 / 2.928)
36. de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, Boers M, Smit EF, Stroobants S, Weber
WA, Hoekstra OS. Repeatability of F-18-FDG Uptake Measurements in Tumors: A Metaanalysis. Journal of Nuclear
Medicine 2012; 53: 701-708 (5 / 6.381)
37. den Burger JCG, Wilhelm AJ, Chahbouni A, Vos RM, Sinjewel A, Swart EL. Analysis of cyclosporin A, tacrolimus, sirolimus,
and everolimus in dried blood spot samples using liquid chromatography tandem mass spectrometry. Analytical and
Bioanalytical Chemistry 2012; 404: 1803-1811 (4 / 3.778)
38. Dikken JL, Coit DG, Klimstra DS, Rizk NP, van Grieken N, Ilson D, Tang LH. Prospective impact of tumor grade assessment
in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma Relevance of the Seventh
Edition American Joint Committee on Cancer Staging Manual Revision. Cancer 2012; 118: 349-357 (4 / 4.771)
39. Dikken JL, van Grieken NCT, Krijnen P, Gonen M, Tang LH, Cats A, Verheij M, Brennan MF, van de Velde CJH, Coit DG.
Preoperative chemotherapy does not influence the number of evaluable lymph nodes in resected gastric cancer.
European Journal of Surgical Oncology 2012; 38: 319-325 (0 / 0)
40. Flach GB, Broglie MA, van Schie A, Bloemena E, Leemans CR, de Bree R, Stoeckli SJ. Sentinel node biopsy for oral and
oropharyngeal squamous cell carcinoma in the previously treated neck. Oral Oncology 2012; 48: 85-89 (5 / 2.857)
41. Frampton AE, Krell J, Giovannetti E, Krell D, Stebbing J, Castellano L, Jiao LR. Defining a prognostic molecular profile for
ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Rev Anticancer Ther 2012; 12:
1275-1278 (3 / 2.652)
42. Gent YYJ, Voskuyl AE, Kloet RW, van Schaardenburg D, Hoekstra OS, Dijkmans BAC, Lammertsma AA, van der Laken CJ.
Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: Findings of a
prospective pilot study. Arthritis and Rheumatism 2012; 64: 62-66 (4 / 7.866)
43. Groenendijk MR, Thunnissen E, Ylstra B, van de Wiel MA, Eijk PP, Paul MA, Smit EF, Postmus PE. An 82-Year-Old Woman
With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?. Journal of Thoracic Oncology 2012; 7: E3-E5 (4 /
3.661)
44. Haan JC, Buffart TE, Eijk PP, van de Wiel MA, van Wieringen WN, Howdle PD, Mulder CJJ, van de Velde CJ, Quirke P,
Nagtegaal ID, van Grieken NCT, Grabsch H, Meijer GA, Ylstra B. Small bowel adenocarcinoma copy number profiles are
more closely related to colorectal than to gastric cancers. Annals of Oncology 2012; 23: 367-U344 (5 / 6.425)
45. Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MCM, Hartmann C, von Deimling A, Martinet D, Schmutz NB,
Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P.
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically
heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta
Neuropathologica 2012; 123: 841-852 (5 / 9.32)
46. Heijnsdijk EAM, Warner E, Gilbert FJ, Tilanus-Linthorst MMA, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay
EA, Warren RML, Hill KA, Hoogerbrugge N, Wasser MNJM, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJT, Klijn JGM,
Plewes DB, Leach MO, de Koning HJ. Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation
Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. Cancer Epidemiology Biomarkers
& Prevention 2012; 21: 1458-1468 (5 / 4.123)
47. Hertog D, Bloemena E, Aartman IHA, van der Waal I. Histopathology of ameloblastoma of the jaws; some critical
observations based on a 40 years single institution experience. Medicina Oral, Patologia Oral y Cirugia Bucal 2012; 17:
e76-e82 (2 / 1.13)
48. Heuveling DA, Flach GB, van Schie A, van Weert S, Karagozoglu KH, Bloemena E, Leemans CR, de Bree R. Visualization of
the sentinel node in early-stage oral cancer: limited value of late static lymphoscintigraphy. Nuclear Medicine
Communications 2012; 33: 1065-1069 (2 / 1.404)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 36
49. Heuveling DA, Karagozoglu KH, van Schie A, van Weert S, van Lingen A, de Bree R. Sentinel node biopsy using 3D
lymphatic mapping by freehand SPECT in early stage oral cancer: a new technique. Clinical Otolaryngology 2012; 37: 8990 (4 / 2.393)
50. Heuveling DA, Visser GWM, de Groot M, de Boer JF, Baclayon M, Roos WH, Wuite GJL, Leemans CR, de Bree R, van Dongen
GAMS. Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel
lymph node. European Journal of Nuclear Medicine and Molecular Imaging 2012; 39: 1161-1168 (5 / 4.991)
51. Hew MN, Zonneveld R, Kummerlin IP, Opondo D, de la Rosette JJ, Laguna M. Age and Gender Related Differences in Renal
Cell Carcinoma in a European Cohort. Journal of Urology 2012; 188: 33-38 (4 / 3.746)
52. Hoefnagel LDC, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA,
Nagtegaal ID, Oudejans J, van der Valk P, van Gils CH, van der Wall E, van Diest PJ. Prognostic value of estrogen receptor
alpha and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012; 118: 4929-4935 (4 /
4.771)
53. Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, Boldt RG, Palma DA. Radiographic changes after
lung stereotactic ablative radiotherapy (SABR) - Can we distinguish recurrence from fibrosis? A systematic review of the
literature. Radiotherapy and Oncology 2012; 102: 335-342 (1 / 0.912)
54. Huijsmans CJJ, Poodt J, Damen J, van der Linden JC, Savelkoul PHM, Pruijt JFM, Hilbink M, Hermans MHA. Single
Nucleotide Polymorphism (SNP)-Based Loss of Heterozygosity (LOH) Testing by Real Time PCR in Patients Suspect of
Myeloproliferative Disease. PloS one 2012; 7: (4 / 4.092)
55. Idema AJS, Hoffmann AL, Boogaarts HD, Troost EGC, Wesseling P, Heerschap A, van der Graaf WTA, Grotenhuis JA, Oyen
WJG. 3 '-Deoxy-3 '-F-18-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma
Patients. Journal of Nuclear Medicine 2012; 53: 1904-1910 (5 / 6.381)
56. Jarzyna PA, Deddens LH, Kann BH, Ramachandran S, Calcagno C, Chen W, Gianella A, Dijkhuizen RM, Griffioen AW, Fayad
ZA, Mulder WJM. Tumor Angiogenesis Phenotyping by Nanoparticle-facilitated Magnetic Resonance and Near-infrared
Fluorescence Molecular Imaging. Neoplasia 2012; 14: 964-973 (4 / 5.946)
57. Kalay H, Ambrosini M, van Berkel PHC, Parren PWHI, van Kooyk Y, Vallejo JJG. Online nanoliquid chromatography-mass
spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis. Analytical Biochemistry
2012; 423: 153-162 (3 / 2.996)
58. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, cevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P,
guirre-Ghiso JA, Ahn HJ, it-Mohamed O, it-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL,
egre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, monte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO,
ndrieu-Abadie N, Anantharam V, Ann DK, noopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K,
Asare NYO, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y,
Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ETW, Banhegyi G, Bartholomew CR, Bassham DC, Bast
RC, Batoko H, Bay BH, Beau I, Bechet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi
L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi XN, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone
DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini
C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH,
Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski
SP, Cadwell K, Cahova M, Cai DS, Cai JY, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, CamposSalinas J, Candi E, Cao LZ, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LAM, Carra S,
Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan
EY, Chang RCC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SSL, Chen WL, Chen X, Chen XM, Chen XQ,
Chen YG, Chen YY, Chen YQ, Chen YJ, Chen ZX, Cheng A, Cheng CHK, Cheng Y, Cheong H, Cheong JH, Cherry S, ChessWilliams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi
AMK, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ,
Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RSB, Clarke PGH, Clarke R, Codogno P, Coller HA, Colombo MI,
Comincini S, Condello M, Condorelli F, Cookson MR, Coppens GHCI, Corbalan R, Cossart P, Costelli P, Costes S, CotoMontes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronje MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, rfeuilleMichaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CAM, De Martino L, De Milito A, De Tata V, Debnath J,
Degterev A, Dehay B, Delbridge LMD, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish
RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Diaz-Araya G, Diaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, DineshKumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Peters GJ, van Egmond M.
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445-544 (4 / 7.453)
59. Kluijt I, Siemerink EJM, Ausems MGEM, Van Os TAM, de Jong D, Simoes-Correia J, van Krieken JH, Ligtenberg MJ,
Figueiredo J, van Riel E, Sijmons RH, Plukker JTM, van Hillegersberg R, Dekker E, Oliveira C, Cats A, Hoogerbrugge N.
CDH1-related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling.
International Journal of Cancer 2012; 131: 367-376 (4 / 5.444)
60. Klumpers UMH, Boellaard R, Veltman DJ, Kloet RW, Hoogendijk WJG, Lammertsma AA. Parametric [C-11]flumazenil
images. Nuclear Medicine Communications 2012; 33: 422-430 (2 / 1.404)
61. Kool M, Korshunov A, Remke M, Jones DTW, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van
Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, Collins VP, Backlund ML, Haberler C,
Bourdeaut F, Delattre O, Doz F, Ellison DW, Gilbertson RJ, Pomeroy SL, Taylor MD, Lichter P, Pfister SM. Molecular
subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of
WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica 2012; 123: 473-484 (5 / 9.32)
62. Kranenburg O, Emmink BL, Knol J, van Houdt WJ, Rinkes IHMB, Jimenez CR. Proteomics in studying cancer stem cell
biology. Expert Review of Proteomics 2012; 9: 325-336 (3 / 3.685)
63. la Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, Czader M, Freeman S, Vyas P, Porwit A, Saft L,
Westers TM, Alhan C, Cali C, van de Loosdrecht AA, Ogata K. Multicenter validation of a reproducible flow cytometric
score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.
Haematologica-The Hematology Journal 2012; 97: 1209-1217 (5 / 6.424)
64. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, Zegers CML, Gillies R, Boellard R,
Dekker A, Aerts HJWL. Radiomics: Extracting more information from medical images using advanced feature analysis.
European Journal of Cancer 2012; 48: 441-446 (4 / 5.536)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 37
65. Lee JH, Giovannetti E, Hwang JH, Petrini I, Wang QY, Voortman J, Wang YH, Steinberg SM, Funel N, Meltzer PS, Wang YS,
Giaccone G. Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in
Resected Pancreatic Cancer. Clin Cancer Res 2012; 18: 524-533 (5 / 7.742)
66. Leenders MWH, Broeders M, Croese C, Richir MC, Go HLS, Langenhorst BLAM, Meijer S, Schreurs WH. Ultrasound and fine
needle aspiration cytology of axillary in breast cancer. To do or not to do?. Breast 2012; 21: 578-583 (4 / 2.491)
67. Leusink FKJ, Van Es RJJ, de Bree R, de Jong RJB, van Hooff SR, Holstege FCP, Slootweg PJ, Brakenhoff RH, Takes RP. Novel
diagnostic modalities for assessment of the clinically node-negative neck in oral squamous-cell carcinoma. Lancet
Oncology 2012; 13: E554-E561 (5 / 22.589)
68. Li JA, de Groot M, Helderman F, Mo JH, Daniels JMA, Grunberg K, Sutedja TG, de Boer JF. High speed miniature motorized
endoscopic probe for optical frequency domain imaging. Optics Express 2012; 20: 24132-24138 (5 / 3.587)
69. Lopes N, Paredes J, Costa JL, Ylstra B, Schmitt F. Vitamin D and the mammary gland: a review on its role in normal
development and breast cancer. Breast Cancer Research 2012; 14: 211 (4 / 5.245)
70. Maguire CA, van der Mijn JC, Degeling MH, Morse D, Tannous BA. Codon-Optimized Luciola italica Luciferase Variants for
Mammalian Gene Expression in Culture and In Vivo. Molecular Imaging 2012; 11: 13-21 (4 / 3.18)
71. Makharia GK, Catassi C, Goh KL, Mulder CJJ. Celiac Disease. Gastroenterology Research and Practice 2012; 758560: (1 /
0.978)
72. Malekzadeh A, de Groot V, Beckerman H, van Oosten BW, Blankenstein MA, Teunissen C. Challenges in multi-plex and
mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods 2012; 56: 508513 (4 / 4.011)
73. Martin JE, Broen JC, Carmona FD, Teruel M, Simeon CP, Vonk MC, van 't Slot R, Rodriguez-Rodriguez L, Vicente E,
Fonollosa V, Ortego-Centeno N, Gonzalez-Gay MA, Garcia-Hernandez FJ, de la Pena PG, Carreira P, Voskuyl AE,
Schuerwegh AJ, van Riel PLCM, Kreuter A, Witte T, Riemekasten G, Airo P, Scorza R, Lunardi C, Hunzelmann N, Distler
JHW, Beretta L, van Laar J, Chee MM, Worthington J, Herrick A, Denton C, Tan FK, Arnett FC, Assassi S, Fonseca C, Mayes
MD, Radstake TRDJ, Koeleman BPC, Martin J. Identification of CSK as a systemic sclerosis genetic risk factor through
Genome Wide Association Study follow-up. Human Molecular Genetics 2012; 21: 2825-2835 (5 / 7.636)
74. Mekenkamp LJM, Tol J, Dijkstra JR, de Krijger I, Vink-Borger ME, van Vliet S, Teerenstra S, Kamping E, Verwiel E, Koopman
M, Meijer GA, van Krieken JHJM, Kuiper R, Punt CJA, Nagtegaal ID. Beyond KRAS mutation status: influence of KRAS copy
number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer
2012; 12: (4 / 3.011)
75. Meliopoulos VA, Andersen LE, Birrer KF, Simpson KJ, Lowenthal JW, Bean AGD, Stambas J, Stewart CR, Tompkins SM, van
Beusechem VW, Fraser I, Mhlanga M, Barichievy S, Smith Q, Leake D, Karpilow J, Buck A, Jona G, Tripp RA. Host gene
targets for novel influenza therapies elucidated by high-throughput RNA interference screens. Faseb Journal 2012; 26:
1372-1386 (5 / 5.712)
76. Morata K, Komori M, Fujinami R, Yamada K, Kuribayashi K, Watanabe N, Sokoll LJ, Elliott D, Chan DW, Martens F, Heijboer
AC, Blankenstein MA, Hershberger SJ, Pfeiffer ZA, Vaidya SV, Dowell BL. Improvement and multicenter evaluation of the
analytical performance of an automated chemiluminescent immunoassay for alpha fetoprotein. Int J Biol Markers 2012;
27: 39-46 (2 / 1.479)
77. Mulder GM, Melenhorst WBWH, Celie JWAM, Kloosterhuis NJ, Hillebrands JL, Ploeg RJ, Seelen MA, Visser L, van Dijk MCRF,
van Goor H. ADAM17 up-regulation in renal transplant dysfunction and non-transplant-related renal fibrosis. Nephrology
Dialysis Transplantation 2012; 27: 2114-2122 (4 / 3.396)
78. Murillo CP, Huang X, Hills A, McGurk M, Lyons A, Jeannon JP, Odell E, Brown A, Lavery K, Barrett W, Sherriff M, Brakenhoff
R, Partridge M. The utility of molecular diagnostics to predict recurrence of head and neck carcinoma. Br J Cancer 2012;
107: 1138-1143 (4 / 5.042)
79. Niers JM, Chen JW, Lewandrowski G, Kerami M, Garanger E, Wojtkiewicz G, Waterman P, Keliher E, Weissleder R, Tannous
BA. Single Reporter for Targeted Multimodal in Vivo Imaging. Journal of the American Chemical Society 2012; 134: 51495156 (5 / 9.907)
80. Niini T, Scheinin I, Lahti L, Savola S, Mertens F, Hollmen J, Bohling T, Kivioja A, Nord KH, Knuutila S. Homozygous
deletions of cadherin genes in chondrosarcoma-an array comparative genomic hybridization study. Cancer Genetics
2012; 205: 588-593 (1 / 1.389)
81. Nijhuis R, van Zwet A, Stuart JC, Weijers T, Savelkoul P. Rapid molecular detection of extended-spectrum beta-lactamase
gene variants with a novel ligation-mediated real-time PCR. Journal of Medical Microbiology 2012; 61: 1563-1567 (3 /
2.502)
82. Oliveira S, Cohen R, Walsum MS, van Dongen GA, Elias SG, van Diest PJ, Mali W, van Bergen en Henegouwen PM. A novel
method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. Eur J Nucl Med Mol
Imaging 2012; 2: 50 (5 / 4.991)
83. Oliveira S, van Dongen GAMS, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, van Diest PJ, van Bergen en
Henegouwen P. Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-infrared
Fluorescent Anti-Epidermal Growth Factor Receptor Nanobody. Molecular Imaging 2012; 11: 33-46 (4 / 3.18)
84. Oprea-Lager DE, Vincent AD, van Moorselaar RJA, Gerritsen WR, van den Eertwegh AJM, Eriksson J, Boellaard R, Hoekstra
OS. Dual-Phase PET-CT to Differentiate [F-18]Fluoromethylcholine Uptake in Reactive and Malignant Lymph Nodes in
Patients with Prostate Cancer. PloS one 2012; 7: (4 / 4.092)
85. Orem J, Sandin S, Weibull CE, Odida M, Wabinga H, Mbidde E, Wabwire-Mangen F, Meijer CJLM, Middeldorp JM,
Weiderpass E. Agreement between diagnoses of childhood lymphoma assigned in Uganda and by an international
reference laboratory. Clinical Epidemiology 2012; 4: 339-347 (0 / 0)
86. Peters TTA, Castelijns JA, Ljumanovic R, Witte BI, Leemans CR, de Bree R. Diagnostic value of CT and MRI in the detection
of paratracheal lymph node metastasis. Oral Oncology 2012; 48: 450-455 (5 / 2.857)
87. Pham TV, Jimenez CR. An accurate paired sample test for count data. Bioinformatics 2012; 28: I596-I602 (5 / 5.468)
88. Pham TV, Piersma SR, Oudgenoeg G, Jimenez CR. Label-free mass spectrometry-based proteomics for biomarker
discovery and validation. Expert Review of Molecular Diagnostics 2012; 12: 343-359 (5 / 4.859)
89. Piriou E, Asito AS, Sumba PO, Fiore N, Middeldorp JM, Moormann AM, Ploutz-Snyder R, Rochford R. Early Age at Time of
Primary Epstein-Barr Virus Infection Results in Poorly Controlled Viral Infection in Infants From Western Kenya: Clues to
the Etiology of Endemic Burkitt Lymphoma. J Infect Dis 2012; 205: 906-913 (5 / 6.41)
90. Radchenko V, Hauser H, Eisenhut M, Vugts DJ, van Dongen GAMS, Roesch F. Nb-90 - a potential PET nuclide: production
and labeling of monoclonal antibodies. Radiochimica Acta 2012; 100: 857-863 (4 / 1.575)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 38
91. Rizvi SNF, Visser OJ, Vosjan MJWD, van Lingen A, Hoekstra OS, Zijlstra JM, Huijgens PC, van Dongen GAMS, Lubberink M.
Biodistribution, radiation dosimetry and scouting of Y-90-ibritumomab tiuxetan therapy in patients with relapsed B-cell
non-Hodgkin's lymphoma using Zr-89-ibritumomab tiuxetan and PET. European Journal of Nuclear Medicine and
Molecular Imaging 2012; 39: 512-520 (5 / 4.991)
92. Rodjan F, de Graaf P, Brisse HJ, Goricke S, Maeder P, Galluzzi P, Aerts I, Alapetite C, Desjardins L, Wieland R, Popovic MB,
Diezi M, Munier FL, Hadjistilianou T, Knol DL, Moll AC, Castelijns JA. Trilateral retinoblastoma: neuroimaging
characteristics and value of routine brain screening on admission. Journal of Neuro-Oncology 2012; 109: 535-544 (3 /
3.214)
93. Rodjan F, de Graaf P, van der Valk P, Moll AC, Kuijer JPA, Knol DL, Castelijns JA, Pouwels PJW. Retinoblastoma: Value of
Dynamic Contrast-Enhanced MR Imaging and Correlation with Tumor Angiogenesis. AJNR American Journal of
Neuroradiology 2012; 33: 2129-2135 (4 / 2.928)
94. Schrevel M, Karim R, ter Haar N, van der Burg S, Trimbos J, Fleuren G, Gorter A, Jordanova E. CXCR7 expression is
associated with disease-free and disease-specific survival in cervical cancer patients. Br J Cancer 2012; 106: 1520-1525
(4 / 5.042)
95. Schumacher U, Nehmann N, Adam E, Mukthar D, Slotki IN, Horny HP, Flens MJ, Schlegelberger B, Steinemann D. MDR-1overexpression in HT 29 colon cancer cells grown in SCID mice. Acta Histochemica 2012; 114: 594-602 (1 / 1.829)
96. Senthi S, Senan S. Imaging for high-precision thoracic radiotherapy. J Thorac Dis 2012; 4: 106-108 (0 / 0)
97. Siggberg L, Alla-Melo S, Linnankivi T, Avela K, Scheinin AI, Kristiansson K, Lahermo P, Hietala M, Metsõhonkala L,
Kuusinen E, Laaksonen M, Saarela J, Knuutila S. High-resolution SNP array analysis of patients with developmental
disorder and normal array CGH results. BMC Medical Genetics 2012; 13: (2 / 2.328)
98. Slobbe P, Poot AJ, Windhorst AD, van Dongen GAMS. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.
Drug Discovery Today 2012; 17: 1175-1187 (5 / 6.828)
99. Spaans VM, Peters AA, Fleuren GJ, Jordanova ES. HLA-E expression in cervical adenocarcinomas: association with
improved long-term survival. Journal of Translational Medicine 2012; 10: (3 / 3.474)
100. te Beek ET, de Boer P, Moerland M, Schmidt ME, Hoetjes NJ, Windhorst AD, van Berckel BNM, Cohen AF, van Gerven JMA,
Lammertsma AA. In vivo quantification of striatal dopamine D-2 receptor occupancy by JNJ-37822681 using [C11]raclopride and positron emission tomography. Journal of Psychopharmacology 2012; 26: 1128-1135 (4 / 3.036)
101. Tewarie P, Teunissen CE, Dijkstra CD, Heijnen DAM, Vogt M, Balk L, Vrenken H, Polman CH, Killestein J. Cerebrospinal
fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis. Journal
of Neuroimmunology 2012; 251: 103-106 (3 / 2.959)
102. Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Chitnis S, Polman C, Vosslamber S, Verweij CL, Olsen NJ,
Aune TM. Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis. Genes and Immunity 2012; 13:
146-154 (4 / 3.872)
103. van Assema DM, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, van Berckel BN, Lammertsma AA.
Reproducibility of quantitative (R)-[11C]verapamil studies. Eur J Nucl Med Mol Imaging 2012; 2: 1 (5 / 4.991)
104. van den Brekel MWM, Lodder WL, Stel HV, Bloemena E, Leemans CR, van der Waal I. Observer variation in the
histopathologic assessment of extranodal tumor spread in lymph node metastases in the neck. Head and Neck-Journal
for the Sciences and Specialties of the Head and Neck 2012; 34: 840-845 (4 / 2.403)
105. van der Laken CJ, Huisman MH, Voskuyl AE. Nuclear imaging of rheumatic diseases. Best Pract Res Clin Rheumatol 2012;
26: 787-804 (3 / 2.653)
106. van der Leest C, Smit E, Baas J, Versteijlen R, van Walree N, Hoogsteden H, Aerts J. SUVmax during 18FDG-PET scanning
in small cell lung cancer: Similar information as in non-small cell lung cancer?. Lung Cancer 2012; 76: 67-71 (4 / 3.434)
107. van Dongen GAMS, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immunoPET and TKI-PET. Tumor Biology 2012; 33: 607-615 (2 / 2.143)
108. van Hooff SR, Leusink FKJ, Roepman P, de Jong RJB, Speel EJM, van den Brekel MWM, van Velthuysen MLF, van Diest PJ,
Van Es RJJ, Merkx MAW, Kummer JA, Leemans CR, Schuuring E, Langendijk JA, Lacko M, De Herdt MJ, Jansen JC,
Brakenhoff RH, Slootweg PJ, Takes RP, Holstege FCP. Validation of a Gene Expression Signature for Assessment of Lymph
Node Metastasis in Oral Squamous Cell Carcinoma. J Clin Oncol 2012; 30: 4104-4110 (5 / 18.372)
109. van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Zijlstra JM. 18F-fluoro-deoxyglucose
positron emission tomography in assessment of myeloma-related bone disease: A systematic review. Cancer 2012; 118:
1971-1981 (4 / 4.771)
110. van Pul KM, Vuylsteke RJCL, Bril H, Stockmann HBAC, de Gruijl TD. Feasibility of flowcytometric quantitation of immune
effector cell subsets in the sentinel lymph node of the breast after cryopreservation. Journal of Immunological Methods
2012; 375: 189-195 (2 / 2.203)
111. van Velden FH, van Beers P, Nuyts J, Velasquez LM, Hayes W, Lammertsma AA, Boellaard R, Loeckx D. Effects of rigid and
non-rigid image registration on test-retest variability of quantitative [18F]FDG PET/CT studies. Eur J Nucl Med Mol
Imaging 2012; 2: 10 (5 / 4.991)
112. Van Weyenberg SJ, van Grieken NCT, van Waesberghe JH. Iron Deficiency After Non-Small Cell Lung Cancer Ileal Polypoid
Angiodysplasia. Gastroenterology 2012; 142: E3-E4 (5 / 11.675)
113. Van Weyenberg SJ, van Grieken NCT. Jejunal pseudomelanosis. Digestive and Liver Disease 2012; 44: 355 (3 / 3.054)
114. Verbeek J, Eriksson J, Syvanen S, Labots M, de Lange ECM, Voskuyl RA, Mooijer MPJ, Rongen M, Lammertsma AA,
Windhorst AD. [11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats.
Eur J Nucl Med Mol Imaging 2012; 2: 36 (5 / 4.991)
115. Verbeek J, Syvanen S, Schuit RC, Eriksson J, de Lange EC, Windhorst AD, Luurtsema G, Lammertsma AA. Synthesis and
preclinical evaluation of [C-11]D617, a metabolite of (R)-[C-11]verapamil. Nuclear Medicine and Biology 2012; 39: 530539 (4 / 3.023)
116. Verhappen MH, Pouwels PJW, Ljumanovic R, van der Putten L, Knol DL, de Bree R, Castelijns JA. Diffusion-Weighted MR
Imaging in Head and Neck Cancer: Comparison between Half-Fourier Acquired Single-Shot Turbo Spin-Echo and EPI
Techniques. American Journal of Neuroradiology 2012; 33: 1239-1246 (4 / 2.928)
117. Vincenten J, Smit EF, Vos W, Grunberg K, Postmus PE, Heideman DAM, Snijders PJF, Meijer GA, Kuik J, Witte BI,
Thunnissen E. Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation
Analysis in Patients with Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2012; 7: 1522-1527 (4 / 3.661)
118. Vos CG, Murk JLAN, Hartemink KJ, Daniels JMA, Paul MA, Debets-Ossenkopp YJ. A rare pulmonary infection caused by
Arthrographis kalrae. Journal of Medical Microbiology 2012; 61: 593-595 (3 / 2.502)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 39
119. Vos MJ, Berkhof J, Hoekstra OS, Bosma I, Sizoo EM, Heimans JJ, Reijneveld JC, Sanchez E, Lagerwaard FJ, Buter J, Noske
DP, Postma TJ. MRI and thallium-201 SPECT in the prediction of survival in glioma. Neuroradiology 2012; 54: 539-546 (3
/ 2.824)
120. Wegdam W, Moerland PD, Meijer D, de Jong SM, Hoefsloot HC, Kenter GG, Buist MR, Aerts JM. A critical assessment of
SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass. Proteome Science 2012; 10:
(2 / 2.328)
121. Westerman LJ, Stel HV, Schipper MEI, Bakker LJ, Neefjes-Borst EA, van den Brande JHM, Boel ECH, Seldenrijk KA, Siersema
PD, Bonten MJM, Kusters JG. Development of a Real-Time PCR for Identification of Brachyspira Species in Human Colonic
Biopsies. PloS one 2012; 7: (4 / 4.092)
122. Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, la Porta MG, Drager
AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S,
Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subira D, Tindell V, Vallespi T, Valent P,
van der Velden VHJ, de Witte TM, Wells DA, Zettl F, Bene MC, van de Loosdrecht AA. Standardization of flow cytometry in
myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.
Leukemia 2012; 26: 1730-1741 (5 / 9.561)
123. Westers TM, van der Velden VHJ, Alhan C, Bekkema R, Bijkerk A, Brooimans RA, Cali C, Drager AM, de Haas V, Homburg
C, de Jong A, Kuiper-Kramer PA, Leenders M, Lommerse I, Marvelde JGT, van der Molen-Sinke J, Moshaver B, Mulder AB,
Preijers FWMB, Schindhelm RK, van der Sluijs A, van Wering ER, Westra AH, van de Loosdrecht AA. Implementation of flow
cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: Report from the Dutch
Working Party on Flow Cytometry in MDS. Leukemia Research 2012; 36: 422-430 (3 / 2.923)
124. Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G,
Kemming D, Glatzel M, Muller V, Westphal M, Pantel K. Relevance of PTEN loss in brain metastasis formation in breast
cancer patients. Breast Cancer Research 2012; 14: R49 (4 / 5.245)
125. Wildeman MA, Fles R, Adham M, Mayangsari ID, Luirink I, Sandberg M, Vincent AD, Fardizza F, Musa Z, Armiyanto,
Middeldorp JM, Gerritsen G, Suwanto R, Tan IB. Short-term effect of different teaching methods on nasopharyngeal
carcinoma for general practitioners in Jakarta, Indonesia. PloS one 2012; 7: e32756 (4 / 4.092)
126. Wurdinger T, Gatson NN, Balaj L, Kaur B, Breakefield XO, Pegtel DM. Extracellular vesicles and their convergence with
viral pathways. Advances in Virology 2012; 2012: 767694 (0 / 0)
127. Yaqub M, van Berckel BNM, Schuitemaker A, Hinz R, Turkheimer FE, Tomasi G, Lammertsma AA, Boellaard R.
Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[C-11]PK11195 brain PET
studies. Journal of Cerebral Blood Flow and Metabolism 2012; 32: 1600-1608 (4 / 5.008)
Scientific papers non-refereed
1.
«auteurs». «titel». «tijdschrift» «jaartal»; «volume»: «paginas».
Scientific publications (books, book chapters, proceedings)
1.
2.
3.
Verweij CL, Vosslamber S. Gene Expression Profiling in Rheumatoid Arthritis. Insights and Perspectives in Rheumatology.
Intech. 2012: 39-62
Verweij CL, Vosslamber S. The interferon system in rheumatoid arthritis. Type I Interferons, Mechanism of Action,
Implications in Inflammatory and Autoimmune Diseases and Clinical Applications. New York, NOVA Science publishers,
Inc. 2012
Verweij CL, Vosslamber S. The interferon system in multiple sclerosis: Towards a personalized medicine approach for
IFN? Therapy. Type I Interferons, Mechanism of Action, Implications in Inflammatory and Autoimmune Diseases and
Clinical Applications. New York, NOVA Science publishers, Inc. 2012
Professional publications
1.
Ang C, Brandenburg AH, van Burgel ND, Bijlmer HA, Herremans T, Stelma FF, Verduyn Lunel F, van Dam AP, namens het
Consensusberaad Lyme. Nationale vergelijking van serologische assays voor het aantonen van Borrelia-antistoffen.. Ned
Tijdschr Med Microbiol 2012; 20: 110-119
2. Ang C, van Burgel ND. Borrelia-serologie in de Nederlandse situatie: interpretatie van testuitslagen en ontwikkelingen.
Ned Tijdschr Med Microbiol 2012; 20: 120-125
3. Bernards AT, Bonten MJM, Cohen Stuart J, Diederen B, Goessens WHF, Grundmann H, Kluijtmans JAJW, Kluytmans-van den
Bergh MFQ, Leverstein-van Hall MA, Mouton JW, al Naiemi N, Troelstra A, Vandenbroucke-Grauls CMJE, Vos MC, Voss A.
Recommendations of the NVMM Guideline Laboratory detection of highly resistant microorganisms. Nederlands
Tijdschrift voor Medische Microbiologie 2012; 20: 13-15
4. Bleeker FE, Bot JCJ, Ronner HE, Postma TJ. Reversibele neurologische uitval jaren na hooggradig glioom: het SMARTsyndroom. Nederlands Tijdschrift voor Geneeskunde 2012; 156: A4704
5. Herremans T, van Burgel ND, Brandenburg AH, Meijer B, Verduyn Lunel F, Nabuurs-Franssen M, Stelma F, Ang C, van Dam
AP, Bijlmer HA, namens het Consensusberaad Lyme. Interlaboratoriumvariatie van de serologie voor de ziekte van Lyme
in Nederland. Ned Tijdschr Med Microbiol 2012; 20: 105-110
6. Kluijtmans JAJW, Bonten MJM. Interview: Antibiotica 'op de bon'. Tijdschrift voor Infectieziekten 2012; 7: 1-3
7. Rebers S, van der Valk T, Meijer GA, van Leeuwen FE, Schmidt MK. Zeggenschap over nader gebruik van
lichaamsmateriaal. Patient is het best gediend met 'geen bezwaar'-procedure. Nederlands Tijdschrift voor Geneeskunde
2012; 156: A4485
8. Savelkoul PHM, van Doorn J, Duim B, Figge M, Heck M, Melles D, Molenkamp R, Schouls L, Top J. Microbiële typering, een
kwestie van onderscheid maken. Nederlands Tijdschrift voor Medische Microbiologie 2012; 20: 16-20
9. Thio HB, Balak DM, Meilof JF, Stegeman CA, Voskuyl AE. Consensus diagnostic small-vessel vasculitis Workgroup
[Guideline 'Diagnostic of small-vessel vasculitis]. Nederlands Tijdschrift voor Geneeskunde 2012; 156: A4317
10. Vosslamber S, Verweij CL. Individueel maatwerk in de behandeling van reumatoide artritis: De toekomst is nu.
Nederlands Tijdschrift voor Reumatologie 2012; 2012: 8-15
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 40
Dissertations
1.
2.
3.
4.
5.
Hutajulu SH. Clinical, virological and host epigenetic markers for early identification of nasopharyngeal carcinoma in high
risk populations in Indonesia.. Vrije Universiteit Amsterdam, 2/16/2012. (Co-)promotores: J.M. Middeldorp, S.M.
Haryana, I.B. Tan, A.E. Greijer (cat B)
de Graaf P. Diagnostic Imaging in retinoblastoma. Vrije Universiteit Amsterdam, 4/5/2012. (Co-)promotores: J.A.
Castelijns, P. van der Valk, A.C. Moll, S. Imhof (cat A)
Cheebsumon P. Quantification and Tumor Delineation in PET. Vrije Universiteit Amsterdam, 2/15/2012. (Co-)promotores:
A.A. Lammertsma, R. Boellaard, F.H.P. van Velden (cat A)
Busard MPH. Advances of MR Imaging in Endometriosis. Vrije Universiteit Amsterdam, 11/1/2012. (Co-)promotores: C.
van Kuijk, J.H.T.M. Waesberghe (cat A)
Balaj L. Exosomes: The biological messengers. Vrije Universiteit Amsterdam, 10/29/2012. (Co-)promotores: W.P.
Vandertop, X. Breakefield, T. Wurdinger, D.P. Noske (cat B)
Program 4: Innovative therapy
Scientific papers refereed
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Adams H, Raijmakers P, Smulders Y. Polymyalgia Rheumatica and Interspinous FDG Uptake on PET/CT. Clinical Nuclear
Medicine 2012; 37: 502-505 (4 / 3.674)
Adar Y, Stark M, Bram EE, Nowak-Sliwinska P, van den Bergh H, Szewczyk G, Sarna T, Skladanowski A, Griffioen AW,
Assaraf YG. Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to
eradicate multidrug-resistant cancers. Cell Death & Disease 2012; 3: (3 / 5.333)
Adema AD, Smid K, Losekoot N, Honeywell RJ, Verheul HM, Myhren F, Sandvold ML, Peters GJ. Metabolism and
accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Investigational New Drugs 2012; 30:
1908-1916 (4 / 3.357)
Aman J, Thunnissen E, Paul MA, Amerongen GPV, Vonk-Noordegraaf A. Successful Treatment of Diffuse Pulmonary
Lymphangiomatosis With Bevacizumab. Annals of Internal Medicine 2012; 156: 839-840 (5 / 16.733)
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni
C, Ciuffreda L, Di Costanzo F, de Marinis F, Crino.L., Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C,
Mattioli R, Cafferata MA, Smit EF. Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in
Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis
With the NVALT7 Trial.. J Clin Oncol 2012; 30: 4501-4507 (5 / 18.372)
Arends S, Grootscholten C, Derksen RHWM, Berger SP, de Sevaux RGL, Voskuyl AE, Bijl M, Berden JHM. Long-term followup of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with
proliferative lupus nephritis. Annals of the Rheumatic Diseases 2012; 71: 966-973 (5 / 8.727)
Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ, Giovannetti E. Molecular
Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in
Pancreatic Cancer Cells. Molecular Cancer Therapeutics 2012; 11: 1735-1746 (4 / 5.226)
Azijli K, Yuvaraj S, Peppelenbosch MP, Wurdinger T, Dekker H, Joore J, van Dijk E, Quax WJ, Peters GJ, de Jong S, Kruyt
FAE. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small
cell lung cancer cells. Journal of Cell Science 2012; 125: 4651-4661 (4 / 6.111)
Bachas C, Schuurhuis GJ, Assaraf YG, Kwidama ZJ, Kelder A, Wouters F, Snel AN, Kaspers GJL, Cloos J. The role of minor
subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of
relapse. Leukemia 2012; 26: 1313-1320 (5 / 9.561)
Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free
therapy. Frontiers in Physiology 2012; 3: 359 (0 / 0)
Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, Vindelov LL, Blaise D, Janssen JJWM, Petersen E,
Socie G, Nagler A, Rocha V, Mohty M. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic
stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European
group for blood and marrow transplantation. Leukemia 2012; 26: 2462-2468 (5 / 9.561)
Baron F, Suciu S, Amadori S, Muus P, Zwierzina H, Denzlinger C, Delforge M, Thyss A, Selleslag D, Indrak K,
Ossenkoppele G, de Witte T. Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final
results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica-The Hematology
Journal 2012; 97: 529-533 (5 / 6.424)
Bastiaannet E, Hoekstra OS, de Jong JR, Brouwers AH, Suurmeijer AJH, Hoekstra HJ. Prognostic value of the standardized
uptake value for F-18-fluorodeoxyglucose in patients with stage IIIB melanoma. European Journal of Nuclear Medicine
and Molecular Imaging 2012; 39: 1592-1598 (5 / 4.991)
Bastiaannet E, Uyl-de Groot CA, Brouwers AH, van der Jagt EJ, Hoekstra OS, Oyen W, Verzijlbergen F, van Ooijen B,
Thompson JF, Hoekstra HJ. Cost-effectiveness of Adding FDG-PET or CT to the Diagnostic Work-up of Patients With Stage
III Melanoma. Annals of Surgery 2012; 255: 771-776 (5 / 7.492)
Beetz I, Schilstra C, Burlage FR, Koken PW, Doornaert P, Bijl HP, Chouvalova O, Leemans CR, de Bock GH, Christianen
MEMC, van der Laan BFAM, Vissink A, Steenbakkers RJHM, Langendijk JA. Development of NTCP models for head and
neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: The role of
dosimetric and clinical factors. Radiotherapy and Oncology 2012; 105: 86-93 (1 / 0.912)
Beetz I, Schilstra C, van der Schaaf A, van den Heuvel ER, Doornaert P, van Luijk P, Vissink A, van der Laan BFAM,
Leemans CR, Bijl HP, Christianen MEMC, Steenbakkers RJHM, Langendijk JA. NTCP models for patient-rated xerostomia
and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: The role of dosimetric
and clinical factors. Radiotherapy and Oncology 2012; 105: 101-106 (1 / 0.912)
Beetz I, Schilstra C, van Luijk P, Christianen MEMC, Doornaert P, Bijl HP, Chouvalova O, van den Heuvel ER, Steenbakkers
RJHM, Langendijk JA. External validation of three dimensional conformal radiotherapy based NTCP models for patientrated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy. Radiotherapy and
Oncology 2012; 105: 94-100 (1 / 0.912)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 41
18. Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, Van Rooijen N, Timmerman JM. Combination of
Cyclophosphamide, Rituximab, and Intratumoral CpG Oligodeoxynucleotide Successfully Eradicates Established B cell
Lymphoma. Journal of Immunotherapy 2012; 35: 534-543 (3 / 3.267)
19. Bex A, Etto T, Vyth-Dreese F, Blank C, Griffioen AW. Immunological Heterogeneity of the RCC Microenvironment: Do
Targeted Therapies Influence Immune Response?. Current Oncology Reports 2012; 14: 230-239 (2 / 2.545)
20. Biere SSAY, Henegouwen MIV, Maas KW, Bonavina L, Rosman C, Garcia JR, Gisbertz SS, Klinkenbijl JHG, Hollmann MW, de
Lange ESM, Bonjer HJ, van der Peet DL, Cuesta MA. Minimally invasive versus open oesophagectomy for patients with
oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012; 379: 1887-1892 (5 / 38.278)
21. Bingham CO, Alten R, de Wit MPT. The importance of patient participation in measuring rheumatoid arthritis flares.
Annals of the Rheumatic Diseases 2012; 71: 1107-1109 (5 / 8.727)
22. Bleeker MCG, Meijer CJLM, Berkhof J. Follow-up after treatment for cervical intraepithelial neoplasia. British Medical
Journal 2012; 345: (5 / 14.093)
23. Blom RL, Klinkenbijl JHG, Hollmann MW, Bergman JJ, Cuesta M, Bemelman WA, Busch OR, Henegouwen MIV. Results of
the introduction of a minimally invasive esophagectomy program in a tertiary referral center.. Journal of Thoracic
Diseases 2012; 12: 467-473 (0 / 0)
24. Blommestein HM, Verelst SGR, Huijgens PC, Blijlevens NMA, Cornelissen JJ, Uyl-de Groot CA. Real-world costs of
autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Annals of
Hematology 2012; 91: 1945-1952 (3 / 2.615)
25. Boers M, Kirwan JR, Bijlsma JWJ. American College of Rheumatology treatment guidelines continue to omit guidance on
glucocorticoids: Comment on the article by Singh et al. Arthritis Care & Research 2012; 64: 1622 (4 / 4.851)
26. Bomers MK, van Agtmael MA, Luik H, van Veen MC, Vandenbroucke-Grauls CMJE, Smulders YM. Using a dog's superior
olfactory sensitivity to identify Clostridium difficile in stools and patients: proof of principle study. British Medical Journal
2012; 345: (5 / 14.093)
27. Bongers EM, Dahele MR, Slotman BJ, Senan S, Bot JC. Proton Stereotactic Body Radiation Therapy for Clinically
Challenging Cases of Centrally and Superiorly Located Stage I Non-Small-Cell Lung Cancer: in Regards to Register et Al.
Int J Radiat Oncol Biol Phys 2011;89:1015-1022. International Journal of Radiation Oncology Biology Physics 2012; 82:
492 (4 / 4.105)
28. Bongers ML, Coupe VMH, Jansma EP, Smit EF, Uyl-de Groot CA. Cost Effectiveness of Treatment With New Agents in
Advanced Non-Small-Cell Lung Cancer A Systematic Review. Pharmacoeconomics 2012; 30: 17-34 (4 / 3.974)
29. Borel F, Han R, Visser A, Petry H, van Deventer SJH, Jansen PLM, Konstantinova P. Adenosine triphosphate-binding
cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs.
Hepatology 2012; 55: 821-832 (5 / 11.665)
30. Boudestein K, Kamps WA, Veerman AJP, Pieters R. Different Outcome in Older Children With Acute Lymphoblastic
Leukemia With Different Treatment Protocols in the Netherlands. Pediatric Blood & Cancer 2012; 58: 17-22 (3 / 1.891)
31. Buis DR, Bot JCJ, Barkhof F, Knol DL, Lagerwaard FJ, Slotman BJ, Vandertop WP, van den Berg R. The Predictive Value of 3D
Time-of-Flight MR Angiography in Assessment of Brain Arteriovenous Malformation Obliteration after Radiosurgery.
American Journal of Neuroradiology 2012; 33: 232-238 (4 / 2.928)
32. Bultink IEM, Vis M, van der Horst-Bruinsma I, Lems WF. Inflammatory rheumatic disorders and bone. Current
Rheumatology Reports 2012; 14: 224-230 (0 / 0)
33. Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, von Schoultz B, Vassilopoulou-Sellin R, El Galta
R, Van Lieshout E, Mol-Arts M, Planellas J, Kubista E. Tibolone increases bone mineral density but also relapse in breast
cancer survivors: LIBERATE trial bone substudy. Breast Cancer Research 2012; 14: (4 / 5.245)
34. Cazander G, Schreurs MWJ, Renwarin L, Dorresteijn C, Hamann D, Jukema GN. Maggot excretions affect the human
complement system. Wound Repair and Regeneration 2012; 20: 879-886 (4 / 2.911)
35. Cenit MC, Simeon CP, Vonk MC, Callejas-Rubio JL, Espinosa G, Carreira P, Blanco FJ, Narvaez J, Tolosa C, Roman-Ivorra JA,
Gomez-Garcia I, Garcia-Hernandez FJ, Gallego M, Garcia-Portales R, Egurbide MV, Fonollosa V, de la Pena PG, LopezLongo FJ, Gonzalez-Gay MA, Hesselstrand R, Riemekasten G, Witte T, Voskuyl AE, Schuerwegh AJ, Madhok R, Fonseca C,
Denton C, Nordin A, Palm O, van Laar JM, Hunzelmann N, Distler JHW, Kreuter A, Herrick A, Worthington J, Koeleman BP,
Radstake TRDJ, Martin J. Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis. Journal of Rheumatology 2012;
39: 2294-2302 (3 / 3.695)
36. Cheng S, Kirtschig G, Cooper S, Thornhill M, Leonardi-Bee J, Murphy R. Interventions for erosive lichen planus affecting
mucosal sites. Cochrane Database Syst Rev 2012; 2: (5 / 5.715)
37. Chi CC, Kirtschig G, Baldo M, Lewis F, Wang SH, Wojnarowska F. Systematic review and meta-analysis of randomized
controlled trials on topical interventions for genital lichen sclerosus. Journal of the American Academy of Dermatology
2012; 67: 305-312 (5 / 3.991)
38. Christianen MEMC, Schilstra C, Beetz I, Muijs CT, Chouvalova O, Burlage FR, Doornaert P, Koken PW, Leemans CR, Rinkel
RNPM, de Bruijn MJ, de Bock GH, Roodenburg JLN, van der Laan BFAM, Slotman BJ, Verdonck-de Leeuw IM, Bijl HP,
Langendijk JA. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: Results of a prospective
observational study. Radiotherapy and Oncology 2012; 105: 107-114 (1 / 0.912)
39. Clarke K, Taremi M, Dahele M, Freeman M, Fung SR, Franks K, Bezjak A, Brade A, Cho J, Hope A, Sun A. Stereotactic body
radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): Is FDG-PET a predictor of outcome?. Radiotherapy and
Oncology 2012; 104: 62-66 (1 / 0.912)
40. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhaeuser M, Juliusson G, Racil Z, Rowe JM, Russell N, Mohty M,
Lowenberg B, Socie G, Niederwieser D, Ossenkoppele GJ. The European LeukemiaNet AML Working Party consensus
statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature Reviews
Clinical Oncology 2012; 9: 579-590 (5 / 11.963)
41. Creutzig U, van den Heuvel-Eibrink M, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D,
Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, Meshinchi S, Pession A, Raimondi SC, Sung LL, Stary J, Zwaan CM,
Kaspers GJL, Reinhardt D. Diagnosis and management of acute myeloid leukemia in children and adolescents:
recommendations from an international expert panel. Blood 2012; 120: 3187-3205 (5 / 9.898)
42. Crolla RMPH, van der Laan L, Veen EJ, Hendriks Y, van Schendel C, Kluytmans J. Reduction of Surgical Site Infections after
Implementation of a Bundle of Care. PloS one 2012; 7: (4 / 4.092)
43. Cuesta MA, Biere SS, Henegouwen MI, van der Peet DL. Randomised trial, minimally invasive oesophagectomy versus
oopen oesophagectomy for patients with resectable oesophageal cancer. J Thorac Dis 2012; 4: 462-464 (0 / 0)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 42
44. Cuesta MA, Biere SSAY, Henegouwen MIV, Hollmann MW, van der Peet DL. Minimally invasive versus open
oesophagectomy for oesophageal cancer reply. Lancet 2012; 380: 885-886 (5 / 38.278)
45. da Silveira JC, Veeramachaneni DNR, Winger QA, Carnevale EM, Bouma GJ. Cell-Secreted Vesicles in Equine Ovarian
Follicular Fluid Contain miRNAs and Proteins: A Possible New Form of Cell Communication Within the Ovarian Follicle.
Biology of Reproduction 2012; 86: (4 / 4.009)
46. Daenen S, van der Holt B, Dekker AW, Willemze R, Rijneveld AW, Biemond BJ, Muus P, van de Loosdrecht AA, Schouten
HC, Kooy MV, Breems DA, Demuynck H, Maertens J, Wijermans PW, Wittebol S, de Klerk EW, Cornelissen JJ. Intensive
chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for
efficacy and feasibility by HOVON. Leukemia 2012; 26: 1726-1729 (5 / 9.561)
47. Dahele M, Verbakel W, Cuijpers J, Slotman B, Senan S. An analysis of patient positioning during stereotactic lung
radiotherapy performed without rigid external immobilization. Radiotherapy and Oncology 2012; 104: 28-32 (1 / 0.912)
48. De Boer NKH, Jharap B, Seinen ML, van Bodegraven AA. Letter: thiopurines during pregnancy and intrauterine exposure
to metabolites. Alimentary Pharmacology & Therapeutics 2012; 35: 964-965 (4 / 3.769)
49. de Boer YS, Bouma G, Wattjes MP, Lips P, Mulder CJJ, van Nieuwkerk CMJ. A case of autoimmune hepatitis and
bisphosphonate-related osteonecrosis of the jaw. Case Reports in Gastroenterology 2012; 6: 309-313 (0 / 0)
50. de Bree R, Haigentz M, Silver CE, Paccagnella D, Hamoir M, Hartl DM, Machiels JP, Paleri V, Rinaldo A, Shaha AR, Takes RP,
Leemans CR, Ferlito A. Distant metastases from head and neck squamous cell carcinoma. Part II. Diagnosis. Oral
Oncology 2012; 48: 780-786 (5 / 2.857)
51. de Crom SCM, van Furth MAM, Peeters MF, Rossen JWA, Obihara CC. Characteristics of pediatric patients with enterovirus
meningitis and no cerebral fluid pleocytosis. European Journal of Pediatrics 2012; 171: 795-800 (3 / 1.879)
52. de Groot M, Iyer A, Zurolo E, Anink J, Heimans JJ, Boison D, Reijneveld JC, Aronica E. Overexpression of ADK in human
astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy. Epilepsia 2012; 53: 58-66 (4 / 3.961)
53. de Groot M, Reijneveld JC, Aronica E, Heimans JJ. Epilepsy in patients with a brain tumour: focal epilepsy requires focused
treatment. Brain 2012; 135: 1002-1016 (5 / 9.457)
54. de Groot MH, van der Jagt-Willems H, van Campen JPCM, Lems WF, Lamoth CJC. Testing postural control among various
osteoporotic patient groups: A literature review. Geriatrics & Gerontology International 2012; 12: 573-585 (3 / 2.164)
55. de Korte N, Kuyvenhoven JP, van der Peet DL, Felt-Bersma RJ, Cuesta MA, Stockmann HBAC. Mild colonic diverticulitis can
be treated without antibiotics. a case-control study. Colorectal Disease 2012; 14: 325-330 (3 / 2.927)
56. de Miranda NFCC, Goudkade D, Jordanova ES, Tops CMJ, Hes FJ, Vasen HFA, van Wezel T, Morreau H. Infiltration of Lynch
Colorectal Cancers by Activated Immune Cells Associates with Early Staging of the Primary Tumor and Absence of Lymph
Node Metastases. Clin Cancer Res 2012; 18: 1237-1245 (5 / 7.742)
57. de Rotte MCFJ, Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RHN, Wulffraat NM, de Jonge R. ABCB1 and ABCC3
Gene Polymorphisms Are Associated with First-year Response to Methotrexate in Juvenile Idiopathic Arthritis. Journal of
Rheumatology 2012; 39: 2032-2040 (3 / 3.695)
58. de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, Lavini C, Linn SC, Boven E, Van Dam FSAM,
Schagen SB. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors:
Converging results from multimodal magnetic resonance imaging. Human Brain Mapping 2012; 33: 2971-2983 (5 / 5.88)
59. De Smet AMGA, Bonten MJM, Kluytmans JAJW. For whom should we use selective decontamination of the digestive tract?.
Current Opinion in Infectious Diseases 2012; 25: 211-217 (4 / 4.93)
60. De Smet AMGA, Kluytmans JAJW, Bonten MJM. Resistance after selective decontamination reply. Lancet Infectious
Diseases 2012; 12: 180-181 (5 / 17.391)
61. de Weger VA, Turksma AW, Voorham QJM, Euler Z, Bril H, van den Eertwegh AJ, Bloemena E, Pinedo HM, Vermorken JB,
van Tinteren H, Meijer GA, Hooijberg E. Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between
Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer. Clin Cancer Res 2012; 18: 882-889 (5 /
7.742)
62. De Wilt LHAM, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FAE.
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Biochemical Pharmacology 2012; 83: 207-217 (4 / 4.705)
63. Deganello A, Gitti G, Parrinello G, Larotonda G, Meccariello G, Leemans CR, Gallo O. Infrahyoid flap reconstruction of oral
cavity and oropharyngeal defects in elderly patients with severe general comorbidities. Head and Neck-Journal for the
Sciences and Specialties of the Head and Neck 2012; 34: 1299-1305 (4 / 2.403)
64. den Hertog J, van Leengoed E, Kolk F, van den Broek L, Kramer E, Bakker EJ, Bakker-van Gijssel E, Bulk A, Kneepkens F,
Benninga MA. The defecation pattern of healthy term infants up to the age of 3 months. Archives of Disease in
Childhood-Fetal and Neonatal Edition 2012; 97: F465-F470 (5 / 3.045)
65. den Uyl D, van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JWJ, Hoes JN, Dijkmans BAC, Diamant M. Metabolic effects
of high-dose prednisolone treatment in early rheumatoid arthritis: Balance between diabetogenic effects and
inflammation reduction. Arthritis and Rheumatism 2012; 64: 639-646 (4 / 7.866)
66. Dicker GJ, Koolstra JH, Castelijns JA, Van Schijndel RA, Tuinzing DB. Positional changes of the masseter and medial
pterygoid muscles after surgical mandibular advancement procedures: an MRI study. International Journal of Oral and
Maxillofacial Surgery 2012; 41: 922-929 (3 / 1.506)
67. Dicker GJ, Tuijt M, Koolstra JH, Van Schijndel RA, Castelijns JA, Tuinzing DB. Static and dynamic loading of mandibular
condyles and their positional changes after bilateral sagittal split advancement osteotomies. International Journal of Oral
and Maxillofacial Surgery 2012; 41: 1131-1136 (3 / 1.506)
68. Dijkema T, Terhaard CHJ, Roesink JM, Raaijmakers CPJ, van den Keijbus PAM, Brand HS, Veerman ECI. MUC5B levels in
submandibular gland saliva of patients treated with radiotherapy for head-and-neck cancer: A pilot study. Radiation
Oncology 2012; 7: (3 / 2.321)
69. Dijkmans AC, de Jong EP, Dijkmans BAC, Lopriore E, Vossen A, Walther FJ, Oepkes D. Parvovirus B19 in pregnancy:
prenatal diagnosis and management of fetal complications. Current Opinion in Obstetrics & Gynecology 2012; 24: 95101 (4 / 2.378)
70. Dirven L, van den Broek M, Kroon HM, Grillet BAM, Han KH, Kerstens PJSM, Huizinga TWJ, Lems WF, Allaart CF. Large-joint
damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small
joints. Rheumatology 2012; 51: 2262-2268 (3 / 4.058)
71. Dirven L, van den Broek M, van Groenendael JHLM, de Beus WM, Kerstens PJSM, Huizinga TWJ, Allaart CF, Lems WF.
Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis.
BMC Musculoskeletal Disorders 2012; 13: (3 / 1.577)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 43
72. Dirven L, Visser K, Klarenbeek NB, Ewals JAPM, Han KH, Peeters AJ, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart
CF. Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis
are different from predictors of rapid radiological progression. Scandinavian Journal of Rheumatology 2012; 41: 15-19 (3
/ 2.472)
73. Dommering CJ, Marees T, van der Hout AH, Imhof SM, Meijers-Heijboer H, Ringens PJ, van Leeuwen FE, Moll AC. RB1
mutations and second primary malignancies after hereditary retinoblastoma. Familial Cancer 2012; 11: 225-233 (1 /
1.302)
74. Donker JMW, van der Laan L, Hendriks YJAM, Kluytmans JAJW. Evaluation of Staphylococcus aureus Nasal Carriage
Screening before Vascular Surgery. PloS one 2012; 7: (4 / 4.092)
75. Doornaert P, Dahele M, Senan S, Slotman B. Non-coplanar volumetric modulated arc therapy for irradiation of paranasal
sinus tumors: In response to Al-Mamgani et al., Highly-conformal intensity-modulated radiotherapy reduced toxicity
without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or
(chemo)radiation.. Oral Oncology 2012; 48: 905-911 (5 / 2.857)
76. Dressel AJ, van der Mijn JC, Aalders IJ, Rinkel RNPM, Van der Vliet HJ. Irinotecan-induced dysarthria. Case Reports in
Oncology 2012; 5: 47-51 (0 / 0)
77. Dukers-Muijrers NHTM, Morre SA, Speksnijder A, van der Sande MAB, Hoebe CJPA. Chlamydia trachomatis Test-of-Cure
Cannot Be Based on a Single Highly Sensitive Laboratory Test Taken at Least 3 Weeks after Treatment. PloS one 2012; 7:
(4 / 4.092)
78. Edelbroek JR, Vermeer MH, Jansen PM, Stoof TJ, van der Linden MMD, Horvath B, van Baarlen J, Willemze R. Langerhans
cell histiocytosis first presenting in the skin in adults: frequent association with a second haematological malignancy.
British Journal of Dermatology 2012; 167: 1287-1294 (4 / 3.666)
79. Eechoute K, Van der Veldt AAM, Oosting S, Kappers MHW, Wessels JAM, Gelderblom H, Guchelaar HJ, Reyners AKL, van
Herpen CML, Haanen JB, Mathijssen RHJ, Boven E. Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and
Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension. Clinical Pharmacology & Therapeutics
2012; 92: 503-510 (5 / 6.043)
80. Elnaggar M, Giovannetti E, Peters GJ. Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs
and Drug Combinations. Current Pharmaceutical Design 2012; 18: 2811-2829 (4 / 3.87)
81. Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ. Polymorphisms to Predict Outcome to the Tyrosine Kinase
Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib. Current Topics in Medicinal Chemistry 2012; 12: 1649-1659 (5 /
4.174)
82. Faber WR, Hoekzema R, Bart A, Zeegelaar JE, de Vries HJH. Cutaneous Leishmaniasis Acquired in Jura, France. Emerging
Infectious Diseases 2012; 18: 183-184 (5 / 6.169)
83. Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A,
Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute
myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood
2012; 120: 858-867 (5 / 9.898)
84. Feeney ER, van Vonderen MGA, Wit F, Danner SA, van Agtmael MA, Villarroya F, Domingo P, Capeau J, Reiss P, Mallon
PWG. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose
tissue mitochondrial DNA. Aids 2012; 26: 2165-2174 (5 / 6.245)
85. Frampton AL, Krell J, Giovannetti E, Jiao LR, Stebbing J. Role of miRNAs in the response to anticancer therapy.
Pharmacogenomics 2012; 13: 1663-1666 (4 / 3.974)
86. Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, Zweegman S, Chan ET, Kirk CJ, Geerke
DP, Schimmer AD, Kaspers GJL, Jansen G, Cloos J. Impaired bortezomib binding to mutant beta 5 subunit of the
proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 2012; 26: 757-768 (5 / 9.561)
87. Galvani E, Peters GJ, Giovannetti E. EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline
polymorphisms in outcome and toxicity. Future Oncology 2012; 8: 1015-1029 (3 / 3.163)
88. Gerlag DM, Raza K, van Baarsen LGM, Brouwer E, Buckley CD, Burmester GR, Gabay C, Catrina AI, Cope AP, Cornelis F,
Dahlqvist SR, Emery P, Eyre S, Finckh A, Gay S, Hazes JM, van der Helm-van Mil, Huizinga TWJ, Klareskog L, Kvien TK,
Lewis C, Machold KP, Ronnelid J, van Schaardenburg D, Schett G, Smolen JS, Thomas S, Worthington J, Tak PP. EULAR
recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study
Group for Risk Factors for Rheumatoid Arthritis. Annals of the Rheumatic Diseases 2012; 71: 638-641 (5 / 8.727)
89. Gerritsen WR, Sharma P. Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on
Immunotherapy. Journal of Clinical Immunology 2012; 32: 25-35 (3 / 3.077)
90. Gerritsen WR. The evolving role of immunotherapy in prostate cancer. Annals of Oncology 2012; 23: 22-27 (5 / 6.425)
91. Geutjes P, Roelofs L, Hoogenkamp H, Walraven M, Kortmann B, de Gier R, Farag F, Tiemessen D, Sloff M, Oosterwijk E,
van Kuppevelt T, Daamen W, Feitz W. Tissue Engineered Tubular Construct for Urinary Diversion in a Preclinical Porcine
Model. Journal of Urology 2012; 188: 653-660 (4 / 3.746)
92. Giovannetti E, Codacci-Pisanelli G, Peters GJ. TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer. New England
Journal of Medicine 2012; 366: 966 (5 / 53.298)
93. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs)
in anticancer drug resistance and implications for clinical practice. Critical Reviews in Oncology Hematology 2012; 81:
103-122 (4 / 4.411)
94. Giovannetti E, Toffalorio F, De Pas T, Peters GJ. Pharmacogenetics of conventional chemotherapy in non-small-cell lung
cancer: a changing landscape?. Pharmacogenomics 2012; 13: 1073-1086 (4 / 3.974)
95. Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, Galla V,
Sudo H, Falcone A, Campani D, Boggi U, Peters GJ. High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic
Role of MiR-211 in Pancreatic Cancer. PloS one 2012; 7: e49145 (4 / 4.092)
96. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F,
Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O,
Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent
P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised International Prognostic Scoring System for
Myelodysplastic Syndromes. Blood 2012; 120: 2454-2465 (5 / 9.898)
97. Gregori D, Foltran F, Ballali S, Berchialla P, Rodriguez H, Zaupa P, Spitzer P, Demetriades C, Slapak I, Sokolova L, Petridou
E, D'Alessandro A, Clemente MACP, Jakubikova J, Van As S, De Koning T, Passali D, Chinsky A, Rodriguez H, Brkic F,
Mladina R, Kalakouta O, Melis A, Machalova M, Caye-Thomasen P, Elsheikh E, Ragab A, Pitkaranta A, Necker PC, Derelle J,
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 44
Duwelz M, Francois M, Pezzettigotta S, Righini C, Stephane P, Buzarov J, Bernhard R, Jahnke V, Onder G, Zieriacks P,
Kalampoki V, Simasko N, Skoulakis C, Camaioni A, Cutrone C, Gaudini E, Grasso D, Mansi N, Messi G, Orlando C, Preziosi
S, Sorrentini I, Trozzi M, Vigo A, Villari G, Passali GC, Passali FM, Nishida Y, Ussatayeva G, De Hoyos R, Ologe FE,
Nasrullah M, Melendez A, Chmielik M, Belchior T, Cobzeanu MD, Gheorghe DC, Lorgulescu A, Caius C, Toader M,
Barkociova J, Havelkova B, Zargi M, Pumarola F, Rubio L, Stierna P, Hsu WC, rj-Ong S, Chomchai C, Hoep L, Rinkel R,
Baskent EA, Erikci VS, Onerci M, Graham J, Khwaja S, Raine C. The Susy Safe project overview after the first four years of
activity. International Journal of Pediatric Otorhinolaryngology 2012; 76: S3-S11 (2 / 1.167)
98. Griffioen AW, Mans LA, de Graaf AMA, Nowak-Sliwinska P, De Hoog CLMM, de Jong TAM, Vyth-Dreese FA, van Beijnum JR,
Bex A, Jonasch E. Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma
Patients. Clin Cancer Res 2012; 18: 3961-3971 (5 / 7.742)
99. Groenewegen G, Walraven M, Vermaat J, de Gast B, Witteveen E, Giles R, Haanen J, Voest E. Targeting the Endothelin Axis
with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. Br J Cancer 2012; 106: 284-289 (4 /
5.042)
100. Gurney BAS, Schilling C, Putcha V, Alkureishi LW, Alvarez AJ, Bakholdt V, Herrero LB, Barzan L, Bilde A, Bloemena E, Salces
CC, Palma PD, de Bree R, Dequanter D, Dolivet G, Donner D, Flach GB, Fresno M, Grandi C, Haerle S, Huber GF, Hunter K,
Lawson G, Leroux A, Lothaire PH, Mamelle G, Silini EM, Mastronicola R, Odell EW, O'Doherty MJ, Poli T, Rahimi S, Ross GL,
Zuazua JS, Santini S, Sebbesen L, Shoaib T, Sloan P, Sorensen JA, Soutar DS, Therkildsen MH, Vigili MG, Villarreal PM, von
Buchwald C, Werner JA, Wiegand S, McGurk M. Implications of a positive sentinel node in oral squamous cell carcinoma.
Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 2012; 34: 1580-1585 (4 / 2.403)
101. Haan AMSG, Pans SJA, Lensen KDF, Meijerink MR, Comans EFI, Smulders YM. Vasculitis revealed by posterior stroke.
Netherlands Journal of Medicine 2012; 70: 81-83 (4 / 2.072)
102. Haasbeek CJA, Palma D, Visser O, Lagerwaard FJ, Slotman B, Senan S. Early-stage lung cancer in elderly patients: A
population-based study of changes in treatment patterns and survival in the Netherlands. Annals of Oncology 2012; 23:
2743-2747 (5 / 6.425)
103. Hadj JO, Den Braven R, Tillier C, Schrijver HM, Verheul HMW, van der Vliet HJ. Reversible posterior leukoencephalopathy
syndrome during sunitinib therapy for metastatic renal cell carcinoma. Oncology Letters 2012; 3: 1293-1296 (1 / 0.108)
104. Hageman IMG, Peek AML, de Haas V, men-Korbijn CM, Kaspers GJL. Value of routine bone marrow examination in
pediatric acute myeloid leukemia (AML): A study of the Dutch Childhood Oncology Group (DCOG). Pediatric Blood &
Cancer 2012; 59: 1239-1244 (3 / 1.891)
105. Haigentz M, Hartl DM, Silver CE, Langendijk JA, Strojan P, Paleri V, de Bree R, Machiels JP, Hamoir M, Rinaldo A,
Paccagnella D, Shaha AR, Takes RP, Ferlito A. Distant metastases from head and neck squamous cell carcinoma. Part III.
Treatment. Oral Oncology 2012; 48: 787-793 (5 / 2.857)
106. Ham JC, Janssen JJWM, Boers JE, Kluin PM, Verdonck LF. Allogeneic Stem-Cell Transplantation for Blastic Plasmacytoid
Dendritic Cell Neoplasm. J Clin Oncol 2012; 30: E102-E103 (5 / 18.372)
107. Hangalapura BN, Timares L, Oosterhoff D, Scheper RJ, Curiel DT, de Gruijl TD. CD40-targeted adenoviral cancer vaccines:
the long and winding road to the clinic. Journal of Gene Medicine 2012; 14: 416-427 (3 / 2.483)
108. Hanna GG, van Sornsen de Koste JR, Dahele MR, Carson KJ, Haasbeek CJA, Migchielsen R, Hounsell AR, Senan S. Defining
target volumes for stereotactic ablative radiotherapy of early-stage lung tumours: a comparison of three-dimensional
18F-fluorodeoxyglucose positron emission tomography and four-dimensional computed tomography. Clinical Oncology
2012; 24: e71-e80 (2 / 2.072)
109. Hazenberg CLE, Ossenkoppele GJ, Smit WM. Raynaud-like phenomenon in two patients on nilotinib. British Journal of
Haematology 2012; 158: 431 (4 / 4.941)
110. Heimans JJ, Reijneveld JC. Factors affecting the cerebral network in brain tumor patients. Journal of Neuro-Oncology
2012; 108: 231-237 (3 / 3.214)
111. Hoffmann V, Baccarani M, Hasford J, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D,
Simonsson B, Pfirrmann M, Hehlmann R. The EUTOS CML score aims to support clinical decision-making. Blood 2012;
119: 2966-2967 (5 / 9.898)
112. Hofstee HMA, Serne EH, Roberts C, Hesselstrand R, Scheja A, Moore TL, Wildt M, Manning JB, Noordegraaf AV, Voskuyl
AE, Herrick AL. A multicentre study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy
assessment. Rheumatology 2012; 51: 749-755 (3 / 4.058)
113. Hofstee HMA, Serne EH, Roberts C, Hesselstrand R, Scheja A, Moore TL, Wildt M, Manning JB, Noordegraaf AV, Voskuyl
AE, Herrick AL. Comment on: A multicentre study on the reliability of qualitative and quantitative nailfold
videocapillaroscopy assessment: reply. Rheumatology 2012; 51: 1922 (3 / 4.058)
114. Hofstee HMA, Voskuyl AE, Noordegraaf AV, Smulders YM, Postmus PE, Dijkmans BAC, Serne EH. Pulmonary Arterial
Hypertension in Systemic Sclerosis Is Associated with Profound Impairment of Microvascular Endothelium-dependent
Vasodilatation. Journal of Rheumatology 2012; 39: 100-105 (3 / 3.695)
115. Hogg-Kollars S, Rostami-Nejad M, Rostami K. Where are We Standing with the Screening of Healthy Population for Celiac
Disease?. Archives of Iranian Medicine 2012; 15: 338-339 (2 / 0.972)
116. Hohenester S, Wenniger LMD, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RPO, Beuers U. A biliary HCO3- umbrella
constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012; 55: 173183 (5 / 11.665)
117. Hollak CEM, de Sonnaville ESV, Cassiman D, Linthorst GE, Groener JE, Morava E, Wevers RA, Mannens M, Aerts JMFG,
Meersseman W, Akkerman E, Niezen-Koning KE, Mulder MF, Visser G, Wijburg A, Lefeber D, Poorthuis BJHM. Acid
sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: Disease spectrum and natural course in
attenuated patients. Molecular Genetics and Metabolism 2012; 107: 526-533 (3 / 3.193)
118. Hooijkaas AI, Gadiot J, van der Valk M, Mooi WJ, Blank CU. Targeting BRAF(V600E) in an Inducible Murine Model of
Melanoma. American Journal of Pathology 2012; 181: 785-794 (5 / 4.89)
119. Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GSW, Chiang AKS. Activation of lytic cycle of Epstein-Barr virus by
suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
International Journal of Cancer 2012; 131: 1930-1940 (4 / 5.444)
120. Huisman EJ, van Hoek B, van Soest H, van Nieuwkerk KM, Arends JE, Siersema PD, van Erpecum KJ. Preventive versus "ondemand" nutritional support during antiviral treatment for hepatitis C: A randomized controlled trial. Journal of
Hepatology 2012; 57: 1069-1075 (5 / 9.264)
121. Israels T, Borgstein E, Pidini D, Chagaluka G, de Kraker J, Kamiza S, Molyneux EM. Management of Children With a Wilms
Tumor in Malawi, Sub-Saharan Africa. Journal of Pediatric Hematology Oncology 2012; 34: 606-610 (2 / 1.159)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 45
122. Israels T, Borgstein E, Pidini D, de Kraker J, Kamiza S, Molyneux E. The Efficacy and Toxicity of Siop Preoperative
Chemotherapy in Malawian Children with A Wilms Tumour. Pediatric Blood & Cancer 2012; 59: 636-641 (3 / 1.891)
123. Israels T. Wilms Tumor in Africa: Challenges to Cure. Pediatric Blood & Cancer 2012; 58: 3-4 (3 / 1.891)
124. Jakob F, Oertel H, Langdahl B, Ljunggren O, Barrett A, Karras D, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Barker C,
Lems WF, Marin F. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates:
36-month results from the European Forsteo Observational Study. European Journal of Endocrinology 2012; 166: 87-97
(3 / 3.423)
125. Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ. Patients nonresponding to etanercept obtain lower etanercept concentrations compared with responding patients. Annals of the
Rheumatic Diseases 2012; 71: 88-91 (5 / 8.727)
126. Jansen MHA, van Vuurden DG, Vandertop WP, Kaspers GJL. Diffuse intrinsic pontine gliomas: A systematic update on
clinical trials and biology. Cancer Treatment Reviews 2012; 38: 27-35 (4 / 6.054)
127. Jansen TL, Mulder CJJ. Rheumatology meets hepatology in 2012: a clinician's guideline for TNF inhibitors in hepatitis B/C
virus carriers. Expert Opinion on Biological Therapy 2012; 12: 391-393 (4 / 3.505)
128. Janssen JJWM, Deenik W, Smolders KGM, van Kuijk BJ, Pouwels W, Kelder A, Cornelissen JJ, Schuurhuis GJ, Ossenkoppele
GJ. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow
cytometric approach and predict for optimal response to imatinib. Leukemia 2012; 26: 977-984 (5 / 9.561)
129. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Marres HA, de Bree R, van der
Kogel AJ, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH. Accelerated Radiotherapy With Carbogen and Nicotinamide for
Laryngeal Cancer: Results of a Phase III Randomized Trial. J Clin Oncol 2012; 30: 1777-1783 (5 / 18.372)
130. Janssens GO, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Pop LA, Kaanders JH. Acute Toxicity Profile and
Compliance to Accelerated Radiotherapy Plus Carbogen and Nicotinamide for Clinical Stage T2-4 Laryngeal Cancer:
Results of A Phase Iii Randomized Trial. International Journal of Radiation Oncology Biology Physics 2012; 82: 532-538 (4
/ 4.105)
131. Jharap B, Seinen ML, van Bodegraven AA, de Boer NK. Intrauterine exposure to thiopurines. Reproductive Toxicology
2012; 33: 124 (4 / 3.226)
132. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MPL, Doodeman VD, Smits PHM, Vincent A, Huitema ADR,
Beijnen JH, Schellens JHM. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving firstline platinum-gemcitabine chemotherapy A Prospective Clinical Study. Cancer 2012; 118: 2466-2475 (4 / 4.771)
133. Kahraman D, Holstein A, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Dietlein M, Wolf J,
Kobe C. Tumor Lesion Glycolysis and Tumor Lesion Proliferation for Response Prediction and Prognostic Differentiation
in Patients With Advanced Non-Small Cell Lung Cancer Treated With Erlotinib. Clinical Nuclear Medicine 2012; 37: 10581064 (4 / 3.674)
134. Karagozoglu KH, Buter J, Leemans CR, Rietveld DHF, van den Vijfeijken S, van der Waal I. Subset of patients with
verrucous carcinoma of the oral cavity who benefit from treatment with methotrexate. British Journal of Oral &
Maxillofacial Surgery 2012; 50: 513-518 (4 / 1.95)
135. Karras D, Stoykov I, Lems WF, Langdahl BL, Ljunggren O, Barrett A, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F,
Marin F. Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year
Results from the EFOS Study. Journal of Rheumatology 2012; 39: 600-609 (3 / 3.695)
136. Kaspers GJ, Jansen MH. A new era for children with diffuse intrinsic pontine glioma: hope for cure?. Expert Rev Anticancer
Ther 2012; 12: 1109-1112 (3 / 2.652)
137. Kaspers GJL. Pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy 2012; 12: 405-413 (3 / 2.652)
138. Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EGE, Barriuso J, Sandhu S, Tan DSW, Hartog V, Kuenen B,
Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E. Phase I study of
saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br J Cancer
2012; 106: 1728-1734 (4 / 5.042)
139. Kazemier G. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or
without resection (Br J Surg 2012; 99: 558-565). British Journal of Surgery 2012; 99: 566 (5 / 4.606)
140. Kenemans P, van der Mooren MJ. Androgens and breast cancer risk. Gynecological Endocrinology 2012; 28: 46-49 (2 /
1.581)
141. Kerr AC, Ferguson J, Haylett AK, Rhodes LE, Adamski H, Alomar A, Serra E, Antoniou C, Aubin F, Vigan M, Biedermann T,
Fischer J, Bourrain JL, Bruynzeel D, Rustemeyer T, Carrascosa JM, Chowdhury MMU, de la Cuadra J, Foti C, Gardeazabal J,
Gawkrodger DJ, Gimenez-Arnau A, Goncalo M, Goossens A, Ibbotson SH, Dawe RS, Lecha M, Marguery MC, Neumann NJ,
Niklasson B, Peyron JL, Pigatto P, Spiewak R, Stone N, Tanew A, Thomas P, Bonnevalle A, Wilkinson SM, Wolf P, GruberWackernagel A, Wulf HC. A European multicentre photopatch test study The European Multicentre Photopatch Test Study
(EMCPPTS) Taskforce. British Journal of Dermatology 2012; 166: 1002-1009 (4 / 3.666)
142. Klarenbeek BR, de Korte N, van der Peet DL, Cuesta MA. Review of current classifications for diverticular disease and a
translation into clinical practice. International Journal of Colorectal Disease 2012; 27: 207-214 (4 / 2.385)
143. Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Combining angiogenesis inhibition and radiotherapy:
A double-edged sword. Drug Resistance Updates 2012; 15: 173-182 (5 / 9.559)
144. Klein M, Duffau H, Hamer PCD. Cognition and resective surgery for diffuse infiltrative glioma: an overview. Journal of
Neuro-Oncology 2012; 108: 309-318 (3 / 3.214)
145. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, VehlingKaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G,
Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Prochazka V, Di Raimondo F, Ribrag V,
Uppenkamp M, Andre M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of Older Patients with MantleCell Lymphoma. New England Journal of Medicine 2012; 367: 520-531 (5 / 53.298)
146. Kluza E, Jacobs I, Hectors SJCG, Mayo KH, Griffioen AW, Strijkers GJ, Nicolay K. Dual-targeting of alpha(v)beta(3) and
galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. Journal of
Controlled Release 2012; 158: 207-214 (5 / 5.732)
147. Knops RRG, Hulscher MEJL, Hermens RPMG, Hilbink-Smolders M, Loeffen JL, Kollen WJW, Kaspers GJL, Caron HN, Kremer
LCM. High-quality care for all children with cancer. Annals of Oncology 2012; 23: 1906-1911 (5 / 6.425)
148. Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Dietlein M,
Wolf J, Kahraman D. Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 46
using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of
Nuclear Medicine and Molecular Imaging 2012; 39: 1117-1127 (5 / 4.991)
149. Kong FM, Ritter T, Quint D, Marsh L, Senan S, Gaspar L, Komaki R, Hurkmans C, Timmerman R, Choy H, Bezjak A, Bradley
J, Mosvas B, Okunieff P, Curran W. Oncology Scan - Gastrointestinal Cancer Reply. International Journal of Radiation
Oncology Biology Physics 2012; 84: 305-306 (4 / 4.105)
150. Koningstein M, Groen L, Geraats/Peters K, Lutgens S, Rietveld A, Jira P, Kluytmans J, de Greeff SC, Hermans M,
Schneeberger PM. The use of typing methods and infection prevention measures to control a bullous impetigo outbreak
on a neonatal ward. Antimicrob Resist Infect Control 2012; 1: 37 (0 / 0)
151. Kracht PAM, Sigurdsson V, Hoogewerf M, Arends JE. A leg with an ulcer. Netherlands Journal of Medicine 2012; 70: 85-+
(4 / 2.072)
152. Kragelund C, Reibel J, Hietanen J, Hadler-Olsen E, Johannessen AC, Kenrad B, Nylander K, Puranen M, Salo T, Syrjanen S,
Soland TM, van der Waal I, van der Wal JE, Warfvinge G. Scandinavian Fellowship for Oral Pathology and Oral Medicine:
guidelines for oral pathology and oral medicine in the dental curriculum. European Journal of Dental Education 2012; 16:
246-253 (3 / 1.183)
153. Kreeft AM, Smeele LE, Rasch CRN, Hauptmann M, Rietveld DHF, Leemans CR, Balm AJM. Preoperative imaging and
surgical margins in maxillectomy patients. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck
2012; 34: 1652-1656 (4 / 2.403)
154. Krekel NMA, Haloua MH, Meijer S, van den Tol MP. Response to "A comparison of three methods for nonpalpable breast
cancer excision". European Journal of Surgical Oncology 2012; 38: 1236-1237 (0 / 0)
155. Krekel NMA, van Slooten HJ, Barbe E, de Klerk ESMD, Meijer S, van den Tol MP. Is breast specimen shrinkage really a
problem in breast-conserving surgery?. Journal of Clinical Pathology 2012; 65: 224-227 (3 / 2.306)
156. Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G. Comparison of Long-Term Clinical
Outcome With Etanercept Treatment and Adalimumab Treatment of Rheumatoid Arthritis With Respect to
Immunogenicity. Arthritis and Rheumatism 2012; 64: 3850-3855 (4 / 7.866)
157. Krieckaert CL, Lems WF. Biologicals and bone loss. Thera Adv Musculoskeletal Dis 2012; 4: 245-247 (0 / 0)
158. Kuiper JL, Lind JSW, Groen HJM, Roder J, Grigorieva J, Roder H, Dingemans AMC, Smit EF. VeriStrat (R) has prognostic
value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Br J Cancer 2012; 107: 1820-1825 (4 /
5.042)
159. Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, Van Buuren MM,
Urbanus JH, Beltman JB, Thor Straten PLYF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA,
Haanen JB, Hadrup SR, Schumacher TN. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma
patients. Oncoimmunology 2012; 1: 409-418 (0 / 0)
160. Lagerwaard FJ, Verstegen NE, Haasbeek CJA, Slotman BJ, Paul MA, Smit EF, Senan S. Outcomes of Stereotactic Ablative
Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer. International Journal of Radiation
Oncology Biology Physics 2012; 83: 348-353 (4 / 4.105)
161. Lam SW, Leenen LPH, van Solinge WW, Hietbrink F, Huisman A. Comparison between the prognostic value of the white
blood cell differential count and morphological parameters of neutrophils and lymphocytes in severely injured patients
for 7-day in-hospital mortality. Biomarkers 2012; 17: 642-647 (3 / 2.215)
162. Lam TJ, Felt-Bersma RJF. A novel device reduces anal pain after rubber band ligation: a randomized controlled trial.
Techniques in Coloproctology 2012; 16: 221-226 (2 / 1.288)
163. Lam TJ, Kuik DJ, Felt-Bersma RJF. Anorectal function evaluation and predictive factors for faecal incontinence in 600
patients. Colorectal Disease 2012; 14: 214-223 (3 / 2.927)
164. Lam TJ, Mulder CJJ, Felt-Bersma RJF. Critical reappraisal of anorectal function tests in patients with faecal incontinence
who have failed conservative treatment. International Journal of Colorectal Disease 2012; 27: 931-937 (4 / 2.385)
165. le Coutre P, Giles F, Hochhaus A, Apperley J, Ossenkoppele G, Blakesley R, Shou Y, Gallagher N, Baccarani M, Cortes J,
Kantarjian H. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance
or intolerance: 24-month follow-up results. Leukemia 2012; 26: 1189-1194 (5 / 9.561)
166. Lebre MC, Jonckheere CL, Kraan MC, van Kuijk AWR, Bos JD, de Rie M, Gerlag DM, Tak PP. Expression of Il-20 in Lesional
Skin and Synovium of Patients with Psoriatic Arthritis Compared to Rheumatoid Arthritis and Its Response to Alefacept
Treatment. Annals of the Rheumatic Diseases 2012; 71: A15 (5 / 8.727)
167. Limper M, van de Stadt L, Bos W, de Kruif M, Spek A, Wolbink G, van Schaardenburg D, van Gorp E. The Acute-phase
Response Is Not Predictive for the Development of Arthritis in Seropositive Arthralgia - A Prospective Cohort Study.
Journal of Rheumatology 2012; 39: 1914-1917 (3 / 3.695)
168. Lind JSW, Senan S, Smit EF. Pulmonary Toxicity After Bevacizumab and Concurrent Thoracic Radiotherapy Observed in a
Phase I Study for Inoperable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2012; 30: E104-E108 (5 / 18.372)
169. Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, Van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ,
Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Donor versus no-donor comparison of
newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012; 119: 6219-6225 (5 /
9.898)
170. London K, Stege C, Cross S, Onikul E, Graf N, Kaspers G, la-Pozza L, Howman-Giles R. F-18-FDG PET/CT compared to
conventional imaging modalities in pediatric primary bone tumors. Pediatric Radiology 2012; 42: 418-430 (3 / 1.674)
171. Lubberink M, Direcks W, Emmering J, van Tinteren H, Hoekstra OS, van der Hoeven JJ, Molthoff CFM, Lammertsma AA.
Validity of Simplified 3 '-Deoxy-3 '-[F-18]Fluorothymidine Uptake Measures for Monitoring Response to Chemotherapy in
Locally Advanced Breast Cancer. Molecular Imaging and Biology 2012; 14: 777-782 (4 / 3.844)
172. Luijten PR, van Dongen GAMS, Moonen CT, Storm G, Crommelin DJA. Public-private partnerships in translational
medicine: Concepts and practical examples. Journal of Controlled Release 2012; 161: 416-421 (5 / 5.732)
173. Lutgens MWMD, van Oijen MGH, Vleggaar FP, Siersema PD, Broekman MMTJ, Oldenburg B. Risk Factors for Rectal Stump
Cancer in Inflammatory Bowel Disease. Diseases of the Colon & Rectum 2012; 55: 191-196 (4 / 3.132)
174. Maas K, Biere S, Van der Peet D, Cuesta M. Minimally invasive esophagectomy: current status and future direction.
Surgical Endoscopy and Other Interventional Techniques 2012; 26: 1794 (5 / 4.013)
175. Maas KW, Biere SSAY, Scheepers JJG, Gisbertz SS, Rodriguez VT, van der Peet DL, Cuesta MA. Minimally invasive
intrathoracic anastomosis after Ivor Lewis esophagectomy for cancer: a review of transoral or transthoracic use of
staplers. Surgical Endoscopy and Other Interventional Techniques 2012; 26: 1795-1802 (5 / 4.013)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 47
176. Maas KW, Biere SSAY, Scheepers JJG, Gisbertz SS, van der Peet DL, Cuesta MA. Laparoscopic versus open transhiatal
esophagectomy for distal and junction cancer. Revista Espanola de Enfermedades Digestivas 2012; 104: 197-202 (1 /
1.548)
177. Mammatas LH, Regelink JC, Klein IE, Barbe E, Huijgens PC. Palmar necrosis during the treatment of acute myeloid
leukaemia. Netherlands Journal of Medicine 2012; 70: 467 (4 / 2.072)
178. Margadant C, van den Bout I, van Boxtel AL, Thijssen VL, Sonnenberg A. Epigenetic Regulation of Galectin-3 Expression
by beta 1 Integrins Promotes Cell Adhesion and Migration. Journal of Biological Chemistry 2012; 287: 44684-44693 (4 /
4.773)
179. Martin JE, Carmona FD, Broen JCA, Simeon CP, Vonk MC, Carreira P, Rios-Fernandez R, Espinosa G, Vicente-Rabaneda E,
Tolosa C, Garcia-Hernandez FJ, Castellvi I, Fonollosa V, Gonzalez-Gay MA, Saez-Comet L, Portales RG, de la Pena PG,
Fernandez-Castro M, Diaz B, Martinez-Estupinan L, Coenen M, Voskuyl AE, Schuerwegh AJ, Vanthuyne M, Houssiau F,
Smith V, de Keyser F, De Langhe E, Riemekasten G, Witte T, Hunzelmann N, Kreuter A, Palm O, Chee MM, van Laar JM,
Denton C, Herrick A, Worthington J, Koeleman BPC, Radstake TRDJ, Fonseca C, Martin J. The autoimmune diseaseassociated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. Genes and Immunity 2012; 13:
191-196 (4 / 3.872)
180. McClung MR, Boonen S, Torring O, Roux C, Rizzoli R, Bone HG, Benhamou CL, Lems WF, Minisola S, Halse J, Hoeck HC,
Eastell R, Wang A, Siddhanti S, Cummings SR. Effect of denosumab treatment on the risk of fractures in subgroups of
women with postmenopausal osteoporosis. Journal of Bone and Mineral research 2012; 27: 211-218 (4 / 6.373)
181. Mees SMD, Algra A, Vandertop WP, van Kooten F, Kuijsten HAJM, Boiten J, van Oostenbrugge RJ, Salman RA, Lavados PM,
Rinkel GJE, van den Bergh WM. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebocontrolled trial. Lancet 2012; 380: 44-49 (5 / 38.278)
182. Melsen WG, De Smet AMGA, Kluytmans JAJW, Bonten MJM. Selective decontamination of the oral and digestive tract in
surgical versus non-surgical patients in intensive care in a cluster-randomized trial. British Journal of Surgery 2012; 99:
232-237 (5 / 4.606)
183. Meulenbeld HJ, van Werkhoven ED, Coenen JLLM, Creemers GJ, Loosveld OJL, de Jong PC, ten Tije AJ, Fossa SD, Polee M,
Gerritsen W, Dalesio O, de Wit R. Randomised phase II/III study of docetaxel with or without risedronate in patients with
metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). European Journal of
Cancer 2012; 48: 2993-3000 (4 / 5.536)
184. Michels M, van der Ven AJAM, Djamiatun K, Fijnheer R, de Groot PG, Griffioen AW, Sebastian S, Faradz SMH, de Mast Q.
Imbalance of Angiopoietin-1 and Angiopoetin-2 in Severe Dengue and Relationship with Thrombocytopenia, Endothelial
Activation, and Vascular Stability. American Journal of Tropical Medicine and Hygiene 2012; 87: 943-946 (4 / 2.592)
185. Mitra D, Kampondeni S, Mallewa M, Knight T, Skinner R, Banda K, Israels T, Molyneux E, Bailey S. Central nervous system
lesions in Malawian children: identifying the treatable. Transactions of the Royal Society of Tropical Medicine and
Hygiene 2012; 106: 567-569 (3 / 2.162)
186. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt's lymphoma.
Lancet 2012; 379: 1234-1244 (5 / 38.278)
187. Mosca M, Boumpas D, Bruce IN, Cervera R, Czirjak L, Dorner T, Houssiau F, Jacobsen S, Schneider M, Smolen JS, Voskuyl
AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: where are we today?. Clinical and Experimental
Rheumatology 2012; 30: S112-S115 (2 / 2.148)
188. Mostert S, Njuguna F, Kemps L, Strother M, Aluoch L, Buziba G, Kaspers G. Epidemiology of diagnosed childhood cancer
in Western Kenya. Archives of Disease in Childhood 2012; 97: 508-512 (4 / 2.881)
189. Muggia F, Diaz I, Peters GJ. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also
gemcitabine. Expert Opinion on Investigational Drugs 2012; 21: 403-408 (5 / 5.274)
190. Nagler A, Labopin M, Shimoni A, Mufti GJ, Cornelissen JJ, Blaise D, Janssen JJWM, Milpied N, Vindelov L, Petersen E,
Gribben J, Bacigalupo A, Malm C, Niederwieser D, Socie GJ, Arnold R, Brown P, Goker H, Rocha V, Mohty M. Mobilized
peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning
transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia
Working Party of EBMT. European Journal of Haematology 2012; 89: 206-213 (3 / 2.614)
191. Nagtegaal MJC, Pentinga SE, Kuik J, Kezic S, Rustemeyer T. The role of the skin irritation response in polysensitization to
fragrances. Contact Dermatitis 2012; 67: 28-35 (4 / 3.509)
192. Nijkamp J, de Haas-Kock DFM, Beukema JC, Neelis KJ, Woutersen D, Ceha H, Rozema T, Slot A, Vos-Westerman H, Intven
M, Spruit PH, van der Linden Y, Geijsen D, Verschueren K, van Herk MB, Marijnen CAM. Target volume delineation
variation in radiotherapy for early stage rectal cancer in the Netherlands. Radiotherapy and Oncology 2012; 102: 14-21
(1 / 0.912)
193. Nowak-Sliwinska P, Weiss A, van Beijnum JR, Wong TJ, Ballini JP, Lovisa B, van den Bergh H, Griffioen AW. Angiostatic
kinase inhibitors to sustain photodynamic angio-occlusion. Journal of Cellular and Molecular Medicine 2012; 16: 15531562 (4 / 4.125)
194. Nurmohamed MT, van der Horst-Bruinsma I, Maksymowych WP. Cardiovascular and cerebrovascular diseases in
ankylosing spondylitis: current insights. Current Rheumatology Reports 2012; 14: 415-421 (0 / 0)
195. Ong CL, Verbakel WFAR, Dahele M, Cuijpers JP, Slotman BJ, Senan S. Fast Arc Delivery for Stereotactic Body Radiotherapy
of Vertebral and Lung Tumors. International Journal of Radiation Oncology Biology Physics 2012; 83: E137-E143 (4 /
4.105)
196. Oosterhoff D, Lougheed S, van de Ven R, Lindenberg J, van Cruijsen H, Hiddingh L, Kroon J, van den Eertwegh AJ,
Hangalapura B, Scheper RJ, de Gruijl TD. Tumor-mediated inhibition of human dendritic cell differentiation and function
is consistently counteracted by combined p38 MAPK and STAT3 inhibition. Oncoimmunology 2012; 1: 649-658 (0 / 0)
197. Oosterhoff D, Sluijter BJR, Hangalapura BN, de Gruijl TD. The dermis as a portal for dendritic cell-targeted
immunotherapy of cutaneous melanoma. Current Topics in Microbiology and Immunology 2012; 351: 181-220 (4 /
4.925)
198. Oostlander AE, Bravenhoer N, van Essen HW, Klein-Nulend J, Lems WF, Schulten BAJM, Dijkstra G, van der Woude CJ, van
Bodegraven AA, Lips P. Bone Cells From Patients With Quiescent Crohn's Disease Show a Reduced Growth Potential and
an Impeded Maturation. Journal of Cellular Biochemistry 2012; 113: 2424-2431 (3 / 2.868)
199. Ossenkoppele G, Evans-Jones G, Jaeger U, Hellstrom-Lindberg E. Towards a joint definition of European hematology.
Haematologica-The Hematology Journal 2012; 97: 636-637 (5 / 6.424)
200. Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes
CJM, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 48
Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GEG, de Weerdt O, Wijermans P, Passweg JR, Lowenberg B. Addition
of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the DutchBelgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).
Blood 2012; 120: 4706-4711 (5 / 9.898)
201. Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L,
Legdeur MC, Theobald M, Jacky E, Bargetzi M, Maertens J, Ossenkoppele GJ, Lowenberg B. Favorable effect of priming
with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation
of cytarabine. Blood 2012; 119: 5367-5373 (5 / 9.898)
202. Palma D, Lagerwaard F, Rodrigues G, Haasbeek C, Senan S. Curative Treatment of Stage I Non-Small-Cell Lung Cancer in
Patients with Severe Copd: Stereotactic Radiotherapy Outcomes and Systematic Review. International Journal of Radiation
Oncology Biology Physics 2012; 82: 1149-1156 (4 / 4.105)
203. Palma DA, Haasbeek CJA, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson R, Liu M, Panarotto J, Griffioen GHMJ,
Gaede S, Slotman B, Senan S. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors
(SABR-COMET): Study protocol for a randomized phase II trial. BMC Cancer 2012; 12: (4 / 3.011)
204. Palma DA, Senan S. Early-Stage Non-Small Cell Lung Cancer in Elderly Patients: Should Stereotactic Radiation Therapy Be
the Standard of Care?. International Journal of Radiation Oncology Biology Physics 2012; 84: 1058-1059 (4 / 4.105)
205. Peccatori FA, Giovannetti E, Pistilli B, Bellettini G, Codacci-Pisanelli G, Losekoot N, Curigliano G, Peccatori HA, Azim GA,
Peters GJ. "The only thing I know is that I know nothing": 5-fluorouracil in human milk. Annals of Oncology 2012; 23:
543-544 (5 / 6.425)
206. Peiser M, Tralau T, Heidler J, Api AM, Arts JHE, Basketter DA, English J, Diepgen TL, Fuhlbrigge RC, Gaspari AA, Johansen
JD, Karlberg AT, Kimber I, Lepoittevin JP, Liebsch M, Maibach HI, Martin SF, Merk HF, Platzek T, Rustemeyer T, Schnuch A,
Vandebriel RJ, White IR, Luch A. Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and
regulatory aspects Current knowledge assembled at an international workshop at BfR, Germany. Cellular and Molecular
Life Sciences 2012; 69: 763-781 (4 / 6,57)
207. Peters GJ, Bijnsdorp IV. TAS-102: more than an antimetabolite. Lancet Oncology 2012; 13: E518-E519 (5 / 22.589)
208. Peters GJ, Giovannetti E. First genome-wide association study to identify novel genes related to irinotecan toxicity.
Pharmacogenomics 2012; 13: 1445-1446 (4 / 3.974)
209. Peters MJL, van Sijl AM, Voskuyl AE, Sattar N, Smulders YM, Nurmohamed MT. The Effects of Tumor Necrosis Factor
Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis. Current Pharmaceutical Design 2012; 18: 1502-1511 (4 / 3.87)
210. Phernambucq ECJ, Hartemink KJ, Smit EF, Paul MA, Postmus PE, Comans EFI, Senan S. Tumor Cavitation in Patients With
Stage III Non-Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy Incidence and Outcomes. Journal of
Thoracic Oncology 2012; 7: 1271-1275 (4 / 3.661)
211. Preusser M, Winkler F, Collette L, Haller S, Marreaud S, Soffietti R, Klein M, Reijneveld JC, Tonn JC, Baumert BG, Mulvenna
P, Schadendorf D, Duchnowska R, Berghoff AS, Lin N, Cameron DA, Belkacemi Y, Jassem J, Weber DC. Trial design on
prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting
2012. European Journal of Cancer 2012; 48: 3439-3447 (4 / 5.536)
212. Raterman HG, Nurmohamed MT. Hypothyroidism in Rheumatoid Arthritis - To Screen or Not to Screen?. Journal of
Rheumatology 2012; 39: 885-886 (3 / 3.695)
213. Reijneveld JC, Klein M, Taphoorn MJB, Postma TJ, Heimans JJ. Improved, personalized treatment of glioma necessitates
long-term follow-up of cognitive functioning. Pharmacogenomics 2012; 13: 1667-1669 (4 / 3.974)
214. Reuwer AQ, Nowak-Sliwinska P, Mans LA, van der Loos CM, von der Thusen JH, Twickler MTB, Spek CA, Goffin V, Griffioen
AW, Borensztajn KS. Functional consequences of prolactin signalling in endothelial cells: a potential link with
angiogenesis in pathophysiology?. Journal of Cellular and Molecular Medicine 2012; 16: 2035-2048 (4 / 4.125)
215. Revicki DA, van den Eertwegh AJM, Lorigan P, Lebbe C, Linette G, Ottensmeier CH, Safikhani S, Messina M, Hoos A,
Wagner S, Kotapati S. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving
ipilimumab treatment. Health and Quality of Life Outcomes 2012; 10: (3 / 2.112)
216. Reyners AKL, de Munck L, Erdkamp FLG, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga ANM, Polee M, Hollema
H, van Vugt MATM, Schaapveld M, Willemse PHB. A randomized phase II study investigating the addition of the specific
COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian
cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals of Oncology 2012; 23: 2896-2902 (5
/ 6.425)
217. Rodrigues G, Eppinga W, Lagerwaard F, de Haan P, Haasbeek C, Perera F, Slotman B, Yaremko B, Yartsev S, Bauman G. A
pooled analysis of arc-based image-guided simultaneous integrated boost radiation therapy for oligometastatic brain
metastases. Radiotherapy and Oncology 2012; 102: 180-186 (1 / 0.912)
218. Rodrigues G, Yartsev S, Tay KY, Pond GR, Lagerwaard F, Bauman G. A phase II multi-institutional study assessing
simultaneous in-field boost helical tomotherapy for 1-3 brain metastases. Radiation Oncology 2012; 7: (3 / 2.321)
219. Roestenberg M, de Vlas SJ, Nieman AE, Sauerwein RW, Hermsen CC. Efficacy of Preerythrocytic and Blood-Stage Malaria
Vaccines Can Be Assessed in Small Sporozoite Challenge Trials in Human Volunteers. J Infect Dis 2012; 206: 319-323 (5 /
6.41)
220. Ruiterkamp J, Voogd AC, Tjan-Heijnen VCG, Bosscha K, van der Linden YM, Rutgers EJT, Boven E, van der Sangen MJC,
Ernst MF. SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with
distant metastases at initial presentation. BMC Surgery 2012; 12: (2 / 1.333)
221. Rutten MJ, Gaarenstroom KN, Van Gorp T, van Meurs HS, Arts HJ, Bossuyt PM, Ter Brugge HG, Hermans RH, Opmeer BC,
Pijnenborg JM, Schreuder HW, Schutter EM, Spijkerboer AM, Wensveen CW, Zusterzeel P, Mol BW, Kenter GG, Buist MR.
Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a
multicentre randomized controlled study. BMC Cancer 2012; 12: (4 / 3.011)
222. Sanabria A, Kowalski LP, Bradley PJ, Hartl DM, Bradford CR, de Bree R, Rinaldo A, Ferlito A. Sternocleidomastoid muscle
flap in preventing Frey's syndrome after parotidectomy: A systematic review. Head and Neck-Journal for the Sciences and
Specialties of the Head and Neck 2012; 34: 589-598 (4 / 2.403)
223. Schenk GJ, Haasnoot PCJ, Centlivre M, Legrand N, Rip J, de Boer AG, Berkhout B. Efficient CRM197-mediated drug
targeting to monocytes. Journal of Controlled Release 2012; 158: 139-147 (5 / 5.732)
224. Schilder L, Nurmohamed SA, ter Wee PM, Girbes ARJ, Beishuizen A, Paauw NJ, Beelen RHJ, Groeneveld ABJ. Effect of
anticoagulation regimens on handling of interleukin-6 and -8 during continuous venovenous hemofiltration in critically ill
patients with acute kidney injury. Cytokine 2012; 60: 601-607 (3 / 3.019)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 49
225. Schipper MH, van Duinen SG, Taphoorn MJ, Kloet A, Walchenbach R, Wiggenraad RG, Vecht CJ. Cerebral
ganglioneuroblastoma of adult onset: Two patients and a review of the literature. Clinical Neurology and Neurosurgery
2012; 114: 529-534 (3 / 1.581)
226. Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, Roekevisch E, Schram M, Allsopp R, Aoki V, Apfelbacher C, BruijnzeelKoomen C, Bruin-Weller M, Charman C, Cohen A, Dohil M, Flohr C, Furue M, Gieler U, Hooft L, Humphreys R, Ishii HA,
Katayama I, Kouwenhoven W, Langan S, Lewis-Jones S, Merhand S, Murota H, Murrell DF, Nankervis H, Ohya Y, Oranje A,
Otsuka H, Paul C, Rosenbluth Y, Saeki H, Schuttelaar ML, Stalder JF, Svensson A, Takaoka R, Wahlgren CF, Weidinger S,
Wollenberg A, Williams H. Towards global consensus on outcome measures for atopic eczema research: results of the
HOME II meeting. Allergy 2012; 67: 1111-1117 (5 / 6.271)
227. Schnabel PA, Smit E, de Castro Carpeno J, Lesniewski-Kmak K, Aerts J, Kraaij K, Visseren-Grul C, Dyachkova Y, Taipale K,
Girvan A, Moro-Sibilot D. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung
cancer in routine care setting: Baseline results of an observational study (FRAME). Lung Cancer 2012; 78: 263-269 (4 /
3.434)
228. Schneiders FL, de Bruin RCG, van den Eertwegh AJM, Scheper RJ, Leemans CR, Brakenhoff RH, Langendijk JA, Verheul
HMW, de Gruijl TD, Molling JW, van der Vliet HJ. Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in
Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up. J Clin Oncol 2012; 30: 567-570 (5 /
18.372)
229. Schook RM, Smit EF, Postmus PE, Hartemink KJ, Paul MA. Benefit of a Second Opinion for Lung Cancer No Recurrent
Disease, but Infection. Journal of Thoracic Oncology 2012; 7: E6-E7 (4 / 3.661)
230. Schook RM, Smit EF, Postmus PE, Hartemink KJ, Paul MA. Benefit of a Second Opinion for Lung Cancer: No Recurrent
Disease, but Infection (vol 7, pg E6, 2012). Journal of Thoracic Oncology 2012; 7: E33 (4 / 3.661)
231. Schrijver A, Reijnen MM, van Oostayen JA, Hoksbergen AW, Lely RJ, van Leersum M, de Vries JP. Initial Results of CatheterDirected Ultrasound-Accelerated Thrombolysis for Thromboembolic Obstructions of the Aortofemoral Arteries: A
Feasibility Study. Cardiovascular and Interventional Radiology 2012; 35: 279-285 (3 / 2.093)
232. Schure RM, Hendrikx LH, de Rond LGH, Ozturk K, Sanders EAM, Berbers GAM, Buisman AM. T-Cell Responses before and
after the Fifth Consecutive Acellular Pertussis Vaccination in 4-Year-Old Dutch Children. Clinical and Vaccine Immunology
2012; 19: 1879-1886 (3 / 2.546)
233. Schuurhuis GJ, Zweegman S, Ossenkoppele GJ. The adverse prognosis for acute myeloid leukemia patients with superior
autologous stem cell mobilization. Leukemia Research 2012; 36: 1323-1324 (3 / 2.923)
234. Seddon JA, Visser DH, Bartens M, Jordaan AM, Victor TC, van Furth AM, Schoeman JF, Schaaf HS. Impact of Drug
Resistance on Clinical Outcome in Children With Tuberculous Meningitis. Pediatric Infectious Disease Journal 2012; 31:
711-716 (5 / 3.577)
235. Senan S, Postmus PE. Reflections on the 14th World Conference on Lung Cancer: A European Perspective. Oncologist
2012; 17: 463-465 (3 / 3.91)
236. Senan S. Stereotactic Body Radiotherapy: Do Central Lung Tumors Still Represent a 'No-Fly Zone'?. Onkologie 2012; 35:
406-407 (1 / 0.868)
237. Senthi S, Lagerwaard FJ, Haasbeek CJA, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative
radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncology 2012; 13: 802-809 (5 /
22.589)
238. Senthi S, Verstegen NE, Senan S. Treatment of Peripheral Lung Tumors Arising After a Prior Pneumonectomy. Chest 2012;
142: 263 (5 / 5.25)
239. Sikkema AH, den Dunnen WFA, Hulleman E, van Vuurden DG, Garcia-Manero G, Yang H, Scherpen FJG, Kampen KR,
Hoving EW, Kamps WA, Diks SH, Peppelenbosch MP, De Bont ELSJ. EphB2 activity plays a pivotal role in pediatric
medulloblastoma cell adhesion and invasion. Neuro-Oncology 2012; 14: 1125-1135 (5 / 5.723)
240. Sinha IP, Altman DG, Beresford MW, Boers M, Clarke M, Craig J, Alberighi OD, Fernandes RM, Hartling L, Johnston BC, Lux
A, Plint A, Tugwell P, Turner M, van der Lee JH, Offringa M, Williamson PR, Smyth RL. Standard 5: Selection,
Measurement, and Reporting of Outcomes in Clinical Trials in Children. Pediatrics 2012; 129: S146-S152 (5 / 5.437)
241. Slort PR, Ozden N, Pape L, Offner G, Tromp WF, Wilhelm AJ, Bokenkamp A. Comparing cystatin C and creatinine in the
diagnosis of pediatric acute renal allograft dysfunction. Pediatric Nephrology 2012; 27: 843-849 (4 / 2.518)
242. Smit E, Socinski M, Mullaney B, Myrand S, Scagliotti G, V, Lorigan P, Reck M, Ciuleanu T, von Pawel J, Karaseva N,
Szczesna A, Ohannesian D, Powell E, Hozak R, Hong S, Guba S, Thatcher N. Biomarker analysis in a phase III study of
pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Annals of Oncology 2012; 23: 1723-1729 (5 / 6.425)
243. Smits M, van Rijn S, Hulleman E, Biesmans D, van Vuurden DG, Kool M, Haberler C, Aronica E, Vandertop WP, Noske DP,
Wurdinger T. EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival. Clin
Cancer Res 2012; 18: 4048-4058 (5 / 7.742)
244. Spijkers-Hagelstein J, Schneider P, Hulleman E, de Boer J, Williams O, Pieters R, Stam R. Elevated S100A8/S100A9
expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia 2012; 26:
1255-1265 (5 / 9.561)
245. Spoelstra FOB, van der Weide L, de Koste JRV, Vincent A, Slotman BJ, Senan S. Feasibility of using anatomical surrogates
for predicting the position of lung tumours. Radiotherapy and Oncology 2012; 102: 287-289 (1 / 0.912)
246. Stukstette MJPM, Hoogeboom TJ, de Ruiter R, Koelmans P, Veerman E, den Broeder AA, Cats H, Bijlsma JW, Dekker J, van
den Ende CHM. A multidisciplinary and multidimensional intervention for patients with hand osteoarthritis. Clinical
Rehabilitation 2012; 26: 99-110 (4 / 2.123)
247. Supriyadi E, Veerman AJP, Sutaryo, Purwanto I, van der Ven PM, Cloos J. Myeloid Antigen Expression in Childhood Acute
Lymphoblastic Leukemia and Its Relevance for Clinical Outcome in Indonesian ALL-2006 Protocol. J Oncol 2012; 2012:
135186 (0 / 0)
248. Swanefeld FH, van Dorp WT, Visser O, de Klerk G. Waldenstr÷m macroglobulinaemia presenting with nephrotic
syndrome.. Netherlands Journal of Medicine 2012; 70: 411-413 (4 / 2.072)
249. Swinnen I, Goossens A, Rustemeyer T. Allergic contact dermatitis caused by C30-38 olefin/isopropyl maleate/MA
copolymer in cosmetics. Contact Dermatitis 2012; 67: 318-320 (4 / 3.509)
250. Syvanen S, Labots M, Tagawa Y, Eriksson J, Windhorst AD, Lammertsma AA, de Lange EC, Voskuyl RA. Altered GABA(A)
Receptor Density and Unaltered Blood Brain Barrier Transport in a Kainate Model of Epilepsy: An In Vivo Study Using C11-Flumazenil and PET. Journal of Nuclear Medicine 2012; 53: 1974-1983 (5 / 6.381)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 50
251. Tack GJ, van Asseldonk DP, van Wanrooij RLJ, van Bodegraven AA, Mulder CJ. Tioguanine in the treatment of refractory
coeliac disease - a single centre experience. Alimentary Pharmacology & Therapeutics 2012; 36: 274-281 (4 / 3.769)
252. Tack GJ, van Wanrooij RLJ, von Blomberg BME, Amiano P, Amini H, Coupe VMH, Bonnet P, Mulder CJJ, Schreurs MWJ.
Serum parameters in the spectrum of coeliac disease: beyond standard antibody testing - a cohort study. BMC
Gastroenterology 2012; 12: 159 (3 / 2.422)
253. Taghipour K, Kirtschig G, Palace J, Groves RW, Venning V, Wojnarowska F. The association of multiple sclerosis with
bullous pemphigoid: Is there a shared antigen response?. Journal of the American Academy of Dermatology 2012; 67:
160-161 (5 / 3.991)
254. Takes RP, Rinaldo A, Silver CE, Haigentz M, Woolgar JA, Triantafyllou A, Mondin V, Paccagnella D, de Bree R, Shaha AR,
Hartl DM, Ferlito A. Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral
Oncology 2012; 48: 775-779 (5 / 2.857)
255. Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, Brade A, Cho J, Sun A, Bissonnette JP, Bezjak A. Stereotactic
Body Radiotherapy for Medically Inoperable Lung Cancer: Prospective, Single-Center Study of 108 Consecutive Patients.
International Journal of Radiation Oncology Biology Physics 2012; 82: 967-973 (4 / 4.105)
256. Taremi M, Hope A, Lindsay P, Dahele M, Fung S, Purdie TG, Jaffray D, Dawson L, Bezjak A. Predictors of Radiotherapy
Induced Bone Injury (RIBI) after stereotactic lung radiotherapy. Radiation Oncology 2012; 17: 159 (3 / 2.321)
257. Tarnanen S, Neva MH, Dekker J, Hakkinen K, Vihtonen K, Pekkanen L, Hakkinen A. Randomized controlled trial of
postoperative exercise rehabilitation program after lumbar spine fusion: study protocol. BMC Musculoskeletal Disorders
2012; 13: (3 / 1.577)
258. Tarp S, Bartels EM, Bliddal H, Furst DE, Boers M, nneskiold-Samsoe B, Rasmussen M, Christensen R. Effect of Nonsteroidal
Antiinflammatory Drugs on the C-Reactive Protein Level in Rheumatoid Arthritis A Meta-Analysis of Randomized
Controlled Trials. Arthritis and Rheumatism 2012; 64: 3511-3521 (4 / 7.866)
259. Terhaar sive Droste JS, Van Weyenberg SJB. Ischemic colitis with diverticular sparing. Gastrointestinal Endoscopy 2012;
75: 424 (4 / 4.878)
260. Terwijn M, Kelder A, Snel AN, Rutten AP, Scholten WJ, Oussoren YJM, van de Loosdrecht AA, Zweegman S, Ossenkoppele
GJ, Schuurhuis GJ. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell
compartment offers additional prognostic information in acute myeloid leukaemia. International Journal of Laboratory
Hematology 2012; 34: 432-441 (1 / 1.176)
261. Teunissen CE, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman CH, Dijkstra CD, Blankenstein MA, Pratico D.
Increased plasma 8,12-iso-iPF2alpha-VI levels in relapsing multiple sclerosis patients are not predictive of disease
progression. Multiple Sclerosis Journal 2012; 18: 1092-1098 (4 / 4.255)
262. Thyssen JP, Sosted H, Uter W, Schnuch A, Gimenez-Arnau AM, Vigan M, Rustemeyer T, Granum B, McFadden J, White JM,
White IR, Goossens A, Menne T, Liden C, Johansen JD. Self-testing for contact sensitization to hair dyes - scientific
considerations and clinical concerns of an industry-led screening programme. Contact Dermatitis 2012; 66: 300-311 (4 /
3.509)
263. Tibaldi C, Giovannetti E, Tiseo M, Leon LG, D'Incecco A, Loosekoot N, Bartolotti M, Honeywell R, Cappuzzo F, Ardizzoni
A, Peters GJ. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine/platinum-treated advanced non-small-cell lung cancer patients. Annals of Oncology 2012; 23: 670-677 (5 / 6.425)
264. Tielemans MM, van Oijen MGH, Mulder CJJ, Vos KJ, Lems WF. Esomeprazole relieves upper gastrointestinal symptoms in
high-risk and average-risk NSAID users in daily clinical practice: results from an open-label study. European Journal of
Gastroenterology & Hepatology 2012; 24: 281-287 (2 / 1.757)
265. Timmers L, Beckeringh JJ, van Herk-Sukel MPP, Boven E, Hugtenburg JG. Use and costs of oral anticancer agents in the
Netherlands in the period 2000-2008. Pharmacoepidemiology and Drug Safety 2012; 21: 1036-1044 (3 / 2.528)
266. Timmers L, Swart EL, Boons CCLM, Mangnus D, van de Ven PM, Peters GJ, Boven E, Hugtenburg JG. The use of
capecitabine in daily practice: a study on adherence and patients' experiences. Patient Preference and Adherence 2012;
6: 741-748 (3 / 1.143)
267. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smith EF,
Ardizzoni A. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with secondline pemetrexed or pemetrexed-carboplatin. Lung Cancer 2012; 78: 92-99 (4 / 3.434)
268. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS. A phase II study of YM155, a
novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Annals of
Oncology 2012; 23: 968-9U9 (5 / 6.425)
269. Uter W, Aberer W, rmario-Hita JC, Fernandez-Vozmediano JM, Ayala F, Balato A, Bauer A, Ballmer-Weber B, Beliauskiene A,
Fortina AB, Bircher A, Brasch J, Chowdhury MMU, Coenraads PJ, Schuttelaar ML, Cooper S, Czarnecka-Operacz M,
Zmudzinska M, Elsner P, English JSC, Frosch PJ, Fuchs T, Garcia-Gavin J, Fernandez-Redondo V, Gawkrodger DJ, GimenezArnau A, Green CM, Horne HL, Johansen JD, Jolanki R, Pesonen M, King CM, Krecisz B, Chomiczewska D, KiecSwierczynska M, Larese F, Mahler V, Ormerod AD, Peserico A, Rantanen T, Rustemeyer T, Sanchez-Perez J, Sansom JE,
Silvestre JF, Simon D, Spiewak R, Statham BN, Stone N, Wilkinson M, Schnuch A. Current patch test results with the
European baseline series and extensions to it from the 'European Surveillance System on Contact Allergy' network, 20072008. Contact Dermatitis 2012; 67: 9-19 (4 / 3.509)
270. Uzun S, Djamin RS, Kluytmans JA, Van't Veer NE, Ermens AA, Pelle AJ, Mulder P, van der Eerden MM, Aerts JGJV. Influence
of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD
(COLUMBUS): Study protocol for a randomised controlled trial. Trials 2012; 13: (3 / 2.496)
271. Valean S, Mulder CJJ, Pascu O, Stanciu C, Diculescu MM, Tantau M, Sporea I, Ciulean TE, Mircea PA. WGO Digestive
Oncology Task Force: Validation of Hepatogastroenterologist Practice in Oncology. Journal of Gastrointestinal and Liver
Diseases 2012; 21: 239-242 (2 / 1.811)
272. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B,
Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wohrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M,
Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer 2012; 12: 767775 (5 / 37.545)
273. van Alkemade H, de Leau M, Dieleman EM, Kardaun JW, van Os R, Vandertop WP, van Furth WR, Stalpers LJ. Impaired
survival and long-term neurological problems in benign meningioma. Neuro-Oncology 2012; 14: 658-666 (5 / 5.723)
274. van Asseldonk DP, Seinen ML, De Boer NKH, van Bodegraven AA, Mulder CJ. Hepatotoxicity associated with 6-methyl
mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6thioguanine therapy in IBD treatment. Journal of Crohns & Colitis 2012; 6: 95-101 (3 / 2.566)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 51
275. van Asseldonk DP, Tack GJ, van Wanrooij RLJ, van Bodegraven AA, Mulder CJ. Commentary: tioguanine in the treatment of
refractory coeliac disease - authors' reply. Alimentary Pharmacology & Therapeutics 2012; 36: 595-596 (4 / 3.769)
276. van de Lande J, von Mensdorff-Pouilly S, Lettinga RG, Piek JM, Verheijen RHM. Open Versus Laparoscopic Pelvic Lymph
Node Dissection in Early Stage Cervical Cancer No Difference in Surgical or Disease Outcome. International Journal of
Gynecological Cancer 2012; 22: 107-114 (2 / 1.646)
277. van de Schans SAM, Issa DE, Visser O, Nooijen P, Huijgens PC, Karim-Kos HE, Janssen-Heijnen MLG, Coebergh JWW.
Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands,
1989-2007. Annals of Oncology 2012; 23: 171-U512 (5 / 6.425)
278. van de Stadt LA, van Schaardenburg D. Alcohol consumption protects against arthritis development in seropositive
arthralgia patients. Annals of the Rheumatic Diseases 2012; 71: 1431-1432 (5 / 8.727)
279. van de Stadt LA, van Sijl AM, van Schaardenburg D, Nurmohamed MT. Dyslipidaemia in patients with seropositive
arthralgia predicts the development of arthritis. Annals of the Rheumatic Diseases 2012; 71: 1915-1916 (5 / 8.727)
280. Van de Vijver P, Scheer L, van Beijnum J, Griffioen A, Hackeng TM. Application of an omonasteine ligation strategy for the
total chemical synthesis of the BRD7 bromodomain. Chemical Communications 2012; 48: 9403-9405 (4 / 6.169)
281. van Dellen E, Douw L, Hillebrand A, Ris-Hilgersom IHM, Schoonheim MM, Baayen JC, De Witt Hamer PC, Velis DN, Klein M,
Heimans JJ, Stam CJ, Reijneveld JC. MEG Network Differences between Low- and High-Grade Glioma Related to Epilepsy
and Cognition. PloS one 2012; 7: e50122 (4 / 4.092)
282. van den Boezem PB, Kruyt PM, Cuesta MA, Sietses C. Single-Incision Versus Conventional Laparoscopic Cholecystectomy:
a Case Control Study. Acta Chirurgica Belgica 2012; 112: 374-377 (1 / 0,432)
283. van den Broek M, Dirven L, de Vries-Bouwstra JK, Dehpoor AJ, Goekoop-Ruiterman YPM, Gerards AH, Kerstens PJSM,
Huizinga TWJ, Lems WF, Allaart CF. Rapid radiological progression in the first year of early rheumatoid arthritis is
predictive of disability and joint damage progression during 8 years of follow-up. Annals of the Rheumatic Diseases
2012; 71: 1530-1533 (5 / 8.727)
284. van den Broek M, Dirven L, Klarenbeek NB, Molenaar THE, Han KH, Kerstens PJSM, Huizinga TWJ, Dijkmans BAC, Allaart
CF. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8year follow-up of the BeSt study. Annals of the Rheumatic Diseases 2012; 71: 245-248 (5 / 8.727)
285. van den Broek M, Lems WF, Allaart CF. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis.
Clinical and Experimental Rheumatology 2012; 30: S35-S38 (2 / 2.148)
286. van den Broek M, Lems WF, Allaart CF. Do we need guidelines to stop as well as to start biological therapies for
rheumatoid arthritis?. Clinical and Experimental Rheumatology 2012; 30: S21-S26 (2 / 2.148)
287. van den Eertwegh AJM, Versluis J, van den Berg HP, Santegoets SJAM, van Moorselaar RJA, van der Sluis TM, Gall HE,
Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AGM, von Blomberg BME, de Gruijl TD, Hege K, Sacks N,
Gerritsen WR. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic
prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 doseescalation trial. Lancet Oncology 2012; 13: 509-517 (5 / 22.589)
288. van Denderen JC, Blom GJ, van der Horst-Bruinsma I, Dijkmans BAC, Nurmohamed MT. Elevated liver enzymes in patients
with ankylosing spondylitis treated with etanercept. Clinical Rheumatology 2012; 31: 1677-1682 (2 / 1.996)
289. van der Burg LRA, ter Wee MM, Boonen A. Effect of biological therapy on work participation in patients with ankylosing
spondylitis: a systematic review. Annals of the Rheumatic Diseases 2012; 71: 1924-1933 (5 / 8.727)
290. van der Horst-Bruinsma I, Nurmohamed MT, Landewe RBM. Comorbidities in Patients with Spondyloarthritis. Rheumatic
Disease Clinics of North America 2012; 38: 523-+ (3 / 3,02)
291. van der Horst-Bruinsma I, Nurmohamed MT. Management and evaluation of extra-articular manifestations in
spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease 2012; 4: 413-422 (0 / 0)
292. van der Leest RJT, Liu L, Coebergh JWW, Neumann HAM, Mooi WJ, Nijsten T, de Vries E. Risk of second primary in situ and
invasive melanoma in a Dutch population-based cohort: 1989-2008. British Journal of Dermatology 2012; 167: 13211330 (4 / 3.666)
293. van der Putten L, Spasiano R, de Bree R, Bertino G, Leemans CR, Benazzo M. Flap reconstruction of the hypopharynx: a
defect orientated approach. Acta Otorhinolaryngol Ital 2012; 32: 288-296 (2 / 0.863)
294. van der Sluis TM, Bui HN, Meuleman EJH, Heijboer AC, Hartman JF, van Adrichem N, Boeve E, de Ronde W, van Moorselaar
RJA, Vis AN. Lower Testosterone Levels With Luteinizing Hormone-Releasing Hormone Agonist Therapy Than With
Surgical Castration: New Insights Attained by Mass Spectrometry. Journal of Urology 2012; 187: 1601-1606 (4 / 3.746)
295. van der Sluis TM, Vis AN, van Moorselaar RJA, Bui HN, Blankenstein MA, Meuleman EJH, Heijboer AC. Intraprostatic
testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic
hyperplasia and prostate cancer. BJU International 2012; 109: 176-182 (3 / 2.844)
296. van der Spek BW, Cuesta MA, Jacobs MA. A patient with biliary colic and intestinal obstruction. Gut 2012; 61: 713-752 (5
/ 10.111)
297. Van der Veldt AA, Lammertsma AA, Smit EF. Scheduling of anticancer drugs Timing may be everything. Cell Cycle 2012;
11: 4339-4343 (4 / 5.359)
298. Van der Veldt AA, Smit EF. Bevacizumab in Neoadjuvant Treatment for Breast Cancer. New England Journal of Medicine
2012; 366: 1637 (5 / 53.298)
299. Van der Veldt AAM, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HNJM, Hendrikse NH, Eriksson J, Windhorst
AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, Smit EF. Rapid Decrease in Delivery of Chemotherapy to
Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs. Cancer Cell 2012; 21: 82-91 (5 /
26.566)
300. Van der Veldt AAM, Vroling L, de Haas RR, Koolwijk P, van den Eertwegh AJM, Haanen JBAG, van Hinsbergh VWM,
Broxterman HJ, Boven E. Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with
metastatic renal cell cancer. International Journal of Cancer 2012; 131: E484-E493 (4 / 5.444)
301. Van der Vliet HJ, Verheul HM. Breast-Cancer Adjuvant Therapy with Zoledronic Acid. New England Journal of Medicine
2012; 366: 188-189 (5 / 53.298)
302. van der Weijden MAC, Claushuis TAM, Nazari T, Lems WF, Dijkmans BAC, van der Horst-Bruinsma I. High prevalence of
low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clinical
Rheumatology 2012; 31: 1529-1535 (2 / 1.996)
303. van der Weijden MAC, van der Horst-Bruinsma I, van Denderen JC, Dijkmans BAC, Heymans MW, Lems WF. High frequency
of vertebral fractures in early spondylarthropathies. Osteoporosis International 2012; 23: 1683-1690 (4 / 4.58)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 52
304. van der Woude D, Visser K, Klarenbeek NB, Ronday HK, Peeters AJ, Kerstens PJSM, Dijkmans BAC, Huizinga TWJ, van der
Helm-van Mil A, Allaart CF. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven
therapy: a comparison of two cohort studies. Rheumatology 2012; 51: 1120-1128 (3 / 4.058)
305. van Dijk A, Naaijkens BA, Jurgens WJFM, Oerlemans R, Scheffer GL, Kassies J, Aznou J, Brouwer M, van Rossum AC,
Schuurhuis GJ, van Milligen FJ, Niessen HWM. The multidrug resistance protein breast cancer resistance protein (BCRP)
protects adipose-derived stem cells against ischemic damage. Cell Biology and Toxicology 2012; 28: 303-315 (3 / 2.511)
306. van Eijk IC, Nielen MMJ, van der Horst-Bruinsma I, Tijhuis GJ, Boers M, Dijkmans BAC, van Schaardenburg D. Aggressive
therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM
randomized trial. Rheumatology 2012; 51: 686-694 (3 / 4.058)
307. van Empel PJ, Van der Veer WM, van Rijssen LB, Cuesta MA, Scheele F, Bonjer HJ, Meijerink WJ. Mapping the Maze of
Minimally Invasive Surgery Simulators. Journal of Laparoendoscopic & Advanced Surgical Techniques 2012; 22: 51-60 (3
/ 1.4)
308. van Es J, Mos I, Douma R, Erkens P, Durian M, Nizet T, van Houten A, Hofstee H, ten Cate H, Ullmann E, Buller H, Huisman
M, Kamphuisen PW. The combination of four different clinical decision rules and an age-adjusted D-dimer cut-off
increases the number of patients in whom acute pulmonary embolism can safely be excluded. Thrombosis and
Haemostasis 2012; 107: 167-171 (4 / 5.044)
309. van Esch EM, Welters MJ, Jordanova ES, Trimbos J, van der Burg SH, van Poelgeest MI. Treatment failure in patients with
HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert
Review of Vaccines 2012; 11: 821-840 (4 / 4.251)
310. van Gils RF, Boot CRL, Knol DL, Rustemeyer T, van Mechelen W, van der Valk PGM, Anema JR. The effectiveness of
integrated care for patients with hand eczema: results of a randomized, controlled trial. Contact Dermatitis 2012; 66:
197-204 (4 / 3.509)
311. van Gils RF, Groenewoud K, Boot CRL, Rustemeyer T, van Mechelen W, van der Valk PGM, Anema JR. Process evaluation of
an integrated, multidisciplinary intervention programme for hand eczema. Contact Dermatitis 2012; 66: 254-263 (4 /
3.509)
312. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIV, Wijnhoven BPL, Richel DJ,
Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, ten Kate FJW, Creemers GJ, Punt
CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet
AHM, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A. Preoperative Chemoradiotherapy for Esophageal or
Junctional Cancer. New England Journal of Medicine 2012; 366: 2074-2084 (5 / 53.298)
313. Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MVM, Sminia P, Stalpers LJA. Valproic acid sensitizes human glioma
cells for temozolomide and gamma-radiation. Journal of Neuro-Oncology 2012; 107: 61-67 (3 / 3.214)
314. van Raalte D, den Uyl D, Nurmohamed M, Diamant M, Lems W. Hyperglycemia and methylprednisolone: Comment on the
article by den Uyl et al Reply. Arthritis and Rheumatism 2012; 64: 3823 (4 / 7.866)
315. van Rijen MML, Bode LGM, Baak DA, Kluytmans JAJW, Vos MC. Reduced Costs for Staphylococcus aureus Carriers Treated
Prophylactically with Mupirocin and Chlorhexidine in Cardiothoracic and Orthopaedic Surgery. PloS one 2012; 7: (4 /
4.092)
316. van Sijl AM, van den Hurk K, Peters MJL, Van Halm VP, Nijpels G, Stehouwer CDA, Smulders YM, Voskuyl AE, Dekker JM,
Nurmohamed MT. Different Type of Carotid Arterial Wall Remodeling in Rheumatoid Arthritis Compared with Healthy
Subjects: A Case-Control Study. Journal of Rheumatology 2012; 39: 2261-2266 (3 / 3.695)
317. van Sijl AM, van den Oever IAM, Peters MJL, Boers M, Dijkmans BAC, Van Halm VP, Smulders YM, Voskuyl AE,
Nurmohamed MT. Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid
arthritis: the CARRE Study. Annals of the Rheumatic Diseases 2012; 71: 341-344 (5 / 8.727)
318. van Spaendonck-Zwarts KY, Badeloe S, Oosting SF, Hovenga S, Semmelink HJF, van Moorselaar RJA, van Waesberghe JH,
Mensenkamp AR, Menko FH. Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at
18 years of age: implications for surveillance. Familial Cancer 2012; 11: 123-129 (1 / 1.302)
319. van Tellingen A, Voskuyl AE, Vervloet MG, Bijl M, de Sevaux RGL, Berger SP, Derksen RHWM, Berden JHM. Dutch
guidelines for diagnosis and therapy of proliferative lupus nephritis. Netherlands Journal of Medicine 2012; 70: 199-206
(4 / 2.072)
320. van Tuyl LHD, Boers M. Patient's Global Assessment of Disease Activity: What Are We Measuring?. Arthritis and
Rheumatism 2012; 64: 2811-2813 (4 / 7.866)
321. van Tuyl LHD, Britsemmer K, Wells GA, Smolen JS, Zhang B, Funovits J, van Schaardenburg D, Felson D, Boers M.
Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in
the forefeet on outcome. Annals of the Rheumatic Diseases 2012; 71: 33-37 (5 / 8.727)
322. van Walsum GAM, de Ridder JAM, Verhoef C, Bosscha K, van Gulik TM, Hesselink EJ, Ruers TJM, van den Tol MP,
Nagtegaal ID, Brouwers M, van Hillegersberg R, Porte RJ, Rijken AM, Strobbe LJA, de Wilt JHW. Resection of liver
metastases in patients with breast cancer: Survival and prognostic factors. European Journal of Surgical Oncology 2012;
38: 910-917 (0 / 0)
323. Van Weyenberg SJ. To Snare a Snare, or Not to Snare?. Gastroenterology 2012; 142: E1-E2 (5 / 11.675)
324. Van Weyenberg SJB, van Turenhout ST, Jacobs MAJM, Bouma G, Mulder CJJ. Video capsule endoscopy for previous overt
obscure gastrointestinal bleeding in patients using anti-thrombotic drugs. Digestive Endoscopy 2012; 24: 247-254 (2 /
1.194)
325. van Wijk BC, Willemse RB, Vandertop W, Daffertshofer A. Slowing of M1 oscillations in brain tumor patients in resting
state and during movement. Clinical Neurophysiology 2012; 123: 2212-2219 (4 / 3.406)
326. Vandenbroucke-Grauls CMJE, Vandenbroucke JP, van der Meer JWM. Resistance after selective decontamination. Lancet
Infectious Diseases 2012; 12: 180-181 (5 / 17.391)
327. Veenhof AAFA, Vlug MS, van der Pas MHGM, Sietses C, van der Peet DL, de Lange-de Klerk E, Bonjer HJ, Bemelman WA,
Cuesta MA. Surgical Stress Response and Postoperative Immune Function After Laparoscopy or Open Surgery With Fast
Track or Standard Perioperative Care A Randomized Trial. Annals of Surgery 2012; 255: 216-221 (5 / 7.492)
328. Verbakel WFAR, van Reij E, Ladenius-Lischer I, Cuijpers JP, Slotman BJ, Senan S. Clinical Application of a Novel Hybrid
Intensity-Modulated Radiotherapy Technique for Stage III Lung Cancer and Dosimetric Comparison With Four Other
Techniques. International Journal of Radiation Oncology Biology Physics 2012; 83: E297-E303 (4 / 4.105)
329. Verbrugge SE, Assaraf YG, Dijkmans BAC, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, Van der
Heijden JW, de Gruijl TD, Scheper RJ, Jansen G. Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug ResistanceAssociated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 53
(Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis. Journal of
Pharmacology and Experimental Therapeutics 2012; 341: 174-182 (4 / 3.828)
330. Vergnenegre A, Smit EF, Toy E, Parente B, Schmitz S, Kraaij K, Soldatenkova V, Visseren-Grul C, Zanotti G, Taipale K,
Moro-Sibilot D. Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment
pathways from the SELECTTION observational study. Current Medical Research and Opinion 2012; 28: 1253-1262 (4 /
2.38)
331. Verhoeven M, Bystrova S, Winnubst L, Qureshi H, de Gruijl TD, Scheper RJ, Luttge R. Applying ceramic nanoporous
microneedle arrays as a transport interface in egg plants and an ex-vivo human skin model. Microelectronic Engineering
2012; 98: 659-662 (3 / 1.557)
332. Verkade E, Bosch T, Hendriks Y, Kluytmans J. Outbreak of Methicillin-Resistant Staphylococcus aureus ST398 in a Dutch
Nursing Home. Infection Control and Hospital Epidemiology 2012; 33: 624-626 (5 / 3.669)
333. Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH,
Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE. Validation of Serum Amyloid alpha as an Independent
Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients. European Urology 2012; 62:
685-695 (5 / 8.493)
334. Vernooij-van Langen AMM, Loeber JG, Elvers B, Triepels RH, Gille JJP, Van der Ploeg CPB, Reijntjens S, Dompeling E, nkertRoelse JE. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax 2012; 67:
289-295 (5 / 6.84)
335. Verselewel de Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of Intraoperative Stimulation
Brain Mapping on Glioma Surgery Outcome: A Meta-Analysis. J Clin Oncol 2012; 30: 2559-2565 (5 / 18.372)
336. Verstegen NE, Lagerwaard FJ, Senan S. Developments in early-stage NSCLC: advances in radiotherapy. Annals of Oncology
2012; 23: 46-51 (5 / 6.425)
337. Vlug M, Bartels S, Wind J, Ubbink D, Hollmann M, Bemelman W. Which fast track elements predict early recovery after
colon cancer surgery?. Colorectal Disease 2012; 14: 1001-1008 (3 / 2.927)
338. von Tresckow B, Pluetschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM,
Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. Dose-Intensification in Early Unfavorable
Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol 2012; 30: 907-913 (5
/ 18.372)
339. Vonkeman HE, deLeest HTJI, van deLaar MAFJ, vanBaarlen J, Steen KSS, Lems WF, Bijlsma JWJ, Kuipers EJ, Houben HHML,
Janssen M, Dijkmans BAC. Assessment of Helicobacter pylori eradication in patients on NSAID treatment. BMC
Gastroenterology 2012; 12: (3 / 2.422)
340. Vos CG, Hartemink KJ, Jiya TU, Feller RE, Oosterhuis JWA, Paul MA. Severe Kyphosis With Spinal Cord Compression After
Resection of a Superior Sulcus Tumor. Annals of Thoracic Surgery 2012; 94: 1003-1006 (5 / 3.741)
341. Vosjan MJWD, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GAMS. Nanobodies Targeting the
Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy. Molecular Cancer Therapeutics 2012; 11:
1017-1025 (4 / 5.226)
342. Voss A, Kluytmans J, Pittet D. A new journal and new global perspective on infection control and public health.
Antimicrob Resist Infect Control 2012; 1: 4 (0 / 0)
343. Walker KM, Pope J. Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails-A
Consensus of Systemic Sclerosis Experts. Seminars in Arthritis and Rheumatism 2012; 42: 42-55 (4 / 4.969)
344. Walsh J, Lems WF, Karras D, Langdahl BL, Ljunggren O, Fahrleitner-Pammer A, Barrett A, Rajzbaum G, Jakob F, Marin F.
Effectiveness of Teriparatide in Women Over 75 Years of Age with Severe Osteoporosis: 36-Month Results from the
European Forsteo Observational Study (EFOS). Calcified Tissue International 2012; 90: 373-383 (2 / 2.376)
345. Weiss A, van den Bergh H, Griffioen AW, Nowak-Sliwinska P. Angiogenesis inhibition for the improvement of
photodynamic therapy: The revival of a promising idea. Biochimica et Biophysica Acta-Reviews on Cancer 2012; 1826:
53-70 (5 / 9.38)
346. Widjajanto PH, Sutaryo S, Purwanto I, Ven PM, Veerman AJP. Early Response to Dexamethasone as Prognostic Factor:
Result from Indonesian Childhood WK-ALL Protocol in Yogyakarta. J Oncol 2012; 2012: 417941 (0 / 0)
347. Wielders CCH, Kampschreur LM, Schneeberger PM, Jager MM, Hoepelman AIM, Leenders ACAP, Hermans MHA, Wever PC.
Early Diagnosis and Treatment of Patients with Symptomatic Acute Q Fever Do Not Prohibit IgG Antibody Responses to
Coxiella burnetii. Clinical and Vaccine Immunology 2012; 19: 1661-1666 (3 / 2.546)
348. Wildeman MA, Novalic Z, Verkuijlen SAWM, Juwana H, Huitema ADR, Tan IB, Middeldorp JM, de Boer JP, Greijer AE.
Cytolytic virus activation therapy for epstein-barr virus-driven tumors. Clin Cancer Res 2012; 18: 5061-5070 (5 / 7.742)
349. Wilhelm AJ, de Graaf P, Veldkamp AI, Janssen JJWM, Huijgens PC, Swart EL. Population pharmacokinetics of ciclosporin in
haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. British Journal of
Clinical Pharmacology 2012; 73: 553-563 (3 / 2.958)
350. Wittenberg R, Peters J, Weber M, Lely R, Cobben L, Prokop M, Schaefer-Prokop C. Stand-alone performance of a computerassisted detection prototype for detection of acute pulmonary embolism: a multi-institutional comparison. British Journal
of Radiology 2012; 85: 758-764 (2 / 1.314)
351. Wondergem MJ, Zijlstra JM, de Rooij M, Visser OJ, Huijgens PC, Zweegman S. Improving survival in patients with
transformed B cell non Hodgkin lymphoma: consolidation with 90Yttrium ibritumomab tiuxetan-BEAM and autologous
stem cell transplantation. British Journal of Haematology 2012; 157: 395-397 (4 / 4.941)
352. Wonders J, De Boer NK, Van Weyenberg SJ. Spot diagnosis: Eruptive melanocytic naevi during azathioprine therapy in
Crohn's disease. Journal of Crohns & Colitis 2012; 6: 636 (3 / 2.566)
353. Zuurbier L, Petricoin EF, Vuerhard MJ, Calvert V, Kooi C, Buijs-Gladdines JGCA, Smits WK, Sonneveld E, Veerman AJP,
Kamps WA, Horstmann M, Pieters R, Meijerink JPP. The significance of PTEN and AKT aberrations in pediatric T-cell acute
lymphoblastic leukemia. Haematologica-The Hematology Journal 2012; 97: 1405-1413 (5 / 6.424)
354. Zwaveling S, Tytgat GAM, van der Zee DC, Wijnen MHWA, Heij HA. Is complete surgical resection of stage 4
neuroblastoma a prerequisite for optimal survival or may > 95 % tumour resection suffice?. Pediatric Surgery
International 2012; 28: 953-959 (2 / 1.253)
Scientific publications (books, book chapters, proceedings)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 54
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
Bartelsman JFWM, Depla A, Brand HS. Ziekten van het maagdarmkanaal; in Brand HS, van Diermen DE, Makkes PC, (eds):
Algemene ziekteleer voor tandartsen. Houten/Diegem, Bohn Stafleu van Loghum. 2012; 177-195
Brand HS, Vissink A. General pathology; in Noble SL, (ed): Clinical textbook of dental hygiene and therapy. Chicester,
Wiley-Blackwell. 2012; 32-52
Chang JY, Shirvani SM, Loo BW, Lamond JP, lotman BJ, agata Y. Primary lung cancer; in Lo SS, The BS, Lu JL, Schefter TE,
(eds): Stereotactic body radiation therapy. Heidelberg, Springer Verlag. 2012; 137-162
Cornelissen JJ, Brand HS. Kwaadaardige aandoeningen van het immuunsysteem; in Brand HS, van Diermen DE, Makkes
PC, (eds): Houten/Diegem, Bohn Stafleu van Loghum. 2012; 63-70
de Boer EMJ. Chronic venous insufficiency and occupation; in Rustemeijer T, Elsner P, John SM, (eds): Kanerva's
occupational dermatology. 2012; 363-370
De Boer NKH, van Bodegraven AA. Ulcerative colitis: clinical course and complications; in I.E.Koutroubakis, D.H.Le, (eds):
Inflammatory Bowel Disease (E-book). Future Science Medicine. 2012; :
de Bree R. How to reconstruct small tongue and floor of mouth defects; Pearls and pitfalls in head and neck surgery.
Basel, Karger. 2012; 56-57
de Gruijl TD, van de Ven R. Adenovirus-Based Immunotherapy of Cancer: Promises to Keep. In: Applications of Viruses for
Cancer Therapy. 2012; 147-220
Gibbs S, Martin SF, Corsini E, Thierse HJ. Identification of Contact Allergens by In Vitro Cell Culture-Based Methods;
Kanerva's Occupational Dermatology. 2012; 106
Jackman AL, Jansen.G., Ng M. Folate receptor targeted thymidylate synthase inhibitors; in A.L.Jackman, C.P.Leamon,
(eds): Targeted drug strategies for cancer and inflammation. New York, Springer Science. 2012; 93-118
Kaspers GJ. Een kind met een opgezette buik; in Draaisma JMTh, Bot.P., Swart JF, (eds): Probleemgeoriënteerd denken in
de kindergeneeskunde. De Tijdstroom. 2012
Kaspers GJ, Reinhardt D. Acute myeloid leukemia; in Stevens M, Caron HN, Biondi A, (eds): Cancer in Children - clinical
management. Oxford University Press. 2012
Kenter GG. Premaligne aandoeningen; in Heineman MJ, (ed): De voortplanting van de mens. Amsterdam, Reed Business.
2012
Lo SL, Sahgal A, Ma L, Slotman BJ, Huang Z, Mayr NA, Kunos CA, The BS, Machtay M, Chang EL. Normal tissue constraints;
in Lo SS, The BS, Schefter TE, (eds): Stereotactic body radiation. Heidelberg, Springer Verlag. 2012; 393-410
Moll AC, Bosscha MI, Dommering CJ. Second primary malignancy; in Ramasubramanian A, Shields CL, (eds):
Retinoblastoma. Jaypee Highlights. 2012; 195-199
Moll AC, Marees T, Bosscha K, van Leeuwen FE. Long-term survivors of retinoblastoma: risk of second primary; Tumors of
the central nervous system. Springer Compagny. 2012; 147-154
Oosterhoff D, Curiel DT, de Gruijl TD. Antigen targeting to dendritic cells for cancer immunotherapy; in Curiel TJ, (ed):
Cancer Immunotherapy: Paradigms, Practice and Potential. Springer. 2012
Peerdeman SM, Okay Saydam, Jimenez CR. Meningiomas: clinical needs and molecular insights. 2012
Postma TJ, Heimans JJ. Neurological complications of chemotherapy to the peripheral nervous system. In: Handbook of
Clinical Neurology / edited by P J Vinken and G W Bruyn. 2012; 105: 917-936
Rustemeyer T, Elsner P, John SM, Maibach HI. Kanerva's occupational dermatology. New York, Springer. 2012
Rustemeyer T, Fartasch M. Immunology and Barrier Function of the Skin; Kanerva's Occupational Dermatology. 2012; 1
Rustemeyer T, Frosch PJ. Occupational Contact Dermatitis in Dental Personnel; Kanerva's Occupational Dermatology.
2012; 143
Rustemeyer T, van Hoogstraten IMW, von Blomberg BME, Scheper RJ. Mechanisms of Allergic Contact Dermatitis;
Kanerva's Occupational Dermatology. 2012; 14
Schneiders FL, Scheper RJ, Bontkes HJ, von Blomberg B, van den Eertwegh AJ, de Gruijl TD, van der Vliet HJ. Clinical trials
with a-Galactosylceramide (KRN7000) in advanced cancer; in Terabe M, Berzofsky J.A., (eds): Natural killer T cells:
Balancing the regulation of tumor immunity, cancer drug discovery and development. Springer Science & Business Media,
LLC, 2012, pp 169-183. 2012; 169-183
Sminia P. Modelsystemen in de radiotherapie; in de Ru VJ, van Diest PJ, Looijenga LHJ, van de Velde CJH, Wagenaar DJT,
(eds): Canon van de Oncollogie. 2012; 98-99
van Bodegraven AA, Van Weyenberg SJ, Wierdsma.N.J., de Wit NJ, Brouwers JRBJ. Gastroenterology [Maag-, darm- en
leverziekten]; in van Everdingen JJJ, Glerum JH, Schobber AFAM, Wiersma T, Berzofsky JA, (eds): Diagnose en Therapie
2013-2014. Houten, BohnStafleu VanLoghum. 2012: 169-183
van der Meij B. Lung cancer / Hemato-oncology; in Vogel J, Beijer S, Doornink N, Wipkink A, (eds): Manual nutrition in
cancer. Utrecht, De Tijdstroom. 2012
van Laar JM, Michels-Amelsfort JMR, Brand HS. Reumatische ziekten; in Brand HS, van Diermen DE, Makkes PC, (eds):
Algemene ziekteleer voor tandartsen. 2012
van Moorselaar RJA. Advanced and metastatic prostate cancer, new results of clinical trials; Course book ESU Course:
What's new in prostate cancer and female urology. 2012; 64-81
van Moorselaar RJA. Localised prostate cancer, there is more than robotic surgery; Course book ESU Course: What's new
in prostate cancer and female urology. 2012; 64-81
van Moorselaar RJA, Piet AHM, Gerritsen WR. Prostaatkanker; in Wymenga ANW, Coebergh JWW, Maas HAAM, Schouten
HC, (eds): Handboek kanker bij ouderen. De Tijdstroom. 2012; 241-248
Zeijlemaker W, Schuurhuis GJ. Minimal residual disease and leukemic stem cells in acute myeloid leukemia; Acute
Leukemia. 2012
Professional publications
1.
2.
3.
4.
Ang C. Diagnostische (on)mogelijkheden bij Borrelia-infecties. Ned Tijdschr Med Microbiol 2012; 20: 126-129
Ang C, Vainio S. Hoe (on-)schuldig is een knuffeltje?. Ned Tijdschr Med Microbiol 2012; 20: 81-82
Baart JA, Bretschneider JH, De Visscher JGAM, van der Waal I. Afwijkingen van de sinus maxillaris: een overzicht..
Nederlands Tijdschrift voor Tandheelkunde 2012; 119: 199-204
Boers M. [Prednisone for rheumatoid arthritis: the detriment of the doubt]. Nederlands Tijdschrift voor Geneeskunde
2012; 155: A5069
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 55
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
Brand HS. Hoofd- en halszaken in de huisarts- en tandartspraktijk. Nederlands Tijdschrift voor Tandheelkunde 2012;
119: 525
Buis DR. Mortaliteit na intracraniale tumorchirurgie bij kinderen en volwassenen. Tijdschrift voor Neurologie &
Neurochirurgie 2012; 113: 40-42
Coenen EA, Balgobing BV, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM. MLL-herschikte acute myelo´de leukemie bij
kinderen: een heterogene ziekte. Nederlands Tijdschrift voor Hematologie 2012; 9: 177-185
de Bree R. De keuze van behandeling bij het klein glottisch larynxcarcinoom: endoscopische resectie of radiotherapie?.
Nederlands Tijdschrift voor Oncologie 2012; 9: 243-244
de Jong I.J., van Moorselaar RJA, Pelger RCM, Mulders PFA, Sleeboom H.P.. Rol van bisfosfonaten bij prostaatcarcinoom..
Tijdschrift voor Urologie 2012; 2: 211-214
de Meij TGJ, Kneepkens CMF. Een meisje met een jeukende huidaandoening. Nederlands Tijdschrift voor Geneeskunde
2012; 156: A4646
de Melker HE, Kenter G, van Rossum T, Conyn-van Spaendonck M. Developments in HPV vaccination.. Nederlands
Tijdschrift voor Geneeskunde 2012; 156: A5410
de Rie M. Translationeel onderzoek: from bench to bedside.. Ned Tijdschr Dermatol Venereol 2012; 22: 139-142
de Rotte MCFJ, den Boer E, Bulatovic M, Calasan M, Heijstek M, te Winkel ML, Heil SG, Lindemans J, Jansen G, Peters GJ,
Kamphuis SSM, Pieters R, Tissing WJE. Personalized medicine of methotrexate therapy.. Ned Tijdschr Klin Ghem
Labgeneesk 2012; 37: 50-53
Haverkort ME, Kilestein J, Simoons-Smit AM, Middeldorp JM, Hazewinkel MJ, Spaander FHM, ten Houten R. EBVgeassocieerde myelitis transversa bij een 16-jarig meisje. Tijdschrift voor Infectieziekten 2012; 7: 66-72
Haverkort ME, van der Spek BW, Lips PTAM, Slieker WA, Bronsveld W, ter Heine R, Huitema AD. Intracellulaire accumulatie
van tenofovir-difosfaat bij een hiv-ge´nfecteerde patiënt met het syndroom van Fanconi en osteomalacie; casereport en
review van de literatuur. Tijdschrift voor Infectieziekten 2012; 7: 120-126
Henselmans JML, van de Loosdrecht AA. Progressieve multifocale leukoencefalopathie: de rol van rituximab en
natalizumab. Tijdschrift voor Neurologie en Neurochirurgie 2012; 113: 60-65
Huijgens PC. Karakterisering van ziekte en zieke in de hemato-oncologie. Tijdschr Psychiatr 2012; 54: 921-925
Karagozoglu KH, Eerenstein SEJ, van der Waal I. Een Afrikaanse man met een zwelling in de hals.. Nederlands Tijdschrift
voor Tandheelkunde 2012; 119: 18-20
Karssemakers LHE, Nolte JW, Saridin CP, Raijmakers PGHM, Becking AG. [Unilateral condylar hyperactivity]. Nederlands
Tijdschrift voor Tandheelkunde 2012; 119: 500-504
Kenter G, Wijma S. NVOG celebrates 125 years. Nederlands Tijdschrift voor Geneeskunde 2012; 155: A5178
Krekel NMA, Haloua MH, Muller S, Bergers E, Rietveld DHF, Meijers S, van den Tol MP. Breast conserving surgery for
breast cancer: still much to be gained. Nederlands Tijdschrift voor Geneeskunde 2012; 156: A3573
Krekel NMA, Meijer S, van den Tol MP. Echogeleide borstsparende chirurgie voor palpabele mammacarcinomen.
Nederlands Tijdschrift voor Geneeskunde 2012; 156: 439-442
Krekel NMA, van Amerongen AHMT, Bergers E, Meijer S, van den Tol MP. Ultrasonically guided breast-conserving surgery
for palpable mammary tumours. Nederlands Tijdschrift voor Geneeskunde 2012; 156: A4173
Lynch MG, van den Berg-van Erp S, Tan ACIT, Pettersson Fernholm AM. Submucosale presentatie van de ziekte van
Whipple: een variant die gemakkelijk wordt gemist.. Nederlands Tijdschrift voor Geneeskunde 2012; 156:
Neve S, Jacobs H, Stoof TJ, Simoons-Smit AM, Meenken C, Hoebe EK, van Agtmael MA. Oculair myositis als uiting van een
vroeg gedissemineerde Borrelia burgdoferi-infectie. Tijdschrift voor Infectieziekten 2012; 7: 175-179
Nieuwland AC, Vierhout L, Eekhoff EMW, van der Waal I. Een adolescente jongen met fibreuze dysplasie van het kaakbot..
Nederlands Tijdschrift voor Tandheelkunde 2012; 119: 541-545
Nievelstein RJ, Schaefer-Prokop C, Heggelman BGF, Boellaard R, Lugtenburg PJ, Zijlstra-Baalbergen JM. Aanbevelingen:
Standaardisatie van aanvraag, uitvoering en verslaglegging van CT beeldvorming in het kader van FDG-PET/CT
onderzoeken bij patiÙnten met een maligne lymfoom. Tijdschr Nucl Geneeskd 2012; 34: 724-732
Schimmer JA, van der Steeg AF, Zuidema WP. Immunologische functie van de milt na embolisatie bij traumapatienten..
Ned Tijdschr Traum 2012; 20: 74-80
Schout BMA, Meuleman EJH. Erectiestoornis en incontinentie na prostatectomie. Behandeling van complicaties van
chirurgie bij prostaatkanker.. Nederlands Tijdschrift voor Geneeskunde 2012; 156: A4667
Schouten CS, Castelijns JA, Hoekstra OS, Leemans CR, de Bree R. Responseevaluatie na chemoradiatie voor uitgebreide
orofarynxcarcinomen met gebruik van PET-CT en MRI: de REACTION-studie. Nederlands Tijdschrift voor Oncologie 2012;
8: 368-372
Sikkens JJ, van Agtmael MA. Verslag Europese antibioticadag 2011: Antibiotica op het humaanveterinaire grensvlak.
Tijdschrift voor Infectieziekten 2012; 7: 187-188
Spijkerman I, Ruijs G, Kluijtmans JAJW. De toekomst van infectiepreventie (1) Richtlijnen en implementatie. Nederlands
Tijdschrift voor Medische Microbiologie 2012; 20: 70-72
Spijkerman I, Ruijs G, Kluijtmans JAJW. De toekomst van infectiepreventie (2) - Norm, samenwerking, opleiding en
financiering. Nederlands Tijdschrift voor Medische Microbiologie 2012; 20: 149-151
Stoker SD, Greijer AE, Wildeman MA, Novalic C, de Boer JP, Huitema ADR, Fles R, Karakullukcu B, Middeldorp JM, Tan IB.
Nieuwe diagnostische middelen en behandeltechnieken voor het nasofarynxcarcinoom. Nederlands Tijdschrift voor
Oncologie 2012; 9: 262-268
Vainio S, Murk JL, Ossenkopp YJ. Ertapenem: achtergronden en klinische toepassing. Tijdschrift voor Infectieziekten
2012; 7: 57-65
van Breemen MS, van der Kuip M, Ang C, van Furth AM, Wolf NI. Torticollis and seizures due to neuroborreliosis in a
child. Nederlands Tijdschrift voor Geneeskunde 2012; 156: A5157
van Dalen EC, Galimont-Collen A, Koldenhof JJ, Kardaun SH, Bousema MT, van der Linden MMD, van Montfrans C.
Behandeling van huidafwijkingen bij doelgerichte medicijnen in de oncologie. Ned Tijdschr Dermatol Venereol 2012; 22:
286-297
van der Putten L, Vergeer MR, de Bree R. Een hypofarynxcarcinoom na bestraling voor tuberculose. Nederlands Tijdschrift
voor Oncologie 2012; 9: 307-310
van der Waal I. Een opaciteit in de onderkaak. Tandartspraktijk 2012; 33: 13-15
van der Waal I. Kaakbotkanker; een valkuil. Tandartspraktijk 2012; 33: 30-31
van der Waal I. Algemene ziekteleer voor tandartsen. Inhoudelijk en waardevol [Bespreking van het boek Algemene
ziekteleer voor tandartsen. Derde, geheel herziene druk]. Nederlands Tandartsenblad 2012; 67: 33
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 56
42. van Gils RF, Boot CR, Knol DL, Rustemeyer T, van der Valk PGM, Anema JR. Integrated care for patients with hand
eczema: results of a randomized, controlled trial. Nederlands Tijdschrift voor Geneeskunde 2012; 156: A5181
43. van Moorselaar RJA. Nieuwe hormonale manipulaties bij castratieresistent prostaatcarcinoom (CRPC). Tijdschrift voor
Urologie 2012; 2: 38-41
44. van Schaardenburg D. Gauging rheumatoid arthritis. Tijdschrift voor Urologie 2012; 2: 22-28
45. van Uhm JIM, Beckers GMA, van der Laarse WJ, Meuleman EJ, Geldof AA, !Lost Data. Ontwikkeling van een
rattenblaasstripmodel om de bioactiviteit van botulinetoxine type A te meten. Tijdschrift voor Urologie 2012; 2: 164-165
46. Vis AN. De theoretische achtergrond van de behandelingen bij castratieresistent prostaatcarcinoom (CRPC). Tijdschrift
voor Urologie 2012; 2: 22-28
47. Vos CG, Dickhoff C, Paul MA, Dahele M, Smit EF, Hartemink KJ. Treatment and prognosis of superior sulcus tumours.
Nederlands Tijdschrift voor Geneeskunde 2012; 156: A5419
Popular publications
1.
2.
Mostert S. VUmc actief in Kenia. Attent 2012; 1: 23-24
van der Waal I. Mondbranden. Alles over het gebit. NMT patiëntenplatform 2012; 5
Dissertations
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Caretti V. Pioneering Preclinical Research in Diffuse Intrinsic Pontine Glioma: Towards New Treatment Strategies. Vrije
Universiteit Amsterdam, 7/3/2012. (Co-)promotores: G.J.L. Kaspers, W.P. Vandertop, T. Wurdinger, D.P. Noske (cat A)
Codacci Pisanelli G. Biochemical Modulation of 5-fluorouracil by uridine and leucovorin. Vrije Universiteit Amsterdam,
11/23/2012. (Co-)promotores: G.J. Peters, C.J. van Groeningen, C.L. van der Wilt (cat B)
Dahele MR. The implementation of advanced technologies in high-precision radiotherapy. Vrije Universiteit Amsterdam,
11/21/2012. (Co-)promotores: S. Senan, B.J. Slotman (cat A)
de Langen AJ. Response evaluation during targeted therapy: early incorporation of imaging biomarkers. Vrije Universiteit
Amsterdam, 4/27/2012. (Co-)promotores: E.F. Smit, O.S. Hoekstra, M. Lubberink (cat A)
de Vries RR. The surgical treatment of bladder cancer. Vrije Universiteit Amsterdam, 11/22/2012. (Co-)promotores: S.
Horenblas (cat B)
Dirven L. Benefits and risks of targeted treatment in rheumatoid arthritis. Vrije Universiteit Amsterdam, 9/14/2012. (Co)promotores: W.F. Lems, T.W.J. Huizinga, C.F. Allaart, P.J.S.M. Kerstens (cat B)
Giannakopoulos GF. Triage and assessment of injuries in early Trauma Care. Vrije Universiteit Amsterdam, 6/1/2012.
(Co-)promotores: H.J. Bonjer, F.C. Bakker (cat A)
Lind JSW. Management of advanced non-small cell lung cancer: moving towards a more personalized approach. Vrije
Universiteit Amsterdam, 3/26/2012. (Co-)promotores: E.F. Smit, S. Senan (cat A)
Ong CL. Volumetric modulated arc therapy for stereotactic body radiotherapy: planning considerations, delivery accuracy
and efficiency. Vrije Universiteit Amsterdam, 9/19/2012. (Co-)promotores: S. Senan, B.J. Slotman, W.F. Verbakel (cat A)
Rostami Nejad M. Celiac disease: epidemiology, genetic and clinical behaviour in Iran. Vrije Universiteit Amsterdam,
12/5/2012. (Co-)promotores: C.J.J. Mulder, M.R. Zali (cat B)
Schreuder TCMA. Non-alcoholic fatty liver disease (NAFLD): from epidemiology to diagnosis. Vrije Universiteit
Amsterdam, 12/13/2012. (Co-)promotores: C.J.J. Mulder, P.L.M. Jansen, C.M.J. van Nieuwkerk (cat A)
Supriyadi E. Diagnostic Advances for Improved Treatment of Childhood Acute Lymphoblastic Leukemia in Indonesia. Vrije
Universiteit Amsterdam, 10/10/2012. (Co-)promotores: G.J.L. Kaspers, A. Sutaryo, J. Cloos (cat B)
Tack GJ. On the workup of (refractory) coeliac disease. Vrije Universiteit Amsterdam, 11/15/2012. (Co-)promotores: C.J.J.
Mulder, M.W.J. Schreurs, B.M.E. von Blomberg-van der Flier (cat A)
van der Veldt AAM. Sunitinib for advanced renal cell cancer: pharmacodynamic aspects. Vrije Universiteit Amsterdam,
7/4/2012. (Co-)promotores: E. Boven, J.B.A.G. Haanen, A.J.M. van den Eertwegh (cat A)
van der Veldt AAM. Towards personalized treatment planning of chemotherapy:[11C] docetaxel studies in lung cancer
patients. Vrije Universiteit Amsterdam, 7/4/2012. (Co-)promotores: A.A. Lammertsma, E.F. Smit, M. Lubberink, N.H.
Hendrikse (cat A)
van Luijn MM. Impaired antigen expression as immune escape mechanism in Acute Myeloid Leukemia. Vrije Universiteit
Amsterdam, 2/15/2012. (Co-)promotores: G.J. Ossenkoppele, A.A. van de Loosdrecht, S.M. van Ham (cat A)
Vosjan MWJD. Nanobodies, a novel class of antibodies to improve imaging and blockage of growth factors and their
receptors in cancer. Vrije Universiteit Amsterdam, 11/29/2012. (Co-)promotores: G.A.M.S. van Dongen, G.W.M. Visser,
P.M.P. van Bergen en Henegouwen (cat A)
Widjajanto PH. Treatment of Childhood Acute Lymphoblastic Leukemia in Low-income Country: the Indonesia's
Experience. Vrije Universiteit Amsterdam, 10/10/2012. (Co-)promotores: G.J.L. Kaspers, A. Sutaryo, J. Cloos (cat B)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 57
Program 5: Quality of life
Scientific papers refereed
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Bernardo D, Pena AS. Developing strategies to improve the quality of life of patients with gluten intolerance in patients
with and without coeliac disease. European Journal of Internal Medicine 2012; 23: 6-8 (3 / 2.000)
Bongers ML, Hogervorst JGF, Schouten LJ, Goldbohm RA, Schouten HC, van den Brandt PA. Dietary Acrylamide Intake and
the Risk of Lymphatic Malignancies: The Netherlands Cohort Study on Diet and Cancer. PloS one 2012; 7: (4 / 4.092)
Braam KI, Overbeek A, Kaspers GJL, Ronckers CM, Schouten-van Meeteren AYN, van Dulmen-den Broeder E, Veening MA.
Malignant melanoma as second malignant neoplasm in long-term childhood cancer survivors: A systematic review.
Pediatric Blood & Cancer 2012; 58: 665-674 (3 / 1.891)
Braamse AMJ, Gerrits MMJG, van Meijel B, Visser O, van Oppen P, Boenink AD, Cuijpers P, Huijgens PC, Beekman ATF,
Dekker J. Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological
malignancies. Bone Marrow Transplantation 2012; 47: 757-769 (4 / 3.746)
Buffart LM, Thong MSY, Schep G, Chinapaw MJM, Brug J, van de Poll-Franse L. Self-Reported Physical Activity: Its
Correlates and Relationship with Health-Related Quality of Life in a Large Cohort of Colorectal Cancer Survivors. PloS one
2012; 7: (4 / 4.092)
Buffart LM, van Uffelen JG, Riphagen I, Brug J, van Mechelen W, Brown WJ, Chinapaw MJ. Physical and psychosocial
benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials.
BMC Cancer 2012; 12: 559 (4 / 3.011)
Buskermolen S, Langius JAE, Kruizenga HM, Ligthart-Melis GC, Heymans MW, Verheul HMW. Weight Loss of 5% or More
Predicts Loss of Fat-Free Mass During Palliative Chemotherapy in Patients With Advanced Cancer: A Pilot Study. Nutrition
and Cancer-an International Journal 2012; 64: 826-832 (3 / 2.783)
Castien RF, van der Windt DAWM, Blankenstein AH, Heymans MW, Dekker J. Clinical variables associated with recovery in
patients with chronic tension-type headache after treatment with manual therapy. Pain 2012; 153: 893-899 (5 / 5.777)
Chinapaw MJM, Buffart LM, van Mechelen W, Schep G, Aaronson NK, van Harten WH, Stuiver MM, Kersten MJ, Nollet F,
Kaspers GJL, van Dulmen-den Broeder E, Huisman J, Takken T, van Tulder M, Brug J. Alpe d'HuZes Cancer Rehabilitation
(A-CaRe) Research: Four Randomized Controlled Exercise Trials and Economic Evaluations in Cancer Patients and
Survivors. International Journal of Behavioral Medicine 2012; 19: 143-156 (4 / 2.625)
Cnossen IC, de Bree R, Rinkel RNPM, Eerenstein SEJ, Rietveld DHF, Doornaert P, Buter J, Langendijk JA, Leemans CR,
Verdonck-de Leeuw IM. Computerized monitoring of patient-reported speech and swallowing problems in head and neck
cancer patients in clinical practice. Supportive Care in Cancer 2012; 20: 2925-2931 (4 / 2.597)
Daams M, Schuitema I, van Dijk BW, van Dulmen-den Broeder E, Veerman AJP, van den Bos C, de Sonneville LMJ. Longterm effects of cranial irradiation and intrathecal chemotherapy in treatment of childhood leukemia: a MEG study of
power spectrum and correlated cognitive dysfunction. BMC Neurology 2012; 12: (3 / 2.167)
de Bruijn MJ, ten Bosch L, Kuik DJ, Witte BI, Langendijk JA, Leemans CR, Verdonck-de Leeuw IM. Acoustic-phonetic and
artificial neural network feature analysis to assess speech quality of stop consonants produced by patients treated for
oral or oropharyngeal cancer. Speech Communication 2012; 54: 632-640 (3 / 1.267)
de Vos J, Gomez-Garcia E, Oosterwijk JC, Menko FH, Stoel RD, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A.
Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the
counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result. Psycho-Oncology 2012;
21: 29-42 (5 / 3.339)
de Vos J, Oosterwijk JC, Gomez-Garcia E, Menko FH, Collee MJ, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A.
Exploring the short-term impact of DNA-testing in breast cancer patients: The counselees' perception matters, but the
actual BRCA1/2 result does not. Patient Education and Counseling 2012; 86: 239-251 (5 / 2.305)
Dekker CMG, Van Esch L, De Vries J, Ernst MF, Nieuwenhuijzen GAP, Roukema JA, van der Steeg AFW. An abnormal
screening mammogram causes more anxiety than a palpable lump in benign breast disease. Breast Cancer Research and
Treatment 2012; 134: 253-258 (4 / 4.431)
Dekker CMG, Van Esch L, Schreurs WH, van Berlo CLH, Roukema JA, De Vries J, van der Steeg AFW. Health care utilization
one year following the diagnosis benign breast disease or breast cancer. Breast 2012; 21: 746-750 (4 / 2.491)
Dekker J. Osteoarthritis Promoting exercise for OA in ambivalent older adults. Nature Reviews Rheumatology 2012; 8:
442-444 (5 / 8.388)
DeSouza N, Hoekstra OS, Nestle U, Stroobants S, Boellaard R, Schaefer-Prokop C, Shankar LK, Pylkkanen L, Hristova I,
Bean JF. EORTC Imaging Group. European Journal of Cancer 2012; 10: 82-87 (4 / 5.536)
Dommering CJ, Garvelink MM, Moll AC, van Dijk J, Imhof SM, Meijers-Heijboer H, Henneman L. Reproductive behavior of
individuals with increased risk of having a child with retinoblastoma. Clinical Genetics 2012; 81: 216-223 (3 / 3.128)
Dommering CJ, van der Hout AH, Meijers-Heijboer H, Marees T, Moll AC. IVF and retinoblastoma revisited. Fertility and
Sterility 2012; 97: 79-81 (4 / 3.564)
Duijts SFA, van Beurden M, Oldenburg HSA, Hunter MS, Kieffer JM, Stuiver MM, Gerritsma MA, Menke-Pluymers MBE,
Plaisier PW, Rijna H, Cardozo AMFL, Timmers G, van der Meij S, van der Veen H, Bijker N, de Widt-Levert LM, Geenen MM,
Heuff G, van Dulken EJ, Boven E, Aaronson NK. Efficacy of Cognitive Behavioral Therapy and Physical Exercise in
Alleviating Treatment-Induced Menopausal Symptoms in Patients With Breast Cancer: Results of a Randomized,
Controlled, Multicenter Trial. J Clin Oncol 2012; 30: 4124-4133 (5 / 18.372)
Efficace F, Taphoorn M. Methodological issues in designing and reporting health-related quality of life in cancer clinical
trials: the challenge of brain cancer studies. Journal of Neuro-Oncology 2012; 108: 221-226 (3 / 3.214)
Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PAW, Commandeur S, Schouten HC,
Sackmann F, Fuentes AK, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz
K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C,
Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A,
Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total
Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among
Patients With MPNs. J Clin Oncol 2012; 30: 4098-4103 (5 / 18.372)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 58
24. Engelen V, Detmar S, Koopman H, Maurice-Stam H, Caron H, Hoogerbrugge P, Egeler RM, Kaspers G, Grootenhuis M.
Reporting health-related quality of life scores to physicians during routine follow-up visits of pediatric oncology patients:
Is it effective?. Pediatric Blood & Cancer 2012; 58: 766-774 (3 / 1.891)
25. Engelen V, van Zwieten M, Koopman H, Detmar S, Caron H, Brons P, Egeler M, Kaspers GJ, Grootenhuis M. The influence
of patient reported outcomes on the discussion of psychosocial issues in children with cancer. Pediatric Blood & Cancer
2012; 59: 161-166 (3 / 1.891)
26. Englbrecht M, Gossec L, DeLongis A, Scholte-Voshaar M, Sokka T, Kvien TK, Schett G. The Impact of Coping Strategies on
Mental and Physical Well-Being in Patients with Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism 2012; 41:
545-555 (4 / 4.969)
27. Ferriolli E, Skipworth RJE, Hendry P, Scott A, Stensteth J, Dahele M, Wall L, Greig C, Fallon M, Strasser F, Preston T, Fearon
KCH. Physical Activity Monitoring: A Responsive and Meaningful Patient-Centered Outcome for Surgery, Chemotherapy,
or Radiotherapy?. Journal of Pain and Symptom Management 2012; 43: 1025-1035 (4 / 2.503)
28. Gordijn MS, Gemke RJBJ, van Dalen EC, Rotteveel J, Kaspers GJL. Hypothalamic-pituitary-adrenal (HPA) axis suppression
after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. Cochrane Database Syst Rev
2012; : (5 / 5.715)
29. Gordijn MS, van Litsenburg RR, Gemke RJBJ, Bierings MB, Hoogerbrugge PM, van de Ven PM, Heijnen CJ, Kaspers GJL.
Hypothalamic-pituitary-adrenal axis function in survivors of childhood acute lymphoblastic leukemia and healthy
controls. Psychoneuroendocrinology 2012; 37: 1448-1456 (5 / 5.809)
30. Harinck F, Kluijt I, van Mil SE, Waisfisz Q, Van Os TAM, Aalfs CM, Wagner A, Olderode-Berends M, Sijmons RH, Kuipers EJ,
Poley JW, Fockens P, Bruno MJ. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast
cancer families with pancreatic cancer is not indicated. European Journal of Human Genetics 2012; 20: 577-579 (4 / 4.4)
31. Haverman L, Grootenhuis MA, van den Berg JM, van Veenendaal M, Dolman KM, Swart JF, Kuijpers TW, van Rossum MAJ.
Predictors of Health-Related Quality of Life in Children and Adolescents With Juvenile Idiopathic Arthritis: Results From a
Web-Based Survey. Arthritis Care & Research 2012; 64: 694-703 (4 / 4.851)
32. Hjermstad MJ, Bergenmar M, Fisher SE, Montel S, Nicolatou-Galitis O, Raber-Durlacher J, Singer S, Verdonck-de Leeuw I,
Weis J, Yarom N, Herlofson BB. The EORTC QLQ-OH17: A supplementary module to the EORTC QLQ-C30 for assessment
of oral health and quality of life in cancer patients. European Journal of Cancer 2012; 48: 2203-2211 (4 / 5.536)
33. Holla JFM, van der Leeden M, Knol DL, Peter WFH, Roorda LD, Lems WF, Wesseling J, Steultjens MPM, Dekker J. Avoidance
of Activities in Early Symptomatic Knee Osteoarthritis: Results from the CHECK Cohort. Annals of Behavioral Medicine
2012; 44: 33-42 (5 / 4.2)
34. Holla JFM, van der Leeden M, Peter WFH, Roorda LD, van der Esch M, Lems WF, Gerritsen M, Voorneman RE, Steultjens
MPM, Dekker J. Proprioception, Laxity, Muscle Strength and Activity Limitations in Early Symptomatic Knee Osteoarthritis:
Results from the Check Cohort. Journal of Rehabilitation Medicine 2012; 44: 862-868 (4 / 2.049)
35. Holla JFM, van der Leeden M, Roorda LD, Bierma-Zeinstra SMA, Damen J, Dekker J, Steultjens MPM. Diagnostic accuracy of
range of motion measurements in early symptomatic hip and/or knee osteoarthritis. Arthritis Care & Research 2012; 64:
59-65 (4 / 4.851)
36. Jansen MHA, Veringa SJ, van Vuurden DG, van Dalen EJ, Kaspers GJL. Temozolomide for children and adolescents with
diffuse intrinsic pontine glioma. Cochrane Database Syst Rev 2012; : (5 / 5.715)
37. Kirsch M, Crombez P, Calza S, Eeltink C, Johansson E. Patient information in stem cell transplantation from the
perspective of health care professionals: A survey from the Nurses Group of the European Group for Blood and Marrow
Transplantation. Bone Marrow Transplantation 2012; 47: 1131-1133 (4 / 3.746)
38. Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neurooncology 2012; 14: 17-24 (5 / 5.723)
39. Knoop J, van der Leeden M, van der Esch M, Thorstensson CA, Gerritsen M, Voorneman RE, Lems WF, Roorda LD, Dekker
J, Steultjens MPM. Association of lower muscle strength with self-reported knee instability in osteoarthritis of the knee:
Results from the Amsterdam Osteoarthritis Cohort. Arthritis Care & Research 2012; 64: 38-45 (4 / 4.851)
40. Krebber AMH, Leemans CR, de Bree R, van Straten A, Smit F, Smit EF, Becker A, Eeckhout GM, Beekman ATF, Cuijpers P,
Verdonck-de Leeuw IM. Stepped care targeting psychological distress in head and neck and lung cancer patients: a
randomized clinical trial. BMC Cancer 2012; 12: (4 / 3.011)
41. Lagerwaard FJ, Aaronson NK, Gundy CM, Haasbeek CJA, Slotman BJ, Senan S. Patient-Reported Quality of Life After
Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. Journal of Thoracic Oncology 2012; 7: 1148-1154 (4 /
3.661)
42. Langius JAE, Kruizenga HM, Uitdehaag BMJ, Langendijk JA, Doornaert P, Leemans CR, Weijs PJM. Resting energy
expenditure in head and neck cancer patients before and during radiotherapy. Clinical Nutrition 2012; 31: 549-554 (4 /
3.731)
43. Linn AJ, van Weert JCM, Schouten BC, Smit EG, van Bodegraven AA, van Dijk L. Words that make pills easier to swallow: a
communication typology to address practical and perceptual barriers to medication intake behavior. Patient Preference
and Adherence 2012; 6: (3 / 1.143)
44. Magasi S, Ryan G, Revicki D, Lenderking W, Hays RD, Brod M, Snyder C, Boers M, Cella D. Content validity of patientreported outcome measures: perspectives from a PROMIS meeting. Quality of Life Research 2012; 21: 739-746 (3 / 2.3)
45. Meesters JJL, de Boer IG, van den Berg MH, Fiocco M, Vlieland TPMV. Evaluation of a website providing information on
regional health care services for patients with rheumatoid arthritis: an observational study. Clinical Rheumatology 2012;
31: 637-645 (2 / 1.996)
46. Meunier F, Lawler M, Pinedo HM. Commentary: Fifty Years of the European Organisation for Research and Treatment of
Cancer (EORTC) - Making the Difference for the European Oncology Community. Oncologist 2012; 17: e6-e7 (3 / 3.91)
47. Mostert S, Sitaresmi MN, Njuguna F, van Beers EJ, Kaspers GJL. Effect of corruption on medical care in low-income
countries. Pediatric Blood & Cancer 2012; 58: 325-326 (3 / 1.891)
48. Nachtegaal J, Festen JM, Kramer SE. Hearing Ability in Working Life and Its Relationship With Sick Leave and Self-Reported
Work Productivity. Ear and Hearing 2012; 33: 94-103 (5 / 2.578)
49. Overbeek A, Broekmans FJ, Hehenkamp WJ, Wijdeveld ME, van Disseldorp J, van Dulmen-den Broeder E, Lambalk CB.
Intra-cycle fluctuations of anti-Mullerian hormone in normal women with a regular cycle: a re-analysis. Reproductive
Biomedicine Online 2012; 24: 664-669 (3 / 2.042)
50. Overbeek A, van den Berg M, Hukkelhoven C, Kaspers GJ, van Dulmen-den Broeder E, Lambalk C, van Leeuwen F. Validity
of Self-Reported Data on Pregnancy Outcomes - Comparing Self-Reported Data of Childhood Cancer Survivors with Data
from A Nationwide Population-Based Registry. Pediatric Blood & Cancer 2012; 59: 974 (3 / 1.891)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 59
51. Overbeek A, van den Berg MH, Kremer LC, van den Heuvel-Eibrink MM, Tissing WJ, Loonen JJ, Versluys B, Bresters D,
Kaspers GJ, Lambalk CB, van Leeuwen FE, van Dulmen-den Broeder E, on behalf of the DCOG LATER-VEVO study group. A
nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female servivors of
childhood cancer: design and methodological challenges. BMC Cancer 2012; 12: 363 (4 / 3.011)
52. Peters GJ, Chatelut E, Larsen AK, Zaffaroni N. EORTC-related new drug discovery and development activities: role of the
Pharmacology and Molecular Mechanisms Group. European Journal of Cancer 2012; 10: 128-140 (4 / 5.536)
53. Pisters MF, Veenhof C, van Dijk GM, Heymans MW, Twisk JWR, Dekker J. The course of limitations in activities over 5
years in patients with knee and hip osteoarthritis with moderate functional limitations: risk factors for future functional
decline. Osteoarthritis and Cartilage 2012; 20: 503-510 (5 / 3.904)
54. Raber-Durlacher JE, Brennan MT, Verdonck-de Leeuw IM, Gibson RJ, Eilers JG, Waltimo T, Bots CP, Michelet M, Sollecito TP,
Rouleau TS, Sewnaik A, Bensadoun RJ, Fliedner MC, Silverman SJ, Spijkervet FKL. Swallowing dysfunction in cancer
patients. Supportive Care in Cancer 2012; 20: 433-443 (4 / 2.597)
55. Reck M, Thatcher N, Smit EF, Lorigan P, Szutowicz-Zielinska E, Liepa AM, Winfree KB, Peterson P, Guba SC, Socinski MA.
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell
lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. Lung Cancer 2012; 78: 276-281 (4
/ 3.434)
56. Sizoo EM, Pasman HRW, Buttolo J, Heimans JJ, Klein M, Deliens L, Reijneveld JC, Taphoorn MJB. Decision-making in the
end-of-life phase of high-grade glioma patients. European Journal of Cancer 2012; 48: 226-232 (4 / 5.536)
57. Talacchi A, Taphoorn M, Miceli G. Reconsidering outcomes that matter to patients INTRODUCTION. Journal of NeuroOncology 2012; 108: 219-220 (3 / 3.214)
58. Taphoorn MJ. Patient-oriented outcome measures in brain tumor patients: catching up after a slow start. Expert Review
of Pharmacoeconomics & Outcomes Research 2012; 12: 1-3 (0 / 0)
59. ter Wee MM, Lems WF, Usan H, Gulpen A, Boonen A. The effect of biological agents on work participation in rheumatoid
arthritis patients: a systematic review. Annals of the Rheumatic Diseases 2012; 71: 161-171 (5 / 8.727)
60. Tomasson G, Boers M, Walsh M, LaValley M, Cuthbertson D, Carette S, Davis JC, Hoffman GS, Khalidi NA, Langford CA,
McAlear CA, Mccune WJ, Monach PA, Seo P, Specks U, Spiera R, St Clair EW, Stone JH, Ytterberg SR, Merkel PA.
Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).
Arthritis Care & Research 2012; 64: 273-279 (4 / 4.851)
61. van Bokhorst-de van der Schueren M, Konijn NPC, Bultink IEM, Lems WF, Earthman CP, van Tuyl LHD. Relevance of the
new pre-cachexia and cachexia definitions for patients with rheumatoid arthritis. Clinical Nutrition 2012; 31: 1008-1010
(4 / 3.731)
62. van Bokhorst-de van der Schueren M, Roosemalen MM, Weijs PJ, Langius JA. High Waste Contributes to Low Food Intake
in Hospitalized Patients. Nutrition in Clinical Practice 2012; 27: 274-280 (2 / 1.594)
63. van den Berg MH, Overbeek A, van Dulmen-den Broeder E, Lambalk CB. Comment on: Li HW, Wong CY, Yeung WS, Ho PC,
Ng EH. Serum anti-Mullerian hormone level is not altered in women using hormonal contraceptives. Contraception
2011;83:582-5. Contraception 2012; 85: 519-520 (4 / 2.724)
64. van den Berg T, Engelhardt EG, Haanstra TM, Langius JA, van Tulder MW. Comment on van den Berg et al: "Methodology
of Clinical Nutrition Guidelines for Adult Cancer Patients: How Good Are They According to AGREE Criteria?" Comment.
Journal of Parenteral and Enteral Nutrition 2012; 36: 504-505 (4 / 3.285)
65. van den Berg T, Engelhardt EG, Haanstra TM, Langius JA, van Tulder MW. Methodology of Clinical Nutrition Guidelines for
Adult Cancer Patients: How Good Are They According to AGREE Criteria?. Journal of Parenteral and Enteral Nutrition
2012; 36: 316-322 (4 / 3.285)
66. van der Esch M, Knoop J, van der Leeden M, Voorneman R, Gerritsen M, Reiding D, Romviel S, Knol DL, Lems WF, Dekker
J, Roorda LD. Self-reported knee instability and activity limitations in patients with knee osteoarthritis: results of the
Amsterdam osteoarthritis cohort. Clinical Rheumatology 2012; 31: 1505-1510 (2 / 1.996)
67. van der Meij B, Langius J, Spreeuwenberg M, Slootmaker S, Paul M, Smit E, van Leeuwen P. Oral nutritional supplements
containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during
multimodality treatment: an RCT. European Journal of Clinical Nutrition 2012; 66: 399-404 (3 / 2.462)
68. van Elsland SL, Springer P, Steenhuis IHM, van Toorn R, Schoeman JF, van Furth AM. Tuberculous Meningitis: Barriers to
Adherence in Home Treatment of Children and Caretaker Perceptions. Journal of Tropical Pediatrics 2012; 58: 275-279 (3
/ 1.388)
69. van Gogh CDL, Verdonck-de Leeuw IM, Langendijk JA, Kuik DJ, Mahieu HF. Long-Term Efficacy of Voice Therapy in
Patients With Voice Problems After Treatment of Early Glottic Cancer. Journal of Voice 2012; 26: 398-401 (3 / 1.39)
70. van Gogh CDL, Verdonck-de Leeuw IM, Wedler-Peeters J, Langendijk JA, Mahieu HF. Prospective evaluation of voice
outcome during the first two years in male patients treated by radiotherapy or laser surgery for T1a glottic carcinoma.
European Archives of Oto-Rhino-Laryngology 2012; 269: 1647-1652 (3 / 1.287)
71. Van Vilsteren M, Boot CR, Steenbeek R, Schaardenburg Dv, Voskuyl AE, Anema JR. An intervention program with the aim
to improve and maintain work productivity for workers with rheumatoid arthritis: design of a randomized controlled trial
and cost-effectiveness study. BMC Public Health 2012; 12: 496 (3 / 1.997)
72. van Weely SFE, van Denderen JC, Steultjens MPM, van der Leeden M, Nurmohamed MT, Dekker J, Dijkmans BAC, van der
Horst-Bruinsma I. Moving instead of asking? performance-based tests and BASFI-questionnaire measure different aspects
of physical function in ankylosing spondylitis. Arthritis Research & Therapy 2012; 14: (4 / 4.445)
73. Verdonck-de Leeuw IM, van Nieuwenhuizen A, Leemans CR. The value of quality-of-life questionnaires in head and neck
cancer. Current Opinion in Otolaryngology & Head and Neck Surgery 2012; 20: 142-147 (4 / 1.826)
74. Veringa SJE, van Dulmen-den Broeder E, Kaspers GJL, Veening MA. Blood pressure and body composition in long-term
survivors of childhood acute lymphoblastic leukemia. Pediatric Blood & Cancer 2012; 58: 278-282 (3 / 1.891)
75. Vincenten J, Smit EF, Ylstra B, Thunnissen FBJM. Applying biomarker testing to clinical practice in lung cancer. Lung
Cancer Management 2012; 1: 145-154 (0 / 0)
76. Vos J, Oosterwijk JC, Gomez-Garcia E, Menko FH, Collee MJ, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A.
Exploring the short-term impact of DNA-testing in breast cancer patients: The counselees' perception matters, but the
actual BRCA1/2 result does not. Patient Education and Counseling 2012; 86: 239-251 (5 / 2.305)
77. Wassenberg M, Kluytmans J, Erdkamp S, Bosboom R, Buiting A, van Elzakker E, Melchers W, Thijsen S, Troelstra A,
Vandenbroucke-Grauls C, Visser C, Voss A, Wolffs P, Wulf M, van Zwet T, de Wit A, Bonten M. Costs and benefits of rapid
screening of methicillin-resistant Staphylococcus aureus carriage in intensive care units: a prospective multicenter study.
Critical Care 2012; 16: (4 / 4.607)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 60
Scientific papers non-refereed
1.
Supriyadi E, Veerman AJP, Sutaryo S, van de Ven PM, Cloos J. Detection of CD10, CD34 and their combined expression on
Childhood Acute Lymphoblastic Leukemia and the association with clinical outcome in Indonesia. Journal of Cancer
Therapeutics & Research 2012; 1: 1-10.
Scientific publications (book, book chapters, proceedings)
1.
2.
Den Oudsten BL, van der Steeg AFW, Roukema JA, De Vries J. Changes in Body Image in Womenwith Early Stage Breast
Cancer; in Mohan R, (ed): Topics in Cancer Survivorship. 2012; 3:
Taphoorn MJB, Klein M. Evaluation of cognitive functions and quality of life. In: Handbook of Clinical Neurology / edited
by P J Vinken and G W Bruyn. 2012; 104: 173-183
Professional publications
1.
2.
3.
4.
Buskermolen S, van der Meij B, van Bokhorst-de van der Schueren M, Langius JAE. Precachexie en cachexie bij patienten
met kanker: actuele inzichten en handvatten voor de diÙtist. Nederlands Tijdschrift voor Voeding en Diëtetiek 2012; 67:
S1-S8
Langius JAE, van den Berg M. Meer duidelijkheid over combinatie voeding en beweging. Nederlands Tijdschrift voor
Voeding en Diëtetiek 2012; 67: 30-31
Vos MC, Jansma A, Mascini E, Troelstra A, de Ruiter GJ, van Dijk Y, Meester HHM. Kwaliteitsrichtlijn voor Infectiepreventie
in Ziekenhuizen (KRIZ) û Tijd voor versie 2.0. Nederlands Tijdschrift voor Medische Microbiologie 2012; 20: 78-79
Zuurmond WWA, Perez RSGM. Pijn bij kanker. Deel 3: Enkele aandachtspunten bij de oncologische pijnbehandeling met
analagetica. Oncollectie 2012; 1: 2-8
Dissertations
1.
Van Litsenburg, RRL. Pediatric acute lymphoblastic leukemia: quality of life and cost-effectiveness of treatment. Vrije
Universiteit Amsterdam, 08/05/2012. (Co-)promotores: R.J.B.J. Gemke, G.J.L. Kaspers, J. Huisman (cat. A)
Appendix Annual Report 2012 VUmc CCA – Scientific Output - 61
Appendix 5: Indicators of esteem
In this appendix an overview is given of the memberships of editorial boards, (inter)national functions, lectures given and
obtained awards. In addition, newly obtained grants are listed to show the recruitment capacity of VUmc-CCA, and news items
are shown.
Memberships of editorial boards
Associate
Journal
Ang CW
•
Nederlands Tijdschrift voor Medische Microbiologie (editor-in-chief)
Appelmelk BJ
•
Innate Immunity
Bitter W
•
FEMS Microbiology Reviews
Blankenstein MA
•
•
•
Annals of Clinical Biochemistry (associate editor)
Clinica Chimica Acta (member editorial board)
International Journal of Biological Markers (associate editor)
Bloemena E
•
•
•
World Journal of Gastrointestinal Oncology
ISRN Gastroenterology
Scandinavian Journal of Gastroenterology
Boers M
Associate Editor:
• Arthritis and Rheumatism
• Letter to the Editor in Rheumatology
Board member:
• Journal for Clinical Epidemiology (Policy Advisory Board)
• Annals of Rheumatic Diseases
• Journal of Rheumatology
Braakhuis BJM
•
•
Oral Oncology
The Open Pathology Journal
Brakenhoff RH
•
Clinical Cancer Research, Oral Oncology
Broxterman HJ
•
•
Molecular Cancer Therapeutics
Drug Resistance Updates
Chamuleau M
•
NTVH
de Bree R
•
•
•
•
European Archives of Otorhinolaryngology
The Open Otorhinolaryngology Journal
Oral Oncology
Nederlands Tijdschrift voor Oncologie
de Rie MA
•
•
Dermatology
Case reports in Dermatology
Dekker J
•
International Journal of Behavioral Medicine
Giovannetti E
•
•
World Journal of Pharmacology
Guest Editor for Current Pharmacological Design
Jansen G
•
Open Arthritis Journal
Janssen JJWM
•
•
•
•
•
•
•
American Society of Hematology
HOVON Stem cell Transplantation Working Party
HOVON Acute Leukemia Working Party
Dutch Society of Hematology
European Blood and Marrow Transplantation group (EBMT)
Nederlandse Internisten Vereniging (Dutch Internist Society)
European Hematology Association
Jimenez CR
•
•
•
Journal of Proteomics
Molecular and Cellular Proteomics
Proteomics
Joenje H
•
•
Anemia
Cellular Oncology
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 62
Associate
Journal
•
•
•
Familial Cancer
The Open Genomics Journal
Open Genetics Reviews
Kaspers GJL
•
Journal of Oncology” and “Expert Reviews of Anticancer Therapy
Kluytmans JAJW
•
•
Journal of Infectious Disease
Antimicrobial Resistance and Infection Control (deputy editor)
Leemans CR
•
•
•
•
•
•
•
•
•
•
Hoofd-hals Journaal (Head and Neck Journal of the NWHHT)
Nederlands Tijdschrift voor Keel-Neus-Oorheelkunde (Netherlands Journal of
Otorhinolaryngology)
European Archives of Oto-Rhino-Laryngology Head and Neck
Oral Oncology
Head Neck
Oral Diseases
Surgical Oncology
Italian Journal of Maxillofacial Surgery
Acta Otorrinolaringología Española
Acta Otorhinolaryngoiatrica Italica
Meijer CJLM
•
•
•
•
•
•
•
American Journal of Dermatopathology
APMIS
Histopathology
Journal of Clinical Pathology/Clinical Molecular Pathology
International Journal of Cancer
Journal of Pathology
Cancer Cytopathology (corresponding member)
Meijer GA
•
•
•
World Journal of Gastrointestinal Oncology (WJGO)
Member Advisory Board Oncology-up-to-date
Member Advisory Board Oncology news International
Menko FH
•
Familial Cancer
Middeldorp JM
•
•
Journal of Clinical Virology
Virological Methods
Morré SA
•
•
World Journal of Gastroenterology
Public Health Genomics
Ossenkoppele GJ
•
Dutch Journal of Hematology
Pegtel M
•
Journal of Extracellular Vesicles (JEV)
Perez RSGM
•
Nederlandstalig Tijdschrift voor Pijn en Pijnbestrijding
Peters GJ
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
European Journal of Cancer (1995-)
Clinical Colorectal Cancer (1999-)
Cancer Chemotherapy and Pharmacology (2000-)
International Journal of Oncology (2001-)
Cancer Therapy (2003-)
Journal of Chemotherapy (2004-)
Annals of Oncology (2005-)
Journal of Pharmacology and Toxicology (2006-)
Journal of Epithelial Biology and Pharmacology (2008-)
Gastrointestinal Cancer Reviews (2009-)
The Open Lung Cancer Journal (2009-2012), Editor-in Chief
Chemotherapy Research and Practice (2009-)
World Journal of Gastrointestinal Oncology (2009-)
World Journal of Gastrointestinal Pharmacology and Therapeutics (2009-)
Journal of Chinese Clinical Medicine (2009-)
World Journal of Clinical Oncology (2010-), Strategy Associate Editor-in-Chief
American Journal of Cancer research (2010-), senior editor
Chinese Journal of Clinicians (2010-)
World Journal of Pharmacology (2011-)
Nucleosides, Nucleotides and Nucleic Acids (2011-)
Journal of Cancer Research and Treatment (2012-), Editor-in-Chief
Experimental Hematology and Oncology (2012-)
Pteridines (2012-)
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 63
Associate
Journal
•
Oncology Discovery (2013-), Editor-in-Chief
Rustemeyer T
•
•
•
•
Contact Dermatitis
Dermatologie in Beruf und Umwelt (Wissenschaftlicher Beirat)
Nederlands Tijdschrift voor Allergologie
Dermatologie in Beruf und Umwelt
Savelkoul PHM
•
Clinical Microbiology and Infection
Scheper RJ
•
Contact Dermatitis (Editor Section Immunology)
Schuurhuis GJ
•
•
•
Open Hematology Journal
International Scholarly Research Network (ISRN)
Dataset Papers in Medicine August 2012
Senan S
•
•
•
The Oncologist
Radiation Oncology
Journal of Thoracic Disease
Slotman BJ
•
•
•
Cureus
Associate editor, Journal of Radiosurgery and Stereotactic Body Radiotherapy
J Radiation Oncology
Snijders PJF
•
International Journal of Oncology
Steenbergen RDM
•
BCM Cancer
Stoof TJ
•
•
Allergie Actueel
Nederlands Tijdschrift voor Dermatologie en Venereologie
Taphoorn MJB
•
•
Expert Review Pharmacoeconomics Outcomes
Neuro-Oncology
Thijssen VL
•
American Medical Journal
van Beusechem VW
•
•
Human Gene Therapy
Genetics Research International
van Bodegraven AA
•
Journal of Crohn’s and Colitis
van den Elsen PJ
•
•
•
Immunogenetics, The Open Immunology Journal
Associate Editor: Frontiers in Molecular Innate Immunity
The Open Immunology Journal
van der Waal I
•
•
•
•
•
•
•
•
•
•
•
ACTA Stomatologica Croatica, Member International Editorial Board
European Journal of Cancer, Consulting Editor
Medicina Oral, Member Editorial Board
Minerva Stomatologica (Italy, per mei 2008), Member Editorial Board
Nederlands Tijdschrift voor Geneeskunde
Oral and Maxillofacial Surgery (OMS), Member Advisory Board
Oral Health & Preventive Dentistry, Member Editorial Board
Oral Oncology, Member of the Board of Senior Advisors
Padjadjaran Journal of Dentistry, International Editor
Revista de Odontologia da Universidade de São Paolo (Journal of Dentistry, University of
São Paolo), Member Editorial Board
STOMA, Member of Scientific Committee
van Furth AM
•
•
European Society of Pediatric Infectious Diseases
Member Infectious Diseases Society of America
van Schaardenburg D
•
•
Arthritis & Rheumatism
Netherlands Journal of Medicine
Vandenbroucke-Grauls CMJE
•
Farmacotherapeutisch Kompas
Verdonck-de Leeuw IM
•
•
World Journal of Clinical Oncology (WJCO)
Voice-, Speech- en Language Pathology (Dutch)
Verweij CL
•
•
•
•
The Open Rheumatology Journal (editor in chief)
Gene and Immunity
Frontiers in immunology
Frontiers in innate Immunology
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 64
Associate
Journal
•
•
•
Arthritis
Recent Patents
Arthritis Research & Therapy
Voskuyl AE
•
Clinical rheumatology
Wesseling P
•
•
•
Acta Neuropathologica
Brain Pathology
Neuro-Oncology
Ylstra B
•
Cellullar Oncology
Zuurmond WWA
•
Nederlands-Vlaams Tijdschrift voor Palliatieve Zorg
Zweegman S
•
Editor in Chief Nederlands Tijdschrift voor Hematologie
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 65
International functions
Associate
Function
Organisation
Ang CW
Committee member
“Sharing of knowledge” (Kennisdelingscommissie), Dutch
Society for Medical Microbiology (NVMM)
Appelmelk BJ
Councillor Microbiology
The International endotoxin and innate immunity society
Bitter W
Member scientific committee
NVMM (Dutch society of medical microbiology)
Boellaard R
Member
Scientific advisory board of the European Association of
Nuclear Medicine (EANM) Research Ltd. (EARL)
Imaging group, European Organisation for Research and
Treatment of Cancer
UPICT working group, Quantitative Imaging Biomarker
Alliance (QIBA) of the RSNA
QIBA profile working group, Quantitative Imaging Biomarker
Alliance (QIBA) of the RSNA
educational board (Medical Imaging), Netherlands Society of
Medical Physics
Chair
Physics Committee, European Association of Nuclear Medicine
Board Member
PET Center of Excellence, Society of Nuclear Medicine
Co-chair / coordinator
Working Group Adapted Treatment Regimens, SIOP PODC
(Pediatric Oncology in developing countries)
Member
Project Committee, Medical Trustee, World Child Cancer
Co-chairman
EULAR Committee on conduct and reporting of long-term
extension studies in rheumatology
Member
EULAR Committee on disease activity measurement in
rheumatoid arthritis
EULAR Committee on monitoring of glucocorticoid therapy in
rheumatoid arthritis
OMERACT Task Force on imaging in rheumatoid arthritis
ASAS, international consensus group on guidelines for
outcome measures in ankylosing spondylitis
COMET Steering Group. International initiative to create
measurement core sets for trials across diseases
Chair
Trial Steering Committee: ZIPP (zoledronate in prevetion of
Paget) trial. P.I. S Ralston, Edinburgh, UK
Braakhuis BJM
(Founding) Member
Research Committee, International Academy of Oral Oncology
Chamuleau M
Secretary
HOVON LLPC working Party
Treasurer
HOVON LLPC working Party
Member
Grant Review committee, Melanoma Research Alliance
Chair
Nederlandse Werkgroep Tumor Immunologie
Chair
NascholingsCie NVDV
Member
Rene Touraine Foundation (Paris, France)
Associate Professor
Physiotherapy – Psychological aspects of rehabilitation,
Faculty of Sports and Health Sciences, University of Jyväskylä,
Finland
Honorary Professor
Jining Medical University, Jining, China
President / Member
The Member of Governing Council, International Society of
Behavioral Medicine
Board Member
Netherlands Behavioral Medicine Federation
Member
Committee on Medical Technology Assessment, Health
Council of the Netherlands (Gezondheidsraad)
International Advisory Board, Behaviour Change Technique
Boers M
De Gruijl TD
De Rie MA
Dekker J
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 66
Associate
Function
Organisation
Taxonomy Project
Franken S
Member
Domeingroep Allergologie en Contactdermatosen van de
Nederlandse vereniging voor Dermatologie en Venereologie
Gibbs S
Member
Dutch institute for regenerative medicine
Contact person VUmc
Topsector Life Sciences and Health - Roadmap Regenerative
Medicine
Board Member
(young researcher) of the Steering Committee of the EORTCPAMM (Pharmacology and Molecular Mechanisms group of the
European Organisation for Research and Treatment of Cancer)
since January 2012
Abstract Selection Committee of the European Pancreatic Club
(EPC) since June 2012 http://www.e-p-c.org/abstractselection-committee
Member
American Association for Cancer Research (AACR)
American Pancreas Club
European Organisation for Research and Treatment of Cancer
(EORTC) PAMM group
European Pancreatic Club (EPC)
Italian Society of Chemotherapy (SIC)
Italian Society of Pharmacology (SIF)
Italian Society for the Study of the Pancreas (AISP)
Heimans
Member
European Federation of Neurological Societies (EFNS) neurooncology group
European Association for Neuro-Oncology (EANO)
Dutch Neuro-Oncology Group (LWNO)
Society for Neuro-Oncology (SNO)
National Health Council The Netherlands (Gezondheidsraad)
Hulleman E
Member
Discipline Group Molecular Research, DCOG
High-grade glioma research group, International Society of
Pediatric Oncology
Co-founder / member
European DIPG network
Coördinator/ president
Netherlands Proteomics Platform
General Council Member
European Proteomics Association (EuPA)
Board of Directors
Human Proteome Organisation
Chair
VUmc Onderzoek Naar Kinderkanker (VONK)
Disease Committee Myeloid Malignancies, DCOG
Protocol committees Relapsed AML 1999/2001 and 2005 and
APL and initial AML, DCOG
Working Group “shared care”, DCOGAML Relapse Working
Group, International BFM Study Group
Member
“Stichting VUmc Kinderstad”, 2011 onwards
Protocol committee ALL-10 and AML2007 (DB-AML01), DCOG
Scientific Committee, DCOG
Supervisory Board SKION = Dutch Childhood Oncology Group
(DCOG)
LAD, NVK, NVvO, KNMG; AACR, ASH, EHA, SIOP
Vice-chair
Ronald McDonald Huis VUmc, 2011 onwards
Program Co-leader
“Quality of Life” of CCA/V-ICI, VU University Medical Center,
Amsterdam
Ambassador
Stichting Semmy
Co-chair
IKNL – Werkgroep Kindertumoren Amsterdam
International P.I.
I-BFM-SG Phase III studies “Relapsed AML 2001/01” and
“Relapsed AML 2010/01”
International coordinator
Phase III study on Pediatric APL (ICC APL 01)
Giovannetti E
Jimenez CR
Kaspers GJL
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 67
Associate
Function
Organisation
Principal investigator
I-BFM-SG and ITCC study 021 “Bortezomib in childhood
relapsed and refractory ALL”
Klein M
Member
Society for Neuro-Oncology (SNO)
Writing committee, Brain Tumour Group EORTC
Steering committee, Primary Central Nervous System
Lymphoma Collaborative Group
Clinical Trials Awards & Advisory Committee on study
“Temozolomide as adjuvant treatment in anaplastic
astrocytoma”, Cancer Research United Kingdom
Clinical Trials Awards & Advisory Committee, French National
Cancer Institute
Nederlandse Vereniging voor Neuropsychologie
Nederlands-Belgische Vereniging voor Experimentele en
Klinische Neurowetenschappen
Landelijke Werkgroep Neuropsychologie bij Epilepsie
Landelijke Werkgroep Functionele Neurochirurgie
National Brain Tumor Society's Clinical Trial Endpoints
Steering Committee
Kluytmans JAJW
Chairman
National Working Party on Infection Control (WIP)
SWAB guideline committee: eradication of MRSA carrier
NVMM guideline committee: detection of Highly Resistant
Micro-organisms
Member
Advisory Committee PREZIES
Concilium Microbiologicum Medical Microbiology
Health Council use of antibiotics in livestock
Boerhaave Infectious Diseases Education Course
Publications Committee SHEA
Scientific Advisory Committee ESCMID
European Advisory Board 3M
International Advisory Board Pfizer
European Expert Group on MRSA of the ECDC
Founder (and member)
ZIEN
Chairman and faculty member
European Course on Hospital Epidemiology and Infection
Control
CO-organizer
ASM conference Emerging Technologies of Medical
Importance for the Diagnosis of Infectious Diseases and the
Detection of Pathogenic Microbes
Fellow
Society for Healthcare Epidemiology of America (SHEA)
The Royal College of Physicians of Edinburgh (RCPE)
Member
Dutch working committee on Hemoglobinopathy treatment
Advisory committee on Neonatal Screening (ANS SIKK) NVK
Working committee on sikkelcellanemia -Netwerk
Kindergeneeskunde regio Amsterdam
Dutch association for treatment of hemophilia
Protocol Committee Aplastic Anemia of DCOG
IKA stem cell working committee
Pediatric working committee trombosisandn stroke
BenigneHematology section of NVK
European Workgroup of the Thalassemia International
Federation
European Hematology Association
Chair
Protocol committee Retinoblastoma DCOG
Member
TBM expertcommissie Vlaanderen, 20 Januari, IWT, Brussel,
Belgie
TBM expertcommissie Vlaanderen, IWT, Brussel, Belgie
Chairman
Regional Neuro-Oncology meeting, IKNL, Amsterdam
Member
European Society for Clinical Nutrition and Metabolism
(ESPEN)
Dutch Dietetic Association (NVD)
Netherlands Society for Parenteral and Enteral Nutrition
(NESPEN)
Kluytmans JAJW
Kors WA
Lagerwaard FJL
Langius JAE
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 68
Associate
Function
Organisation
Leemans CR
President
Dutch Head and Neck Oncology Cooperative Group (NWHHT)
Netherlands Society for Otorhinolaryngology and CervicoFacial Surgery
Member
Netherlands Society of Oncology
American Head and Neck Society
American Academy of Otolaryngology-Head and Neck Surgery
Concilium Oto-rhino-laryngologicum in the Netherlands
British Association of Head and Neck Oncologists
European Rhinological Society
Collegium Oto-rhino-laryngologicum Amicitiae Sacrum
(CORLAS)
European Salivary Gland Society (ESGS)
Spanish Society of Otorhinolaryngology-Head and Neck
Surgery (Sociedad Española de Otorrinolaringología y
Pathología Cérvico-Facial; SEORL-PCF)
Chair
Subcommittee Surgery, Head and Neck Cancer Cooperative
Group of the European Organization for Research and
Treatment of Cancer (EORTC)
Secretary
Working Party Head and Neck Surgery of the Netherlands
Society for Otorhinolaryngology and Cervico-Facial Surgery
Founding Board Member
European Head and Neck Society
Founding Fellow
International Academy of Oral Oncology
Mebius RE
President Program Committee
Nederlandse Vereniging voor Immunologie
Meijer GA
Member Advisory Board
Oncology-up-to-date
Oncology news International
Middeldorp JM
Editiorial board member
Journal of Clinical Virology
Journal of Virological Methods
Molthoff CFM
Member
The Netherlands Society of Immunology
The Netherlands Institute of Biology
Dutch working group on “Advanced Drug Delivery/Drug
Targeting”
Coordinator
HRRT (animal) PET scanner
Director
European Society for Chlamydia Research
Representative
RIVM and European CDC
Coordinator
Chamydia trachomatis Referentie Laboratorium, RIVM
ICTI en EpiGenChlamydia Consortium
Mostert S
Member
SIOP PODC Abandonment of Treatment Working Group
Ossenkoppele G
Member editorial board
Dutch Journal of Hematology
Pegtel M
Editorial board member
Journal of Extracellular Vesicles (JEV)
Peters GJ
Member
European Organization for Research and treatment of Cancer
EORTC General Assembly
EORTC-Translational Research Advisory Committee (TRAC)
Scientific committee, American Association for Cancer
Research
Winter EORTC-PAMMmeeting, Toulouse, France
Chair
EORTC Pharmacology and Molecular Mechanisms Group
Secretary
Purine and Pyrimidine Society (PPS)
Vice chair
EORTC Drug Discovery Committee NCI compounds task force
Member
scientific committee Puridine and Pyrimidine Metabolism in
Man, Tokyo, Japan
Member
European Federation of Neurological Societies (EFNS) neurooncology group
Morré SA
Postma TJ
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 69
Associate
Function
Organisation
European Association for Neuro-Oncology (EANO)
Dutch Neuro-Oncology Group (LWNO)
Society for Neuro-Oncology (SNO)
Steering committee, Ci-Perinoms study (European
collaboration project on the assessment of chemotherapyinduced peripheral neuropathy
Reijneveld JC
Rustemeyer T
Savelkoul PHM
Member
European Association for Neuro-Oncology (EANO)
Society for Neuro-Oncology (SNO)
Steering committee, Brain Tumour Group European
Organisation for Research and Treatment of Cancer (EORTC)
Executive committee, Quality of Life Group European
Organisation for Research and Treatment of Cancer (EORTC)
Chairman
Dutch Neuro-Oncology Group (LWNO)
Board Member
European Environmental and Contact Dermatitis Research
Group (EECDRG)
Bestuur en Raad van Toezicht van de Stichting Nationaal
Huidfonds
Bij- en Nascholingscommissie van het Concilium
Dermatologica
Nederlandse Vereniging voor Allergologie
European Prevention of Occupational Skin Diseases (EPOS)
Stichting Milieu- en Arbeidsdermatologie
Member
Domeingroep Allergologie en Contactdermatosen van de
Nederlandse vereniging voor Dermatologie en Venereologie
European Surveillance System on Contact Allergens (ESSCA)
Richtlijn “Lichen sclerosus” van de Nederlandse vereniging
voor Dermatologie en Venereologie en Nederlandse
Vereniging voor Allergologie
Werkgroep Allergische Beroepsziekten Amsterdam &
Omgeving
Werkgroep Beroepsgebonden Huid- en Longklachten van het
VUmc, AMC, OLVG
Ontwikkeling van elektronisch patiënten dossier “EVA”van
VUmc en AMC
Scientific Expert
EU commission group on “Risk assessment of consumer
products’’
Ministerie voor Volksgezondheid, Welzijn en Sport (VWS),
Voedsel en Waren Autoriteit (VWA), Rijksinstituut voor
Volksgezondheid en Milieu (RIVM)
Dutch representative
EU commissions on “Consumer safety” and “Occupational
Health”
Participant
EU integrated FP6 project: Sens-it-iv
Chairperson
Richtlijn “Contacteczeem” van de Nederlandse Vereniging
voor Dermatologie en Venereologie, voor
Huisartsgneeskunde, voor Klinische Arbeidsgeneeskunde en
Nederlandse Vereniging voor Allergologie
Zorgpaden insulineallergie (operationeel sinds 2010) en
contactdermatosen (sinds 2012)
PMS cosmetica - Nederlandse Vereniging voor Dermatologie
en Venereologie
CESES program van het Ministerie voor Volksgezondheid,
Welzijn en Sport (VWS), Voedsel en Waren Autoriteit (VWA) en
Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
Member
Scientific Affairs Subcommittee (SAS), European Study Group
on Molecular Diagnostics (ESCMID)
Commissie Wetenschap van de Nederlandse Vereniging voor
Microbiologie, Dutch Society of Microbiology (NvvM)
European Study Group on Epidemiological Markers (ESGEM)
Concilium opleiding Medisch Microbiologisch Onderzoeker
(MMO)
Concilium opleiding MMM, Dutch Society of Medical
Microbiology (NVMM)
Nederlandse Werkgroep Klinische Virologie, Dutch Society of
Medical Microbiology (NVMM)
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 70
Associate
Function
Organisation
Werkgroep Moleculaire Diagnostiek Infectieziekten, Dutch
Society of Medical Microbiology (NVMM)
Chairman
Vereniging voor Moleculair Diagnostici in de
Gezondheidszorg
Chairman
The international working party flowcytometric assessment of
minimal residual disease in acute myeloid leukemia
Member
European LeukemiaNet
Senan S
Member
Faculty member for Chest Tumors, European Society for
Medical Oncology
International Advisory Panel, Cancer Research UK Clinical
Trials Awards and Advisory Committee
Foundation Council Member, European Thoracic Oncology
Platform
Advanced Radiation Technology Committee, International
Association for the Study of Lung Cancer
Career Development Committee, International Association for
the Study of Lung Cancer
Faculty member, Course on Clinical Practice & Implementation
of Image-Guided Stereotactic Body Radiotherapy, European
Society for Radiotherapy and Oncology
Scientific Committee, 37th European Society of Medical
Oncology Congress 2012, European Society of Medical
Oncology
Scientific Committee for European Multidisciplinary Congress
in Thoracic Oncology 2013, European Society of Medical
Oncology
Slotman BJ
Member
Accreditation committee, American Radium Society
ISRS Congress Meeting & Scientific Committee Toronto 2013
Scientific committee, American Society Radiation Oncology
ESTRO HERO task force
Program Director
Novalis Circle Meetings
Chairman
Novalis Best ractice Committee Lung Cancer
Board member
Dutch Commission on Radiation Dosimetry (NCS)
Organizing committee member
The International meeting of the Dutch Society for
Radiobiology (NVRB), Noordwijkerhout, April 19-20, 2012
Member
Evaluation committee of the Ph. D. dissertation of L. Sleire,
University of Bergen, Norway
European Radiation Research Society (ERRS)
Neuro-Oncology group Integral Cancer Center Netherlands
(IKNL)
European Society for Therapeutic Radiology and Oncology
(ESTRO)
Advisory Board Stichting Hersentumor.nl
European Association of Neuro Oncology (EANO)
First opponent
Thesis defense dr. L. Sleire, University of Bergen, Norway,
June 1, 2012.
Board member
Dutch Commission on Radiation Dosimetry (NCS)
Organizing committee member
The International meeting of the Dutch Society for
Radiobiology (NVRB), Noordwijkerhout, April 19-20, 2012
Schuurhuis GJ
Sminia P
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 71
Associate
Function
Organisation
Member
Evaluation committee of the Ph. D. dissertation of L. Sleire,
University of Bergen, Norway
European Radiation Research Society (ERRS)
Neuro-Oncology group Integral Cancer Center Netherlands
(IKNL)
European Society for Therapeutic Radiology and Oncology
(ESTRO)
Advisory Board Stichting Hersentumor.nl
European Association of Neuro Oncology (EANO)
First opponent
Thesis defense dr. L. Sleire, University of Bergen, Norway,
June 1, 2012.
Board Member
International Society of Dermatopathology
Nederlandse Werkgroep voor Dermatopathologie
Member
Concilium Dermatologicum et Venereologicum
Medische Specialisten Registratie Commissie
Member
Werkgroep Vulvapathologie van de Stichting Onderwijs
Oncologische Gynaecologie
Nederlandse Vereniging voor Vulva Pathologie
Nederlandse Werkgroep voor Dermatopathologie
Medical advisory board PVN
Medical Advisor
Nationale Vereiniging L.E. Patiënten (NVLE)
Psoriasis Vereniging Nederland (PVN)
Taphoorn MJB
Member
Dutch Neuro-Oncology Group (LWNO)
Society for Neuro-Oncology (SNO)
European Association of Neuro-Oncology (EANO)
European Society for Medical Oncology (ESMO)
Educational committee for Neuro-Oncology of the European
Society for Medical Oncology (ESMO)
International Society for Quality of Life Research (ISOQOL)
EORTC Brain Tumour Group
EORTC Quality of Life Group
Samantha Dickson Brain Tumour Trust Grant Review and
Monitoring Committee UK
Cancer Research UK Clinical Trials Awards and Advisory
Committee
American Academy of Neurology (AAN)
American Neurological Association (ANA)
Van Moorselaar RJA
Member
Ethics of Live Surgery Committee, European Association of
Urology
Medical Innovation Board, TNO
Steering Committee Guidelines on Prostate Cancer, Dutch
Urological Association
Werkgroep Oncologische Urologie, Nederlandse Vereniging
voor Urologie
Board member
European School of Urology (ESU)
Dutch Urological Oncological Study Group (DUOS)
Chairman
Subgroup Minimal Invasive Oncology SWEN (workingParty
Endourology), Dutch Urological Association
Urology committee, comprehensive cancer center Amsterdam
Editor in chief
Website prostaat.nl
Van Asseldonk DP
Secretary
Young Initiativ on Crohns and Colitis
Van Beusechem VW
Treasurer / Board Member
Netherlands Society of Gene and Cell Therapy
President
Science committee, Netherlands Society of Gene and Cell
Therapy
Member
Expert group on Advanced Therapy Medicinal Products,
Medicine Evaluation Board (CBG)
Member
Committee on Pharmacotherapy, with specific topic
Biologicals, Dutch Association of Gastroenterologists (NVMDL)
Starink TM
Stoof TJ
Van Bodegraven AA
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 72
Associate
Function
Organisation
Board Member
Netherlands Society for Enteral and Parenteral Nutrition
(NESPEN)
President
Initiative on Crohn and Colitis (ICC)
Associate editor
Frontiers in Molecular Innate Immunity
Member Editorial Board
The Open Immunology Journal
Associate Professor
Rheumatology
Vice Chair
Dagelijks Bestuur Stafconvent VUmc
Acting Head of Department
Reumatologie
Chair
NVR-werkgroep landelijke richtlijn Spondyloartrtritis
Member
Bestuur GENetica Research (GENRA) Amsterdam
Stuurgroep ziekenhuisverplaatste zorg VUmc
Stuurgroep verwijzers VUmc
Commissie wetenschappelijke stages VICI
Werkgroepen zorgpad ontwikkeling ziekte van Bechterew en
artritis psoriatica VUmc-Reade/JBI
Van der Laken J
Committee Member
National working group imaging in Rheumatology (IRON)
(Rheumatology Ultrasound)
Van der Sar AM
Member
Scientific Advisory Board, Vertebrate Antibodies, UK,
http://vertebrateantibodies.com/
Scientific Advisory Board, FishForPharma (2012-2015), a Marie
Curie Initial Training Network on zebrafish infection models
for Phamaceutical screens
Van der Waal I
Member
American Academy for Oral and Maxillofacial Pathology
British Association of Oral and Maxillofacial Surgeons
British Society for Oral Pathology
British Society for Oral Medicine
European Association for Cranio-Maxillofacial Surgery
European Association of Oral Medicine
International Association of Oral Pathologists
International Association of Oral & Maxillofacial Surgery
Nederlands Tandheelkundig Genootschap
Nederlandse Maatschappij tot bevordering der
Tandheelkunde
Nederlandse Vereniging voor Mondziekten, Kaak- en
Aangezichtschirurgie
Nederlandse Vereniging voor Pathologen
Nederlandse Vereniging van Tandartsen
Nederlandse Werkgroep Hoofd-Hals Tumoren
Scandinavian Society for Oral Pathology and Oral Medicine
Van Dulmen-den Broeder E
Board Member
DCOG LATER-Research Group
Member
DCOG-LATER taskforce
Work Group Leader
One of the work packages of the “Female gonadal dysfunction
in childhood cancer survivors international guidelines
harmonization group”
Advisor
Nederlandse Meningitis Stichting
Board member
BMC Infectious Diseases
Boardmember “Purple Pages” Pediatric Infectious Diseases
Journal
Reviewer
Nederlands Tijdschrift voor Geneeskunde
Pediatric Research
European Journal of Clinical Microbiology & Infectious
Diseases
Pediatric Infectious Disease Journal
BMC Infectious Diseases
Journal of Neurology, Neurosurgery & Psychiatry
Journal of Pediatric Infectious Diseases
Experimental Neurology
Van den Elsen P
Van der Horst-Bruinsma IE
Van Furth AM
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 73
Associate
Function
Organisation
Acta Neuropathologica
Van Montfrans C
Board Member
Dutch Society of Dermatology and Venereology
EADV
Member
European society of Dermatology and Venereology
Member
EULAR study group for risk factors for RA
Co-organizer
The first international workshop on preclinical RA, Reade,
Amsterdam 26.1.2011; second workshop was held prior to
ACR Annual Meeting, November 2011 Chicago and the next
one will be held in January 2013 in Stockholm (member of the
international organizational committee)
Van Vuurden D
Chair
European Society of Pediatric Oncology (SIOPE) Diffuse
Intrinsic Pontine Glioma (DIPG) Network
DIPG Protocol Committee (PC) of the Dutch Childhood
Oncology Group (DCOG)
Supratentorial Primitive Neuro-Ectodermal Tumors (sPNET) PC
of the DCOG
Vandenbroucke-Grauls CMJE
Chairman
Adviescommissie Centrum Infectieziektenbestrijding van het
RIVM
Registratiecommissie ISIS, Centrum Infectieziektenbestrijding
van het RIVM
Antonie van Leeuwenhoek Stichting
Member
Programmacommissie Infectieziektenbestrijding van ZonMw
Programmacommissie Antimicrobiële Resistentie van ZonMw
NWO, TOP Commissie
Bestuur Nederlandse Vereniging voor Medische Microbiologie
Commissie Wetenschap Sint Lucas Andreas Ziekenhuis
Concilium Microbiologicum Medical Microbiology
Founder (and member)
ZIEN
Evaluator
European Comission, FP7-HEALTH-2011-single-stage
Fellow
The Royal College of Physicians UK (RCP)
Committee member
ALL-11 prococol committee, DCOG
Member taskforce DCOG LATER
Member
Nederlandse Vereniging voor Kindergeneeskunde
Adviescommissie Neonatale Screening (ANS SIKK) NVK
Landelijke Werkgroep Hemoglobinopathie Behandelaren
`Werkgroep Benigne Hematologie van de sectie
kinderoncologie-hematologie van de NVK
Nederlandse Vereniging voor Hemofilie Behandelaren
Landelijke pediatrische werkgroep trombose en stroke
Member
local organizing committee of the 15th World Congress of
Psyhco-Oncology and Psychosocial Academy, Rotterdam, The
Netherlands, 4-8 November 2013
European Org. of Research and Treatment of Cancer (EORTC)
Quality of Life Group
Advisory board Patient panel Living with Cancer (NIVEL)
Multinational Association for Supportive Care in Cancer
(MASCC)
Dutch Psychology Society (NIP)
Dutch Psychosocial Oncology Society (NVPO)
Dutch ENT Society (KNO)
Dutch Society of Logopedics and Phoniatrics (NVLF)
Dutch Society of Voice, Speech, and Language Pathology
(NVSST)
Dutch Phonetic Sciences Society (NVFW)
American Psychosocial Oncology Society (APOS)
International Psychosocial Oncology Society (IPOS)
International Society of Internet Research (ISRI)
Chair
VUmc CCA Research Institute program 5 Quality of life
VUmc CCA and EMGO+ Research Institutes Quality of life in
Cancer Patients
Van Schaardenburg D
Veening MA
Verdonck-de Leeuw IM
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 74
Associate
Function
Organisation
Co-chair
MASCC Study Group on Cancer Survivorship and
Rehabilitation
Board Member
`Borstkanker Vereniging Nederland` (breast cancer patient
society)
Advisory Board Member
“Stichting Klankbord” (patient society, head and neck cancer)
“Stichting Olijf” (patient society, cancer of the female
productive organs)
Program Leader
V-ICI program 3: Disease Profiling
Member
Advisory committee BioScience Biomarker summit symposia
Netherlands Society for Rheumatology (NVR)
Netherlands Organization for Immunology (NVvI)
Netherlands Inflammation Network (NIN)
International Society for Translational Medicine (ISTM)
European Association for Predictive and Personalised
Medicine (EPMA)
Biomarker Qualification Working Group of the FDA
President
Dutch working party of systemic sclerosis
Sichting Registratie Systeemziekten Nederland
Educational board of concilium rheumatologicum for AIOS
education
Member
Treat to target in systemic lupus erythematosus
Secretary and president elect
Dutch working party on systemic lupus erythematosus
Waisfisz Q
Member
Scientific Research Committee (CWO), VUmc CCA, VU
University Medical Center
Wintzen M
Member
Domeingroep Allergologie en Contactdermatosen van de
Nederlandse vereniging voor Dermatologie en Venereologie
Nederlandse Vereniging voor Allergologie
Wondergem MJ
Member
EHA
ASH
NVVH
NIV
Ylstra B
Editorial board member
Cellullar Oncology
Zijlstra JM
Member
Nederlandsche Internisten Vereeniging (NIV)
Nederlandse Vereniging voor Hematologie (NVvH)
European Haematology Association (EHA)
Steering Committee German Hodgkin Study Group
Chairman
HOVON Imaging Werkgroep
HOVON Imaging working party
Reviewer
Haematologica, Journal of Nuckear Medicine
Chairman
Center of expertise for palliative car,e VUMC
Member
Programm committee palliative CareL
Medical director
Hospice Kuria
Principal investigator
Joint HOVON/NMSG international study on multiple myeloma
Dutch Local Liaison Physician
The Severe Neutropenia International Registry (SNIR)
Chairman
Hematology Working Group, Cancer Center Amsterdam
Board member
HOVON Multiple Myeloma Working group
Executive board member
The European Myeloma Net Trialist Group, European Myeloma
Network
Reviewer
International peer reviewed journals; Haematologica,
Experimental Journal of Hematology, Annals of Hematology
Annual Meeting 2012 European Hematology Association
Verweij CL
Voskuyl AE
Zuurmond WWA
Zweegman S
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 75
Associate
Function
Organisation
Member
Werkgroep Niet-Oncologische Hematologievan de
Nederlandse Vereniging voor Hematologie, voorzitter
subcommissie myeloproliferatieve aandoeningen
Commissie Klinische Studies, Koningin Wilhelmina Fonds
(KWF)
The European Multiple Network biobanking committee,
European Myeloma Network
Werkgroep Zorgpaden, zwaartepunt Kanker, VUMC
Selectiecommissie Klinische Fellowships KWF
The Myeloproliferative Neoplasms Quality of Life (MPN-QOL)
International Study Group
The international Myeloproliferative Disorders Research
Consortium MPD-RC
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 76
Lectures
Associate
Title
Organisation
Ameziane N
The first real FA-M patient identified through
next generation sequencing
24th Annual Fanconi Anemia Research Fund
Scientific Symposium, September 27-30, Denver,
USA
Ang CW
Serologic tests for Lyme disease – how
reliable are they?
13th Lyme & other tick-Borne Disease, New Scientific
& Clinical Directions, Sept 29 & 30, Philadelphia, PA,
USA (invited lecture)
Ankersmit M
Laparoscopische schildwachtklierprocedure
met een near-infrared dye bij colon
carcinoom patienten; eerste klinische
resultaten
Chirurgendagen 2012
Appelmelk BJ
The mycobacterial cell surface in host
pathogen interaction .....and as a potential
vaccine target?
Invited Seminar January 13, Novartis Siena, Italy
The role of glycolipids and protein secretion
systems in immunomodulation by
pathogenic mycobacteria
COST bm_1003 “ Cystic Fibrosis” Joint meeting,
June 4, Naples, Italy
Anthony P. Moran memorial lecture: From H.
pylori to M. tuberculosis …..and back…
10th International Workshop on Pathogenesis and
Host Response in Helicobacter infections, June,
Helsingør, Denmark
Mycobacterium tuberculosis and
Helicobacter pylori .Role of glycolipids in
host-pathogen interaction
Invited seminar 19 July, National Institute of
Chemistry, Ljubljana, Slovenia
What I learned from Helmut..and what I did
with it…..
Symposium, 12-13 Oct, Research Centre Borstel,
Germany
Mycobacterium tuberculosis Glycolipids and
host-pathogen interaction
Invited seminar, Dec. 12, University of Umeå,
Sweden
Bitter W
Type VII secretion in pathogenic
mycobacteria: from substrate recognition to
virulence
Infection biology seminars, May 9, 2012, Basel,
Switserland
Bloemena E
Pathological examination of the sentinel
node
5th International Symposium on Sentinel Node
Biopsy in Head and Neck Cancer, Amsterdam, May
24 2012
Boellaard R
Educational presentation on quantitative
parametric analysis of neuroreceptor PET
studies
TOPIM meeting of the European Society of Molecular
Imaging, Les Houches, 2012
Presenter and session chair/organiser on
amyloid PET imaging
Society of Nuclear Medicine conference, Miami 2012
Presentation on standardisation of FDG
PET/CT for quantitative multi-centre studies
at the technologist’s session
EANM conference, Milan, 2012
Presenter and member of discussion panel
at the PET/MR workshop
Tuebingen in March 2012
Presentation on standardisation,
quantification and quality control of PET/CT
studies
MIRO conference, Vienna, 2012
Presentation on standardisation of FDG
PET/CT for quantitative multi-centre studies
30thsymposium “Radioactive Isotopes in Clinical
Medicine & Research” in Bad Hofgastein, Austria,
2012
Improving outcome in rheumatoid arthritis.
Burns Festival of Bone and Joint Disease Scientific
Symposium. Kelso, UK.
Boers M
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 77
Associate
Title
Organisation
• General conference introduction: Outcome
Measures in Rheumatology: The OMERACT
Filter.
• A conceptual framework to select outcome
measures: OMERACT Filter 2.0.
• Introduction for fellows.
• Final presentation of Filter 2.0.
• Drug Information Association (DIA) Annual
conference, Philadelphia, USA
Combining harm and benefit in clinical
trials in one scale: review + suggestion
from OMERACT
OMERACT 11 consensus conference, Pinehurst, NC
USA.
• How do we combine modern imaging in
the RA remission criteria?
• EULAR points to consider when conducting
long-term extension studies of trials. 90
minute workshop on scientific graphs.
EULAR annual conference Berlin.
Braakhuis BJM
Treatment choice for locally advanced head
and neck cancers on the basis of risk
factors: biological risk factors
ESMO (European Society of Medical Oncology)
congress, September 29, Vienna, Austria
Braamse A
A web-based stepped care intervention for
psychological distress after auto-SCT:
randomized controlled trial
EACLPP/ECPR [The European Association for
Consultation Liaison Psychiatry and Psychosomatics
/ The European Conference on Psychosomatic
Research], June 29th, 2012, Aarhus, Denmark
A web-based stepped care intervention for
psychological distress after auto-SCT
International Congress of Behavioral Medicine
August 30th, 2012, Budapest, Hungary
Which factors predict health-related quality
of life in patients treated with HSCT for
hematological malignancies?
Ïnternational Congress of Behavioral Medicine
September 1st, 2012, Budapest, Hungary
Identification of novel therapeutic targets for
head and neck cancer by functional genetic
screens
Annual meeting AACR 2012
The molecular biology of head and neck
cancer
PER/IADR, Helsinki
• Identification of synthetic lethal micrornas
by a functional genetic screen in head and
neck squamous carcinoma cells.
• CD98 marks a subpopulation of head and
neck squamous cell carcinoma cells with
stem cell properties
AHNS, Toronto
De rol van het humaan papillomavirus in
hoofd-hals tumoren: toename in incidentie
en klinische consequenties
DONAMO, Amsterdam
• Molecular carcinogenesis of HPV+ve and
HPV-ve head and neck cancer
• Differences between HPV+ve and HPV-ve
head and neck cancers at the molecular
level
Eurogin, Praag
The molecular biology of head and neck
cancer
EHNS Poznan
Buffart L
How does exercise improve cancer survivors’
quality of life?
Oct 31 – Nov 3 2012, International Conference on
Physical Activity and Public Health (ICPAPH): “Be
Active 2012”- Sydney, Australia.
Cloos J
Definition of the leukemic stem cell
8th Biennial Childhood Leukemia Symposium
April 22 to 24, 2012, Santiago, Chile
Relevance of small immature subpopulations
in pediatric AML
23rd Annual Meeting of the I-BFM Study Group
April 20 to 22, 2012, Santiago, Chile
Brakenhoff RH
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 78
Associate
Title
Organisation
Relevance of small immature subpopulations
at diagnosis for the development of relapse
in pediatric AML
4th Open AML-BFM Research Symposium
May 23 to 25, 2012, Hannover, Germany
Accurate definition of the stem cell burden
in diagnosis and follow-up pediatric AML for
improved risk group stratification
Int. Pediatric AML Working Group
Dec 9 , 2012, Atlanta, USA
Management of Oral Cancer
European Meeting on Oral Disease: diagnosis and
management. 11 mei 2011, Amsterdam
Controversies in management of clinically
negative neck
SSHNO Annual Meeting. 27April 2012, Copenhagen
The detection of occult cervical lymph node
metastases
5th International symposium on sentinel node biopsy
in head and neck cancer, 24 May 2012, Amsterdam
Sentinel node biopsy in T1-T2 oral and
oropharyngeal cancer reduces the risk of
occult lymph node metastases
Collegium Oto-Rhinolaryngologicum Amicitiae
Sacrum. 28 August 2012, Rome, Italy
Quality of life in advanced head and neck
cancer
Electrochemotherapy inhead and neck cancer. 23
November 2012, Pavia, Italy
de Crom S
Een prospective analyse van het klinisch
spectrum van verschillende subtypen
humaan Enterovirus en Parechovirus
NVK, November 2012, Veldhoven, The Netherlands
de Cuba E. M et al
VEGF expressie in peritoneaal metastasen
correleert met overleving na HIPEC
Presentatie Stafwetenschapsdag Afdeling Heelkunde
VUmc, Amsterdam oktober 20
De rol van de Fanconipathway in Mitomycine
C gevoeligheid bij HIPEC patiënten.
Integraal Kankercentrum Nederland February 2012
Lymphoid and myeloid biomarkers for
clinical outcome of ipilimumab and Prostate
GVAX treatment
Tumor Vaccine & Cell Therapy Working Group
Meeting, 30 March 2012, Chicago IL
Virus-based immunotherapy of cancer
Progress in combination therapy of cancer using
novel immunomodulators, 1-3 November 2012,
Athens, Greece
Virus Dendritic cell subsets in human skin
and their role in T-cell activation
20th scientific meeting Fondation René Touraine
pour la dermatologie, 30 November 2012,
Paris, France
de Jonge R
Bacteriële meningitis: van fundament naar
patiënt
RAAK, December 2012, Amsterdam, The
Netherlands
de Rie MA
Methotrexate from a global perspective
International Federation Psoriasis Assocations, 30
Juni 2012, Stockholm, Sweden
de Winter JP
A novel Fanconi anemia gene identified by
exome sequencing
DNA repair group, 20-01-2012, Rotterdam
Generation of head and neck cancer cell
lines from Fanconi anemia patients
Second Düsseldorfer Fanconi-Anamie symposium
21-05-2012, Dusseldorf, Germany
Replication coupled genome maintenance
and human disease
Working visit the Weatherall Institute of Molecular
Medicine, 28-05-2012, Oxford, UK
Dekker J
Screening for psychological distress in
somatic disease
May 2012, Jining, China
Eeltink C
Discussing sexuality
Turkse hematologie vereniging, maart 2012 Antalya
Turkije
Fertility issues in haemato-oncological
survivors
EBMT nurses group, april 2012 Geneve
Zorg voor oudere patient met MDS
ESH masterclass, 14 juni Amsterdam
Tumours of the salivary glands. Voice
rehabilitation after total laryngecomy
5th European Head and Neck Course, Birmingham
October 2012
de Bree R
de Gruijl T
Eerenstein SEJ
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 79
Associate
Title
Organisation
Gibbs S
3D allergenicity models (invited speaker)
Workshop – animal alternatives: Sao Paulo
University, Brazil, 16 November, 2012, Sao Paulo,
Brazil
Tissue engineered skin and mucosa for
wound healing and in vitro assays (invited
speaker)
Workshop – animal alternatives: Sao Paulo
University, Brazil, 17 November, 2012, Sao Paulo,
Brazil
Retrospective analysis of patients with
(arterio-)venous, post-traumatic or pressure
ulcers treated with autologous skin
substitute (invited speaker)
EPUAP (European Presuure ulcer) Focus Meeting, 17
April, 2012, Tel Aviv, Israel
Skin-on-a-chip (invited speaker
KNAW organ on a chip workshop, 20April, 2012,
Trippenhuis, Amsterdam
Retrospective analysis of patients with
(arterio-)venous, post-traumatic or pressure
ulcers treated with autologous skin
substitute (invited speaker)
FEDERA Medisch Wetenschappelijke Dag 2012, 8
June, 2012, UMCU, Utrecht
Tissue engineered skin for hard-to-heal
wounds - Optimal vascularization is essential
for graft take (invited keynote speaker)
NIRM, 26 June, 2012, Meeting Plaza, Utrecht
A potential epidermal equivalent assay to
determine sensitizer potency (invited
speaker)
Cosmetics Europe Workshop for integrated testing
strategy, 3-4 December, 2012, Brussels, Belgium
Skin Equivalent made from TERT
immortalized keratinocytes and fibroblasts
for in vitro assays
ERGECD, 10-12 October, 2012, Trier, Germany
A potential epidermal equivalent assay to
identify sensitizers and determine sensitizer
potency
ERGECD, 10-12 October, 2012, Trier, Germany
Gibbs S (Christianne
Reinders PostDoc)
Retrospective analysis of patients with ulcers
of (arterio-)venous, traumatic or decubitus
origin treated with an autologous skin
substitute (invited lecture)
Landelijk Decubitus congres 2012, November 2012,
Kerkrade, the Netherlands
Gibbs S (Grace
Limandjaja OIO)
Abnormal terminal differentiation and
increased thickness of
the epidermis in keloid scars
4th international scar-club meeting, 4-5 october
2012, Montpellier, France
Gibbs S (Ilona Kosten)
Comparison of inflammatory mediators
secreted by skin and gingival
ERGECD, 10-12 October, 2012, Trier, Germany
Gibbs S (Sander
Spiekstra)
Skin Equivalent made from TERT
immortalized keratinocytes and fibroblasts
for in vitro assays
ITCASS, 31 August, 2012, Copenhagen, Denmark
Gibbs S (Christianne
Reinders)
Retrospective analysis of patients with
(arterio-)venous, post-traumatic or pressure
ulcers treated with autologous skin
substitute
TERMIS world meeting, 5-7 September, 2012,
Vienna, Austria
Gibbs S (Lenie van den
Broek)
Development and validation of an in vitro
hypertrophic scar model
TERMIS world meeting, 5-7 September, 2012,
Vienna, Austria
Giovannetti E
Molecular mechanisms underlying the role
of microRNAs (microRNAs) in anticancer
drug resistance: Implications for clinical
practice
XXXIII Winter Meeting of the EORTC-PAMM, La
Laguna, Tenerife, Spain, 27-29 January
New studies in pancreatic cancer: analysis of
copy number and miRNA
XXXVI AISP Congress, Bologna, 4-6 October 2012
Molecular determinants of pancreatic cancer
chemoresistance
Marburg University Gastroenterology Department
Meetings (Host: Dr. K. Quint), Marburg, Germany, 7
March 2012
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 80
Associate
Title
Organisation
Gorter R. R et al
Armfunctie en kwaliteit van leven na inductie
chemoradiatie gevolgd door resectie van
sulcus superior tumoren
Presentatie Chirurgendagen 2012, Veldhoven
Influence of T1 nerve root resection on the
arm and shoulder function and quality of life
after trimodality treatment for superior
sulcus tumours
ESTS 2012 Essen June 10-13 2012
Houben E
Composition of the Type VII secretion
system membrane complex
Tuberculosis 2012, EMBO Conference, September
11-15, 2012, Paris, France
Huibers MHW
Vitamin D deficiency among non-Western
immigrant children in Amsterdam
Amsterdam Kindersymposium
17 February 2012, Amsterdam, The Netherlands
Vitamin D deficiency among non-Western
immigrant children in Amsterdam
Sint Lucas Andres Ziekenhuis, 16 mei 2012,
Amsterdam, The Netherlands
Vitamin D deficiency among non-Western
immigrant children in Amsterdam
NVK, 1 November 2012, Veldhoven, The
Netherlands
Hulleman E
Drug response and drug resistance in highgrade glioma and DIPG
SIOPe, 23-06-2012, Toronto, Canada
Israels T
Management of children with a Wilms
tumour in Malawi, sub-Saharan Africa
Annual meeting SIOP (International Society of
Pediatric Oncology), October 5 – 8, 2012, London
Toxicity and efficacy of preoperative
chemotherapy for children with Wilms
tumour in Malawi
SIOP Africa continental meeting, March 2012, Cape
Town , South Africa
Molecular mechanisms of resistance to an
esterase-sensitive aminopeptidase inhibitor
prodrug
33rd EORTC-PAMM Winter Meeting, January 25-28,
2012, Puerto de la Cruz, Tenerife, ESP
Folate and antifolates in chronic
inflammatory diseases
15th International Symposium on Pteridines and
Folates, May 9-13, 2012, Antalya, Turkey
Gene expression profiling of folate/MTX
transporters and metabolizing genes in
rheumatoid arthritis patients
4th International Symposium on Folate Receptors
and Transporters, October 7-11, 2012, Cozumel.
Mexico
Label-free mass spectrometry-based
proteomics for cancer biomarker discovery,
Protein quantitation by spectral counting: A
pragmatic perspective
5 March. 2012, Utrecht. NBIC, Hot topics day:
Peptide and protein quantification using Mass
Spectrometry
New CSF biomarkers for AD: report from the
cNEUPRO discovery phase
8 juni 2012, Assisi, Italy. 2nd workshop Biomarkers
in the early diagnosis of neurodegenerative
disorders
New CSF biomarkers for AD: report from the
cNEUPRO discovery phase
15 juni 2012, NUBIN2012 symposium, Amsterdam
Cancer biomarker discovery and validation:
Label-free mass spectrometry-based
proteomics
26 June, 2012. The 19th Arbeitstagung
Micromethods in Protein Chemistry, Bochum
Oncologic emergencies
3rd Workshop on Pediatric Oncology, 17 January
2012, Eldoret, Kenya
Signs Symptoms and approach to a patient
with suspected haematological malignancy
3rd Workshop on Pediatric Oncology, 17 January
2012, Eldoret, Kenya
Shared care kinderoncologie
Dutch Hematology Congres (Nederlandse Vereniging
voor Hematologie/HOVON), 25 January 2012
Rapportage ziektecommissie myeloide
maligniteiten
SKION dagen, 2 February 2012, Utrecht, NL
Voortgang taak- en werkgroep shared care
SKION dagen, 3 February 2012, Utrecht, NL
Translational research in diffuse intrinsic
pontine gliomas (DIPG)
Eerste Amsterdams Symposium Kindergeneeskunde,
16 February 2012, Amsterdam, NL
Jansen G
Jimenez CR
Kaspers GJL
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 81
Associate
Klein M
Kluytmans JAJW
Title
Organisation
Report on behalf of DCOG
Meeting of NOPHO AML committee, 20 March 2012,
Oslo, Norway
panellid
Masterclass Amsterdamse Kindergeneeskunde, 17
February 2012, Amsterdam, NL
Bortezomib
Annual I-BFM-SG meeting, 20 April 2012, Santiago,
Chile
Pediatric APL: current standards/perspectives
Annual I-BFM-SG meeting, 20 April 2012, Santiago,
Chile
AML: perspectives (Round Table)
Annual I-BFM-SG meeting, 20 April 2012, Santiago,
Chile
New drugs – what is their relevance?
Introduction
Annual I-BFM-SG meeting, 20 April 2012, Santiago,
Chile
FLT3-ITD inhibition, meta-analysis
Annual I-BFM-SG meeting, 21 April 2012, Santiago,
Chile
Dasatinib in KIT-mutated patients?
Annual I-BFM-SG meeting, 21 April 2012, Santiago,
Chile
iBFM Relapse trial
Bi-annual symposium on Childhood Leukemia, 24
April 2012, Chile
Acute Promyelocytic Leukemia
4th AML-BFM Research Symposium, 23 May 2012,
Hannover, Germany
Behandeling van leukemie bij kinderen:
nu en in de toekomst
Bij- en nascholing Esperanz oncologie, 19 June 2012,
Midbeemster
Report on behalf of DCOG
Pediatric AML-BFM Meeting, 31 October 2012,
Hannover, Germany
Kinderoncologie
Jaarlijkse cursus Oncologie IKNL, 2 November 2012,
Amsterdam, NL
Shared care in het “NKOC” tijdperk
2e landelijke SKION dag shared care, 16 November
2012, Amsterdam, NL
Down syndroom en de hemato-oncologie
Bij- en nascholing klinisch chemici, 28 November
2012, Amsterdam, NL
International Projects in Pediatric AML
International Pediatric AML Group, 9 December 2012,
Atlanta, USA
International Efforts in Pediatric AML
Seminars Children’s Hospital of Philadelphia, 11
December 2012, Philadelphia, USA
Measuring quality of life and recognizing
impairment in neuro-oncology patients – an
introduction
17th Annual Scientific Meeting and Educational Day
of the Society for Neuro-Oncology, November 15-18,
Washington, DC.
How to integrate QOL and cognition in
phase III studies
10th Congress of the European Association of
Neuro-Oncology (EANO X), September 6-9, Marseille,
France
Neurocognition in patients with brain
metastases
2nd Annual Brain Metastases Research and
Emerging Therapies Conference, September 5,
Marseille, France
Importance of cognitive outcome for glioma
resections
Spring Meeting of the Dutch Society of
Neurosurgery, May 11; Garderen, The Netherlands
Neurocognitive function
EORTC Brain Metastases BTG-ROG Strategic Meeting,
February 9th, February 9th; Vienna, Austria
The human problem of MRSA and ESBL and
the question of zoonotic aspect
Conference Combating Antimicrobial Resistance –
Time for Joint Action, 14–15 maart 2012,
Kopenhagen
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 82
Associate
Title
Organisation
LA-MRSA
Third ISC MRSA Consensus Conference, 17–18 maart
2012, Napels
Prevention and theraphy of MRSA infection
22nd ECCMID, 31 maart–3 april 2012, Londen
The year in infection control
22nd ECCMID, 31 maart–3 april 2012, Londen
Voordracht tijdens Medische Contactdagen
“Kruistocht in witte jas”
Medische Contactdagen, 11-14 april 2012, Malta
Humans, animals, bacteria and antibiotics: a
recipe for trouble
Annual Danish Infectious Diseases Society Meeting,
13–14 april 2012, Middelfahrt
Screening and topical prophylaxis in surgery
Mosar Final Meeting, 22 mei 2012, Parijs
A Multifaceted Approach to Preventing
Surgical Site Infections
52nd ICAAC, 9–12 september 2012, San Francisco
Implementing a Bundle Strategy to Prevent
Surgical Site Infections
52nd ICAAC, 9–12 september 2012, San Francisco
Surgical site infections
ESCMID-SHEA Course in Hospital Epidemiology, 1–4
oktober 2012, Potsdam
Antimicrobial use
ESCMID-SHEA Course in Hospital Epidemiology, 1–4
oktober 2012, Potsdam
MRSA
ESCMID-SHEA Course in Hospital Epidemiology, 1–4
oktober, Potsdam
Bundels and infection control
ESCMID-SHEA Course in Hospital Epidemiology, 1–4
oktober 2012, Potsdam
Mission ans strategy planning in infection
control
ESCMID-SHEA Course in Hospital Epidemiology, 1–4
oktober 2012, Potsdam
Eradication of carriage. Workshop on
development of new antibacterial
EMA Science Medicines Health, 25–26 oktober 2012
A widespread outbreak of Klebsieli p. with
Oxa 48 in The Netherlands
2. Workshop Antibiotikaresistenz am RKI, 8–9
november 2012, Berlijn
Wondinfecties: de ultieme uitdaging van de
infectiepreventie
22e Dag van de Ziekenhuishygiëne: Zorgbundels in
het vizier, 6 december 2012, Gent
Kors WA
Diagnosis and treatment of retinoblastoma
Workshop on Pediatric Oncology, 25 April 2012
Kwakman R et al
Mitomycine C gevoeligheid van
colorectaalcarcinoomcellijnencorreleert met
BLM expressive
Oral presentation SEOHS, Amsterdam November
2012
Lagerwaard FJ
Recente innovaties in intracraniële
radiochirurgie
NvMBR wetenschappelijke vergadering, Breda, The
Netherlands, 16 April, 2012
Epidurale metastasen en hoge dosis
radiotherapie
Raakvlakken symposium: Neurologie en Oncologie,
Garderen, The Netherlands, 22 - 23 Juni, 2012
Stereotactic Radiotherapy for operable lung
cancer
10eme Biennale Monégasque de Cancérologie,
Monte-Carlo, Monaco, 25 - 28 January 2012
Stereotactic body radiotherapy using
RapidArc technology
Russian Oncology and Radiology Meeting, Moskow,
Russia, 14 - 15 March 2012
Color intensity projection for AVM
delineation
4th European Brainlab RT User Meeting,
Copenhagen, Denmark, 16 - 17 March, 2012
Results of modern radiotherapy alone from
stage I to stage III
European Respiratory Society 2012, Vienna, Austria,
1 - 5 September, 2012
Stereotactic Radiotherapy Application in
Modern Clinical Practice
Oncology and Radiology Congress of CIS States,
Astana, Kazakhstan, 5 - 7 September, 2012
The role of WBRT with radiosurgery for
multiple brain metastases
Gammaknife symposium, Amsterdam, The
Netherlands, 23 November, 2012
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 83
Associate
Leemans CR
Title
Organisation
Stereotactic body radiotherapy for lung
cancer
Multidisciplinary Approaches in Oncology congress,
Moscow, Russia, 5 - 7 April, 2012
RapidArc Stereotactic radiotherapy for lung
cancer
Radiation Oncologist scientific exchange meeting,
London, UK, 16 May, 2012
Clinical Application of Modern Technology
for Stereotactic Radiotherapy
Polish Oncology Congress, Wroclaw, Poland, 10 - 12
October, 2012
Role of stereotactic body radiation therapy
13th Central European Lung Cancer Conference,
Prague, Czech Republic, 24 - 27 June 2012
Biological rationale & role of radiation doseescalation for brain metastases
ESMO 2012, Vienna, Austria, 28 September - 2
October, 2012
Stereotactic radiotherapy for lung cancer
using RapidArc
International conference on modern Radiotherapy,
Palanga, Lithuania, September 14 - 15, 2012
SABR for peripheral early stage NSCLC
SBRT symposium, Amsterdam, The Netherlands, 3 5 December, 2012
Simultane geïntegreerde stereotactische
boost bij hersenbestraling
Themadag Implementatie van geavanceerde
boosttechnieken, Eindhoven, The Netherlands, 29
March, 2012
Where are we now in head and neck cancer?
Make Sense Think Tank
January 19-20, 2012, London, UK. (Invited Speaker
and Co-organiser).
Organ Preservation for Oropharyngeal
Carcinoma: For All?
M. D. Anderson Cancer Center, Department of Head
and Neck Surgery, Houston, TX, USA, February 14,
2012
Surgical Salvage for Head and Neck Tumors
after Chemoradiation Failure
M. D. Anderson Cancer Center, Department of Head
and Neck Surgery, Houston, TX, USA, February 15,
2012
Salvage Surgery for Head and Neck Tumors
after Primary Organ-preservation Treatment
7th Leipzig International Course in Head and Neck
Surgery and Oncology Larynx and Hypopharynx.
Leipzig, Germany. February 29 - March 3, 2012
(Invited Speaker).
Surgical Salvage for Head and Neck Tumors
after Organ Preservation Strategies
6th European Conference on Head and Neck Cancer.
Poznań, Poland. April 18 – 21, 2012 (Invited
Speaker).
Advanced Oropharyngeal Cancer: What’s
New?
2nd International Meeting of the Italian Head and
Neck Society (Associazione Italiana di Oncologia
Cervico-Cefalica) - Head and Neck Oncology: Where
Can We Improve? Modena, Italy. May 7-9, 2012
(Invited Speaker).
Elective Treatment of the Neck
5th International Sentinel Node Biopsy Symposium
in Head and Neck Cancer. Amsterdam, The
Netherlands. May 24-25, 2012 (invited speaker).
Surgical Management of Squamous Cell
Cancer of the Oral Cavity
EHNS-ESMO-ESTRO Teaching Course on
Multidisciplinary Management of Head and Neck
Oncology. Cordoba, Spain. July 1-4, 2012.
Surgical Management of Squamous Cell
Cancer of the Oropharynx
EHNS-ESMO-ESTRO Teaching Course on
Multidisciplinary Management of Head and Neck
Oncology. Cordoba, Spain. July 1-4, 2012.
Morbidity after Surgery
EHNS-ESMO-ESTRO Teaching Course on
Multidisciplinray Management of Head and Neck
Oncology. Cordoba, Spain. July 1-4, 2012.
Management of Recurrent Tumours
EHNS-ESMO-ESTRO Teaching Course on
Multidisciplinary Management of Head and Neck
Oncology. Cordoba, Spain. July 1-4, 2012.
Increasing prevalence rates of HPV-infected
oropharyngeal SCC in the Netherlands as
assessed by a validated test algorithm
Collegium Oto-Rhino-Laryngologicum Amicitiae
Sacrum Rome, Italy. August 26-29, 2012.
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 84
Associate
Lems WF
Lübbers J
Title
Organisation
Adenoid Cystic Carcinoma of the Head and
Neck
The Amsterdam Experience. 45th Congress of the
Polish Society of Otolaryngologists/Head and Neck
Surgeons. Gdańsk, Poland. September 5-8, 2012
Head and Neck Surgery in the EORTC:
Quality Assurance
Meeting Portuguese Head and Neck Group. Instituto
Português de Oncologia Francisco Gentil, Porto,
Portugal. September 13, 2012
Key Challenges in Head and Neck Cancer.
Make Sense C ampaign
September 20-21, 2012, London, UK
Head and Neck Cancer Environment. Make
Sense Campaign
September 20-21, 2012, London, UK
Oral Cancer. Current Concepts in Head and
Neck Surgery and Oncology
International Federation of Head and Neck
Oncologic Societies. Ocober 4-6, 2012. Amsterdam.
The Netherlands (Panellist).
General Concepts of the Management of
Head and Neck Cancer
5th European Head and Neck Course. Birmingham,
UK. October 15-17, 2012.
Moderator: Case Discussions Neck
Management. 5th European Head and Neck
Course
Birmingham, UK. October 15-17, 2012
Parapharyngeal Tumours
5th European Head and Neck Course. Birmingham,
UK. October 15-17, 2012
Panellist: Case Discussions Salivary Gland
5th European Head and Neck Course. Birmingham,
UK. October 15-17, 2012. (Course Director).
Salvage Following Chemoradiation
5th European Head and Neck Course. Birmingham,
UK. October 15-17, 2012
Panellist: Post-Treatment Complications
International Masterclass in Head and Neck
Reconstruction and Rehabilitation. Birmingham, UK.
October 18, 2012.
Panel Chair: Controversies in the Neck
International Masterclass in Head and Neck
Reconstruction and Rehabilitation. Birmingham, UK.
October 18, 2012
Prednison-geìnduceerde Osteoporose en
moderne behandeling RA.
Paramaribo, 9 en 10 maart 2012
Is rheumatoid arthritis a bone disease?
ECCEO, Bordeaux, 22 maart 2012
What is New (in osteoporosis)?
EULAR, Berlijn, 8 Juni 2012
Physical disability, cartilage and bone
damage in RA.
Osteoimmunology meeting, Genua, 29 September
2012
What is New (in osteoporosis)?
EULAR, Praag, 23 November 2012:
Glucocorticoid Induced Osteoporosis.
Brussel (voor Belgische Vereniging voor
Reumatologie), 1 december 2012
Clinical Relevance of Gene Signatures in the
Development of Rheumatoid Arthritis
Dutch society for immunology meeting, 20
December 2012, Noordwijkerhout, NL
Interferon and B-cell gene signatures
contribute to diagnosis of for the pre-clinical
phase of Rheumatoid Arthritis
American College of Rheumatology, 14 November
2012, Washington DC, USA
Validation of Gene Signatures to Predict
Rheumatoid Arthritis Development
Dutch Society for Rheumatology meeting, 27
September 2012, Papendal, NL
Validation of Gene signatures to predict
Rheumatoid Arthritis development
European Congress Of Rheumatology (EULAR), 7
June 2012, Berlin, Germany
Gene signatures to predict Rheumatoid
Arthritis development
European workshop of Rheumatology Research, 23
February 2012, Stockholm, Sweden
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 85
Associate
Title
Organisation
Mebius RE
Control of mucosal immune responses by
vitamin A
Keystone symposia “Chemokines and leukocyte
trafficking in homeostasis and inflammation, Jan 813, 2012, Breckenridge, Colorado, USA
Lymph node stromal cells
Stromal Immunology Group Inaugural Meeting,
March 15, 2012, York, England
Organogenesis of the immune system
7th ENII EFIS/EJI Spring school on advanced
immunology, April 15-22, 2012, Porte Conte,
Sardinia, Italy
The stromal cells of the immune system
Chemotactic chemokines, May 27 - June 1, 2012,
Lucca (Barga), Italy
Lymph node stromal cells
41st Annual Scientific Meeting of the ISEH, Society of
haematology and stem cells, August 23-26, 2012,
Okura, Amsterdam
Development of the gut associated lymphoid
tissue
European Charcot Foundation Symposium 2012,
Nov 29- Dec 1, 2012, Marbella, Spain
Colorectal Cancer- Molecular pathways and
pathology
German Society for Pathology, Annual meeting,
Berlin, June 2, 2012
Molecular Testing and clinical implications
EPGS Update on colorectal cancer, Amsterdam, June
25, 2012
Monitoring anti-CD44 (RO5429083) efficacy
in an experimental breast
cancer model using [18F]FLT and [18F]FDG
PET
IMAGINGin2020, Imaging in complex biology,
Jackson, Wyoming, USA, September 30 - October 4,
2012
Preclinical development of folate receptor
targeting PET tracers
The 4th International Symposium on Folate
Receptors and Transporters, Cozumel, Mexico,
October 7 - 11, 2012
A genomics approach to mitigating tubal
infertility due to Chlamydia infection: A
working example of how genomics could
benefit public health
Translational Genomics Pipeline: From Populations
to Individuals, 18-21 June 2012, Wellcome Trust
Conference Centre, Wellcome Trust Genome
Public Health Genomics of Chlamydia
trachomatis
From Populatiooin Helath to Personal Health, 17th
April 2012, GRaPH-Int Symposium, Rome, Italy
Mostert S
Adherence of health-care providers with
childhood cancer treatment in Manado,
Indonesia
SIOP congress, 7 October 2012, London, United
Kingdom
Nielsen K et al
Behandeling van patiënten met irresectabele
colorectale levermetastasen met RFA;
resultaten van langdurige follow-up en
behandeling van randrecidieven
Chirurgendagen 2012
Ossenkoppele GJ
Review in AML treatment
Hematology Society of Norway, Oslo, februari 2012
• New developments in AML/MDS
• T reatment in second line for resistant
CML
• Immune modulation in AMl
At EHA June 2012 Amsterdam
• The imortance of MRD in AML
• AML: Cytotoxic treatment, is more really
better?
• AML: Focus on immune control and
targeted therapy
At ELN Frontiers Oct 2012 Istanbul
Label-free Selected Reaction Monitoring for
Biomarker verification
29 March 2012, Rolduc, NVMS-BSMS International
conference on mass spectrometry
Label-free Selected Reaction Monitoring for
Biomarker verification
June 2012, Applied Biosystems, User meeting,
Eindhoven
The role of SalvageSurgery
World Congres on Lung Cancer, Amsterdam, 3 - 7
Juli 2012
Meijer GA
Molthofff CFM
Morré SA
Oudgenoeg G
Paul MA
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 86
Associate
Pegtel M
Peters GJ
Reijneveld JC
Rustemeyer T
Title
Organisation
Stereotactic Ablatative Radiotherapy versus
Surgery
World Congres on Lung Cancer, Amsterdam, 3 - 7
Juli 2012
Stereotactic Radiotherapy versus Surgery in
Stage I NSCLC
STS 48th Annual Meeting Fort Lauderdale, Florida,
USA, 28 Febr - 1 Maart 2012
Salvage surgery for complications of
chemoradiotherapy
6th Amsterdam Longsurgical Symposium,
Amsterdam 14 December 2012
A Virus-model to study intercellular
communication through exosomes
American Society of Cell Biology (UCSF) San
Francisco, USA , December 15th 2012
How functional is the functional RNA in
exosomes?
ISEV RNA research seminar New York City, USA
(session chair) October 2nd 2012
Tracking Exosomes In Vivo Small RNA
distribution in tumor exosomes for
diagnostics
Select Biosciences Title: London, UK, May 10th 2012
Intercellular communication via exosomes;
lessons from human tumor virus
Stem Cell ESF Symposium “Around Mesenchymal
Stem Cells: Dissection and Exploitation of Secretory
Activity of MSC for Regenerative Medicine and
Anticancer Therapies” Bologna, Italy, April 12th
2012
The role of PAMM in personalized treatment
How to use pharmacokinetics,
pharmacodynamics and pharmacogenetics?
EORTC-PAMM group, January 27, 2012, Tenerife,
Spain
Gemcitabine pharmacokinetics,
pharmacodynamics and pharmacogenetics:
role of deamination
Advances in anti-neoplatic drug dose management
10 April 2012, Prague, Czech Republic
Thymidylate synthase inhibitors for Thoracic
Cancer
15th International symposium on Pteridines and
Folates, 12 May 2012, Antalya, Turkey
Polymorphisms correlated with the Clinical
Outcome of Locally Advanced or Metastatic
Colorectal Cancer Patients Treated with ALIRI
vs FOLFIRI
15th International symposium on Pteridines and
Folates, 12 May 2012, Antalya, Turkey
Folate homeostasis of cancer cells affects
sensitivity to not only antifolates but also
other non-folate drugs: effect on and of MRP
expression
15th International symposium on Pteridines and
Folates, 12 May 2012, Antalya, Turkey
Role of transport and accumulatiom in the
efficacy of targeted drugs
Society for Medicin and Natural Science of Parma,
Departments of Oncology and Experimental
Medicine, 30 May 2012, Parma, Italy
Reevaluation of the role of reduced folate
transporters in antifolate rescue and 5FU
modulation
The Fourth International Symnposium on Folate
Receptors and Transporters, 8 May 2012, Cozumel,
Mexico
Predictive role of repair enzymes in the
efficacy of cisplatin combinations in lung
and pancreatic ca
11th International Symposium on Platinum
Coordination compounds in Cancer Chemotherapy.
Stem cells, DNA repair mechanisms, DNA damaging
agents, 13 October 2012, Verona, Italy
Quality of life of patients with brain
metastases
EORTC brain metastases Brain Tumour Group –
Radiation Oncology Group strategic meeting,
February 9th, 2012, Vienna, Austria
Health-related quality of life and patient
proxy assessment in clinical trials; is it
valuable?
3rd European Organization for Research and
Treatment of Cancer (EORTC) & European Union
conference on Quality of Life, October 19th, 2012,
Brussels, Belgium
Immunological mechanisms to implants
(invited speaker)
Swiss Society of Allergy, 20-01-2012, Mittenwald,
Zwitserland
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 87
Associate
Title
Organisation
Contact allergy and drug exanthema to
drugs (invited speaker)
EACCI, 13-04-2012, Munich, Germany
Contact allergy to palladium (invited speaker
/ chairperson)
EECDRG, 21-04-2012, Bari, Italy
European Baseline Series Allergens (invited
speaker / chairperson)
EECDRG, 22-04-2012, Bari, Italy
Proposal for new members of the society
(invited speaker / chairperson)
EECDRG, 22-04-2012, Bari, Italy
Impact of contact allergy to hair dyes
inEurope (invited speaker / chairperson)
EU commission on consumers’safety, 14-05-2012,
Brussels, Belgium
Immunological mechanisms and
irreversibility of contact allergy (invited
speaker)
Hearing of the EU commission on consumers’safety,
15-05- 2012, Brussels, Belgium
Allergy to metals (invited speaker /
chairperson)
European Society of Contact Allergy, 13-06-2012,
Malmo, Sweden
Immunology of contact allergy (invited
speaker)
European Society of Contact Allergy, 13-06-2012,
Malmo, Sweden
T cell subsets in contact allergy (invited
speaker / chairperson)
European Society of Contact Allergy, 13-06-2012,
Malmo, Sweden
State of the art in allergy to insulins (invited
speaker / chairperson)
NovoNordisk, 23-08-2012, Amsterdam, The
Netherlands
European Baseline Series Allergens (invited
speaker)
EECDRG, 20-10-2012
Lisabon, Portugal
Palladium contact allergy (invited speaker)
EECDRG, 20-10-2012, Lisabon, Portugal
Allergologie (invited speaker)
5e Jaarsymposium Dermatologie , 13-12-2012,
Utrecht, The Netherlands
Titanium contact allergy: proposal of a new
European study (invited speaker)
EECDRG, 20-10-2012, Lisabon, Portugal
Atopic Dermatitis: New insights in
pathomechanisms and therapeutic
approaches (invited speaker)
Post Academic Training, 23-11-2012, Amsterdam,
The Netherlands
Savelkoul PHM
Analysis of Multi-Bacterial Specimen by
ISPRO
ASM Conference on Regulating with RNA in Bacteria,
4/5/6 March, San Juan, Puerto Rico
Schuurhuis GJ
The role of flowcytometry in rest disease in
AML (invited)
European Haematology Association, June 14th 2012,
Amsterdam
Leukemic stem cells in AML (invited)
European Haematology Association, June 14th 2012,
Amsterdam
High prognostic impact of flowcytometric
minimal residual disease detection in acute
myeloid leukemia: prospective data from the
HOVON/SAKK 42A study (invited)
European Society for Clinical Cell Analysis (ESCCA)
(invited), Sept 14th 2012, Budapest
The role of flowcytometry in rest disease in
AML (invited)
European Haematology Association, June 14th 2012,
Amsterdam
Leukemic stem cells in AML (invited)
European Haematology Association, June 14th 2012,
Amsterdam
High prognostic impact of flowcytometric
minimal residual disease detection in acute
myeloid leukemia: prospective data from the
HOVON/SAKK 42A study (invited)
European Society for Clinical Cell Analysis (ESCCA)
(invited), Sept 14th 2012, Budapest
Treatment of choice in Stage IIIA-N2 NSCLC:
Neo-adjuvant before surgery versus radical
radio-chemotherapy
5th Symposium on radio-chemotherapy in Lung
Cancer, Santiago de Compostela, Spain, February
17, 2012
Senan S
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 88
Associate
Title
Organisation
Radio-chemotherapy in lung cancer and new
therapeutic targets
5th Symposium on radio-chemotherapy in Lung
Cancer, Santiago de Compostela, Spain, February
17, 2012
Stereotactic Ablative Radiotherapy for lung
cancer
Annual scientific meeting of the Singapore
Radiological Society, Singapore, February 11 - 12,
2012
Population Based Survivals in Early Stage
NSCLC for European Populations
Annual scientific meeting of the Singapore
Radiological Society, Singapore, February 11 - 12,
2012
4-Dimensional CT imaging for stereotactic
radiotherapy for lung tumors
Annual scientific meeting of the Singapore
Radiological Society, Singapore, February 11 - 12,
2012
Treating High-Risk Operable Early-Stage
NSCLC: What’s New in 2012
Symposium held at the Annual meeting of the
Society of Thoracic Surgeons, Ft. Lauderdale,
Florida, January 30, 2012
Stereotactic radiotherapy for lung cancer
Thoracic Oncology in Munich, Munich, Germany,
March 2 – 3, 2012
Debate: Which treatment for screening
detected tumors? The radiotherapeutic
approach
Perspectives in Lung Cancer: 13th European
Congress, Amsterdam, The Netherlands, 9 - 10
March, 2012
Debate: Stereotactic radiotherapy in early
NSCLC and metastases
Perspectives in Lung Cancer: 13th European
Congress, Amsterdam, The Netherlands, 9 - 10
March, 2012
Debate: Clinical approach to combined
modality and toxicity
Perspectives in Lung Cancer: 13th European
Congress, Amsterdam, The Netherlands, 9 - 10
March, 2012
Localised therapy of metastatic disease to
the lung: The role of stereotactic
radiotherapy
3rd European Lung Cancer Conference, Geneva,
Switzerland, 18 - 21 April, 2012
Stereotactic radiotherapy for Lung Cancer
International Conference On Multidisciplinary
Management Of Common Cancers, Kovalam, India,
May 4 – 6, 2012
Management Strategies for Stage III Lung
Cancer
International Conference On Multidisciplinary
Management Of Common Cancers, Kovalam, India,
May 4 – 6, 2012
Contouring target volumes for lung cancer
International Conference On Multidisciplinary
Management Of Common Cancers, Kovalam, India,
May 4 – 6, 2012
Clinical achievements in extracranial
stereotactic: Facts or promises
Annual meeting of the European Society for
Radiotherapy and Oncology, Barcelona, Spain, May 9
- 13, 2012
IMRT and stereotactic radiotherapy for lung
cancer
ESTRO course on IMRT and Other Conformal
Techniques, Amsterdam, The Netherlands, 3 - 7
June 2012
Image guidance in IMRT and stereotactic
radiotherapy
ESTRO course on IMRT and Other Conformal
Techniques, Amsterdam, The Netherlands, 3 - 7
June 2012
Treatment of early-stage NSCLC in unfit
patients: Stereotactic ablative radiotherapy.
Pro-con debate.
3rd International Conference on Thoracic Oncology,
Naples, Italy, 28 - 30th June, 2012
State of the Art: Modern radiotherapy
4th Australian Lung Cancer Conference, Adelaide,
Australia, 23 - 25 August, 2012
Radiotherapy for Mesothelioma: Time to call
it a day?
4th Australian Lung Cancer Conference, Adelaide,
Australia, 23 - 25 August, 2012
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 89
Associate
Senan S et al
Slotman BJ
Title
Organisation
PRO-CON debate on Localised disease in the
borderline patient - radiotherapy vs surgery
4th Australian Lung Cancer Conference, Adelaide,
Australia, 23 - 25 August, 2012
Stereotactic radiotherapy for lung cancer
ESTRO Course on Clinical Practice & Implementation
of Image-Guided Stereotactic Body Radiotherapy,
Würzburg, Germany, September 2 - 6, 2012
Starting a stereotactic radiotherapy program:
Clinicians perspective
ESTRO Course on Clinical Practice & Implementation
of Image-Guided Stereotactic Body Radiotherapy,
Würzburg, Germany, September 2 - 6, 2012
Stereotactic ablative radiation therapy for
NSCLC: Patient selection and fractionation
regimes
3rd International Thoracic Oncology Congress,
Dresden, Germany, September 13 – 15, 2012
Developments in early stage non-small cell
lung cancer - Advances in radiotherapy
37th European Society of Medical Oncology
Congress, Vienna, Austria, 28 Sept. - 2 Oct., 2012
N2 positive non-small cell lung cancer Multidisciplinary interactive session
37th European Society of Medical Oncology
Congress, Vienna, Austria, 28 Sept. - 2 Oct., 2012
Patterns Of Disease Recurrence Following
Either Stereotactic Ablative Radiotherapy
(sabr) Or Lobectomy By Video-assisted
Thoracoscopic Surgery (vats) In Stage I-ii
Non-small Cell Lung Cancer: Outcomes Of A
Propensity Score-matched Analysis
ASTRO 2012 Boston October 28-31 2012
Stages I-II non-small cell lung cancer treated
using either lobectomy by videoassistedthoracoscopic surgery (VATS) or
stereotactic ablative radiotherapy (SABR):
Outcomes of a propensity score-matched
analysis
ASCO 2012 Chicago June 1-5 2012
Dutch experience of SABR in Stage I NSCLC
Stanford University, Palo Alto, USA, January 31, 2012
©REST trial: Design and Accrual
Stanford University, Palo Alto, USA, January 31, 2012
SBRT for NSCLC
University California San Francisco, San Francisco,
USA, February 1, 2012
Role of radiotherapy in SCLC
University California San Francisco, San Francisco,
USA, February 1, 2012
SBRT lung: selection criteria,
treatmenttechniques and outcome
Singapore Radiol Society, Singapore, February 9,
2012
Lung SABR: Case discussion with evidence
from the literature
Singapore Radiol Soc, Singapore, February 9, 2012
Lung stereotactic radiotherapy: The Dutch
experience
Cleveland Clinic 5th SBRT Symposium, Orlando, USA,
February 26, 2012
Stereotactic ablative body radiosurgery for
non-small cell lung cancer
Eur. BrainLAB meeting, Copenhagen, Denmark,
March 3, 2012
SBRT for early stage NSCLC. Lung Cancer
Management: Personalize or Punt?
MD Anderson Cancer Center Postgraduate Course,
Las Vegas, USA, April 28, 2012
Current status of SABR for Lung Cancer. Var.
Meeting American Radium Soc, Las Vegas, USA, April
29, 2012
Are there fewer fractions in your future
The European perspective. American Radium
Society, Las Vegas, USA, April 30, 2012
©REST: update on thoracic radiotherapy in
ES-SCLC
RTOG, Philadelphia, USA, June 16, 2012
SABR. Latin American Conference on Lung
Cancer
IASLC, Rio de Janeiro, Brazil, July 25, 2012
Role of stereotactic ablative radiotherapy in
Stage I NSCLC
Latin American Conference on Lung Cancer. IASLC,
Rio de Janeiro, Brazil, July 26, 2012
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 90
Associate
Sminia P
Steenbergen R
Taphoorn MJB
Title
Organisation
Implementing SBRT. Opening lecture at III
Congresso Brasileiro de Radiocirurgia
Florianopolis, Brazil, October 18, 2012
Overview of randomized trilas on
radiosurgery with our without whole brain
radiotherapy for cerebral metastases
III Congresso Brasileiro de Radiocirurgia.
Florianopolis, Brazil, October 19, 2012
SABR for vertebral metstases
III Congresso Brasileiro de Radiocirurgia.
Florianopolis, Brazil, October 19, 2012
Current status and future prospects of SBRT
in lung cancer
III Congresso Brasileiro de Radiocirurgia.
Florianopolis, Brazil, October 19, 2012
Innovations in SBRT for lung cancer:
Experience from Europa
Panel at Annual meeting Am Soc Radiation Oncology
ASTRO, Boston, USA, October 30, 2012
Developments in modern radiotherapy
Annual meeting Japanese Soc Radiat Oncol, Tokio,
Japan, November 24, 2012
Developments in SBRT. 2nd Int
Symposium on SBRT, Amsterdam , The Netherlands,
December 6, 2012
Hypofractionation. 2nd Int
Symposium on SBRT, Amsterdam , The Netherlands,
December 6, 2012
In vitro studies on Radiation, Temozolomide
and PI3Kinase-Akt inhibition in human
glioma
“Radiotherapy in Clinical Practice III” meeting.
Department of Radiation Oncology, University of
Debrecen, Hongarije, February 3 - 7, 2012
In vitro studies on human glioma: effects of
irradiation, temozolomide and PI3Kinase-Akt
inhibitors
Oncomatrix Research Laboratory, Department of
Biomedicine, University of Bergen, Norway, May 31,
2012
Interaction between irradiation,
temozolomide and valproic acid on MGMT
promoter methylated and unmethylated
human glioma cells
10th congress of the European Association of
NeuroOncology, Marseille, France, September 6-9,
2012
Re-irradiation tolerance of the Human Brain
and Possible Role of Ion Beam Therapy.
Symposium uber Neuro-Onkologie und
nichtklinische Forschung bei MedAustron. Wiener
Neustadt, Austria, November 29-30, 2012
Radiobiologische aspecten van VMAT
bestraling
Cursus VMAT en RapidArc – Fysische en klinische
implementatie. NKI-AvL, September 21, 2012
Cell survival following high dose rate
flattening filter free and conventional dose
rate irradiation
Proceedings Sixth NCS Lustrum
Symposium,”Radiation dosimetry: balance between
safety and cure”. Leiden, The Netherlands, October
5, 2012
‘Tumorcelrepopulation and Overall
Treatment Time’
Training hour for residents Radiation Oncology,
Department of Radiation Oncology VUmc, April 25,
2012
Radiation and chemical carcinogenesis
Batchelar Oncology course, May 7, 2012
Clinical Radiobiology
OOA Radiation Oncology course, June 6, 2012
Tumorbiologie: LET, RBE, tumormodellen, in
vivo eindpunten, 5 R’s
NVRO/NVRB Landelijke basiscursus Radiobiologie,
Utrecht, 21 mei 2012
The 5 Rs of Radiobiology
Lecture Innovative Tumor Therapies Master Course
Oncology, December 5, 9.30 – 10.15 h, 2012.
Methylation markers for triage of high-risk
HPV-positive women (keynote).
International Society of Cellular Oncology (ISCO)
meeting, March 7, 2012, Palma de Mallorca, Spain
Methylation markers for triage of HPVpositive women
Eurogin 2012 Conference, Prague, Czech Republic,
July 10, 2012
Altered miRNA expression and chromosomal
changes in cervical cancer
Eurogin 2012 Conference, Prague, Czech Republic,
July 11, 2012
Meet the experts session: Symptoms and
Problems in the End of Life Phase.
European Association for Neuro-Oncology (EANO),
September 7, 2012, Marseille, France
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 91
Associate
Title
Organisation
Does it make sense to assess Health-Related
Quality of Life in Brain Cancer?
3rd European Organization for Research and
Treatment of Cancer (EORTC) & European Union
conference on Quality of Life, October 18, 2012,
Brussels, Belgium
Quality of Life and other “soft” measures
3rd Swiss Neuro-Oncology Winter (SNOW) Meeting,
December 7, 2012, Luzern, Switzerland
Thielen N et al
Imatinib Versus Imatinib in Combination
with Cytarabine in Patients with First Chronic
Phase Myeloid Leukemia: a Phase III trial
Dutch Hematology Congress Papendal January 2012
Thijssen VL
Galectins in endothelial cell biology and
angiogenesis
Galectin related therapeutics, Boston, USA, 17 - 18
September, 2012
Thunnissen E
Recent Progress in the Management of Non
Small Cell Lung Cancer
Perspectives in lung cancer, Amsterdam March 9,
2012
Reproducibility of squamous cell carcinoma
diagnosis in the lung
IASLC pathology panel meeting Chicago September
6, 2012
ALK other detection methods
European Society of Pathology meeting, Prague, 11
september 2012
van Beusechem VW
Options for treatment in the FA patient:
oncolytic adenovirus
FARF Squamous Cell Carcinoma in Fanconi Anemia
Patients conference, April 16-17, 2012, Chicago, IL,
USA
van Bodegraven AA
Update in IBD
Symposium ‘Gastroenterology and the Brain’. Dutch
Society of Psychiatry (Consultation and Hospital
Psychiatry), Nieuwegein, November 2012
Proctitis: ins and outs
Regional Meeting Gastroenterology, Wenckebach
Institute, University Medical Centre Grongingen,
Groningen, November 2012
Diagnosis of bone mineral disease; methods
and pitfalls
Presented orally at UEGW, Amsterdam, October
2012
A multicenter retrospective head-to-head
comparison of adalimumab and infliximab
for Crohn’s disease
Presented orally at UEGW, Amsterdam, October
2012
Faecal microbiota in pediatric functional
constipation: a role for proteobacteria?
Presented as poster at UEGW, Amsterdam, October
2012
Data integration framework for IBD
genotypes, phenotypes and molecular
profiles
Presented as poster at UEGW, Amsterdam, October
2012
Induction therapy in IBD
GE-course Dutch Society of Gastroenterology (NVGE).
Utrecht, Oct 2012.
Developments in IBD medication
ICC-CCUVN-Vumc Patient Day for IBD. Amsterdam,
Sept 2012.
AntiTNF, an investment in the future
4th ICC-IBD day Utrecht, Sept 2012
RAC1 modulation by thiopurine therapy in
IBD patients
Presented as a poster at AGA Digestive Disease
Week (1230), San Diego, CA, May 2012.
Gastroenterology 2012;142:Suppl 1:S780
Results of a phase II, randomized, double
blind, controlled trial of the efficacy of active
therapeutic immunization with TNF-Kinoid in
patients with moderate to severe Crohn's
disease with secondary resistance to TNFαantagonist
Presented as a poster at AGA Digestive Disease
Week (1230), San Diego, CA, May 2012.
Gastroenterology 2012;142: Suppl 1:S567-8.
Osteoporosis in IBD
ECCO Congress, Barcelona, Spain, February 2012
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 92
Associate
Title
Organisation
Anti TNF-α therapy is a major cost driver in
inflammatory bowel disease: results from
the COIN study
Presented orally at ECCO Congress, Barcelona,
Spain, February 2012. J Crohn Colitis
2012:6:OP09,S5 , and presented as a poster at AGA
Digestive Disease Week (1284), San Diego, CA, May
2012. Gastroenterology 2012;142: Suppl 1:S263
Intrauterine exposure and pharmacology of
conventional thiopurine therapy in pregnant
inflammatory bowel disease patients
Presented at ECCO Congress, Barcelona, Spain,
February 2012. J Crohn Colitis 2012:6:P385, S163
Adding ciprofloxacin to adalimumab results
in a higher fistula closure rate in perianal
fistulizing Crohn's disease
Presented orally at ECCO Congress, Barcelona,
Spain, February 2012. J Crohn Colitis 2012:6:OP16,
S8, and presented orally at AGA Digestive Disease
Week (1160), San Diego, CA, May 2012.
Gastroenterology 2012;142: Suppl 1:S212
Adenomas in patients with inflammatory
bowel disease: increased risk of advanced
neoplasia
Presented orally at ECCO Congress, Barcelona,
Spain, February 2012. J Crohn Colitis 2012:6:OP14,
S7, and presented as a poster at AGA Digestive
Disease Week (1598), San Diego, CA, May 2012.
Gastroenterology 2012;142: Suppl 1:S638
Is there a difference in quality of life or costs
between ulcerative colitis patients with a
pouch or an ileostomy?
Presented orally at ECCO Congress, Barcelona,
Spain, February 2012. J Crohn Colitis 2012:6:S87,
and presented as a poster at AGA Digestive Disease
Week (1285), San Diego, CA, May 2012.
Gastroenterology 2012;142: Suppl 1:S263
Diagnosis of bone mineral disease; methods
and pitfalls.
UEGW, October 2012, Amsterdam
Osteoporosis in IBD
ECCO, February 2012, Barcelona
van den Broek E
Structural Variant Detection in Colorectal
Cancer
• The Cancer Genome Atlas 2nd Annual Scientific
Symposium: Enabling Cancer Research Through
TCGA (28 Nov 2012, Washington DC). @ YouTube:
http://www.youtube.com/watch?v=YHgi2VQ74Q4
• Benelux Bioinformatics Conference 2012, 10 Dec
2012, Nijmegen
van den Tol MP
Intra-operative ultrasound in breastconserving surgery for palpable breast
cancer: an undeniably effective technique
resulting in cost savings.
16th Congress of the European Society of Surgical
Oncology (ESSO), Valencia, Spanje sept. 2012
(proffered paper session)
Opmerkelijke verbetering van radicaliteit en
excisievolume door peroperatieve echografie
bij mammasparende chirurgie: resultaten
van een multicentrische prospectief
gerandomiseerde studie
Voorjaarsvergadering Nederlandse Vereniging voor
Heelkunde, Veldhoven mei 2012
Behandeling van patiënten met irresectabele
colorectale levermatastasen met RFA:
resultaten van langdurige follow-up en
behandeling van randrecidieven
Voorjaarsvergadering Nederlandse Vereniging voor
Heelkunde, Veldhoven mei 2012
A comparison of three methods for nonpalpable breast cancer
Radiologendagen2012, 's-Hertogenbosch sept.2012
Nieuwe techniek in lokale behandeling van
tumoren: Irreversibele Electroporatie
Wetenschapsdag Heelkunde VUMC, Amsterdam okt.
2012
Local site recurrences after RFA treated
CRLM; long term results after re-treatment.
A good prognosis
98th Scientific Assembly and Annual Meeting
Radiological Society of North America ((RSNA),
Chicago, Verenigde Staten nov. 2012
Intra-operative ultrasound in breastconserving surgery for palpable breast
cancer significantly improves both surgical
accuracy and cosmetic outcome while saving
costs
Wetenschapsdag Heelkunde VUMC, Amsterdam okt.
2012
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 93
Associate
Title
Organisation
COBALT studie; hoe nu verder?
Regionale multidsciplinaire mammabijeenkomst,
Ede april 2012 (invited speaker)
Opmerkelijke verbetering van radicaliteit en
excisievolume door peroperatieve echografie
bij mammasparende chirurgie: resultaten
van een multicentrische prospectief
gerandomiseerde studie
Radiologendagen2012, 's-Hertogenbosch sept.2012
Intra-operative ultrasound in breastconserving surgery for palpable breast
cancer significantly improves both surgical
accuracy and cosmetic outcome while saving
costs
Yearly Meeting Danish Society for Breast Surgery
2012, Aabenraa, Denmark nov. 2012 (invited
speaker)
Echo op de ok als voorbereiding op een
ingreep
Congres Mammacarcinoom: van wetenschap naar
werkvloer, Ermelo jan. 2012 (invited speaker)
Intra-operative ultrasound in breastconserving surgery for palpable breast
cancer: an undeniably effective technique
resulting in cost savings
Radiologendagen2012, 's-Hertogenbosch sept.2012
Intra-operative ultrasound is imparitive to
obtain adequate tumour margins and
excision volume in breast conserving
surgery for palpable breast cancer: results of
a randomised controlled trial
European Breast Cancer Conference (EBCC) 2012,
Wenen, Oostenrijk maart 2012 (best paper session,
late breaking abstracts)
Echogeleide borstsparende chirurgie voor
palpabel mammacarcinoom
Regionale mammawerkgroep IKA regio Leiden;
Leiden,nov. 2012 (invited speaker)
Intra-operative ultrasound in breastconserving surgery for palpable breast
cancer significantly improves both surgical
accuracy and cosmetic outcome while saving
costs
34th Annual San Antonio Breast Cancer Symposium,
San Antonio, Verenigde Staten dec. 2012
lecture on treatment of Ankylosing
Spondylitis Madrid, Spain
26 January: Congress Excellence in Rheumatology
lectures on Uveitis in Spondylarthopathy,
Treatment of SpA with biologicals,
Interactive cases
25-17 April : ASAS international Educational
Courses, Amsterdam
lectures on Uveitis in Spondylarthopathy,
psoriasis in SpA Treatment of SpA
23 mei Confererence on SpA, Brussel, Belgium
lectures on Uveitis in Spondylarthopathy and
Genetics
2-4 October ASAS international Educational Courses
in SpA, Gent, Belgium
lectures on Uveitis in Spondylarthopathy,
psoriasis
25 and 25 October ASAS international Educational
Courses in SpA Treatment of SpA, Madrid, Spain
van der Kuip M
Bacteriële meningitis: van fundament naar
patiënt
RAAK, December 2012, Amsterdam, The
Netherlands
van der Laken J
State of the art lecture on Nuclear Imaging
of Inflammatory Rheumatic diseases at the
annual meeting of the European League
Against
Rheumatism (EULAR conference), June 2012, Berlin
van der Sar AM
The zebrafish embryo early granuloma
infection model: Target finding and antitubercular compound screens in vivo
Cold Spring Harbour Asia, the 5th Annual Zebrafish
Disease Models Meeting: “Fishing for Answers:
Zebrafish Models of Human Development and
Disease”, April 16-20, 2012, Suzhou, China
Zebrafish as model for mycobacterial
infection, studies on pathogenesis
Summer Mastercourse: Animal models II, 2012 part
of Infection and Immunity research master,
September 5, Erasmus University, Rotterdam
Zebrafish a much used model organism for
biomedical molecular systems biology
Biomedical Systems Biology, October 11, VA,
Amsterdam
van der HorstBruinsma IE
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 94
Associate
Title
Organisation
van der Waal I
The non-squamous cell oral cancers
Spanish Society of Oral Medicine, Granada, Spain, 17
February 2012
Mondpathologie bij kinderen
Minisymposium aan de vooravond van de
Voorjaarsvergadering Nederlandse Vereniging voor
Mondziekten, Kaak- en Aangezichtschirurgie,
Amsterdam, 15 maart 2012
Mondaandoeningen: een diaquiz
Praktijkgerichte lezing tijdens "Medische aspecten in
de tandartspraktijk", Amsterdam, 11 mei 2012
Clinicopathologic case presentations (2
cases)
41st Annual Meeting of the SFOPOM (Scandinavian
Fellowship for Oral Pathology and Oral Medicine)
Oslo, Norway, 15-17 August 2012
Introduction: terminology and classification
11th Biennial congress of the European Association
of Oral Medicine (EAOM), entitled "Potentially
malignant disorders: new concepts and future
prospects in diagnosis and management"
Athens, Greece, 13-15 September 2012
Orale leukoplakie; ontwikkelingen in de
afgelopen dertig jaar
Najaarsvergadering Nederlandse Vereniging voor
Mondziekten, Kaak- en Aangezichtschirurgie
Noordwijk, 1-2 november 2012
Are we able to reduce the mortality and
morbidity of oral cancer
IV International Symposium "Advances in Oral
Cancer", Universidad del País Vasco, Bilbao, Spain,
15-16 November 2012
New insights in the pathology of Dermatitis
Herpetiformis
Dutch Celiac Disease Day, Vianen, The Netherlands,
April 2012
IgA as novel therapeutic drugs
F-Star Biotech company, London, UK, May 2012
IgA and neutrophil Fc RI for better or
worse?
FASEB Summer Research Conference
‘Immunoreceptors’ (Snowmass Village, Colorado),
July 2012
Immunoglobulin A and Fc RI in mucosal
immunity revisited
University of California Davis, CA Seminar Series:
Emerging Challenges in Microbiology and
Immunology, November 2012
IgA as novel therapeutic drugs
Invited seminar May 2012 F-Star Biotech company,
London, UK. Host Dr. K. Moulder
New insights in the pathology of Dermatitis
Herpetiformis'.
Invited seminar April 2012. Dutch Celiac Disease
Day, Vianen, The Netherlands.
'Immunoreceptors' (Snowmass Village,
Colorado). IgA and neutrophil Fc?RI for
better or worse?
Invited seminar July 2012. FASEB Summer Research
Conference
Emerging Challenges in Microbiology and
Immunology. Immunoglobulin A and Fc?RI in
mucosal immunity revisited.
Invited seminar November 2012 University of
California Davis, CA Seminar Series:
Pediatric adherence in children with
HIV/AIDS in rural and urban districts in
South Africa
Sustainable rural health research summit 2012 , 2601-2012 tot en met 27-01-2012, Robertson, South
Africa
Selected participant for youth in motion
(emerging voices)
Global forum for health research 2012 (Forum 2012
- COHRED), 24-04-2012 tot en met 26-04-2012,
Cape Town, South Africa
Managing change at multiple levels to make
the transition from in-hospital treatment to
home based care
Second Global Symposium, 31-10-2012 tot en met
03-11-2012, Beijing, China
The Netherlands MenC vaccination schedule.
MenACWY-TT candidate vaccine in
childhood/adolescent vaccination
April 2012, Novara, Italy
van Egmond M
van Elsland SL
van Furth AM
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 95
Associate
Title
Organisation
Meningitis en de gevolgen voor het jonge
kind
7e jaarssymposium, Kindergeneeskunde, February
2012, Utrecht, The Netherlands
Behandeling van voorschools astma en virus
induced wheeze
VAALZ, February 2012, Vaalsbroek, The Netherlands
Systems biology of cerebral granuloma
formation caused by mycobacterium
tuberculosis
Amsterdam Kindersymposium, February 2012,
Amsterdam, The Netherlands
Upper airway infections in Down syndrome
congress: 11th International Congress of the
European Society of Pediatric Otorhinolaryngology
(ESPO 2012), 20-23 May 2012, Amsterdam, The
Netherlands
Paediatrics: The Year in Review”,
Infectieziekten en vaccinaties
Meeting: Academische Avond Kindergeneeskunde
Nascholingscursus, October 2012, Amsterdam, The
Netherlands
Bacteriële meningitis: van fundament naar
patiënt
RAAK, December 2012, Amsterdam, The
Netherlands
van Leeuwen L
Bacteriële meningitis: van fundament naar
patiënt
RAAK, December 2012, Amsterdam, The
Netherlands
van Moorselaar RJA
Ethics of Live Surgery
Board Meeting ESU. 02 juni 2012, Mallorca, Spain
CRPC and Bladder Cancer
Oncoforum Summer School. 26 juni 2012,
Amsterdam
Testis cancer: Diagnosis and treatment of
stage I disease
The European Urology Residents Education
Programme (EUREP), 10th EUREP Course, 31 August
– 5 September 2012, Prague, Czech Republic
Renal Cancer. Management of locally
advanced and metastatic disease
The European Urology Residents Education
Programme (EUREP), 10th EUREP Course, 31 August
– 5 September 2012, Prague, Czech Republic
European School of Urology: Unique
education opportunity for urologists
ESU Course: What’s new in Prostate cancer and
Female urology. 28 September 2012, Yerevan,
Armenia
Localised prostate cancer, there is more than
robotic surgery
ESU Course: What’s new in Prostate cancer and
Female urology. 28 September 2012, Yerevan,
Armenia
Advanced and metastatic prostate cancer,
new results of clinical trials
ESU Course: What’s new in Prostate cancer and
Female urology. 28 September 2012, Yerevan,
Armenia
Prostaatcarcinoom: worden de nieuwe
middelen gegeven door de uroloog of de
oncoloog?
Oncologiedagen voor Nederland en Vlaanderen. 8
november 2012, Arnhem
Locally advanced and metastatic prostate
cancer
Oncoforum summary meeting. 16 december 2012,
Brussel, Belgie
The patient perspective on remission in
rheumatoid arthritis
EULAR, 08-06-2012, Berlin, Germany
van Tuyl L
van Vuurden D
VandenbrouckeGrauls CMJE
Invited speaker at the National Congress of the
Portuguese Neuro-Oncology Association (27-102012; Porto; Portugal)
ESBL in animals
16th Workshop for hospital epidemiology, January
2012, Berlin, Germany
Basic principles of epidemiology
ESCMID-SHEA Course in Hospital Epidemiology, 1–4
oktober 2012, Potsdam, Germany
Infectiepreventie bij VRE uitbraken
VRE, wat moet je ermee, October 4, 2012, Nijmegen,
Nederland
ESBL te land, te water en in de mens
Mythen, Missers en Meesterwerken, September 5,
2012, Ede, Nederland
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 96
Associate
Title
Organisation
Veening MA
Vincristine; peripheral polyneuropathy
Workshop on Pediatric Oncology, 25 April 2012,
Yogyakarta, Indonesia
Verdonck-de Leeuw IM
Integrating e-Health in psychosocial care in
cancer patients: shared decision making,
screening, self-help, and stepped care
12th International Congress of Behavioral Medicine,
Budapest, Hungary, August 29, 2012.
Leven met kanker. Referaat Klinische
Psychologie
Vrije Universiteit, Amsterdam, June 18, 2012
Leven met kanker: innovatieve
zorgprogamma's en e-health
Colloquium Universiteit Twente, Enschede, Februari
23, 2012
Stepped care, zelfmanagement en e-health
om de nazorg bij patiënten met hoofdhalskanker te faciliteren, innoveren en
optimaliseren
Paramedische Werkgroep Hoofd-Hals Tumoren,
Utrecht, Februari 3, 2012
Mindfulness: wat hebben patienten met
kanker eraan?
Symposium Mindfulness van dummie tot expert.
Vrije Universiteit, Amsterdam, Januari 20, 2012
Building an e-health portal for patients after
total laryngectomy for laryngeal cancer
CPLOL Congress, The Hague, May 24-26, 2012
Self-management to prevent speech,
swallowing and shoulder problems in head
and neck cancer patients
CPLOL Congress, The Hague, May 24-26, 2012
Associations between swallowing and voice
quality in patients treated for head and neck
cancer
CPLOL Congress, The Hague, May 24-26, 2012
Personalising therapy: An introduction to
prognostic factors
Rheumatology Europe Forum, 29 Nov.- 1 Dec.,2012,
Vienna, Austria
Prediction of the response to rituximab
Biomarker Summit Europe 2012, 7-8 September,
2012, Zurich, Switzerland
Personalized Medicine in Rheumatoid
Arthritis: The Future is Now!"
Seminar program Karolinska Institute, 25 May 2012,
Stockholm, Sweden
Prediction of the response to rituximab
Genomics Summit, 19-21 April. 2012, Boston USA
Personalized medicine in rheumatoid
arthritis: The Future is now!
IQ Science symposium, 29-30 March 2012, London,
UK
Prediction of development and therapy
response in rheumatoid arthritis
Seminar program, Genentech, 20 March, 2012,
South San Francisco, USA
Prediction of the response to rituximab
World Biomarker Summit, 14-17 March 2012, San
Diego, USA
Visser D
Bacteriële meningitis: van fundament naar
patiënt
RAAK, December 2012, Amsterdam, The
Netherlands
Vos C. G et al
Voorspellende waarde volumetrische
response na inductie chemoradiatie bij
Pancoast tumoren
Presentatie Chirurgendagen 2012, Veldhoven.
Voskuyl AE
Treat to target
Treat to target, april 2012, Amsterdam
Vosslamber S
Personalized Medicine in Rheumatoid
Arthritis: the Future is Now!
Annual CMSB symposium, 5 October 2012,
Rotterdam, NL
Windhorst AD
New PET radiopharmaceuticals in Oncology
SSPT-USGEB, January 27-28, 2011, Zurich,
Switzerland
Rational design of new tracers
XII Turku PET Symposium, May 28-31, Turku,
Finland
Preclinical evaluation of new PET tracers
EANM, October 15-19, 2011, Birmingham, England
New PET radiopharmaceuticals in onclogy
EANM, October 15-19, 2011, Birmingham, England
Verweij CL
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 97
Associate
Zuurmond WWA
Zweegman S
Title
Organisation
New Tyrosine Kinase inhibitor PET
radiopharmaceuticals
Seminar November 21, 2011, University of Helsinki,
Finland
Radiopharmaceutical chemistry’
CHAINS2011, November 28, 2011, Maarssen , The
Netherlands
Pijnstilling bij kanker. Gebruik nieuwe
toedieningsvormen morfinomimetica
Oncologiedagen Nederland en Vlaanderen NVMO
Papendal 9-11-2012
Palliatieve zorg
Basiscursus Oncologie NvVO. Ellecom 16-3-2012
State of the art Palliatieve zorg en
pijnbestriding
Specialisten Ouderengeneeskunde Koudum 19-3-2012
Onvermijdelijk voor kwalitatief goede zorg in
een high tech omgeving
Moderator Workshop Palliatieve zorg in het ziekenhuis
Papendal Arnhem 12-4-2012
Invasieve pijnbestrijding
Oncologische pijn en palliatieve zorg voor artsassistenten. Maastricht 16-4-2012.
Oncologische pijn
Nascholing Oncologie, de rol van de huisarts.
Amsterdam 8-5-2012.
Palliatieve zorg en anesthesiologie
NVAM Amsterdam 15-9-2012
Invasieve pijnbestrijding
Oncologische pijn en palliatieve zorg voor artsassistenten. Maastricht 29-10-2012.
Doorbraakpijn bij kanker
Pijndagen 2012 Van samen werken naar
samenwerken. Sectie Pijnbestrijding NVA Papendal 2311-2012
Revlimid in relapsed refractory Myeloma
Czech Myeloma Group meeting, Slowakia, 15-1-11
EMNTG; HOVON NMSG what are the current
asked questions?
13th International Myeloma Workingshop 2011,
Paris, France, 5-5-2011
The added value of cooperation in Myeloma
Trials in Europe
European Hematology Association London, England,
9-6-2011
Translating the clinical heterogeneity of
elderly patients into tailored treatment
approaches: tools and therapeutic strategies
6th European Multiple Myeloma Academy, Madrid,
Spain, 8-10-11
Management of symptoms, emergencies,
and treatment-related adverse events in
multiple myeloma
7th European Multiple Myeloma Academy,
Stockholm, Sweden, 09-03-12/10-03-12
State of the art of the current treatment of
Multiple Myeloma; where are we now and
where are we going to?
Future of Blood, Utrecht, the Netherlands, 16-03-12
Introduction to MM elderly protocols;
Clinical aspects
5th Trialist Forum European Myeloma Network,
Baveno, Italy, 13-05-12/14-05-12
Are we improving survival outcomes for
elderly patients with myeloma?”, Satellite
symposium “Optimizing outcomes in
multiple myeloma: what do the data tell us?”
European Hematology Association, Amsterdam, the
Netherlands, 14-06-12
Scientific Workshop “Treatment strategies
for the elderly”
Multiple Myeloma Experience Exchange Meeting,
Berlin, Germany, 05-10-12/06-10-12
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 98
Awards
Name
Award
Place and date
Afdeling kinderoncologiehematologie
Jacie accreditatie het verrichten van autologe
stamceltransplantaties
Amsterdam, Februari 11th 2012
Avan A
CCA/V-ICI Scholarship for PhD education
Amsterdam, 15 April 2012
Bretschneider JH
One of six most innovative educators of the
world
Apple Education Conference 2012
Dekker J
honorary professor aan de Jining Medical
University, Jining, China
Fedrigo CA
travel Award from the European Association
of Neuro Oncology
Marseille, France, September 6-9, 2012
Gibbs S
Fenna Diemer Lindeboom Chair: Skin and
mucosa regenerative medicine
July 2012, The Netherlands
IGZ ‘GMP’’ certificate for cleanroom ATMP
production of Tissue engineered Skin”
VUmc, 2012
Gibbs S (Grace Limandjaja OIO)
poster prize (300 euro) at the European
Tissue Repair Society
meeting
Athens, Greece, 4-5 October 2012
Gibbs S, de Boer EM, van Montfrans
C
NFU topreferente functies
2012, The Netherlands
Giovannetti E
Berlucchi Award for Young Italian
Researchers
2012; Brescia, Italy, 11 June 2012
young Researcher Travel grant 2012
European Pancreatic Club 2012
Congress, Prague 20-23 June 2012
Invitation to the Early Career Investigators
platform kick-off meeting “EORTC ECI
platform”
50th European Organization for
Research and Treatment of Cancer
(EORTC) Anniversary Meeting, Brussels,
Belgium, 16th March 2012
Hartong DT
Dondersprijs
Groningen, 29 march 2012
Kamphorst W
Officier in de Orde van Oranje-Nassau
Amsterdam 31 april 2012
Langius JAE
NESPEN abstract award
Voorjaarscongres NVGE, Veldhoven 2223 maart 2012
Leemans CR
Helmuth Goepfert Distinguished Visiting
Professor
M.D. Anderson Cancer Center,
Department of Head and Neck Surgery,
Houston, TX, USA, February 14, 201
Maftouh M
VU Fellowship
VU University Amsterdam, 2012-2013
Morré SA
FD Gazellen Award 2012
Amsterdam 29 November 2012
Mulder C
honorary and distinguished fellow of the
Royal College of Physicians
Muris J, Feilzer A, Kleverlaan CJ,
Rustemeyer T
European Society of Contact Dermatitis
Research Award on Palladium contact allergy
2012, Malmo, Sweden
Peters GJ
Toekenning Basis Kwalificatie Onderwijs
(BKO)
2012, Amsterdam, The Netherlands
Pinedo B
K. Dornbush Award 2012
11 mei in Arlington, Virginia
Rekers NH, Sminia P, Peters G
Piero Periti Review Article Award
Rustemeyer T
NFU topreferentefuncties
2012, Den Hague, The Netherlands
BKO
2012, Amsterdam, The Netherlands
FD Gazellen Award 2012
Amsterdam 29 November 2012
Savelkoul PHM
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 99
Name
Award
Place and date
Scheper R
Ridder in de Orde van de Nederlandse Leeuw
Amsterdam 31 april 2012
van der Waal I
Honorary Member of the Scandinavian
Society of Oral Pathology and Oral Medicine
Oslo, 17 augustus 2012
van Furth AM
Associate professor extraordinary:
paediatrics and child health
Stellenbosch University, Tygerberg,
South Africa
van Kooyk Y
Nederlandse Vereniging voor Immunologie
(nvvi) een Europese prijs voor het vergroten
van de kennis over haar vakgebied bij het
publiek
Veldhuijzen van Zanten SEM
Best presentation
Nederlandse Vereniging voor
Kindergeneeskunde (NVK) Congres,
Veldhoven, October 31, 2012
Veringa S
Nijbakker Morra prijs
08-02-2012, Amsterdam
2e prijs, Beste wetenschappelijke stage
Kindergeneeskunde, VUmc
Amsterdam, 10 februari 2012
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 100
Grants obtained in 2012
Project leader(s)
Title project
Funding / budget
Beelen RHJ, Vervloet M
Effect of paricalcitol on klotho in vit D
deficient and uremic rats
Abott, 60.000 euro
Bijnsdorp I, Geldof A, van
Moorselaar R, Pegtel M, Ylstra B,
Rozendaal L, Jimenez C, Gerritsen
W, van den Eertwegh A, Würdinger
T
To treat or not to treat; prostasome prostate
cancer diagnostics
VUmc CCA, 150.000 euro
Bitter W and van der Sar A
PreDiCT TB
EU-IMI grant, 680.000 euro
Boers M
EU-FP7, 100.000 euro
Boers M and van Tuyl L
The patient perspective on remission in
rheumatoid arthritis
EULAR, 74.000 euro
Brakenhoff R and de Winter J
Targeted Treatment of Oral Cancer and
Precancer in FA
Fanconi Anemia Research fund,
Eugene, Oregon, 324.000 euro,
postdocs C. Stoepker and S. Martensde Kemp
Brakenhoff R, Braakhuis B, Leemans
C and van Beusechem V
Targeted therapy of precancerous fields in
head and neck mucosa
VUmc CCA, 300.000 euro, PhD
student D. de Boer
Buffart L, Altenburg T, Verheul H,
de Ruiter J, Gelelijn E, Huijsmans R,
Chin A Paw M and Buffart T
How may exercise reduce fatigue in patients
with cancer? A pilot study examining the
role of the muscle
Zuidasrun: Fit ondanks kanker,
17.000 euro
Cloos J and Jansen G
Antimicrobial peptide (AMP) activity in
Velcade-resistant hematological and solid
tumor cell lines
N8 Medical USA, 54.000 euro
de Gruijl T and Stockmann H
Targeting tumor-induced immune
suppression: a promising strategy in the
battle against breast cancer
Research grant from “A Sister’s Hope”,
123.000 euro, PhD student K. van Pul
De Vries HE
Understanding blood-brain barrier
alterations underlying capillary amyloid
angiopathy: a route to novel diagnostics
€ 121.000
Valid Tech
To-BBB, € 42.324
Dekker J and van Meijel B
Distress and quality of life of patients
treated with autologous stem cell
transplantation following high-dose
chemotherapy: outcome of stepped care
EMGO+ travel grant 2012, 3.000 euro,
PhD student A. Braamse
Dekker J and van Meijel B
Distress and quality of life of patients
treated with autologous stem cell
transplantation following high-dose
chemotherapy: outcome of stepped care
KWF stagebeurs, 1.840 euro, PhD
student A. Braamse
Giovanetti E, Würdinger T,
Schuurhuis G and Peters G
Unravelling and targeting key molecular
determinants and pathways in the biology of
cancer stem cells using bioluminescent
orthotropic tumours from primary
pancreatic cancer cells characterised for
their genetic signature in comparison with
the originator tumours
VUmc CCA, 270.000 euro, PhD
student A. Avan (2012-2016)
Giovannetti E
Unraveling key microRNA & signalling
pathways in differential pancreatic neoplatic
lesions to fight pancreas cancer aggressive
behaviour and chemoresistance
Grant of the Istituto Toscano Tumori
Giovannetti E and Peters G
Predictive parameters for the activity of
pemetrexed in mesothelioma
Eli Lilly & Co, 50.000 euro (2012-2013)
Hartong D and Moll A
Complicaties, functionele, en cosmetische
uitkomsten bij behandelde retinoblastoom
patiënten in Nederland
ODAS foundation, 332.755 euro, PhD
student D. Mourits
Horrevoets AJC, van Royen N
Regenerative therapies in coronary disease
NIRM: Netherlands Institute for
Regenerative Medicine
Hulleman E
Rapid preclinical development of a targeted
The Lyla Nsouli Foundation for
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 101
Project leader(s)
Title project
Funding / budget
therapy combination for DIPG
Children’s Brain Cancer Research,
14.000 euro
Israels T
Childhood Cancer in Malawi
St Baldricks Foundation, 6.500 euro
Jansen G, Peters G and
Ossenkoppele G
Exploration of anti-leukemic and antiinflammatory effects elicited by
myelomonocytic cell-targeted
aminopeptidase inhibitors with an esterasesensitive motif
VUmc CCA, 149.059 euro (20122014)
Janssen J
Phosphoproteomics for personalized
treatment of acute myeloid leukemia with
kinase inhibitors
VUmc CCA, 250.464 euro
A phase II, single arm, multicenter study of
nilotinib in combination with pegylated
interferon-α2b in patients with suboptimal
molecular response or stable detectable
molecular residual disease after at least two
years of imatinib treatment
(NordDutchCML009) plus side studies.
Novartis Pharma AG
Whole transcriptome sequencing in CM
Stichting Leukemie.nl
Jimenez C
Funding for proteomic equipment
VUmc CCA, 200.000 euro
Kaspers G and Hulleman E
State of the art in diffuse intrinsic pontine
glioma
KNAW academy colloquium, 14.500
euro
Kaspers G, van Vuurden D and
Hulleman E
Chemosensitivity and drug efflux
transporters in pediatric high grade glioma
KNAW Van Walree Fonds, PhD S.
Veringa
Lems W, Boers M and van Tuyl L
COBRA cohort study and patient reported
remission outcomes
Pfizer, 204.650 euro
Moll A, de Graaf P and de Boer J
Diagnosis of vital tumor tissue by OCT and
MRI in retinoblastoma patients
KIKA, 266.605 euro
Morré S
Identifying Biomarkers and Genetic Risk
Factor
NIH grant, 140.000 euro
Tuba-scan: companion diagnostic for
Chlamydia associated subfertility and tubal
pathology
NGI grant, 250.000 euro
Peters G
Mechanism of action of RX-3117
Rexahn, USA/Teva, Israel, 145.000
euro (2012-2013)
Peters G and Jansen G
Role of stereoisomers of leucovorin in 5FU
modulation
Spectrum Pharmaceuticals USA,
56.000 euro
Regulation of uptake and metabolism of lLeucovorin (Fusilev®); interaction with other
drugs
Spectrum Pharmaceutical, San
Francisco, CA, USA , 70.000 euro
(2012-213)
Zilver nanoparticles
3rd party sponsored, 30.000 euro,
PhD student M. Visser
Low dosis UVB therapy in psoriasis patients
3rd party sponsored, 60.000 euro,
PhD student S. Franken
Arbeidsdermatologische problematieken
3rd party sponsored, 100.000 euro
Skin irritation and prevention
3rd party sponsored, 250.000 euro,
PhD student M. Visser
MODAPEP study
Eurostar, 500.000 euro
Translational grant
ZONMW, 500.000 euro
ResFood
FP7, 200.000 euro
Schuurhuis G and Ossenkoppele G
Activity of novel antibody-drug-conjugates
in primary AML
Industry grant, WP benchfee
Taphoorn M, Reijneveld J
Epilepsy in the end of life phase in glioma
Zoleon IKNL / Chanrone Stichting /
Rustemeyer T
Savelkoul P
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 102
Project leader(s)
Title project
Funding / budget
patients
Jacobusstichting, 150.000 euro, PhD
student J. Koekkoek
Objectifying improvement of function by
measuring movement in Ankylosing
Spondylitis patients
Reumafonds, 24.000 euro, PhD
student S. van Weelij
Open-label, phase 4 study, investigating the
Incidence of Extra-Articular Manifestations
in Subjects with Ankylosing Spondylitis
treated with Golimumab (GO-EASY study):
national investigator initiated study
80.000 euro, PhD students C. van der
Bijl and S. Heslinga
Assessment of disease activity of ankylosing
spondylitis with [18F]fluoride PET-CT
Reumafonds, 80.000 euro
Aanvullende financiering op Reumafonds
project: Imaging and therapeutic targeting
of macrophage folate receptor-β in
rheumatoid arthritis
65.000 euro
van der Laken J and van Dongen G
PRIAT: Profiling responders in antibody
therapies
7th Framework programme of the EU,
493.333 euro (2012-2014)
van der Sar A
Granuloma in Zebrafish
Mr Willem Backhuys Roozeboom
Stichting, 20.000 euro
van Dongen GAMS
IMPACT: imaging patients for cancer drug
selection. Towards patient tailored cancer
treatment supported by moleculer imaging
KWF/Alpe d’HuZes, 5.500.000 euro
(01-11-12 till 01-11-17)
STRADA, being “SelecTive aRmed Antibodies
as Drugs Against cancer
Collaborative project (SME focused
research project) under the 7th
Framework Programme of the EU,
930.000 euro (2013-2017)
van Dongen G and Boellaard R
ZonMw: Multimodality preclinical imaging
facility for fundamental research and
efficient drug development
ZonMW grant for equipment, 900.000
euro (2013)
Van Kooyk Y
TLR ligands and oligosaccharides
TIPharma, 200 K
van Vuurden D, Vandertop W and
Kaspers G
Drug distribution and local drug delivery in
diffuse intrinsic pontine glioma
Stichting Semmy, 240.000 euro, PhD
student S. Veldhuijzen van Zanten
Vandenbroucke-Grauls, C and Bitter
W
a genome-based generalized strategy to
activate cryptic antibiotic
biosynthesis gene clusters in
Actinomycetales
CRYPTON II, STW, 82.000 euro
Verdonck-de Leeuw I
Psychological distress in partners of cancer
patients: efficacy of an online self help
intervention
KWF, 252.1000 euro, PhD student N.
Kohle (2012-2016)
Voskuyl A
Development and manitenance of a longterm national patient outcomes registry for
systemic lupus erythmatosus in the
Netherlands- The PORSLEN registry
sponsor GlaxoSmithKline, 60.000
euro
Würdinger T
Diagnosing cancer from platelets for
personalised applications
NGI Pre-Seed Grant; NWO, 250.000
euro
thromboDx: Diagnosing cancer from
platelets
NWO, 75.000 euro
Würdinger T, Cloos J
Development of preclinical pediatric brain
tumor imaging models
KiKa, 230.000 euro
Würdinger T, Noske D
Drug screening for glioma
Stophersentumoren.nl, 142.000 euro
Zijlstra J, Zweegman S and van
Dongen G
Personalised therapy for lymphoma patients
using immuno-PET and tissue-analysis
VUmc CCA, 104.916 euro, PhD
student Y. Jauw
van der Horst-Bruinsma I
van der Laken J
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 103
Meeting organization
Project leader(s)
Meeting
Place / date
Bloemena E
SENT Pathology review
Amsterdam, February 28-29, 2012
SENT Pathology review
Amsterdam, October 1, 2012
Molecular Imaging and Radiation Oncology
(MIRO)
Vienna, Austria, March 2012
session chair/organiser on amyloid PET
imaging at the Society of Nuclear Medicine
conference
Miami, USA, June 2012
Organisation of precongres symposium on
PET imaging
Milan, Italy, October 2012
Organisation and presenter of Dutch PET
course
Groningen, April 2012
Boers M
Organization of congresses. 11th OMERACT
International consensus conference
Pinehurst, USA, May 2012
de Bree R
organization of congresses
5th International symposium on sentinel
node biopsy in head and neck cancer
Amsterdam, May 24-25, 2012
Electrochemotherapy in head and neck
oncology
Amsterdam, January 13, 2012
Dekker J
Member of the program committee of the
12th International Congress of Behavioral
Medicine
Budapest, Hungary, August 2012
Gibss S
FEDERA Medisch Wetenschappelijke Dag
Utrecht, June 8, 2012
Israels T
PODC programme SIOP Annual meeting
London, UK, October 5 and 8, 2012
Boellaard R
Jansen G
th
15 International Symposium on Pteridines
and Folates
Antalya, Turkey, May 9-13, 2012
4th International Symposium on Folate
Receptors and Transporters
Cozumel, Mexico, October 7-11, 2012
Jansen W
4e Nationaal Congres Palliatieve Zorg
Lunteren, November 13-16, 2012
Jimenez C
Organisor, Fall meeting Netherlands
Proteomics Platform
Amsterdam, November 30, 2012
Kaspers G
Third Workshop on Pediatric Oncology
Eldoret, Kenya, January 2012
Kluytmans J
ESCMID-SHEA Course in Hospital
Epidemiology
Potsdam, October 1-4, 2012
Leemans C
Make Sense Campaign
London, UK, September 20-21, 2012
Course director: 5th European Head and
Neck Course
Birmingham, UK, October 15-17, 2012
Morré S
8th European Chlamydia Meeting
Amsterdam, July 1-6, 2012
Ossenkoppele G
ELN Frontiers
Istanbul, October 9-11, 2012
Peters G
Winter EORTC-PAMM meeting
Puerto de la Cruz, Tenerife, January 2012
th
Rustemeyer T
15 International Symposium on Chemistry
and Biology of Pteridines and Folates
Antalya, Turkey, May 2012
24th EORTC-NCI-AACR congress on new drug
development
Dublin, Ireland, November 2012
Voorjaarsvergadering van de Nederlandse
Vereniging voor Allergologie
Leusden, March 16, 2012
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 104
Project leader(s)
Meeting
Place / date
PMS cosmetica
Amersfoort, April 4, 2012
AAD review congres
Utrecht, April 17, 2012
EECDRG
Bari, Italy, April 20-22, 2012
State of the art in allergy to insulins
Amsterdam, August 23, 2012
Contact irritation: update on immunological
mechanisms
Amsterdam, October 1, 2012
Post EADV congres
Utrecht, October 11,2012
EECDRG
Lisboa, Portugal, October 19-21, 2012
Najaarsvergadering van de Nederlandse
Vereniging voor Allergologie
Leusden, November 16, 2012
5e Jaarsymposium Dermatologie
Utrecht, December 13, 2012
Savelkoul P
Cursus Typeren
Utrecht, January 24-26, 2012
Slotman B
Workshop SBRT, Singapore Radiological
Society
Singapore, 2012
International symposium on SBRT
Amsterdam 2012
ISRS
Congress
Meeting
Committee Toronto 2013
Sminia P
&
Scientifi
Toronto 2013
Co-organizer of the OOA Seminar with guest
speaker dr. A. Haimovitz-Friedman and
“Meet the Expert” session on the topic
“Angiogenesis inhibition in combination
with radiotherapy and chemotherapy”
Amsterdam, April 18, 2012
Member of the Organizing Committee of the
International meeting of the Dutch Society
for Radiobiology (NVRB)
Noordwijkerhout, April 19-20, 2012
van der Horst-Bruinsma I
Eighth International Congress on
Spondyloarthropathies, chair of session
Early Diagnosis: Improved outcomes
van der Laken J
Organisation of regional MRI education for
rheumatologists
van der Waal I
Mondpathologie. Een nascholingscursus
voor de KNO-artsen en dermatologen
Amsterdam, February 3, 2012
Een nascholingscursus voor
mondhygiënisten
Breukelen, March 23, 2012
Oncologie en de mondhygiënist". Een
nascholingscursus voor mondhygiënisten
Almere, October 5, 2012
Van Furth A
ESCMID
Siena, Italy, May 14-17, 2012
Veening M
Herfstpalet 2012
Amsterdam, November 21, 2012
Verdonck-de Leeuw I
Living with cancer
Amsterdam, December 19, 2012
Paving the future of supportive cancer care:
is e-health the way forwards? Workshop at
the International symposium on supportive
care in cancer (MASCC ISOO)
New York, USA, June 26, 2012
Heel de mens: kennismaking met de
psychologische interventies Life Review,
Zingevingstherapie en Spirituele
Autobiografie. Workshop at the Congress of
the Netherlands Society for Psychosocial
Oncology
Utrecht, March 16, 2012
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 105
Project leader(s)
Meeting
Place / date
Verweij C
Chairman session “preclinical RA” and
member of the abstract selection committee
of the European Workshop for
Rheumatology Research
Stockholm, Sweden, February 23-24, 2012
Chairman session “Biomarkers in
inflammation” of the Genomics summit
2012
Boston, USA, April 20, 2012
Member organizing committee,
Rheumatology Fall Symposium
Papendal
Chair bi-annual congress of the International
Society of Cellular Oncology
Palma de Mallorca, Spain
Ylstra B
Appendix Annual Report 2012 VUmc CCA – Indicators of esteem - 106
Appendix 6. Societal impact
Social-cultural relevance
Professional publications and products
Bultink IEM
•
Permanent columnist for the Dutch Arthritis Foundation: Writing
professional publications four times yearly in the magazine of the Dutch
Arthritis Foundation
Ossenkoppele GJ
•
Development of European Passport for hematologists in H-Net important
for harmonization of training of hematologists
Peters GJ
•
•
Interview in Seniorenmagazine (Voorschoten)
Boekbespreking in NRC betreffende “Ontspoorde Wetenschap
Sminia P
•
Contribution to the ‘Canon van de Oncologie’ Chapter 45: “Modelsystemen
in de radiotherapie” pp 98-99, 2012. Edited by VJ de Ru, PJ van Diest, LHJ
Looijenga, CJH van de Velde and DJT Wagenaar. dchg medische
communicatie, ISBN/EAN 978-94-90826-21-5
van der Horst-Bruinsma IE
•
Contribution for the continuous education of Rheumatologists worldwide
on Ankylosing Spondylitis
Development Dutch Rheumatology guideline for the diagnosis and
treatment of Spondyloarthritis
•
Voskuyl AE
•
Quaterly colum as president of Medisch Advies Raad in”” NVLE venster””
(National patient league for Lupus Erythemtosus, Scleroderma,
antphospholipid syndrome and Mixed Connective Tissue Disease)
Memberships of an advice council in the public field
Bultink IEM
•
•
•
Membership of the medical advice council of the “Nationale vereniging
voor lupus, sclerodermie en MCTD patiënten (NVLE)”
Membership of the steering committee of the Dutch network for “Patient
research partners in Rheumatology”.
Medical advisor of the local patient department of the Dutch Arthritis
Foundation (“Reuma patiëntenvereniging Amstelland en omstreken”)
Chamuleau M
•
Advisor EMA/CBG
Dekker J
•
Member of Committee Social Oncology, Dutch Cancer Society- KWF
Mebius RE
•
LSBR Scientific Advisory Council
Meijer GA
•
•
•
Member advisory board Genalice BV
Member Scientific Advisory Board mCRC Merck Serono
Member scientific advisory board MDXHealth
Ossenkoppele GJ
Advisor of patient organizations:
• NFK/ Stichting Leukemie
• CML advocacy group
Rustemeyer T
•
•
•
EU commission on Consumers´ Health, VWS en VWA, EU commission
Arbo Expert Groep Nederland, VWS
Cosmetica en consumentenveiligheid, VWS, RIVM
Slotman BJ
•
•
•
Voorzitter Taskforce Radiotherapie
Lid CvB, Nederlandse Vereniging Radiotherapie en Oncologie
Lid Concilium Radiotherapie
Sminia P
•
Member of the “Denktank” of the Stichting Hersentumor.nl, impact on
public informing website (www.hersentumor.nl)
Van Beusechem VW
•
Member, user committee Technology Foundation STW project on “Directed
evolution of artificial viruses” at University of Utrecht, Utrecht
Van Bodegraven A
•
•
ADVISOR CCUVN
ADVISOR / Representative NVMDL at CFU concerning Infliximab in
Ulcerative Colitis
Appendix Annual Report 2012 VUmc CCA – Societal Impact - 108
Voskuyl AE
•
•
Het Reumafonds : advisory board/ scientific committee
NVLE (patient league) : president Medisch Advies Raad
Zuurmond WWA
•
Lid Comité van Aanbeveling Ingeborg Douwes Centrum, multidisciplinair
centrum voor psycho-sociale zorg.
•
•
Lid Comité van Aanbeveling Stichting Joods Hospice te Amsterdam
Contributions based on research
Indications in a directive, protocol or policy note
Rustemeyer T
•
•
Richtlijnencommissien `Lichen sclerosus` (member on behalf of the NVDV
and the NVVA)
Richtlijnencommissie `Contacteczeem` (chairperson on behalf of the
NVDV and the NVVA)
Richtlijnencommissie `Koemelkallergie` (member on behalf of the NVVA)
•
National consensus on the diagnosis and treatment of lupus nephritis
•
Live on television during the program of KWF Kankerbestrijding: “Sta Op
Tegen Kanker” - 28 november
Pegtel M
•
Interview as one of the ‘thought-leaders’ in exosomal RNA for a televised
(documentary) concerning the 2012 International RNA-exosomes workgroup New York City, USA – documentaire - Michiel Pegtel - oktober
Rustemeyer T
•
VARA interview and TV presentation on skin irritation and allergy due to
cosmetic tissues - Rustemeyer, T – 16 april
Buffart L
•
Referral in the New York Times on May – Laurien Buffart - 16th 2012.
Kluytmans J
•
‘Resistentie is van alle tijden. De invloed van de mens is vooral het
grootschalige gebruik van antibiotica die dan vervolgens in de natuur
terechtkomen en daar de al aanwezige resistentiemechanismen selecteren
en mobiliseren.’ Microbioloog Jan Kluytmans over resistente bacteriën.
Volkskrant, 13 april
Meijer GA
•
‘Vanuit mijn vak haal ik uit weefsel relevante informatie om bijvoorbeeld
het onderscheid tussen goed- en kwaadaardig te maken. Maar dit zegt nog
niets over of de patiënt baat heeft bij een specifieke behandeling. Er is
naar mijn mening te weinig aandacht voor diagnostiek, een eerste vereiste
voor meer persoonlijke medicatie.’ Patholoog Gerrit Meijer over nieuwe
ontwikkelingen in de medicatie tegen kanker. nrc (bijlage), maart
Sneldiagnostiek – Gerrit Meijer, P Scholten W de Jong - De Volkskrant – 11
maart
•
Voskuyl AE
Media attention
National television
Kaspers GJL
Local television
National newspaper
•
Meijerink M
•
‘Door de elektrische stroomstootjes worden minuscule gaatjes in de
celmembraan van de kankercellen geschoten, waardoor ze dood gaan en
het lichaam ze opruimt. Het omringende weefsel heeft daar geen last van.’
Martijn Meijerink, interventieradioloog, over de nieuwe nanoknifetechniek.
Volkskrant 20 oktober
Plukker F
•
‘Dit is overweldigend. Hierdoor kunnen wij nog meer onderzoek doen naar
kanker, een ziekte die iedereen in onze maatschappij treft. Het bedrag
wordt besteed aan vroegere opsporing van kanker, therapie op maat en
verbeteren van de kwaliteit van leven van patiënten.’ Fred Plukker,
voorzitter van de rvb, over de opbrengst van de Amsterdam Marathon.
Volksrant.nl, woensdag 24 oktober
Van Bodegraven AA
•
“Door Herceptin hebben vrouwen met deze agressieve tumor een
aanzienlijk grotere kans om in leven te blijven.” Epie Boven, medisch
oncoloog. Elsevier, 24 november ‘Het darmstelsel is doorgaans een heel
vriendelijke plek waar allerlei bacteriën rustig kunnen leven. En hoe
gevarieerder de darmbacteriën, hoe gezonder de darm.’ Ad van
Bodegraven, mdlarts, Vrij Nederland, 15 december
Appendix Annual Report 2012 VUmc CCA – Societal Impact - 109
Verdonck-de Leeuw IM
•
•
Verheul H
•
•
‘Je zet onmacht om in kracht, de Alpe d’HuZes. Om kanker te overwinnen,
of om een geliefde bij te staan in de strijd, is kracht nodig. Vroeger
vonden mensen die wellicht in God. Of in rituelen. Die tocht is de ultieme
krachtmeting. Mensen staan er zelf verbaasd van.’ Irma Verdonck-de
Leeuw, hoogleraar leven met kanker, over het wielerevenement Alpe
d’HuZes in Frankrijk. NRC, 5 juni
Kwaliteit van leven, interview met Irma Verdonck. In: Financieel Dagblad,
Media Planet themanummer 3: Aandacht voor kanker. Maart 2012.
‘Groot voordeel is dat in het VUmc Cancer Center de verschillende artsen
en onderzoekers samenwerken, zowel in onderzoek als in de zorg. Op die
manier proberen we behandelingen te verbeteren. Daarbij is er een grote
interactie tussen laboratorium en kliniek.’ Oncoloog Henk Verheul over
multidisciplinaire aanpak van VUmc Cancer Center. nrc (bijlage), maart
“Onderzoekers en dokters kunnen optimaal samenwerken door de
faciliteiten die gerealiseerd zijn, zoals het researchgebouw waardoor er in
onderzoek en in patiëntenzorg veel vooruitgang is geboekt.’ Oncoloog
Henk Verheul bij wervingsbijeenkomst onder donateurs. Telegraaf, 4 april
Radio
Huijgens PC
•
‘Ik denk dat het goed voor de afdeling is, dat ze zien dat iemand met een
geheel andere invalshoek interesse heeft voor hun ziekte en hoe onze
medewerkers daarmee omgaan. En dat helpt.’ Hematoloog Peter Huijgens
over ‘schrijver op locatie’ Kristien Hemmerechts, die meeliep op zijn
afdeling. Tros Nieuwsshow, Radio 1, 21 januari
Hulleman E & Wurdinger T
•
Nu zijn wij onderzoekers vaak aan het fietsen, steppen en hardlopen om
geld op te halen voor onderzoek, terwijl we beter meer tijd in het lab
zouden kunnen doorbrengen.’ Esther Hulleman en Tom Würdinger,
onderzoekers. BNR radio, 15 december
Van der Veldt A
•
‘Ik ben in 2006 begonnen met het onderzoek naar de werking van
vaatremmers bij uitgezaaide nierkanker, omdat het vanaf dat moment
werd toegepast in de kliniek. Ik heb ook onderzoek gedaan naar het effect
van chemotherapie: hoeveel van het therapeuticum komt daadwerkelijk bij
de tumor terecht?’ Promovenda Astrid van der Veldt over haar
dubbelpromotie. NOS Radio 1 journaal, 4 juli
Van Dongen GAMS
•
‘Voor Nederland is dit de eerste gecombineerde PET/MRI scanner. Je kan
daarmee zowel naar de anatomie als naar de functie van het lichaam
kijken.’ Guus van Dongen, projectleider van het VUmc Imaging Center
Amsterdam, over de nieuwe scanner. bnr Radio, 16 oktober
Verdonck-de Leeuw IM
•
De zondag van Hans van Willigenburg. Interview met Irma Verdonck over
leven met kanker. Radio-uitzending Radio 5. 9 september 2012.
Bloemena E
•
Hepatopathologie - Lever, nieuwsblad van de Nederlandse vereniging voor
Hepatologie – E. Bloemena interview
Cillessen S
•
Apoptoseonderzoek in EATL – Saskia Cilllessen - Vitalia - interview/artikel
Kluytmans J
•
‘We hebben mogelijk te maken met nieuwe transmissieroutes van de vMRSA. Maar we hebben nog geen idee welke dat zijn. Ziekenhuizen willen
het zekere voor het onzekere nemen en zijn zeer alert op eventuele
mutaties van de bacterie.’ Microbioloog Jan Kluytmans over de mrsaproblemen in de veehouderij. Boerderij Vandaag, 13 januari
Rustemeyer T
•
Consumentenbond: interviewhuidirritaties en allergische reacties door
cosmentica – Rustemeyer T - najaar
Consumentenbond: interview eczeem, achtergrond en aanpak op de
afdeling dermato-allergologie van het VUmc - T. Rustemeyer, november
Trade journals & magazines
•
•
Kanker laat je nooit meer los. Interview met Irma Verdonck. Psychologie
Magazine, oktober 2012.
Hooijberg E
•
Artikel: Clin Cancer Res. 2012;18(3):882-9: Clinical effects of adjuvant
active specific immunotherapy etc. - Vermelding op Website Global
Medical Discovery – Erik Hooijberg, september abstract artikel
Huijgens PC
•
‘Als je allemaal aparte registraties hebt voor darmkanker en borstkanker et
Verdonck-de Leeuw IM
News on website
Appendix Annual Report 2012 VUmc CCA – Societal Impact - 110
cetera, dan heb je geen organisatie van de kankerzorg.’ Hematoloog Peter
Huijgens over het patiëntvolgsysteem Pharos voor patiënten met bloed- en
beenmergkanker. iknl nieuws, april
•
‘Ik ben er trots op dat TCS het VUmc Cancer Center Amsterdam wil
ondersteunen. We kunnen als VUmc CCA nu beter invulling geven aan
onze missie om de levensverwachting van mensen met kanker te
verbeteren.’ Oncoloog Henk Verheul over CCA als goede doel bij
marathon. Amsterdam Oost Dichtbij, 23 mei
Meijer GA
•
Unravelling the mystery of how a disease works - brochure Pamgene –
interview Gerrit Meijer, juni
Verdonck-de Leeuw IM
•
Impression CPLOL_congress_25_may_2012. Interview met o.a. Irma
Verdonck. YouTube, 5 juni 2012.
Viore, een huis om te ont-moeten. Presentatie Irma Verdonck bij de
opening van Viore, inloophuis voor patienten met kanker en hun naasten.
Hilversum, 29 februari 2012.
Zelfmanagement na laryngectomie ter preventie van spraak- , slik en
schouderklachten. Presentatie Irma Verdonck op de landelijke
ontmoetingsdag NSvG (patiënten vereniging voor stembandlozen),
Arnhem, September 29, 2012.
Uw patiënt beter in beeld - Irma Verdonck Oncologische Revalidatie.
Medilex, Amersfoort, September 25, 2012.
Verheul H
Other
•
•
•
Perceptible impact on public informing and/or authoritative websites
Jimenez CR
•
Kankerbreed (2012, maart issue) ‘OncoProteomics voor ontdekken van
biomarkers en drug targets’
Rustemeyer T
•
•
•
•
•
•
•
•
www.sens-it-iv.eu
www.A-skin.nl
www.nirm.nl
www.NECOD.nl
http://www.vumc.nl/
www.beroepsziekten.nl
www.escd.org
orgs.dermis.net/eecdrg
Verdonck-de Leeuw IM
•
Release public website www.verderzonderstembanden.nl November 2012
Zuurmond WWA
•
•
•
Palliatieve zorg. VUconnected Enschede 28-3-2012
Palliatieve zorg. Hospice De Schelp, Krommenie 17-4-2012
Palliatieve Zorg VUconnected Apeldoorn 20-11-2012
Perceptible impact on public opinion and/or political decision-making
Bitter W
•
•
Article in BioNieuws (June 23, 2012) on results of PNAS paper (Daleke MH
et al., 2012)
VPRO Labyrint, 17 Oktober, Uitgewerkte antibiotica
Bitter Wilbert , Astrid van der Sar and
Christina Vandenbroucke-Grauls
•
VPRO Labyrint, 12 April 2012, Antibiotica en resistentie
Rustemeyer T
•
EU commission on Consumers´ Health (scientific expert), VWS, RIFM en
VWA (scientific expert)
Interactieve beoordelingssessie arbeidsgerelateerde zorg, op uitnodiging
van KPMG/Plexus, Ministerie van Sociale Zaken en Ministerie van VWS, 1912-2012
•
Technical or economic impact
Memberships of an advice council in the commercial field
Van der Sar AM
•
Scientific Advisory Board, Vertebrate Antibodies, UK,
http://vertebrateantibodies.com/
Voskuyl AE
•
Roche, Actelion
Appendix Annual Report 2012 VUmc CCA – Societal Impact - 111
Patent applications
Jimenez CR, Warmoes MO, Pham TV,
Rottenberg S, Jonkers J
•
Protein markers and BRCAness signature for identification of patients with
homology repair deficiencies and stratification for DNA damaging therapy
Meijer GA, Carvalho B and Bosch LJW
•
Patent filed: Methylation Markers Predictive for Drug Response
Pegtel M
•
EBV and Systemic Lupus Erythematosus
Schuurhuis GJ
•
initiated in Nov 2011: Stem cell kit for acute myeloid leukemia. Product
development with company Becton Dickinson: diagnostic kit for leukemia
stem cells and residual disease
Van Beusechem VW
•
•
6 active patent families in 2012
1 US patent granted in 2012
Wurdinger T
•
Incorporation of thromboDx BV
Gibbs S
•
CSO of A-Skin BV (see www.A-skin.nl)
Meijer GA
•
Preseed grant on clinical development stool proteins marker into a noninvasive test
Van Beusechem VW
•
CSO van ORCA Therapeutics
Verweij CL
•
Preselect Diagnostics BV
Spin off” start-ups
Appendix Annual Report 2012 VUmc CCA – Societal Impact - 112
Appendix 7. Ongoing projects
Program 1
Characterization of DNA stability genes and other cancer predisposition genes
1. Fanconi anemia: a genomics approach
A. Haitjema, D.A. Rockx, B. Brand, N. Ameziane, J.P. de Winter, H. Joenje, J.C. Dorsman
Department of Clinical Genetics, VU University Medical Center, Amsterdam
Fanconi Anemia Research Fund, Eugene, Oregon, USA
2. Genomic profiles for inherited breast cancer
M. Massink, S. van Mil, J.P. de Winter, Q. Waisfisz, H. Meijers-Heijboer
Department of Clinical Genetics, VU University Medical Center, Amsterdam
NWO VIDI Meijers-Heijboer
3. Human genes essential for the defence against oxygen toxicity
M. Corbin, D.A. Rockx, A.B. Oostra, H. van Beek, H. Joenje, J.C. Dorsman
Department of Clinical Genetics, VU University Medical Center, Amsterdam
NWO Mozaïek and Fanconi Anemia Research Fund, Eugene, Oregon, USA
4. Identification of novel players in the Fanconi anemia pathway
N. Ameziane1, J.A. Balk, J.C. Dorsman1, J.T. den Dunnen2, J.P. de Winter1
1Department of Clinical Genetics, VU University Medical Center, Amsterdam, 2Department Human and Clinical Genetics,
LUMC Leiden
KWF VU2010-4767
5. Identification of pathway(s) compensating for Fanconi anemia gene defects
K. Roohollahi, D.A. Rockx, B. Rooimans, N, Ameziane, J.P. de Winter, H. Joenje, J.C. Dorsman
Department of Clinical Genetics, VU University Medical Center, Amsterdam
Fanconi Anemia Research Fund, Eugene, Oregon, USA
6. Sister chromatid cohesion as a novel foothold for cancer therapy
J. de Lange1, RH Brakenhoff2, VW Van Beusechem3, J de Winter1
Department of Clinical genetics and 2Department of Otolaryngology/Head-Neck Surgery, 3Medical Oncology, VU
University Medical Center
NKB VU 2011-4983
7. Sister chromatid cohesion: lessons from yeast, mice and men
A. Faramarz1, H. van Attikum2, H.te Riele3, J.P. de Winter1
1Department of Clinical Genetics, VU University Medical Center, Amsterdam, 2Department Toxicogenetics, LUMC Leiden,
3Molecular Biology, The Netherlands Cancer Institute, Amsterdam
NWO TOP-GO 854.10.013
8. The Fanconi anemial/BRCA pathway in head and neck squamous cell carcinomas
C. Stoepker1, N. Ameziane1, P. van de Lelij1, J.A. Balk1, A.B. Oostra1, M.A. Rooimans1, J. Steltenpool1, S. Martens-de
Kemp2, R.H. Brakenhoff2, H. Joenje1, J.P. de Winter1
1Department of Clinical genetics and 2Department of Otolaryngology/Head-Neck Surgery, VU University Medical Center
(CCA/V-ICI), 3Department of Oncology, University of Oxford
CCA/V-ICI
9. Towards targeted treatment of (familial) breast cancer
J. Bakker1, S. van Mil1, A.B. Oostra1, J.A. Balk1, H. Verheul2, H. Meijers-Heijboer1, J.P. de Winter1, Q. Waisfisz1
1Department of Clinical Genetics and 2Department of Medical Oncology, VU University Medical Center
CCA/V-ICI
Colorectal cancer
10. Clinical and biological relevance of focal deletions in colorectal cancer
O. Krijgsman1, G.A. Meijer1, B. Carvalho1, R.D. Steenbergen1, B. Ylstra1
Department of Pathology, VU University Medical Center, Amsterdam
Stichting Avanti STR
11. Datamanagement voor moleculaire vroegdiagnostiek en therapieselectie bij darmkanker
J. Beliën, G.A. Meijer
Department Of Pathology, VU University Medical Center, Amsterdam
Stichting Avanti STR
12. Development of an improved molecular test for population-wide colorectal cancer screening
A.C. Hiemstra, B. Carvalho, R.J.A. Fijneman, C.R. Jimenez, C.J. Mulder, G.A. Meijer
Department of Pathology, Medical Oncology and Gastroenterology, VU University Medical Center, Amsterdam
Vrienden van het CCA
13. Development of screening tests for early detection of CRC
L. Bosch1, B. Carvalho1, M. van der Wiel1, V. Coupé1, M. van Engeland4 Y. van der Burgt5, W. van Criekinge6, C.R.
Jimenez2, R. Fijneman1, C.J. Mulder3, G.A. Meijer1
1Department Of Pathology, 2Department Medical Oncology (OncoProteomics Laboratory), 3Department
Gastroenterology, VU University Medical Center, 4MUMC, 5LUMC, MdXHEalth, 6Univ Gent
CTMM
14. Early detection of colorectal cancer by faeces derived microRNA testing
L. Timmer1, B. Diosdado1, E. Cuppen2, G.A. Meijer1
Department Of Pathology1, VU University Medical Center, Amsterdam, Hubrecht Laboratorium Utrecht2
KWF VU 2009-4276
15. Improving FOBT based colorectal cancer screening by faeces DNA testing
G.A. Meijer1, M. van Engeland2
Department Of Pathology, VU University Medical Center Amsterdam1, MUMC Maastricht2
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 113
ZonMw
16. Structural chromosomal rearrangements in colorectal cancer
E. van den Broek, R.J.A. Fijneman, G.A. Meijer
Department Of Pathology, VU University Medical Center, Amsterdam
VUmc CCA
Detection and treatment of oral preneoplasia
17. Fanconi anemia: course of disease in the Dutch patient cohort and early recognition of cancer
S. Smetsers3, D.A. Rockx1, J.C. Dorsman1, J.P. de Winter1, R.H. Brakenhoff2, M. Bierings3
1Department of Clinical genetics and 2Department of Otolaryngology/Head-Neck Surgery, VU University Medical Center,
3Wilhelmina Children’s Hospital University Medical Center Utrecht
Kika
18. Targeted therapy of precancerous fields in head and neck mucosa
D.V. de Boer1, B.J.M. Braakhuis1, V.W. van Beusechem2, R.H. Brakenhoff1
Department 1Otolaryngology/Head-Neck Surgery and 2Medical Oncology, VU University Medical Center, Amsterdam
CCA grant
19. Targeted treatment of oral cancer and precancer in FA
C. Stoepker1, R.H. Brakenhoff2, J.P. de Winter1
Department 1Clinical Genetics and 2Otolaryngology/Head-Neck Surgery and Department of Pathology, VU University
Medical Center
Fanconi Anemia Research Fund
EBV oncogenesis
20. Early detection of primary and recurrent nasopharyngeal carcinoma (NPC) using (anti-) EBV based tumor markers and
options for using photodynamic therapy (PDT) in the treatment of local disease
I.B. Tan, S.M. Haryana, J.M. Middeldorp
Department of Pathology, VU University Medical Center Amsterdam, AKI-AvL, Amsterdam, UGM, Yoguakarta, Indonesia
KWF
21. EBV non-coding RNAs hijack components of the miRNA machinery promoting viral oncogenesis
D. Koppers-Lalic, J.M. Middeldorp, G. Scheffer, R.J. Scheper, C.R. Jimenez, D.M. Pegtel
Department of Pathology, VU University Medical Center
AICR 11-0157
22. Physiological role of EBV-LMP1 in MHC-II+exosomes for tumor immune escape across the immunological synaps:
Implications for prognosis and immunotherapy
F. Verweij, E. Hooijberg, J.J.C. Neefjes, J.M. Middeldorp, D.M. Pegtel
Department of Pathology, VU University Medical Center
KWF 2007-3775
Exosomes
23. Exosome-mediated communication in the pathogenesis of human sarcomas
S.R. Baglio, M. Pegtel
Department Of Pathology, VU University Medical Center Amsterdam
27.250,00
24. Genomic biomarkers in tumor vesicles for minimally-invasive cancer diagnosis
M. Pegtel
Department of Pathology, VU University Medical Center Amsterdam
KWF 2012-5510
25. Prostate cancer
M. Pegtel
Department of Pathology, VU University Medical Center Amsterdam
eerste geldstroom
Head and neck cancer predisposition
26. Genetic characterization of HNSCC of young adults
B.J.M. Braakhuis1, A. Nieuwint2, C.R. Leemans1, R.H. Brakenhoff1
1Section Tumor Biology, Department of Otolaryngology/Head-Neck Surgery, 2Department of Clinical Genetics and
Human Genetics, VU University Medical Center, Amsterdam
Intramural support
27. High sensitivity to DNA damage in the aetiology of head and neck squamous cell carcinoma in young adults and
individuals not exposed to tobacco smoke and excessive alcohol (SenseDNA)
B.J.M. Braakhuis1, A. Nieuwint2, C.R. Leemans1, R.H. Brakenhoff1
1Section Tumor Biology, Department of Otolaryngology/Head-Neck Surgery, 2Department of Clinical Genetics and
Human Genetics, VU University Medical Center, Amsterdam
Intramural support
Head and neck carcinogenesis and cancer genes
28. Clinical significance of human papillomavirus infection in oropharyngeal squamous cell carcinoma
M. Rietbergen, C.R. Leemans, P.J.F. Snijders, B.J.M. Braakhuis, E. Bloemena, R.H. Brakenhoff
1Department Otolaryngology/Head-Neck Surgery and Department of Pathology, VU University Medical Center
KWF grant VU 2009-4531
29. Functional characterization of TP53 mutations in head and neck squamous cell carcinoma, and association with clinical
outcome
M. Buijze, R.H. Brakenhoff, C.R. Leemans, B.J.M. Braakhuis
Department Otolaryngology/Head-Neck Surgery, VU University Medical Center, VU University Medical Center, Amsterdam
CCA/V-ICI 2009, Avanti STR-Foundation
30. Identification of oncogenic microRNAs and cancer genes involved in head and neck squamous cell carcinoma by a
functional genomics approach
M. van der Plas, B.J.M. Braakhuis, C.R. Leemans, R.H. Brakenhoff
Section Tumor Biology, Department of Otolaryngology/Head-Neck Surgery, VU University Medical Center, Amsterdam
CCA/V-ICI
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 114
31. MicroRNAs in head and neck cancer
vacature, M. de Maaker, R.H. Brakenhoff
Departments. Otolaryngology/Head-Neck Surgery, VU University Medical Center
InteRNA
HPV-induced tumors
32. Clinical evaluation of methyulation markers for risk assessment of high-risk HPV-positive women for cervical cancer and
its high grade precursors
L. de Strooper, C.J.L.M. Meijer, P.J.F. Snijders, D.A.M. Heideman
Department Of Pathology, VU University Medical Center Amsterdam
KWF 2009-4522
33. Comprehensive analysis of the long-term oncogenic capacity and in vitro transforming property of the 15 high-risk
human papillomavirus types
D.M. Schütze, R. van Baars, J. van der Marel, P.J.F. Snijders, R.D.M. Steenbergen, W. Quint, C.J.L.M. Meijer
Department of Pathology, VU University Medical Center, Amsterdam
HUMAVAC
34. Comprehensive molecular characterisation of a longitudinal in vitro model of high-risk HPV-mediated transformation
V. Miok1, S.M. Wilting1, R.D.M. Steenbergen1, W.N. van Wieringen2, P.J.F. Snijders1
Department Pathology1 and Epidemiology & Biostatistics2, VU University Medical Center Amsterdam
St. VUmc CCA
35. Health-economic modelling of prevention strategies for HPV-related diseases in European countries
H. Berkhof, C.J.L.M. Meijer
Department of Pathology and Biostatistiek&Epidemiologie, VU University Medical Center, Amsterdam
EU en ZonMw
36. HPV vaccination
M. Mollers, M. Scherpenisse, C.J.L.M. Meijer
Department Of Pathology, VU University Medical Center, Amsterdam
RIVM
37. Identification and clinical validation of methylation markers for cervical adenocarcinomas and their precursor lesions
S. Snellenberg, C.J.L.M. Meijer, P.J.F. Snijders, R.D.M. Steenbergen
Department of Pathology, VU University Medical Center, Amsterdam
KWF 2007-3771
38. Identification of miRNAs and other ncRNAs as biomarkers for cervical cancer and assessment of their potential
functional relevance in HPV-mediated transformation
S.Wilting , P.J.F. Snijders, R.D.M. Steenbergen
Department of Pathology, VU University Medical Center, Amsterdam
Stichting Avanti STR
39. Improving detection-efficiency of CIN2+ in non responder-women that test positive for hrHPV in a self-collected sample:
design of PROTHECT 3 trial
V. Verhoef, F. van Kemenade1, D.A.M. Heideman1, P.J.F. Snijders1, M. van Baal2, L. Masuger3, R. Bekkers3, W.
Melchers4, R. Hol5
Department Of Pathology1 and Gynaecology2, VU University Medical Center Amsterdam, Department Gynaecology,
UMCN3, Mol. Diagnostics, UMCN4, Delphi Biosciences5
St. Bevolkingsonderzoek midden-west
40. Improving detection-efficiency of CIN3+ in non responder-women that test positive for hrHPV in a self-collected sample:
design of PROTHECT 3 trial
F. van Kemenade1, D.A.M. Heideman1, P.J.F. Snijders1, M. van Baal2, L. Masuger3, R. Bekkers3, W. Melchers4, R. Hol5
Department Of Pathology1 and Gynaecology2, VU University Medical Center Amsterdam, Department Gynaecology,
UMCN3, Mol. Diagnostics, UMCN4, Delphi Biosciences5
St. Bevolkingsonderzoek midden-west
41. Profiling of aberrant microRNA methylation events that are functionally relevant during cervical carcinogenesis
S.M. Wilting, R.D.M. Steenbergen, P.J.F. Snijders
Department Of Pathology, VU University Medical Center
KWF 2010-4668
42. Self screen: biomarker-based companion diagnostic of HPV positive woman to detect cervical cancer
D.A.M. Heideman, P.J.F. Snijders, R.D.M. Steenbergen, C.J.L.M. Meijer
Department of Pathology, VU University Hospital Amsterdam
NGI-Preseed
43. Simplified monitoring post-treatment CIN 2/3 women by molecular testing for hrHPV and methylation markers
M. Uijterwaal1, C.J.L.M. Meijer1, Th.J.M Helmerhorst2, R.D.M. Steenbergen1
1VU University Medical Center, Amsterdam, 2Erasmus University Medical Center, Rotterdam
KWF 2009-4413
Lung cancer
44. Evaluation of molecular sputum test diagnostic for lung cancer
A.J. Hubers, D.A.M. Heideman, E.F. Smit, F.B.J.M. Thunnissen
Department of Pathology1 and Pulmonology2, VU University Medical Center, Amsterdam
KWF VU 2008-4220
Molecular diagnosis and genomics-based staging and personalized therapy of head and neck cancer
45. Improving molecular staging of surgically treated head and neck cancer patients: towards rationalized adjuvant
treatment
A.P. Graveland1, M. de Maaker1, E. Bloemena2, B.J.M. Braakhuis1, C.R. Leemans1, R.H. Brakenhoff1
Departments. 1Otolaryngology/Head-Neck Surgery and 2Pathology, VU University Medical Center, Amsterdam,
3Department Biomolecular Mass Spectrometry, University Utrecht
NKB/KWF 2005-3285 en 2006-3694
46. Molecular diagnosis of lymph node metastasis in primary head and neck squamous cell carcinoma
Q. Voorham, C.R. Leemans, B. Ylstra, R.H. Brakenhoff, B.J.M. Braakhuis
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 115
Department Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
NKB/KWF 2006-3694
Personalized chemo-radiation of lung and head and neck cancer: airforce
47. Determinants of chemotherapy sensitivity
S.R. Maartens-de Kemp1, C.R. Nagel1, B.J.M. Braakhuis1, A. Brink1, C.R. Leemans1, V.W. van Beusechem2, J.P. de
Winter3, R.H. Brakenhoff1
1Section Tumor Biology, Department. of Otolaryngology/Head-Neck Surgery, 2Medical Oncology, VU University Medical
Center, Amsterdam
CCA/V-ICI grant
48. Determinants of radio and EGFR-mediated therapy sensitivity
C.R. Nagel, C.R. Leemans, B.J.M.Braakhuis, R.H. Brakenhoff
Department of Otolaryngology/Head-Neck Surgery, VU University Medical Center
Airforce
Retinoblastoma: genetics
49. Genomics to improve diagnostics and care of retinoblastoma patients
E.I. Kooi1,5, B.M. Mol1, T. van Harn2, A.C. Moll3, J. Cloos4,5, G.J.L. Kaspers5, H. te Riele1,2, J.C. Dorsman1
Departments of 1Clinical Genetics, 3Opthalmology, 4Hematology, 5Pediatric Oncology/ Hematology, VU University
Medical Center, Amsterdam, The Netherlands. 2Division of Molecular Biology, The Netherlands Cancer Institute,
Amsterdam
Stichting KIKA Kinderen Kankervrij
50. Retinoblastoma, molecular genetics and clinical consequences
C.J. Dommering1, H. Meijers-Heijboer1, L. Henneman1, A.C. Moll2
1Department of Clinical Genetics, 2Department of Ophthalmology, VU University Medical Center
51. The molecular carcinogenesis of retinoblastoma
B.M. Mol1, E.I. Kooi1, A.C. Moll2, D.A.P. Rockx1, W.A Kors3, M.I. Bosscha2, C. Dommering1, H. Joenje1, H. te Riele1,5, J.
Cloos3,4, J.C. Dorsman1
Departments. of 1Clinical Genetics, 2Ophthalmology, 3Pediatric Oncology/Hematology, 4Hematology VU University
Medical Center, Amsterdam and 5Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam
CCA/V-ICI Stichting Avantie STR (round 2008)
Other projects
52. A quantitative proteome progression model for squamous cell cancer
M. Rietbergen, E. Bloemena
Department of Pathology, VU University Medical Center Amsterdam
Nat Prot. Center
53. HAVANA-studie: HPV amongst vaccinated and non-vaccinnated adolescents
R. Donken, H. de Melker, C.J.L.M. Meijer
Rijksinstituut voor Volksgezondheid en Milieu, Department of Pathology, VU University Medical Center Amsterdam
54. Identification of novel oncogenes/oncomirs located at 13q involved in the progression of colorectal adenoma to
carcinoma
F.L.M. de Groen, R.D.M. Steenbergen, G.A. Meijer, B. Carvalho
Department Of Pathology, VU University Medical Center, Amsterdam
VUmc CCA
55. Molecular biomarkers for the stratification of metastatic colorectal cancer patients
M. Cordes, D. Sie, B. Ylstra, G.A. Meijer
Department Of Pathology, VU University Medical Center Amsterdam
56. Optimizing fecal immunochemical tests for early detection of colorectal cancer and adenomas
1I. Ben Larbi, 1S.T. van Turenhout, 1F.A. Oort, 1J.S. Terhaar sive Droste, 2V.M.H. Coupé, 3R.W.M. van der Hulst, 4A.A.
Bouman, 7R.A. Kraaijenhagen, 5G.A. Meijer, 1C.J.J. Mulder
Departments. of 1Gastroenterology and Hepatology, 2Epidemiology and Biostatistics, 4Clinical Chemistry, 5Pathology,
VU University Medical Center, 3Gastroenterlogy and Hepatology Kennemer Gasthuis Haarlem, 6Epidemiology, and
7NDDO Institute for Prevention and Early Diagnostics (NIPED), Amsterdam
57. Schadelastreductie baarmoederhalskanker door vernieuwend beleid ten aanzien van niet-deelnemers BVO-BMHKBHMK
F. van Kemenade1, D.A.M. Heideman1, P.J.F. Snijders1, M. van Baal2, L. Masuger3, R. Bekkers3, W. Melchers4, R. Hol5
Department Of Pathology1 and Gynaecology2, VU University Medical Center Amsterdam, Department Gynaecology,
UMCN3, Mol. Diagnostics, UMCN4, Delphi Biosciences5
Achmea Gezondheidszorg
58. Towards improved melanoma treatment: gene identification, in vivo modeling and drug target discovery
D. Peeper, W.J. Mooi
Department Of Pathology, VU University Medical Center, Amsterdam
KWF
Program 2
Exosomes
1. EBV-MicroRNA containing exosomes: Trojan vesicles carrying hostile message
D.M. Pegtel, D.A. Thorley-Lawson, J.M. Middeldorp
Department of Pathology, VU University Medical Center and Tufts University, Boston, USA
NWO-Veni, ZonMW2008 OZ05PAT110038
In situ targeting and modulation of dendritic cells for tumor
2. In situ targeting and modulation of dendritic cells for immunotherapy: reversal of suppression
D. Oosterhoff1, J.J. Lindenberg1, R. van de Ven1, H. van Cruijsen1, S.M. Lougheed1, V.W. van Beusechem1, P. van den
Tol3, D.T. Curiel4, W.R. Gerritsen1, A.J.M. van den Eertwegh1, R.J. Scheper2, T.D. de Gruijl1
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 116
Departments. of 1Medical Oncology, 2Pathology, and 3Surgical Oncology,VU University Medical Center, Amsterdam and
Division of Human Gene Therapy, UAB, Birmingham, Alabama.
NWO VIDI 917.56.321
Mycobacterial host-pathogen interaction
3. Immune modulation by ESX-5 secreted proteins of mycobacteria
E.M. Weerdenburg, W. Bitter, B.J. Appelmelk
Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
V-ICI
4. Live mycobacterium bovis BCG bacteria as a platform for the induction of enhanced tumor-antigen-specific immunity
L.S. Ates, B. Appelmelk, J. Geurtsen, W. Bitter
Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
5. Mycobacterial factors involved in granuloma formation
Esther Stoop, Gunny van den Brink- van Stempvoort, Theo Verboom, Wilbert Bitter, Christina Vanderbroucke-Grauls,
Astrid van der Sar
Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
Smart Mix
6. Mysteries beyond the mycomembrane:biogenesis of the mycobacterial capsule and its role in the host-pathogen
interaction
R. van de Weert, B. Appelmelk, C. Vandenbroucke-Grauls, J.J.G. Geurtsen
Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
NWO/ALW VENI
7. Targeting of proteins to the mycobacterial type VII secretion system ESX-5
M.H. Daleke, W. Bitter
Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
NWO/ALW
8. Unraveling a novel bacterial protein transport system: characterization of mycobacterial secretion system ESX-5
E.N.G. Houben, W. Bitter
Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam
Type 1 diabetes and coeliac disease
9. Type 1 diabetes and celiac disease in adults: Glycemic control and diabetic complications
S.F. Bakker1, M.E. Tushuizen1, T.N. Wijmenga4, B.M.E. von Blomberg2, C.J. Mulder1, S. Simsek3
1. Departments of Gastroenterology and Hepatology; 2. Medical Immunology, VU University Medical Center, Amsterdam
and Department of 3Internal Medicine, Medical Center Alkmaar, Alkmaar and Department of Medical Genetics4 of the
University Medical Center Groningen
Coeliac Disease Consortium
Other projects
10. A prediction model for the development of rheumatoid arthritis in anti-CCP and/or IgM rheumatoid factor positive
arthralgia patients
D. van Schaardenburg1,2, L. v.d. Stadt2, W.H. Bos1, C.L. Verweij1, K.A.G. Gelderman6, D. Hamann4, M. Boers5, B.A.C.
Dijkmans1,2
1 Jan van Breemen Research Institute / Reade, 2 Department of rheumatology, VU University Medical Center, Sanquin
Research4, Clinical Epidemiology5 and Pathology6 VUMC
Reumafonds DAA 0801034
11. Anti-inflammatory therapy and biomarker analysis during peritoneal dialysis
A. Stavenuiter, E. Ferrantelli, T. Foster, K. Farhat, N. Paauw, D. Schooneman, P.M. ter Wee1, R.H.J. Beelen
Departments of Molecular Cellular Biology and Immunology and 1Dept. Nephrology, VU University Medical Center,
Amsterdam, The Netherlands
Abbott, Dutch Kidney Foundation, Marie Curie ITN
12. Biomarkers in systemic lupus erythematosus
J. Jacobs, M.W.P. Tsang-A-Sjoe, L-A. Korswagen, B.A.C. Dijkmans, I.E.M. Bultink, A.E. Voskuyl
Department of Rheumatology, VU University Medical Center
13. Ceramic microneedle arrays for skin vaccination
R.J. Scheper, R. Luttge, T.D. de Gruijl
Department of Pathology, VU University Medical Center, Amsterdam
Technical University Tweente seeding grant
14. Contribution of molecular epidemiology and host-pathogen genomics to understand Chlamydia trachomatis and Bacterial
meningitis
S.A. Morré1, EpiGenChlamydia Consortium2
1. Laboratory of Immunogenetics, Department of Medical Mirobiology and Infection Control, 2. EpiGenChlamyda
Consortium, (www.EpiGenChlamydia.eu): 20 European, African and US Universities and Institutes
EU FP6 funded (Contract N°: 037637) and new funding NIH (2011-2014), NGI (2012-2014) and ETB grants (2011-2014
15. Cross-talk between MGL and galectin-1 in the regulation of tolerogenic responses in multiple sclerosis
J.M. Ilarregui, G.A.Rabinovich1 and Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam, 1IBYME;CONICET,
Buenos Aires, Argentina
Dutch Foundation MS Research
16. Dendritic cell targeting using nanovesicles to improve anti-cancer therapy
W.W.J. Unger, M. Litjens, M. Verstege, Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
SENTERNOVEM
17. Dendritic cell-targeted in vivo tumor vaccination: towards optimised prime-boost protocols
B.N. Hangalapura1, D. Oosterhoff1, van de Ven1, J. van Moorselaar2, A.G.M. Stam3, R. E. Hooijberg3, V.W. van
Beusechem1, W.R. Gerritsen1, A.J.M. van den Eertwegh1, R.J. Scheper3, Y. van Kooyk4, T.D. de Gruijl1
Departments. of 1Medical Oncology, 2Urology, 3Pathology, and 4Molecular Cell Biology and Immunology, VU University
Medical Center, Amsterdam
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 117
KWF-VU / Stichting CCA 2005-3284
18. Determination of the contribution of neuronal vs. mesenchymal expression of Raldh2 to lymph node development
S.A. van de Pavert, T. Konijn, R.E. Mebius
Department Mol. Cell Biology and Immunology, VU University Medical Center
NWO 854.10.005
19. Development of a dermal substitute from human donor skin
C.D. Richters1,2, N.J. Paauw1, R.H.J. Beelen, M.M. Ulrich3
1Department of Molecular Cell Biology and Immunology, VU University Medical Center, 2Euro Skin Bank, Beverwijk,
3Vereniging van Samenwerkende Brandwondencentra Nederland, Beverwijk
Dutch Burn Foundation
20. Diagnosis and prognosis in early arthritis
D. van Schaardenburg1, 2, K. Britsemmer1, L. van Tuyl, B.A.C. Dijkmans1, 2
1. Jan van Breemen Research Institute / Reade, 2. Department of Rheumatology, VU University Medical Center
Jan van Breemen Research Institute
21. Effect evaluation of home treatment program TBM, Cape Town, South Africa
S. van Elsland1; P. Springer2; J. Schoeman2; A.M. van Furth1
Departments. of 1Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center, Amsterdam, The
Netherlands; 2 Tijgerberg Hospital, Cape Town, SA
22. Enteroviral infections in children
S. de Crom 1, Dr. Ch. Obihara 1, M. Peeters 2, S.A. Morré 3 , A. M. van Furth 4
1Department of Pediatrics, St. Elisabeth Ziekenhuis, Tilburg; 2 Department of Medical Microbiology , St. Elisabeth
Ziekenhuis, Tilburg; 3Laboratory of Immunogenetica, Department of Medical Mirobiology and Infection Control,VUmc,
Amsterdam; 4Department of Pediatric Infectious Diseases, Immunology, and Rheumatology, VUmc, Amsterdam
23. Evaluation of a new anti inflammatory treatments to improve healing of burns
J Akershoek, C.D. Richters12, N.J. Paauw1, E. Middelkoop2, R.W. Kreis2, R.H.J. Beelen1, M. Ulrich2
1Dept. of Molecular Cell Biology and Immunology, VU University Medical Center, 2Vereniging van Samenwerkende
Brandwondencentra Nederland, Beverwijk
Dutch Burn Foundation
24. Exploration of novel therapeutic options for refactory CD (RCD) and EATL
S. Cillessen, M. von Blomberg, H.J. Bontkes, G. Bouma, C. Mulder
Department Of Pathology and Gastroenterology, VU University Medical Center, Amsterdam
Celiac Disease Consortium (CDC/NGI)
25. Exploring the sweet spot in colon cancer mutations
K. Lenos 1, R.J. Fijneman 2, Y. van Kooyk 1, S.J. van Vliet 2
Department of Molecular Cell Biology1 and Pathology 2 VU University Medical Center
VUmc CCA
26. Galactofuranose containing glycoconjugates in the cell wall of Aspergillus: aspects of their biosynthesis and
immunological function
B. Tefsen1, J.H. Park2, A. Ram2, I. van Die1
1Department of Molecular Cell Biology & Immunology, VUmc, Amsterdam and 2Institute of Biology, Leiden University,
Leiden
STW
27. Generation of tolerogenic dendritic cells
P. Papadopoulos, G. Kraal
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
Eurostar
28. Genetic profiling in bacterial meningitis
M. Sanders1, S. Ouburg1 , S.A. Morré1 , A.M. van Furth2
1Laboratory of Immunogenetica, Department of Medical Mirobiology and Infection Control,VUmc, Amsterdam;
2Department of Pediatric Infectious Diseases, Immunology, and Rheumatology, VUmc, Amsterdam
29. Glycan specificity of C-type lectins
K. Bloem, S. van Vliet, N. Koning, Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
TIPharma
30. Glycosylation changes in colon carcinoma
E. Saeland, G. Meijer1, Y. van Kooyk
Departments of Molecular Cell Biology and Immunology and 1Pathology, VU University Medical Center Amsterdam
AICR
31. Glycosylation controls immune homeostasis
J. J. Garcia-Vallejo, H. Kalay, I. Vuist, B. ‘t Hart2, Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam, 2Immunobiology,
Biomedical Primate Research Center, Rijswijk
NWO-ALW VENI
32. Glycosylation of the Prostate Antigen PSA as predictive marker for prostate cancer
M. van den Berk, S.J. van Vliet, Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
Eurostars
33. Helminth glycoproteins: a new therapeutic option to prevent or ameliorate MS?
G. Kooij, L. Laan, C.D. Dijkstra, I. van Die
Department of Molecular Cell Biology & Immunology, VUmc, Amsterdam
the Dutch Foundation MS Research
34. HLA-DQ genotype distribution in Type 1 Diabetes Mellitus patients with concomitant Celiac Disease
S.F. Bakker1, M.E. Tushuizen1, J.B.A. Crusius 2, S Simsek3 , C.J.J. Mulder1, B.M.E. von Blomberg4
1 Department of Gastroenterology and Hepatology, VU University Medical Center, The Netherlands, 2 Laboratory of
Immunogenetics,Department of Medical Mirobiology and Infection Control, VU University Medical Center, Amsterdam,
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 118
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
The Netherlands, 3 Department of Internal Medicine, Medical Center Alkmaar, The Netherlands, 4 Department of
Medical Immunology, VU University Medical Center, The Netherlands Coeliac Disease Consortium
Identification of differentialy glycosylated glycoproteins in human milk and their effects on DCs
N. Koning, E. Saeland, K. Bloem, S.J. van Vliet, Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
TIPharma
Immunogenetic, pharmacological and neurodevelopmental aspects of nosocomial sepsis and meningitis in preterm AGA
and SGA infants
F. van den Dungen1 , S.A. Morré2, P. Savelkoul3, M. M. van Weissenbruch1, A.M. van Furth4
1Department of Neonatology, VUmc, Amsterdam 2 Laboratory of Immunogenetica, Department of Medical
Mirobiology and Infection Control,VUmc, Amsterdam; 3Department of Medical Microbiology, VUmc, Amsterdam,
4Department of Pediatric Infectious Diseases, Immunology, and Rheumatology, VUmc, Amsterdam
Immunogenetics and environmental factors in infectious diseases
S. Ouburg1, Y. Pannekoek3, J. Lyons1, S. Verweij, M. Sanders, G. van Well, V. Smelov, J. Land5, C. Bruggeman6, C.
Hoebe6, A. Catsburg8, P.H. Savelkoul8, C.M.J.E. Vandenbroucke-Grauls8, M. van Agtmael9, M. van Furth 10, J.B.A.
Crusius1, A.S. Peña1, S.A. Morré1
1Laboratory Immunogenetics, Department of Medical Mirobiology and Infection Control,, 2GGD Amsterdam, 3AMC Med
Microbiol, 5AZM, Department Gynecol, 6AZM, Department Med Microbiol, 7Department Basic Dental Sci, 8Med Microbiol
Infect Prev, 9Int Med, 10 Pediatrics, VUmc, NL
Immunoglobulin A and neutrophil immunoglobulin A Fc receptor (Fc-alpha-RI) in mucosal infections
M.W.M. van Hout1, L. van der Steen1, J.E. Bakema1,2, M. van Egmond1,2
Departments. of 1Molecular Cell Biology and Immunology, and 2Surgery, VU University Medical Center
NWO
Immunoglobulin A Fc receptor (Fc-alpha-RI)-induced inflammatory diseases
L. van der Steen1, M.W.M. van Hout1, R. Korthouwer1, S. Pouw1, J.E. Bakema1, M. van Egmond1,2
Departments. of Molecular Cell Biology and Immunology, and Surgery, VU University Medical Center
NWO, Agentschap NL, MaagLeverDarmStichting
Immunoprofiling in chronic inflammatory disease: (refractory) coeliac disease
S.Gross1, R.L. van Wanrooij2, I.M.W. van Hoogstraten1, H.J. Bontkes1, K.A. Gelderman1, S.A.G.M. Cillessen1, B.M.E. von
Blom¬berg1, R.L.J. van Wanrooij, G. Bouma2, C.J.J. Mulder2
Departments. of Pathology1 and Gastroenterology2, VU University Medical Center
Celiac Disease Consortium (CDC/NGI)
Immunoprofiling in chronic inflammatory disease: contact allergy
D. Rachmawati1, J. Muris2, I.M.W. van Hoogstraten1, R.J. Scheper1, B.M.E. von Blom¬berg1, C.J. Cleverlaan2, A.J.
Feilzer2, T. Rustemeyer3
Departments of 1Pathology1 and 3Dermatology3, VU University Medical Center; Department of Dental Materials
Science2, ACTA, Amsterdam
Immunoprofiling in malignant disease
H.J. Bontkes1, I.M.W. van Hoogstraten1, K.A. Gelderman1, B.M.E. von Blom¬berg1, A.G.M. Stam2, TD de Gruijl2
Departments. of Pathology1 and Oncology2, VU University Medical Center, Amsterdam
Importance of glycosylation on the function of dendritic cells
M. Bax, J.J. García Vallejo, Y. van Kooyk
Department of Molecular Cellular Biology and Immunology, VU University Medical Center Amsterdam
VUmc CCA and Bridging grant from the Consortium for Functional Glycomics
Improving early diagnosis of tuberculous meningitis in children
R. Solomons1, J. Schoeman1, A.M. van Furth2
Departments. of 1Tijgerberg Hospital, Cape Town, SA; 2Pediatric Infectiology, Immunology and Rheumatology, VU
University Medical Center, Amsterdam, The Netherlands
Inflammatory host defense in children with Down syndrome
C.J.M. Broers1, M.E.Wijerman1,2 ; R.J.B.J. Gemke1 , A.M. van Furth3,4
1Department of Pediatrics, VU medical center, 2Department of Pediatrics, Diaconesseziekenhuis, Leiden; 3 Department
of Pediatric Infectious Diseases-Immunology and Rheumatology, VU University Medical Center, Amsterdam; 4Laboratory
of Experimental Internal Medicine, Academical Medical Center, Amsterdam
iNKT and Vγ9Vδ2-T cell based immunotherapies for solid tumors
F.L. Schneiders1, R.C. de Bruijn1, R.J. Scheper2, B.M.E. von Blomberg-van der Flier2, A.J.M. van den Eertwegh1, G.A.M.S.
van Dongen3, R.C. Roovers4, H.M. Verheul1, T.D. de Gruijl,1 H.J. van der Vliet1
Departments of 1Medical Oncology, 2Pathology, and 3Otolaryngology/Head and Neck Surgery, VU University Medical
Center, Amsterdam and 4 Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University,
Utrecht, The Netherlands
ZonMw Clinical Fellowship, KWF Clinical Cancer Research Fellowship
Innovaties in beeldvorming en lokale behandeling van colorectale levermetastasen
K. Nielsen1, M.P. van den Tol1, E.F.I. Comans2, M.R. Meijerink2, S. Meijer1
Departments of 1Surgery, 2Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam
Interactions between CD169+ macrophages and dendritic cells
H. Veninga, E. Borg, H. Kalay, Y. van Kooyk, G. Kraal, J.M.M. den Haan
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
KWF VU2009-4504
Large scale generation and analysis of glycovariants of Derp1 that down modulate the immune response in allergic
asthma
J.J. Garcia Vallejo1, J.M. Ilarregui1, H. Kalay1, I. Heijink2, Y. van Kooyk1
Departments. of 1Molecular Cell Biology & Immunology, VU University Medical Center, and 2Laboratory of Allergology
and Pulmonary Diseases, Department of Pathology and Medical Biology, University Medical Center Groningen, ,
Groningen
Astma Fonds 3.2.10.040
Macrophages and tumour development
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 119
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
R. Braster1, M. Bögels1,2, R.H.J. Beelen2, M. van Egmond1,2
Departments. of 1Surgery and, 2Molecular Cell Biology and Immunology, VU University Medical Center
Eerste geldstroom via MCBI
Macrophages as effector cells for monoclonal antibody therapy of cancer
M. Bögels1,2, N. Gül2, R.H.J. Beelen2, J. Bonjer1, M. van Egmond1,2
Departments. of 1Surgery and, 2Molecular Cell Biology and Immunology, VU University Medical Center
Heelkunde
Mechanisms of mesenchymal cell differentiation towards stromal lymph node cells
J.J. Koning, G. Goverse, T. Konijn, R.E. Mebius
Department Mol. Cell Biology and Immunology, VU University Medical Center
NWO VICI grant 918.56.612
Metabolomics Study of Tuberculous Meningitis in Children
S. Mason1, R.Solomons2, J.Schoeman2,R.Wevers3, C.Reinecke1, A.M. van Furth4
Departments. of 1Centre for Human Metabolomics, Potchefstroom, SA; 2 Tijgerberg Hospital, Cape Town, SA; 3 Clinical
Chemistry, UMC, Nijmegen; 4Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center,
Amsterdam, The Netherlands
Microbial control of the mucosal barrier function
I. Hiemstra, K. Vrijland, G. Bouma, G. Kraal, J.M.M. den Haan
Depts of Molecular Cellular Biology and Immunology and Gastroenterology, VU University Medical Center, Amsterdam
Mocosa: an alternative test method for risk assessment of potentially harmful substances in the oral cavity
J. Reijnders1, S.W. Spiekstra,1 , B.P. Vriens2,3, S. Gibbs1
1Dermatology, VU University Medical Centre, 2 ACTA, 3 Mucosa BV, Amsterdam
ZON-MW Pre-Seed 40-41300-98-9044
MOG glycosylation and the induction of anti-inflammatory responses in Multiple Sclerosis
I. Vuist, J.J. Garcia-Vallejo, B. ‘t Hart1, Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam, 1Department
Immunobiology, BPRC, Rijswijk
Dutch Foundation MS Research
Nerve regeneration in porcine wound models
C.S. van den Brand 1,2, L. van der Steen1, N.J. Paauw1, R.H.J. Beelen1, M.M.W. Ulrich2, E. Middelkoop2, C.D. Richters,2,3
1Department of Molecular Cell Biology and Immunology, VU University Medical Center, 2Vereniging van Samenwerkende
Brandwondencentra Nederland, Beverwijk, 3Euro Skin Bank, Beverwijk
Dutch Burn Foundation
Notch-signaling in tumor-specific T cells to improve anti-tumor immunity
L.Kuijk, MI Verstege, T.de Gruijl, E. Hooijberg, Y. van Kooyk, WWJ Unger
Department Mol Cell biol and Immunol , Pathology and Medical Oncology, VU University Medical Center, Amsterdam
VUmc CCA
Novel in vitro assays for detection of sensitizers
J. Reinders1, G. dos Santos1, S.W. Spiekstra1, B.M.E. von Blomberg2, R.J. Scheper2, T. Rustemeyer1, S. Gibbs1
Departments of 1Dermatology and 2Pathology, VU University Medical Centre
Preclinical rheumatoid arthritis
M.M.J. Nielen1, W.H. Bos1, L.A van de Stadt1, R.J. van de Stadt1, I.E. van der Horst-Bruinsma2, J.W.R. Twisk3, H.W.
Reesink4, D. Hamann4, B.A.C. Dijkmans1, 2 D. van Schaardenburg1, 2
1 Jan van Breemen Research Institute / Reade, 2 Department of rheumatology, medical statistics3, VUMC, Sanquin Blood
Bank4.
Predicting T-cell lymphoma development in refractory celiac disease patients by profiling of apoptosis pathways in
intestinal T-lymphocytes
J.M.W. van de Water1, L.R. de Baaij1, N.J.Hijmering2, W. Vos2, O.J. Visser3, J.J. Oudejans2,4, B.M.E. von Blomberg2, M.W.J.
Schreurs2, C.J.L.M. Meijer2, C.J.J. Mulder1, S.A.G.M. Cillessen2
Departments. of 1Gastro-enterology and Hepatology,2Clinical Pathology, 3Hematology, VU University Medical Center,
Amsterdam. 4Department of Pathology, Diakonessenhuis, Utrecht
VUmc CCA PV06/18MDL
Prevalidation of a two-tiered approach to determine the skin sensitising capacity and potency of chemicals
J. Reijnders1, S.W. Spiekstra,1 , E. Corsini2 , R. Roggen3 , R. Pieters4, S. Casati5. C. Krul6, S. Gibbs1
1Dermatology, VU University Medical Centre, 2 University of Milan, Milan, 3 Novozymes, Denmark, 4 Hoge School,
Utrecht, 5 ECVAM, Ispra, 6 TNO, Utrecht
ZON-MW PAD grant 40-40100-94-09015
Prognostic and diagnostic marker analysis in (refractory) celiac disease
S. Gross, B. M.E. von Blomberg, H.J. Bontkes, I.M.W. van Hoogstraten, K.A.G. Gelderman, G. Bouma, S. Cillessen, C.J.
Mulder, F. Koning
Department Of Pathology and Gastroenterology, VU University Medical Center Amsterdam, LU University Medical Center
Leiden
Celiac Disease Consortium (NGI)
Proteasome inhibitors and effects on immune effector cells in autoimmunity and cancer
G. Jansen, T.D. de Gruijl, R.J. Scheper, B. Dijkmans
Department of Reumatology, Medical Oncology and Pathology, VU University Medical Center Amsterdam
Protection against inflammatory bowel diseases by glycan antigens
E.J. Klaver1, L.M. Kuijk1, G. Kraal1, G. Bouma2, I. van Die1
1Department of Molecular Cell Biology & Immunology, VUmc, Amsterdam; 2Department Gastroenterology, VU University
Medical Center, Amsterdam
the Broad Medical Research Program of the Broad Foundation (USA)
Psoriasis and daily low emission phototherapy; effects on disease and vitamin D level
S. Franken1, B. Witte2, S. Pavel3, T. Rustemeyer1
1Department of Dermatology, VUmc, 2Department of Statistics, VUmc, 3Department of Dermatology, LUMC
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 120
1Department of Dermatology, VUmc, 2Department of Statistics, VUmc, 3Department of Dermatology, LUMC
67. Regulation of functional differences between cord blood versus adult periperhal blood innate cells
Y. Bar-Ephraïm, K. Lakeman, A. Baptista, R.E. Mebius
Department Mol. Cell Biology and Immunology, VU University Medical Center
LSBR (Landsteiner Foundation for Blood Transfusion Research)
68. Regulation of immune reactivity in inflammatory bowel disease
A. Zwiers, M. Bajek, G. Bouma*, G. Kraal
Departments of Molecular Cellular Biology and Immunology, and Gastroenterology, VU University Medical Center,
Amsterdam
69. Retinoic acid mediates macrophage differentiation towards a separate lineage
G. Goverse, T. Konijn, R.E. Mebius
Department Mol. Cell Biology and Immunology, VU University Medical Center
NWO
70. Role of fibroblasts and subpopulations macrophages and other cell types in wound healing
J.E. Glim, M. van Walraven, L. Butzelaar, N.J. Paauw1, F.J. Niessen, M. van Egmond, M.M. Ulrich, R.H.J. Beelen1
1Dept. of Molecular Cell Biology and Immunology, VU University Medical Center, 2Vereniging van Samenwerkende
Brandwondencentra Nederland, Beverwijk
Dutch Burn Foundation. MOVE, NIRM
71. Role of immune responses focussing on DC in the pathogenesis of low risk and high risk myelodysplastic syndromes:
implications for immunotherapy
N. Kerkhoff, S. Kordasti, G. Mufti, T.D. de Gruijl, T.M. Westers, H. Bontkes, R. Mebius, A.A. van de Loosdrecht, G.J.
Ossenkoppele
Department Of Hematology, Medical Oncology, Pathology and Molecular Cellular Biology and Immunology, VU Universtity
Medical Center, Amsterdam
72. Screening of new carbohydrate components that prevent pathogen binding to DC-SIGN
M. Perdicchio, M. Ambrosini, W. Unger, Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
Carmusys FP7 EU Marie Curie Network
73. Signaling pathways in homeostasis and function of dendritic cells
M. Beijer, G. Kraal and J.M.M. den Haan
Department of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
NWO-ALW Meervoud to J.M.M. den Haan
74. Skin and mucosal allergies to dental metals
D Rachmawati, J. Muris1) von Blomberg BME, R.J. Scheper, .M.W. van Hoogstraten
Department Of Pathology, VU University Medical Center, Amsterdam; 1) Department dental materials Science, ACTA,
Amsterdam, Department Nat. Educ. Indon., Directorat General of Higher Degree education
Dept. Nat. Educ. Indon., Directorat General of Higher Degree education
75. Spatial dynamics of lectin-carbohydrate interactions
S.J. van Vliet and Y. van Kooyk
Department of Molecular Cellular Biology and Immunology, VU University Medical Center Amsterdam
VENI NWO
76. Surgery induced development of liver metastases
S. Grewal1,2, N. Gül1, R.H.J. Beelen1, J. Bonjer2, M. van Egmond1,2
Departments. of 1Molecular Cell Biology and Immunology, and 2Surgery, VU University Medical Center
NWO, Mozaiek
77. Synergistic effects of TLR ligands and oligosaccharides
M.Boks and Y. van Kooyk
Department Mol Cell biol and Immunol, VU University Medical Center, Amsterdam
Tipharma
78. Targeting dendritic cells with glycosylated liposomes in defense against prostate cancer
A.J. van Beelen1, B. Hangalapura2, T.D. de Gruijl2, Y. van Kooyk1
Departments. of 1Molecular Cell Biology and Immunology, VU University Medical Center, and 2Medical Oncology, VU
University Medical Center
CCA/V-ICI
79. Targeting mMGL-1 and mMGL-2 on murine DCs to modulate immune responses
I. Ouwehand, E. Saeland, Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
VUmc Research Institute: CCA/V-ICI
80. The design of glyco-peptide dendrimers to improve DC targeted antigen presentation
M. Ambrosini, M. Perdicchio, H. Kalay, J.J. Garcia Vallejo, Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
Carmusys FP7 EU Marie Curie Network
81. The development of immuno-competent human skin and oral mucosa equivalents and their use in determining factors
involved in T cell skewing and imprinting
I. Kosten1, S.W. Spiekstra1, B.M.E. von Blomberg2, T. Rustemeyer1, R.J. Scheper2, T.J. De Gruijl2, S. Gibbs1
Departments of 1Dermatology and 2Pathology, VU University Medical Center
VUmc CCA OIO
82. The effect of HIV infection and AZT-3TC-NVP/EVF therapy on vascular and metabolic changes in patienst with HIV
T.Msoka1, Y.Smulders2, M.van Agtmael2, J.Bartlett3, A.M. van Furth4
Departments. of 1Centre for Human Metabolomics, Potchefstroom, SA; 2 VUmc, Amsterdam, The Netherlands; 3 John
Hopkins, Baltimore, USA; 4Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center,
Amsterdam, The Netherlands
83. The generation of tolerance inducing vaccines
J.B. Vos, K. Vrijland, G. Kraal
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 121
Eurostar
84. The host immune response to tuberculous meningitis
D. Visser 1 , R.Solomons2, J.Schoeman2, A.M. van Furth1
Departments. of 1Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center, Amsterdam, The
Netherlands; 2 Tijgerberg Hospital, Cape Town, SA
85. The influence of vitamin A metabolism on immune cell differentiation in the gut
Y. Bar-Ephraïm, G. Goverse, K. Lakeman, R.E. Mebius
Department Of 1Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam
CCA
86. The potential of Fc-alpha-RI as trigger molecule for antibody therapy of cancer
J.E.Bakema1, S. Ganzevles , C. Tuk1, M. van Egmond1,2
Depts. of 1Molecular Cell Biology and Immunology, and 2Surgery, VU University Medical Center
eerste geldstroom
87. The rich focus in tuberculous meningitis: from pathology to mathematics
M. van der Kuip1, M. El-Kebir1, D. Kirschner2, A.M. van Furth1
Departments. of 1Pediatric Infectiology, Immunology and Rheumatology, VU University Medical Center, Amsterdam, The
Netherlands and 2Microbiology and Immunology, The University of Michigan Medical School, Ann Arbor, MI, USA
European Society for Paediatric Infectious Diseases / Wyeth (to MvdK) and the National Institutes of Health HL092853-01
(to DK)
88. The role of galectins in interaction of tumour cells with the immune system
A. Belo, B. Tefsen, I. van Die
Department of Molecular Cell Biology & Immunology, VUmc, Amsterdam
the Portuguese FCT to A. Belo and STW
89. The role of retinoic acid in regulation of gene expression during lymph node formation
D. Schooneman, R.E. Mebius, S.A. van de Pavert
Department Mol. Cell Biology and Immunology, VU University Medical Center
NGI-Horizon
90. To develop a certified diagnostic test for monitoring disease activity in patients with inflammatory bowel disease
(Eurostar project)
A. Budding1, Applied Math2, P. Savelkoul1
Department of 1Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, 2St. MartensLatem-Belgie
91. Translating immune escape and genetic make-up of metastatic tumor cells into therapeutic targets for cervical cancer
E.S. Jordanova 1,2, D. Ferns1, T. De Gruil 3, G.G. Kenter1
Departmenth Gynaecology1 , pathology 2 and immunology 3 VU University Medical Center
92. Vaccine delivery: alternatives for conventional multiple injection vaccines
T. van Es, A.J. van Beelen, W.W.J. Unger, S.C.M. Bruijns and Y. van Kooyk
Department of Molecular Cellular Biology and Immunology, VU University Medical Center Amsterdam
TIPharma
93. Variations in T cell glycosylation direct the interaction with dendritic cells
S.J. van Vliet and Y. van Kooyk
Departments of Molecular Cellular Biology and Immunology, VU University Medical Center, Amsterdam
Mizutani Foundation for Glycosciences
Program 3
AML proteomics
1. Identification of protein profiles of the bone marrow microenvironment associated with apoptosis-resistance of acute
myeloid leukemia
S. Zweegman*, F.L. Kessler*, S.R. Piersma^, T. Pham^, J. Cloos*, G.J. Schuurhuis*, C.R. Jimenez^
* Department of Hematology, VU University Medical Center, the Netherlands, ^Oncoproteomics Laboratory, Department
Medical Oncology, VU University Medical Center, the Netherlands
VUmc Cancer Center Amsterdam
Antibody-based therapy with emphasis on head and neck cancer
2. Antibody derivatives as molecular agents for neoplastic targeting
D. Vugts1, G.W.M. Visser2, A. Vervoort, I. de Roos, G.A.M.S. van Dongen1,2
Department of 1Otolaryngology/Head-Neck Surgery, and 2Radiology & Nuclear Medicine, VU University Medical Center,
Amsterdam
Roche
3. Development of dual-specific nanobodies for cancer diagnosis and treatment
M.J.W.D. Vosjan1, M. Stigter–van Walsum1, G.W.M. Visser2, R. Roovers3, P.M P. van Bergen en Henegouwen3, G.A.M.S.
van Dongen1,2
Department of 1Otolaryngology/Head-Neck Surgery VU University Medical Center, 2Radiology & Nuclear Medicine, VU
University Medical Center, 3Department Cellular Architecture & Dynamics, Utrecht University, and 4Swiss Federal
Institute of Technology, Zürich, Switzerland
NWO/STW 10074
4. Imaging of cell surface antigen with radiolabeled antibodies
D. Vugts, G.A.M.S. van Dongen
Department of Otolaryngology/Head-Neck Surgery VU University Medical Center
Roche
5. The selective targeting of angiogenesis and of tumour stroma
R. Cohen1, R. de Bree1, M. Stigter-van Walsum1, G.W.M. Visser2, D. Neri3, C.R. Leemans1, G.A.M.S. van Dongen1,2
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 122
Department 1Otolaryngology/Head-Neck Surgery, 2Radiology & Nuclear Medicine, VU University Medical Center, 3Swiss
Federal Institute of Technology,Zürich, Switzerland
European commision FP6-LSHC-CT-2003-503233
Brain cancer proteomics
6. Marker identification on brain tumor stem cells from malignant glioma
U. Rajcevic1, S. Bougnaud2, J.C. Knol3, S. Piersma3, M. Sanzay2, T.V. Pham3, P. Nazarov4, N. Podergajs5, TT Lah5, M.
Popović6, T. Strojnik7, R. Kavalar7, C.R. Jimenez3 and S.P. Niclou2
1 Blood Transfusion Center of Slovenia, R&D, Slajmerjeva 6, Ljubljana, Slovenia; 2 Norlux Neuro-oncology, Department of
Oncology, CRP-Santé, Luxembourg; 3 OncoProteomics Laboratory, Department of Medical Oncology, VU University
Medical Center, Amsterdam, The Netherlands; 4 Microarray Center, CRP-Santé, Luxembourg; 5 National Institute of
Biology, Ljubljana, Slovenia; 6 University of Ljubljana, Faculty of Medicine, Inst. of Pathology, Ljubljana, Slovenia; 7
University Medical Center, Departments. of Neurosurgery and Pathology, Maribor, Slovenia
FNR Luxembourg (grant PDR-08-007 to UR) and CRP-Santé Luxembourg.
7. Immunohistochemical validation in human breast cancer of selected protein members of the mouse 45 protein BRCA1
deficiency signature
P. van der Groep1,2, M. Warmoes3, J. Lam3, Y. Smolders2, E. Boven3, S. Rottenburg4, J. Jonkers4, P. van Diest2, E. van
der Wall1, C. Jimenez3
1Division of Internal Medicine and Dermatology and 2Department of Pathology, University Medical Center Utrecht,
Utrecht, 3Oncoproteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam,
4Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
8. Proteomics of mouse BRCA1-deficient and proficient mammary cell line secretomes reveals candidate biomarkers for
non-invasive testing
M. Warmoes¹*, S.W. Lam1*, T.V. Pham1, S.R. Piersma1, S. Rottenberg2, E. Boven1, P. van der Groep3, P.J. van Diest3, P.
Nederlof2, J. Jonkers2, C.R. Jimenez1
1 Oncoproteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, The
Netherlands; 2 Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;
3Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. *Equal contribution.
9. Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with diagnostic and prognostic
value in human breast cancer
M.O. Warmoes¹, J. Jaspers2, T.V. Pham1, S. Piersma1, G. Oudgenoeg1, M.P.G. Massink3, H. Meijers-Heijboer3, Q.
Waisfisz3, S. Rottenberg2, E. Boven1, J. Jonkers2, C.R. Jimenez1
1Oncoproteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, The
Netherlands 2Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
3Department Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands
CenE/Van Lanschot and the VUmc Cancer Center Amsterdam
10. Proteomics of mouse breast cancer models identifies fatty acid metabolism proteins as predictive markers for cisplatin
resistance
M. Warmoes1*, J. Jaspers2*, S. Rottenberg2, B. Kumar2, S. Piersma1, J. Jonkers2*, C.R. Jimenez1*
1OncoProteomics Laboratory, Department Medical Oncology, VU University Medical Center, Amsterdam, The
Netherlands, 2Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
CenE/Van Lanschot and the VUmc Cancer Center Amsterdam
Cervix cancer proteomics
11. Unravelling protein expression changes during HPV-induced transformation using a label-free proteomics approach
C. van Alphen1, T.V. Pham1, S.R. Piersma1, P.J.F. Snijders2, R.D.M. Steenbergen2*, C.R. Jimenez1*
1OncoProteomics Laboratory, Department Medical Oncology, and 2Department Pathology, VUmc Cancer Center
Amsterdam, VU University Medical Center, Amsterdam, The Netherlands. *Shared corresponding authors
VUmc Cancer Center Amsterdam
12. Colorectal cancer tissue spheroids: an in-depth proteomics analysis
U. Rajcevic1, J.C. Knol2, S. Piersma2, S. Bougnaud1, T.V. Pham2, E. Sundlisaeter3, P. Enger3, R. Bjerkvig1,3, S.P. Niclou1
and C.R. Jimenez2
1NorLux Neuro-Oncology, CRP-Santé, Luxembourg, 2OncoProteomics Laboratory, Department Medical Oncology, VU
University Medical Center, Amsterdam; 3Department of Biomedicine, University of Bergen, Bergen, Norway
Fonds National de la Recherche (FNR) of Luxembourg and the VUmc Cancer Center Amsterdam
13. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential
therapeutic target
Van Houdt WJ1, Emmink BL1, Pham TV2, Piersma SR2, Verheem A1, Vries RG3, Fratantoni SA2, Pronk A4, Clevers H3,
Borel Rinkes IH1, Jimenez CR2*, Kranenburg O1* *Shared corresponding authors
1University Medical Center Utrecht, Department of Surgery, Utrecht; 2 OncoProteomics Laboratory, VU University Medical
Center, Amsterdam; 3Hubrecht institute KNAW and University Medical Center Utrecht; 4Diakonessenhuis, Department of
Surgery, Utrecht, The Netherlands
14. Proteomics of colorectal metastase tissue: high expression of serpinB5 (Maspin) is associated with poor survival in stage
III and IV colorectal cancer
Snoeren N1*, Emmink BL1*, Goos JA3, Piersma SR2, de Wit M3, Pham TV2, Belt EJ4, Bril H5, Stockmann HB6, Fijneman
RJ3, Meijer GA3, Jimenez CR2, Kranenburg O1, Borel Rinkes IHM1
1 Department of Surgery, University Medical Center Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands, 2
Department of Medical Oncology VU University Medical Center, De Boelelaan 1117, 1081HV, The Netherlands, 3
Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands, 4
Department of Surgery, VU University Medical Center, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands, 5
Department of Pathology, Kennemer Gasthuis, Boerhaavelaan 22, 2035 RC Haarlem, The Netherlands, 6 Department of
Surgery, Kennemer Gasthuis, Boerhaavelaan 22, 2035 RC Haarlem, The Netherlands
15. The Secretome of Colon Cancer Stem Cells Contains Drug-metabolizing Enzymes
Emmink BL1, Van Houdt WJ1, Pham TV2, Piersma SR2, Verheem A1, Fratantoni SA2, Borel Rinkes IH1, Jimenez CR2,
Kranenburg O1
1 University Medical Center Utrecht, Department of Surgery, Utrecht; 2OncoProteomics Laboratory, VU University Medical
Center, Amsterdam, The Netherlands
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 123
16. Building data bridges and services between biological and medical infrastructures in Europe
R. Voorham, J. van Denderen, J. Beliën, J.W. Boiten, G.A. Meijer
Department of Pathology, VU University Medical Center Amsterdam
EU-KP7
Colorectal cancer proteomics
17. Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal
adenoma-to-carcinoma progression
M. de Wit1,2, C.R. Jimenez2, B. Carvalho1, J.A.M. Belien1, P.M. Delis-van Diemen1, S. Mongera1, S.R. Piersma2, M.
Vikas4, S. Navani4 , F. Pontén3, G.A. Meijer1, R.J.A. Fijneman1
VU University Medical Center, Department of 1Pathology (Tumor Profiling Unit) and 2Medical Oncology (OncoProteomics
Laboratory), De Boelelaan 1117, 1081HV Amsterdam, The Netherlands. 3Uppsala University, The Rudbeck Laboratory,
Department of Genetics and Pathology, SE-751 85 Uppsala, Sweden. 4Lab Surg Path, Mumbai, India.
Phillips research and the VUmc Cancer Center Amsterdam
18. Chromatin-associated proteins in colorectal adenoma and carcinoma tissues
J.C. Knol1, J. Albrethsen1, T.V. Pham1, S.R. Piersma1, S. Mongera2, B. Carvalho2, M. de Wit2, R.J.A. Fijneman2, G.A.
Meijer2, and C.R. Jimenez1
1OncoProteomics Laboratory, Department Medical Oncology, 2Department Pathology, VU University Medical Center,
Amsterdam. The Netherlands
VUmc-Cancer Center Amsterdam
19. Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal
cancer
R.J.A. Fijneman1, M. de Wit2, M. Pourghiasian1,2, S. Piersma2, M.O. Warmoes2, M. Lavaei2, P.M. van Diemen1, C. Piso1,
E.C. Robanus-Maandag3, R. Smits4, R. Fodde4, V.W.M. van Hinsbergh2,5, G.A. Meijer1 and C.R. Jimenez2
1Department of Pathology, 2Department of Medical Oncology, 5Department of Physiology, VU University Medical Center,
3Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands 4 Department of Pathology,
Josephine Nefkens Institute, Erasmus MC, Rotterdam, the Netherlands
Aegon International Scholarship in Oncology, and by the VUmc-Cancer Center Amsterdam
20. Stool proteomics reveals novel candidate biomarkers for colorectal cancer screening
L.J.W. Bosch1*, M. de Wit2*, G. Oudgenoeg2, A.C. Hiemstra1, S. Mongera1, S.R. Piersma2, T.V. Pham2, J.S. Terhaar sive
Droste3, F.A. Oort3, S.T. van Turenhout3, I. Ben Larbi3, C.J.J. Mulder3, B. Carvalho1, C.R. Jimenez2, R.J.A. Fijneman1,
G.A. Meijer1 *These authors have contributed equally to this work.
1Department of Pathology, 2Medical Oncology and 3Gastroenterology and Hepatology, VU University Medical Center,
Amsterdam, The Netherlands
VUmc Cancer Center Amsterdam and CTMM-DeCoDe
Data mining
21. Computational analysis of phosphoproteomics data
T.V. Pham, S.R. Piersma, J. Knol and C.R. Jimenez
OncoProteomics Laboratory, Department of Medical Oncology, VUmc-Cancer Center Amsterdam, VU University Medical
Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands
Avanti
Highthroughput serum peptide mass profiling for pattern diagnostics
22. Mass spectrometric serum peptide profiling for drug response prediction: signature validation
T.V. Pham1, J.C. Knol1, J.S.W. Lind2, H.M.W. Verheul1, E.F. Smit2, C.R. Jimenez1
1Department of Medical Oncology, VU University Medical Center, 2Department of Pulmonary Diseases, VU University
Medical Center
VUmc Cancer Center Amsterdam and Avanti
23. Serum peptide profiling in non-small cell lung cancer patients treated with sorafenib and erlotinib: signature discovery
T.V. Pham1, J.S.W. Lind2, J.C. Knol1, A.-M.C. Dingemans3, H.J.M. Groen4, P.E. Postmus1, E.F. Smit2*, C.R. Jimenez1*
Departments of 1Medical Oncology and 2Pulmonary Diseases VU University Medical Center Amsterdam, 3Maastricht
University Medical Center and 4University Medical Center Groningen
VUmc Cancer Center Amsterdam
Imaging: Brain tumours
24. Assessment of blood-brain barrier function in pharmacoresistant patients with tumor-related epilepsy
F. Froklage1, R.A. Voskuyl7, J.J. Heimans1, N.H.M. Hendrikse3,4, J.C. Baayen2, R.M.C. Debets6, D. Velis5, A.A.
Lammertsma3, J.C. Reijneveld1,5,
Departments of 1Neurology, 2Neurosurgery and 3Radiology & Nuclear Medicine, 4. Clinical Pharmacology and Pharmacy,
VU University Medical Center, Department of 5Neurology, Academic Medical Center, Amsterdam, Departments of
5Neurology and 6Clinical Neurophysiology, Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, and
7Department of Pharmacology, Leiden/Amsterdam Center for Human Drug Research (L/A CHDR), Leiden
Europese Unie Framework Program 7 (FP7 EURIPIDES project)
Imaging: Colorectal tumours
25. Molecular imaging of early stage disease
M. de Wit, R. Fijneman, M. van der Wiel, R. Lamerichs, C. Jimenez, J. Stoker, G.A. Meijer
Department Of Pathology, VU University Medical Center, Amsterdam
CTMM
Imaging: Generic
26. Effect of anti-CD44 (RO5429083) and the bispecific antibody (A2V) treatment on tumor uptake of 11C-docetaxel in preclinical xenograft studies
C.F.M. Molthoff1, I. de Greeuw1, M.Verlaan1, R. Bergstra1, A.A. Lammertsma1
Department of 1Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam
Roche Diagnostics, Germany
27. FLT- and FDG-PET imaging to support dose-finding for the CD-44 (RO5429083) program in pre- clinical xenograft studies
C.F.M. Molthoff1, I. de Greeuw1, M.Verlaan1, R. Bergstra1, A.A. Lammertsma1
Department of 1Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam
Roche Diagnostics, Germany
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 124
28. In vivo imaging of Epstein Barr Virus Activation by cytolytic antiviral therapy in nasopharyngeal carcinoma cell lines and
xenograft models
A.E. Greijer1, Z. Novalic1, M. Verlaan2, J. Eersels2, C.F.M. Molthoff2, J.M. Middeldorp1
Departments. of 1Pathology and 2Radiology & Nuclear Medicine & PET Research, VU University Medical Center,
Amsterdam
ZonMW2010, KWF VU 2010-4809
29. Quantitative imaging in cancer: connecting cellular processes with therapy: Data and Image Analysis (WP4)
L.L. Hoyng, M. Yaqub, F. van Velden, R. Boellaard
Department Of Radiology & Nuclear Medicine, Vu University Medical Center, Amsterdam
IMI EU project QuicConcept (EORTC, CR-UK, EFPIA)
30. Technical validation of DW-MRI, FLT and ICMT-PET as read-outs of proliferation and apoptosis in drug development
V. Frings1, L. Hoyng1, JPA Kuijer2, IC Pieters1, R Boellaard1, EF Smit3, W Menke-van den Houven v Oordt4, OS Hoekstra1
Department of 1Radiology & Nuclear Medicine, 2Physics & Medical Technology, 3Pulmonary Oncology, 4Medical
Oncology, VU University Medical Center, Amsterdam
IMI EU project QuicConcept (EORTC, CR-UK, EFPIA)
31. Towards personalized treatment planning of chemotherapy: 11C-docetaxel PET studies in lung cancer patients
A.A.M. van der Veldt1, M. Lubberink1, N.H. Hendrikse1,2, E.F. Smit3, A.A. Lammertsma1
Departments of 1Radiology & Nuclear Medicine, 2Clinical Pharmacology and Pharmacy, 3Pulmonology, VU University
Medical Center, Amsterdam
CCA
32. Towards targeted therapy: quantitative imaging with PET and long lived isotopes
N. Makris, R. Boellaard, M.C. Huisman, A.A. Lammertsma
Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam
Philips Healthcare
33. Validation of imaging response criteria in oncology: focus on FDG PET-CT
S.N.F. Rizvi, A. Vincent, R. Boellaard, H. van Tinteren, O.S. Hoekstra
Department Nucl Med & PET research, VU University Medical Center, and Department of Biostatistics, Neth Cancer
Institute, Amsterdam
2 NIBIB projects funded by Rad Soc North America (RSNA)
Imaging: Haematological malignancies
34. Immuno PET to personalize therapy in malignant lymphoma
Y Jauw1, JM Zijlstra1, GAMS van Dongen2, MC Huisman2, R Boellaard2, D Vugts2, D de Jong3, OS Hoekstra2, S
Zweegman1.
Departments of 1Haematology, 2Radiology & Nuclear Medicine, 3Pathology, VUmc
KWF fellowship
35. Positron Emission Tomography (PET) for detection of histologic transformation of indolent non-Hodgkin’s Lymphoma
M.J. Wondergem1, J.M. Zijlstra1, S.A.G.M. Cillessen2, J.J. Oudejans2, O.S. Hoekstra3, M.E.D. Chamuleau1, S. Zweegman1,
P.C. Huijgens1
Department of Hematology1, Pathology2, Radiology & Nuclear medicine, VU University Medical Center
de Vilder Stichting
Imaging: Lung Cancer
36. Quantification and tumor delineation with PET
I. Nissen1, FH van Velden1, M Yaqub1, OS Hoekstra1, EF Smit2, R Boellaard1
Departments of 1Radiology & Nuclear Medicine & 2Pulmonology, VU University Medical Center
CTMM AirForce
Imaging: Paediatric tumours
37. Development of pediatric brain tumor. Diffuse intrinxic pontine glioma (DIPG) models for improvement of imaging and
therapy
P. Wesseling1, T. Würdinger2, E. Hulleman3, G.J. Kaspers3
Departments of 1pathology, 2Neurooncology Research Group, 3Pediatric Oncology/ Hematology, VU University Medical
Center, 4VU University RNC, 5Massachusetts General Hospital and Harvard Medical School, Boston, MA
Stichting Kika
Imaging: Prostate cancer
38. Towards personalized therapy in prostate cancer: the role of imaging (preclinical and clinical studies)
D. Oprea-Lager, A.J.M. van den Eertwegh, R.J.A. van Moorselaar, W.R. Gerritsen, A.A. Geldof, R. Boellaard, O.S. Hoekstra
Departments Radiology and Nuclear Medicine, Medical Oncology, Urology, VU University Medical Center, Amsterdam
Imaging: Rheumatoid diseases
39. Detection of subclinical synovitis with (R)-11C-PK11195 positron emission tomography in Rheumatoid Arthritis patients
in DAS clinical remission
Y.Y.J. Gent, A.E. Voskuyl1, N. Ahmadi2, R.W. Kloet 2, O.S. Hoekstra2, A.A. Lammertsma2, B.A.C. Dijkmans1, C. van
Kuijk2, C.J. van der Lakenl1
Departments of 1Rheumatology, 2Radiology & Nuclear Medicine, VU University Medical Center
40. Development of imaging markers, using PET(-CT), for early detection of RA and therapy monitoring
Y.Y.J. Gent1, K. Weijers1, I. de Greeuw2, M. Verlaan2, B. Windhorst2, A.A. Lammertsma2, O.S. Hoekstra2, B.A.C.
Dijkmans1, G. Jansen1, C.F.M. Molthoff2, C.J. van der Laken1
Departments. of 1Rheumatology, 2Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam
41. Imaging of ankylosing spondylitis by PET-CT
S.T. Bruijnen1 ,M.A.C. van der Weijden1, N.Hoetjes2, A.E. Voskuyl1, O.S. Hoekstra2, R. Boellaard2, J.P. Klein2, B.A.C.
Dijkmans1, I. E. van der Horst-Bruinsma1, C. J. Van der Laken1
Departments of 1Rheumatology, 2Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam
Immuno-PET, TKI-PET and optical imaging for diagnosis and therapy planning
42. Design and production of anti-body drug conjugates (ADC), anti-body tracer conjugates (ATC) and other disease-targeted
devices
D. Waalboer, G.A.M.S. van Dongen
Department of Otolaryngology/Head-Neck Surgery VU University Medical Center
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 125
LinXis
43. FLT PET and DW MRI as markers of proliferation: technical validation
1V Frings, 1IC Pieters-van den Bos, 2JPA Kuijer, 1OS Hoekstra, 2EF Smit, 3CW Menke-van den Houven v Oordt, 1R
Boellaard
Departments of 1Radiology & Nuclear Medicine, 2Physics & Medical Technology, 3Pulmonology, 4Medical Oncology,
VUmc
EU IMI project Quic-Concept
44. PET tracers for (chemo)radiation of lung and head and neck cancer
A. Poot1, N.H. Hendrikse2,3, G.A.M.S. van Dongen1,2
Departments. of 1Otolaryngology/Head-Neck Surgery, 2Radiology & Nuclear Medicine and 3Clinical Pharmacology and
Pharmacy, VU University Medical Center,
CTMM Air Force
45. Pharmacokinetic modelling of PET tracers in oncology
E Verwer, AA Lammertsma, EF Smit, OS Hoekstra, R Boellaard
Departments of Pulmonology, Radiology & Nuclear Medicine, VUmc
CTMM AiRForce
46. Phenotyping thyroid cancer using PET imaging
1J Kist, 2B de Keizer, 3OS Hoekstra, 3M van der Vlies, 3A van Lingen, 3MC Huisman, 4W Vogel
Department of 1Surgery, 2Nuclear Medicine UMCU, 3Radiology & Nuclear Medicine VUmc, 4Nuclear Medicine AvL/NKI
KWF
47. Profiling responders in antibody therapies
vacature, L. van der Laken, G.A.M.S. van Dongen
Department of Otolaryngology/Head-Neck Surgery, Radiology & Nuclear Medicine, VU University Medical Center
European Community 7th Framework Project
48. SelecTive aRmed Antibodies as Drugs Against cancer
vacature, G.A.M.S. van Dongen
Department of Otolaryngology/Head-Neck Surgery VU University Medical Center
European Communitu Collaborative project
49. The development of radiolabeled tyrosine kinase inhibitors for PET imaging
P. Slobbe, G.A.M.S. van Dongen
Department of Otolaryngology/Head-Neck Surgery, Radiology & Nuclear Medinie, VU University Medical Center,
Amsterdam
VUmc Cancer Center Amsterdam
50. Validation of 11C-Erlotinib PETto personalize NSCLC therapy
I Bahce1, EF Smit1, Yaqub M2, AA Lammertsma2, NH Hendrikse2,3
Departments of 1Pulmonology, 2Radiology & Nuclear Medicine, 3Clinical Pharmacology and Pharmacy, VUmc
KWF
51. Validation of 11C-sorafenib PET to stratify NSCLC patients for therapy
W Mellema1, E Verwer2, R Boellaard2, AA Lammertsma2, OS Hoekstra2, EF Smit1
Departments of 1Pulmonology, 2Radiology & Nuclear Medicine, VUmc
Improvement of the diagnosis of head and neck squamous cell carcinoma (HNSCC)
52. Detection of residual neck disease after chemoradiation by PET-CT
S. Faraj-Hakim1, O.S. Hoekstra2, R. de Bree3
Department of 1Otolaryngology/Head-Neck Surgery, 2Otolaryngology/Head and Neck Surgery, VU University Medical
Center, Amsterdam
53. Development and validation of DW-MRI in head&neck oncology
DP Noij1, R de Bree2, OS Hoekstra1, IC Pieters-van den Bos1, EFI Comans1, JA Castelijns2
Departments of Radiology & Nuclear Medicine, Otolaryngology/Head and Neck Surgery, VUmc
54. Evaluation and prediction of response
L. van der Putten1, O.S. Hoekstra2, C.R. Leemans1, R. de Bree1
Departments. of 1Otolaryngology/Head-Neck Surgery, 2Radiology & Nuclear Medicine, 3Oral and Maxillofacial Surgery,
4Pathology, VU University Medical Center
ZonMw and CCA 945-04-311, 80-82305-98-08106
55. Improvement of the sentinel node procedure in head and neck cancer by PET-CT lymfoscintigraphy, optical techniques
and minimal invasive surgery. Molecular targeting of intracellular proteins in cancer
Heuveling D1, G.A.M.S. van Dongen1,2, A. van Schie2, O.S. Hoekstra2, C.R. Leemans1, R. de Bree1
Department 1Otolaryngology/Head and Neck Surgery, 2Radiology & Nuclear Medicine, VU University Medical Center,
Amsterdam
56. Molecular targeting of intracellular proteins in cancer
D. Heuveling1, G.A.M.S. van Dongen1,2, C.R. Leemans1, R. de Bree1
Department of 1Otolaryngology/Head-Neck Surgery, 2Radiology & Nuclear Medicine, VU University Medical Center,
Amsterdam
57. Response evaluation after chemoradiation for advanced oropharyngeal cancer using PET-CT and MRI
C.S. Schouten1, J.A. Castelijns2, O.S. Hoekstra2, R. de Bree1
Department of 1Otolaryngology/Head-Neck Surgery, 2Radiology & Nuclear Medicine, VU University Medical Center,
Amsterdam
ZonMw 171201005
58. Ultrasound guided fine needle aspiration cytology and sentinel node biopsy in the detection of occult lymph node
metastases of early oral and oropharyngeal cancer
G.B. Flach, J. Castelijns, O.S. Hoekstra, A. van Schie, E. Bloemena, G.A.M.S. van Dongen, I. van der Waal, C.R. Leemans, R.
de Bree
Department Otolaryngology/Head and Neck Surgery, Radiology & Nuclear Medicine, VU University Medical Center,
Amsterdam
ZonMw 80-82305-98-08106
Lung cancer proteomics
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 126
59. Exploration of sputum to develop protein-based assays for early detection, prognosis and drug response of lung cancer
T.B.M. Schaaij-Visser1, B. Colak1, J. Hubers2, E.F. Smit3, (Erik) F.B.J.M. Thunnissen2, C.R. Jimenez1
1 OncoProteomics Laboratory, Department of Medical Oncology; 2 Department of Pathology, 3Department Pulmonology,
VU University Medical Center, Amsterdam, The Netherlands
VUmc Cancer Center Amsterdam
60. Novel candidate biomarkers for cisplatin response prediction and monitoring in NSCLC
T.B.M. Schaaij-Visser1, N. Proost2, R. Nagel3, S.R. Piersma1, T.V. Pham1, R.H. Brakenhoff3, F.B.J.M. Thunissen4, E.F.
Smit5, A. Berns2, C.R. Jimenez1
1OncoProteomics Laboratory, Department of Medical Oncology, 2Division of Molecular Genetics and Centre for
Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Department of
Otolaryngology/Head and Neck surgery, 4Department Pathology, 5Department Pulmonology, VU University Medical
Center, Amsterdam, The Netherlands
CTMM Airforce
Mining high dimensional proteomics data
61. Strategies for analyzing spectral count data in label-free tandem mass spectrometry-based proteomics
T.V. Pham, J.C. Knol, S.R. Piersma, C.R. Jimenez
OncoProteomics Laboratory, Department of Medical Oncology, VUmc-Cancer Center Amsterdam, VU University Medical
Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands
VUmc Cancer Center Amsterdam and Avanti
MKZ
62. Leukoplakie, histopathological, epidemiological and clinical analysis
E. Brouns, E. Bloemena
Department Of Pathology, VU University Medical Center
MKZ
Retinoblastoma: imaging
63. Clinical and experimental high resolution ocular MR imaging: towards improved detection of retinoblastoma tumor
extent
P. de Graaf1, P. van der Valk2, A.C. Moll3, S.M. Imhof7, A.Y.N. Schouten-van Meeteren4, D.L. Knol5, P.W.J. Pouwels6, J.A.
Castelijns1
Departments of Radiology & Nuclear Medicine1, Pathology2, Ophthalmology 3 and Epidemiology and Biostatistics5,
Physics and Medical Technology6, VU University Medical Center, Department of Pediatric Oncology4, Emma Children’s
Hospital, Academic Medical Center, Amsterdam, and Department of Ophthalmology, University Medical Center Utrecht
Grant ZonMw-AGIKO 2006, ODAS Foundation, National Foundation for the Blind and Visually Impaired, Blindenhulp
Foundation, Dutch Eye Fund (Grant 2004-23)
64. Diagnosis of vital tumor tissue by OCT and MRI in retinoblastoma patients
De Boer1, J.F., De Graaf P 2. Moll A.C.3
1Institute LaserLaB Amsterdam, Department of Physics, 2 Department of Radiology & Nuclear Medicine, 3 Department of
Ophthalmology
KIKA
65. Imaging of retinoblastoma: advanced MRI techniques and associated abnormalities
F. Rodjan1, P. de Graaf1, A.C. Moll2, P.J.W. Pouwels3, J.A. Castelijns1
1Department of Radiology & Nuclear Medicine, 2 Department of Ophthalmology, 3 Physics & Medical Technology, VU
University Medical Center, Amsterdam, The Netherlands
ODAS Foundation
66. Multicenter implementation of MR imaging studies in children with retinoblastoma for assessment of response to
chemotherapy and early detection of pineoblastoma and cranio-facial second primary malignancies
M.C. de Jong1, P. de Graaf1, P. van der Valk2, W.A. Kors 3, P.W.J. Pouwels4, A.C. Moll5, J.A. Castelijns1
Departments of 1 Radiology & Nuclear Medicine,, 2 Pathology, 3 Pediatric Oncology, 4 Physics & Medical Technology, 5
Ophthalmology, VU University Medical Center, Amsterdam, The Netherlands
ODAS Foundation
67. Radiogenomics in retinoblastoma patients
M.C. de Jong1, B.M. Mol2, A.C. Moll3, J.C. Dorsman1, J.A. Castelijns1, P. de Graaf1
Departments of 1 Radiology & Nuclear Medicine, 2Clinical Genetics, 3Opthalmology, VU University Medical Center,
Amsterdam, The Netherlands
ODAS Foundation
68. Trilateral retinoblastoma: meta-analysis and cost-effectiveness of brain screening
M.C. de Jong1, P. de Graaf1, J.A. Castelijns1, A. Moll2
1Department of Radiology & Nuclear Medicine, 2 Department of Ophthalmology, VU University Medical Center,
Amsterdam, The Netherlands
ODAS Foundation
Signaling pathway proteomics
69. Global profiling of endogenous phosphorylation events by titanium dioxide based phosphoproteomics for signaling
pathway and drug perturbation studies in cancer
S.R. Piersma1, B.K. Sampadi1, T.V. Pham1, J.C. Knol1 and C.R. Jimenez1
1OncoProteomics Laboratory, Department Medical Oncology, VU University medical center, Amsterdam, The Netherlands
VUmc Cancer Center Amsterdam.
70. Phosphoproteomics of glioblastoma cells: ΔEGFR targets and erlotinib effects
J.C. van der Mijn1*, R. Piersma2*, Thang V. Pham3, Tom Wurdinger3, Henk Verheul1*, and Connie R. Jimenez2*
1Angiogenisis Laboratory, 2OncoProteomics Laboratory, Department of Medical Oncology, 3Department Neurosurgery,
VU University Medical Center, Amsterdam, the Netherlands. *Equal contribution.
VUmc Cancer Center Amsterdam and VHS
71. Phosphotyrosine immunoprecipitation for phosphotyrosine-based phosphoproteomics
S.R. Piersma1, R. de Haas2, K. van der Mijn2, J.C.. Knol1, T.V. Pham1, H. Broxterman2, H.M.W. Verheul2 and C.R.
Jimenez1
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 127
1OncoProteomics Laboratory, 2Angiogenesis Laboratory, Department of Medical Oncology, VU University Medical Center,
Amsterdam, the Netherlands
VUmc Cancer Center Amsterdam
Targeted proteomics strategies for biomarker discovery
72. Novel identified proteins in cancer cell derived exosomes can change the behavior of healthy prostate cells
I.V. Bijnsdorp1, M. Lavaei2, S.R. Piersma2, A.A. Geldof1, C. Jimenez2
1. Department of Urology;2. OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center,
Amsterdam, The Netherlands
VUmc Cancer Center Amsterdam
73. Proteomics of exosomes secreted by cancer cell lines and primary cells reveals oncogenic signaling and biomarker
potential
M. de Wit1, R.J.A. Fijneman2 , M. Lavaei1, D.M. Fluitsma3, J.C. Knol1, S.R. Piersma1, T.V. Pham1, R. Steenbergen2, G.A.
Meijer2, H.M.W. Verheul1, M. Pegtel2, C.R. Jimenez1
1Department Pathology, 2Department Medical Oncology, 3Department Mol. Cell. Biology and Immunology, VU University
Medical Center
VUmc-Cancer Center Amsterdam
74. Secretome proteomics of breast and colon cancer cell lines: Carcinoma origin dictates differential functional macrophage
phenotype
Collaboration OncoProteomics lab (C. Jimenez), Pathology (R. Fijneman) and MCBI/Surgery (M. van Egmond)
Collaboration OncoProteomics lab, Pathology and MCBI/Surgery, VU Univeristy Medical Center, Amsterdam
75. Protein Composition of exosomes yields new insights into the endosomal-exosomal pathway of B cells during infection
and malignant transformation
Koppers-Lalic D1,Knol J2, Pham TV2, Verweij F1, Piersma S2, Middeldorp J1, Jimenez CR2, Pegtel M1
1Department of Pathology, VUmc, 2OncoProteomics Laboratory, Department Medical Oncology, VU University Medical
Center
Other projects
76. A predictive role for noncancerous prostate cells; low connexin-26 expression in radical prostatectomy tissues predicts
metastasis
IV Bijnsdorp1, L Rozendaal2, RJA van Moorselaar1, AA Geldof1
1. Department of Urology, VU University Medical Center, Amsterdam, 2. Department of Pathology
Stichting W. Pon
77. Advanced glioma and correlation with histological and molecular characteristics
P. de Witt Hamer1, O. Hoekstra2, R. Boellaard2, F. Barkhof2, P. Wesseling3, J.C. Reijneveld4
Department of 1Neurosurgery, 2Radiology & Nuclear Medicine, 3Pathology, 4Neurology, VU University Medical Center
Amsterdam
VUmc CCA
78. Advanced medical imaging with PET and MRI to personalize therapy in prostate cancer patients
D. Oprea-Lager1, R. Reinhard1, R.J.A. van Moorselaar2, A.J.M. van den Eertwegh3, I. Bijnsdorp2, A.A. Geldof1,2, W.R.
Gerritsen4, R. Boellaard, O.S. Hoekstra
Departments of 1Radiology& Nuclear Medicine, 2Urology, 3Medical Oncology Vumc; Department of 4Medical Oncology
UMCN
79. Allergenicity of palladium, development of new diagnostic techniques
J. Muris1, C. van Kleverlaan1, M. von Blomberg2, I. van Hoogstraten2, R. Scheper2, T. Rustemeyer3, A. Feilzer1
1Department of Dental Materials Science, ACTA, 2Department of Pathology, VUMC, 3Department of Dermatology, VUmc
80. Assessing the need for isolation in a single room of patients colonized with highly resistant microorganisms
C.M.J.E. Vandenbroucke-Grauls, J.A.J.W. Kluytmans
Department of Medical Microbiology and Infection Control, VU University Medical Center
ZonMw
81. B cells in the preclinical phase of rheumatoid arthritis
S. Ozturk, C.L. Verweij
Department of Pathology, VU University Medical Center Amsterdam
82. Blood platelet-based diagnostics
P. Schellen1,2, M. Grabowska1,2, J. Nilsson2, Noske1,2, T. Wurdinger1,2
Departments of 1Neurosurgery, 2Neuro-oncology Research Group, VU University Medical Center, Amsterdam
CCA/V-ICI, NWO Pre-Seed, NWO PoC, NWO VIDI
83. Bone disease in Multiple Myeloma
J.C. Regelink1, P. Sonneveld2, I.C. Pieters-van den Bos3, P.G. Raijmakers3, M. van Duin2, O.S. Hoekstra3, J.M. Zijlstra1,
P.C. Huijgens1, S. Zweegman1
Department of hematology1, VU University Medical Center, Department of Hematology2, Erasmus Medical Center
Rotterdam, Department of Radiology & Nuclear Medicine3 VU University Medical Center
84. Carbapenemase-producing Enterobacteriaceae in The Netherlands: development of phenotypical and molecular assays
for detection and evaluation of the prevalence, risk factors and molecular epidemiology
J.A.J.W. Kluytmans, C.M.J.E. Vandenbroucke-Grauls
Department of Medical Microbiology and Infection Control, VU University Medical Center
ZonMw
85. Cervix-care: biomarkers-based triage diagnosics for HPV positive women to detect cervical cancer
C.J.L.M. Meijer
Department of Pathology, VU University Medical Center Amsterdam
Eurostrats
86. Characterization of salivary gland tumors
H. Matse, E. Bloemena
Department of Pathology, VU University Medical Center Amsterdam
ACTA IOT
87. Characterizing genetic alterations in diffuse lage B-cell lymphomas occuring in immune provileged sites
M.G.M. Roemer, B. Chapuy, M. Shipp, D. de Jong
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 128
Department Of Pathology, VU University Medical Center and Dana-Farber Cancer Institute, Harvard Medical School
88. Cross-regulation between TNF and IFN in rheumatidc arthritis
T.D. de Jong1, S. de Ridder1, J. Beliën1, P. Welsing2, J. Luime3. C. Verweij1
1Department of Pathology, 2UMCU, 3Emc
CTMM Reumafonds
89. Crypton: A genome-based generalized strategy to activate cryptic antibiotic biosynthesis gene clusters in
Actinomycetales
C.M.J.E. Vandenbroucke-Grauls, W. Bitter
Department of Medical Microbiology and Infection Control, VU University Medical Center (samenwerking met RUG)
STW Genbiotics grant
90. Development and validation of PET image analyis methodology
L. Hoyng, O.S. Hoekstra, R. Boellaard
Department of Radiology & Nuclear Medicine VUmc, Department of Biostatistics AvL/NKI
91. Development validation of predictive PET tracers in patients with colorectal cancer liver metastases
J.A.C.M. Goos1,2, R. Fijneman2, J. Verbeek1, M.P. van den Tol3, H. Verheul4, A.D. Windhorst1, A.A. Geldof1, O.S.
Hoekstra1, G.A. Meijer2
Departments of 1Radiology & Nuclear medicine, 2Pathology, 3Surgery, 4Medical Oncology, Vumc
CTMM DeCoDe
92. Diagnostic monitoring of NPC and building a second center of expertise in Indonesia
Gondowiyardjo S1, L. Adham1, A.N. Kurniawan1, J.M. Middeldorp2
1Univ Indonesia, Jakarta, 2Department of Pathology, VU University Medical Center, Amsterdam
KWF
93. Dutch National Tissue Portal
C. Steegers, F. van Kemenade, G.A. Meijer
Department of Pathology, VU University Medical Center Amsterdam
BBMRI-NL
94. EBV markers in CLL cases from Spain
De Sanjose, J.M. Middeldorp
Department Of Pathology, VU University Medical Center Amsterdam
95. ESBL-producing Enterobacteriaceae in The Netherlands and Egypt: a molecular comparison of human and poultry isolates
C.M.J.E. Vandenbroucke-Grauls, N. al Naiemi, P.H.M. Savelkoul
Department Medical Microbiology and Infection Control, VU University Medical Center Amsterdam
Egyptische Ministerie van Volksgezondheid
96. EU IMI project Quic-ConceptDevelopment and validation of perfusion measurement imaging methodology
G. Kramer1, M. Yaqub1, A.J. de Langen2, E.F. Smit2, O.S. Hoekstra1, R. Boellaard1
Department of 1Radiology & Nuclear medicine, and 2Pulmonology, VU University Medical Center Amsterdam
97. Genomic biomarkers to predict development of RA (VERA, ERA) and therapy responsiveness (ESRA)
J. Lübbers1, E. Mantel, A.E. Voskuyl, R. Out, C. Verweij
1Department Of Pathology, 2Department Of Rheumatology, VU University Medical Center, Amsterdam, Flexgen
CTMM
98. ICT and data analysis
J. Beliën, G.A. Meijer
Department Of Pathology, VU University Medical Center, Amsterdam
CTMM
99. Identification of clinically relevant genetic aberrations in pediatric glioneuronal tumors
B. Ylstra1, P. Wesseling1, E. Aronica2, Schouten2
Department Of Pathology, 1VU University Medical Center Amsterdam, 2Amsterdam Medical Center
Edli Foundation
100. Identification of differentially expressed genes in CML stem cells
J.J.W.M. Janssen, W. Pouwels, B. van Kuijk, A. Zevenbergen, G.J. Schuurhuis, G.J. Ossenkoppele
Department of Hematology, VU University Medical Center
Stichting Vanderes
101. Immunogenetics and disease profiling of Chronic inflammatory, autoimmune and Infectious diseases
J.B.A. Crusius1, I.E. van der Horst-Bruinsma2, S. Verweij, M. Sanders, G. van Well, V. Smelov, N. de Vries3, G.J.
Wolbink4,5, A.A. van Bodegraven6, B.M.J. Uitdehaag7, C.H. Polman8, M. van Furth9, C. Verweij, A.S. Peña1, S.A. Morré1
1Laboratory of Immunogenetics, Department Medical Microbiology and Infection Control, VU University Medical Center,
2Department Rheumatology VU University Medical Center, 3Department Rheumatology, Academic Medical Center,
4Reade/Jan van Breemen Institute, 5Sanquin Research, 6Department Gastroenterology VU University Medical Center,
7Department Epidemiology & Biostatistics, 8Department Neurology, VU University Medical Center, Amsterdam.
9Pediatrics, VUmc. 10Department Pathology, VUmc
amongst others NGI (2011), and 2x NIH (2011). EU FPs: IBD-CHIP and EpiGenChlamydia ended in 2011
102. Improvement of the diagnosis of head and neck squamous cell carcinoma (HNSCC)
R. de Bree1, L. van der Putten1, A. Senft1, G. Flach1 , D.A. Heuveling1, S. Faraj-Hakim1, C.S. Schouten, 1 I. van der
Waal2,, H. Karakazoglu2, E.F.I. Comans3, A. Van Schie3, O.S. Hoekstra3, I. Pieters-Van den Bos3, J.A. Castelijns3, E.
Bloemena4, R.N.P.M. Rinkel1, C.R. Leemans1
Departments. of 1Otolaryngology/Head-Neck Surgery, 2Oral and Maxillofacial Surgery, 3Radiology and Nuclear Medicine,
and 4Pathology, VU University Medical Center, Amsterdam
103. Involvement of miRNAs in gastric cancer
G.A. Meijer
Department of Pathology, VU University Medical Center Amsterdam
FCT
104. Laboratory tests in primary colorectal cancer
B. Carvalho1, M. van Engeland2, W. Corver3, B. Janssen4, W. van Criekinge5, G.A. Meijer1
Department Of 1Pathology, VU University Medical Center, Amsterdam, 2MUMC, 3LUMC, 4ServiceXS, MDXHEalth, Univ.
Gent
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 129
CTMM
105. Measuring intraprostatic androgen concentrations using LC-MS/MS: from bench to bedside
T. van der Sluis1, H.N. Bui2, IV Bijnsdorp1, J.J.L. Jacobs1, A.A. Geldof1, M.A. Meuleman1, M.A. Blankenstein, L2.
Rozendaal3, A. Heijboer2, R.J.A. van Moorselaar1 and A. Vis1
Department of Urology1, Clinical Chemistry2 and Pathology3 VU University Medical Center, Amsterdam
106. Medical technology assessment
C. Uyl, V. Coupé, G.A. Meijer
Department Of Pathology, VU University Medical Center, Amsterdam
CTMM
107. Metastatic colorectal molecular laboratory tests
B. Ylstra1, B. Carvalho1, M. van Engeland2, W. Corver3, B. Janssen4, W. van Criekinge5, G.A. Meijer1
Department Of 1Pathology, VU University Medical Center, Amsterdam, 2MUMC, 3LUMC, 4ServiceXS, MDXHEalth, Univ.
Gent
CTMM
108. miR-200a inhibits meningioma cell migration and tumor growth by directly targeting non-muscle heavy chain Iib
O. Senol1, T.B.M. Schaaij-Visser2, T.V. Pham2, S.R. Piersma2, S.M. Peerdeman3, T. Ströbel4, C.R. Jimenez2 and O.
Saydam,1,5
1Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston,
Massachusetts, USA, 2 OncoProteomics Laboratory, Department of Medical Oncology, VU University Medical Center,
3Department of Neurosurgery, VU University Medical Center, Amsterdam, The Netherlands, 4Institute of Neurology,
Medical University of Vienna, 5Molecular Neuro-Oncology Research Unit, Department of Pediatrics, Medical University of
Vienna, Vienna, Austria
109. Multimodal imaging of orthotopic tumors: validation study
C.F.M. Molthoff1, A. Avan2, E. Giovanetti2, T. Lagerweij3, R. Bergstra1, I. de Greeuw1, G.J. Peters2, T. Würdinger3, D.
Fuchs4, P. Trochet4, J. Jose4
Departments. of 1Radiology & Nuclear Medicine, 2Medical Oncology, 3Neuro-oncology Research Group, VU University
Medical Center, Amsterdam and 4VisualSonics Europe, Amsterdam
110. Multiplex NPC families in Taiwan
A. Hildesheim2, J.M. Middeldorp1
1Department Of Pathology, VU University Medical Center Amsterdam, 2 NCI-NIH, USA
RTI, USA
111. Nucleotide variations in the human genome. Suitable markers for tissue identification and allelic instability testing
M. Hermans2, H. van der Linden2, P. Savelkoul1
Department of 1Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, 2Jeroen Bosch
Ziekenhuis, Den Bosch
JBZ
112. Overcoming Temozolomide (TMZ) resistance in glioma
T. Würdinger1, P. Wesseling2
Department Of Neurosurgery1 and Pathology2, VU University Medical Center, Amsterdam
St. Stop Hersentumoren
113. Peri-implantitis, implant loss and radio-osteonecrosis in head and neck tumor patients
H. Dekker, R. Ramawadh, E. Bloemena
Department of Pathology, VU University Medical Center Amsterdam
ACTA IOT, Straumann, MKA
114. Peritoneal metastases from colorectal carcinoma; Diagnostic markers to identify patients that will benefit from radical
surgical resection
E. de Cuba1, H.J. Bonjer1, G.A. Meijer2, E.A. te Velde1
Department Of 1Surgery and 2Pathology, VU University Medical Center, Amsterdam
115. Personalized Medicine in the treatment of rheumatoid arthritis
C.L. Verweij
Department of Pathology, VU University Medical Center Amsterdam
VUmc CCA
116. Personalized therapy in recurrent colorectal cancer
J. Goos1, R. Fijneman1, A.A. Geldof2, O.S. Hoekstra2, L. Perk3, G.A. Meijer1
Department of 1Pathology, 2Nuclear Medicine & PET reserach, VU University Medical Center, Amsterdam, 3BV Cyclotron
CTMM
117. Phosphoproteomics for personalized treatment of acute myeloid leukemia with kinase inhibitors
J.J.W.M. Janssen*, C. van Alphen, J. Cloos, G.J. Schuurhuis, G.J. Ossenkoppele, H.M.W. Verheul, C.R. Jimenez*
Department of Hematology and Medical Oncology, VU University Medical Center
Stichting VUmc CCA
118. Prediction of progression in low-grade glioma using chromosomal copy number alterations
H.F. van Thuijl1,2, J.J. Heimans1, P. van der Valk2, B. Ylstra2, P. Wesseling2, J.C. Reijneveld1,3
Departments of 1Neurology and 2Pathology, VU University Medical Center, Amsterdam, Department of 3 Neurology,
Academic Medical Center, Amsterdam
KWF Kankerbestrijding VU 2009-4470
119. Prediction of response in cervical cancer by genetic and proteomic profiling
E.S. Jordanova1, 2 , I. Van Luijk 3, H. Zijlmans 4, P. Ottevanger 5, G.G. Kenter 1, 4
Departmenth Gynaecology1 and pathology2 VU University Medical Center, Departmenth Gynaecology Medical Centre
Haaglanden 3, Departmenth of gynaecology of the NKI-AVL 4 , Departmenth of Medical Oncology University Medical
Center Nijmegen5
120. Prediction of response to drug therapy in advanced colorectal cancer based on DNA copy number profiles of primary
tumors
J. Haan, J.H.J.M. van Krieken, C.J.A. Punt, G.A. Meijer
Department Of Pathology, VU University Medical Center, Amsterdam
KWF 2007-3832
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 130
121. Predictive genomic biomarker methods for combination Bevacizumab (Avastin) therapy in metastatic colorectal cancer
B. Ylstra
Department of Pathology, VU University Medical Center Amsterdam
EU
122. Projectmanagement
M. van Engeland1, C.J.H. van de Velde2, G.A. Meijer2
Department of Pathology, MUMC1, VU University Medical Center Amsterdam2
CTMM
123. Protein arrays and metabolite biomarkers to predict development of RA and response to therapy
M. Blits, J. Lubbers, J. Wesseling, A.E. Voskuyl, P. van der Putte, C. Verweij
Department Of Pathology and Rheumatology, VU Universtiy Medical Center Amsterdam, Flexgen
CTMM
124. Reducing CRC death in stage II carcinomas by identifying high/risk stage II cancer patients who could benefit from
adjuvant chemotherapy
B. Diosdado, R.Q.J. Schaapveld1, G.A. Meijer
Department of Pathology, VU University Medical Center Amsterdam, 1InteRNA Technologies BV
inteRNA
125. Tailoring of (immune-)therapy in R-CHOP refractory diffuse large B-cell lymphoma (DLBCL) patients
N. Rekers1, S.A.G.M. Cillessen1, G.J. Ossenkoppele2, J.C. Kluin-Nelemans3, C.J.L.M. Meijer1
Departments. of 1Pathology, 2Hematology, VU University Medical Center, Amsterdam. 3Department of Hematology,
UMCG
KWF 2007-3858
126. The role of focal adhesion kinas (FAK) in response to anti-EGFR therapy in KRAS wild-type colorectal cancers
G.A. Meijer
Department of Pathology, VU University Medical Center Amsterdam
PathSoc
127. To treat or not to treat: prostasome prostate cancer diagnostics
I.V. Bijnsdorp, A.A. Geldof, M. Pegtel, B. Ylstra, L. Rozendaal, C. Jimenez, A.J.M. van den Eertwegh, T. Wurdinger, R.J.A.
van Moorselaar
Department of Urology, VU University Medical Center, Amsterdam
CCA
128. Towards a molecular understanding of the preclinical phase and therapy responsiveness in rheumatoid arthritis
C.L. Verweij
Department of Pathology, VU University Medical Center Amsterdam
VUmc CCA
129. TRACER ICT
J. Lubbers, M. Blits, S. de Ridder, J. Beliën, C. Verweij
Department of Pathology and Reumatology, VU University Medical Center Amsterdam
130. Translational Research IT
R. Fijneman1, C. Jimenez2, B. Ylstra1, J.W. Boiten1, J. Beliën1, G.A. Meijer1
Department of 1Pathology, 2Medical Oncology, VU University Medical Center, Amsterdam
CTMM
131. Understanding the molecular basis of the differential INFB response in relapsing remitting MS
C. Verweij1, Ch. Polman2, J. Killestein2
Department of 1Pathology, 2 Neurology, VU University Medical Center Amsterdam
MS stichting
132. Validating FDG PET as a biomarker of response
S.N.F. Rizvi, A. Vincent, H. van Tinteren, R. Boellaard, O.S. Hoekstra
Department of Radiology & Nuclear Medicine VUmc, Department of Biostatistics AvL/NKI
NIBIB (USA)
133. Validation of citrulline as a marker of small intestine absorption capacity: a pilot study
J.H.C. Peters1, N.J. Wierdsma2, C.J.J. Mulder1, P.A.M. van Leeuwen3 and A.A. van Bodegraven1
1Department of Gastroenterology, Small Bowel Disease Unit, 2Department of Nutrition and Dietetics, 3Department of
Experimental Surgery, VU University medical center, Amsterdam, the Netherlands
134. Validation of quantitative procedures for immunoPET
N. Makris, R. Boellaard, M.C. Huisman
Department Radiology & Nuclear Medicine, VU University Medical Center Amsterdam
Philips Health Care
Program 4
AML and CML
1. Application of bortezomib in pediatric acute lymphoblastic leukemia
D. Niewerth1,2, J. van Meerloo1, S. Zweegman2, G.J.L. Kaspers1, G. Jansen3, J. Cloos1,2
Departments. of 1Pediatric Oncology/Hematology, 2Hematology and 3Rheumatology, VU University Medical Center,
Amsterdam
Stichting KIKA
2. Characterization of relapsed acute myeloid leukemia
C. Bachas1,2, Z.J. Kwidama1,2, G.J. Schuurhuis2, G.J.L. Kaspers1 J. Cloos1,2.
Departments. of 1Pediatric Oncology/ Hematology and 2Hematology, VU University Medical Center, Amsterdam
KWF KWF 2005-3666
3. Drug resistance in childhood leukemia
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 131
N.E. Franke1, J. van Meerloo1,2, D Niewerth1,2, S.E. Verbrugge3, R.X. de Menezes4, W.J. Chng6, B.A.C. Dijkmans3, Y.G.
Assaraf7, G.J.L. Kaspers1, G. Jansen3, J. Cloos1,2
Departments. of 1Pediatric Oncology/Hematology, 2Hematology, 3Rheumatology and 4Epidemiology and Biostatistics ,
VU University Medical Center, Amsterdam, 4Department of Medicine, National University of Singapore, 7Department of
Biology, Technion-Israel Institute of Technology, Haifa, Israel
Stichting Translation Research and ZonMw PV06/08 CCA
4. Improvement of diagnosis of childhood leukemia in the Yogyakarta special region in Indonesia
E. Supriyadi1, A.J.P. Veerman2, Purwanto1, P.H. Widjajanto1, S. Mostert2, M.N. Sitaresmi1, Sutaryo1, J. Cloos2,3.
1Department of Pediatrics, Dr Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia; 2Departments of
Pediatric Oncology/Hematology and 3Hematology, VU University Medical Center, Amsterdam
KWF IN-2006-22
5. Improvement of prognosis of pediatric AML by identification and characterization of (stem) cells responsible for
development of relapse
R. Wouters1,2, Z.J. Kwidama1,2, G.J. Schuurhuis2, G.J.L. Kaspers1 J. Cloos1,2.
Departments. of 1Pediatric Oncology/ Hematology and 2Hematology, VU University Medical Center, Amsterdam
VUmc CCA
6. Protein tyrosine phosphatases as novel treatment targets in acute myeloid leukemia
M. Irandoust1,2, M. Akyuz1,2, E. de Bruijn3, A.J.F. Broekhuizen1,2, G.J.L. Kaspers1, E. Cuppen3, J. Cloos1,2
Departments. of 1Pediatric Hematology/Oncology and 2Hematology, VU University Medical Center, Amsterdam,
3Genomic Biology Department, Hubrecht institute, Utrecht
Stichting KiKa
7. Targeting of CLEC12A positive AML stem cells with antibody-drug conjugates and bispecific CLL-1xCD3 BiTE antibody
P. Noordhuis, M. Terwijn, A.R. Rutten, S. Piersma, C. Jimenez., G.J.Ossenkoppele, G.J.Schuurhuis
Department of Hematology and Onco Proteomics Laboratory, VU University Medical Center, Amsterdam
Crucell Nederland
8. The function of EVI-1 in leukemic stem cells of acute myeloid leukemia
B. Venniker-Punt, G. Brasser, H. Verhagen, D. de Leeuw, A. Rutten, P. Merle, G. Ossenkoppele, G.J. Schuurhuis, L. Smit
Department of Hematology University Medical Center, Amsterdam, The Netherlands
Interna and St. Vu Steunfonds Hematologie
9. The role of impaired FPGS splicing in methotrexate response in childhood acute lymphoblastic leukemia
A.M. Wojtuszkiewicz1,2, G.J. Peters3, G. Jansen4, Y.G. Assaraf5, G.J.L. Kaspers1, J. Cloos1,2
Oncology/Hematology, 2Hematology, 3Medical Oncology and 4Rheumatology, VU University Medical Center, Amsterdam,
5Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel
Stichting KIKA (kinderen kankervrij)
10. The role of minimal residual disease, and leukemic stem cells herein, in clinical decision making
W. Zeijlemaker, G.J. Ossenkoppele, GJ. Schuurhuis
Department Of Hematology, VU University Medical Center, Amsterdam
St. VU Steunfonds Hematologie
Brain
11. Drug distribution and local drug delivery in diffuse intrinsic pontine glioma
S.E.M. Veldhuijzen van Zanten, D.G. van Vuurden, M.H.A. Jansen, W.P. Vandertop, G.J.L. Kaspers
Department Of Paediatric Oncology and Neurosurgery, VU University Medical Center Amsterdam
12. Targeted therapy in pediatric brain tumors
D.G. van Vuurden1,4, E. Hulleman2,4, P. van der Stoop2,4, T. Wurdinger2,4, M. Irandoust1,3, G.J.L. Kaspers1, J. Cloos1,3
Departments of 1Pediatric Oncology/ Hematology, 2Neurosurgery, 3Hematology and 4Neuro-Oncology Research Group,
VU University Medical Center, Amsterdam
VONK
13. Testing novel treatment modalities for diffuse intrinsic pontine glioma (DIPG) in in vivo animal models
A.C.P. Sewing2,3, M.H. Jansen2, D.P. Noske1,3, R.K. Puri, E. Hulleman2,3, G.J.L. Kaspers2
Departments of 1Neurosurgery and 2Pediatric oncology / 3Neuro-oncology Research Group Cancer Center Amsterdam,
VU University Medical Center Amsterdam, 4Center for Biologics Evaluation and Research, Food and Drug Administration,
NIH
KiKa
14. Towards novel therapeutics for the treatment of pediatric high-grade glioma
S.J.E. Veringa,1,2, D.G. van Vuurden1,2, M.H.A. Jansen1, D. Biesmans1,2, L.E. Wedekind1,2, I. Horsman3, P.
Wesseling2,4, W.P. Vandertop5, D.P. Noske2,5, T. Wurdinger2,5, G.J.L. Kaspers1, E. Hulleman1,2,#
Departments of 1Pediatric Oncology/Hematology, 2Neuro-oncology research group, 3Clinical Genetics, 4Pathology and,
5Neurosurgery, VU University Medical Center, Amsterdam
EDLI foundation/ VUmc CCA
Combination radiotherapy, chemotherapy and molecular markers
15. Study on the interaction between angiogenesis inhibition and radiotherapy
E.A. Kleibeuker1, K. Castricum1, S. Senan1, A.W. Griffioen2, H.M. Verheul2, B. Slotman1, V.L.J.L. Thijssen1,2
Departments. of 1Radiation Oncology, VU University Medical Center, and 2Medical Oncology, VU University Medical
Center (Stichting VUmc Cancer Center Amsterdam
Stichting VUmc Cancer Center Amsterdam CCA2011-1-03
Combined radiotherapy with conventional chemotherapy and molecular targeted agents
16. Combined radiotherapy with conventional chemotherapy and molecular targeted agents
Senan S, Lagerwaard FJ, Spoelstra F, Lind JSW, Phernambucq ECJ, Smit EF, Thijssen VLJL, Slotman BJ
Departments of Radiation Oncolog, Pulmonology and Medical Oncology, VU University Medical Center, Amsterdam
Imaging: Colorectal tumours
17. Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumor uptake of 89Zrlabeled cetuximab assessed by PET
C.W. Menke-van der Houven van Oordt, G.A.M.S. van Dongen, O.S. Hoekstra, J.J. van der Vliet, M. Labots, C. van
Montfrans, A. Beeker, H.M.W. Verheul
Department of Medical Oncology VU University Medical Center Amsterdam
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 132
Imaging: Paediatric tumours
18. Development of preclinical pediatric brain tumor imaging models
L. Hiddingh1,2,3, V. Caretti1,2,3, T. Lagerweij1,2,3, E. Hulleman1,2,3, G.J. Kaspers1, W.P. Vandertop2, C. Molthoff4, B.A.
Tannous4, D. Noske2,3, T. Wurdinger2,3,5
Departments of 1Pediatric Oncology/ Hematology, 2Neurosurgery, 3Neurooncology Research Group, VU University
Medical Center, 4VU University RNC, 5Massachusetts General Hospital and Harvard Medical School, Boston, MA
Stichting KiKa
19. Treatment strategies and new diagnostic tools for malignant pontine gliomas
M.H.A. Jansen1, D.G. van Vuurden1, W.P. Vandertop2, G.A.M.S. van Dongen3,4, O.S. Hoekstra4, G.J.L. Kaspers1
1Department Pediatrics, Pediatric Oncology/-Hematology, 2Department Neurosurgery, 3Department
Otolaryngology/Head and Neck Surgery and 4Radiology & Nuclear Medicine, 4Department Nuclear Medicine, VU
University Medical Center, Amsterdam
VONK, Semmy Foundation
Imaging: Rheumatoid diseases
20. Imaging and targeting of macrophage folate receptor-beta in rheumatoid arthritis
K. Weijers1, Y.Y.J. Gent1, G. Jansen1, C.F.M. Molthoff2, A.D. Windhorst2, J.W. van der Heijden1, A. Voskuyl1, P.S. Low3,
M. Ratnam4, Y.G. Assaraf 5, A.A. Lammertsma2, B.A.C. Dijkmans1, and C.J van der Laken1
Departments. of 1Rheumatology and 2PET-Center/Nuclear Medicine, VU University Medical Center, Amsterdam, The
Netherlands, 3Endocyte, West Lafayette, IN, USA, 4Department of Biochemistry and Molecular Biology, Medical University
of Toledo, Toledo, OH. U.S.A., 5Department of Biology, The Technion, Israel Institute of Technology, Haifa, Israel
Nationaal Reumafonds NRF-09-404
Immunotherapy
21. A phase I open-label clinical trial, evaluating the therapeutic vaccine hVEGF-trunc/PEP-A10 in patients with advanced solid
tumors
M. Wentink, T. de Gruijl, J. van der Vliet, H. Verheul et al
Department of Medical Oncology, VU University Medical Center Amsterdam
22. Development of DCOne and novel AML-derived cell lines for DC-based allogeneic tumor vaccination
R. van de Ven1, S.J.A.M. Santegoets1, D. Oosterhoff2, M. Koppes3, P.J.G.T.B. Wijnands2, A. Reurs2, M. Meerendonk2, J.
Kaspers2, S. van Wetering2, A.J.M. van den Eertwegh1, Rik J. Scheper1,4, G.J. Ossenkoppele3, A.A. van de Loosdrecht3,
A.M. Kruisbeek2, T.D. de Gruijl1
Department of 1Medical Oncology, 2DC Prime BV, and the Departments of 3Hematology and 4Pathology, VU University
Medical Center, Amsterdam, The Netherlands.
DC Prime, Biopartner FSG & Senter Grant, ZonMW Translationeel Research Grant 40-41200-98-9106
23. Immune correlates of clinical response and survival in castration resistant prostate cancer patients treated with Prostate
GVAX and anti-CTLA4 immunotherapy
S.J.A.M. Santegoets2, A.J.M. van den Eertwegh1, A.G.M. Stam2, S.M. Lougheed1, H. Gall1, P.E.T. Scholten2, B.M.E. von
Blomberg2, E. Hooijberg2, K. Jooss4, N. Sacks4, K. Hege4, I. Lowy5, R.J. Scheper2, W.R. Gerritsen1, T.D. de Gruijl1
Departments of 1Medical Oncology and 2Pathology of the VU University medical center, Amsterdam, The Netherlands;
3Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA; 4Cell Genesys Inc.,South San
Francisco, CA; 5Medarex, Bloomsbury, NJ
Prostate Cancer Foundation Research Award, Dutch Cancer Society KWF-VU 2006-3697
24. Immunomodulation of the sentinel lymph node
B.D. Koster1, M.F.C.M. van den Hout2, R. van de Ven1, B.J.R. Sluijter3, K.M. van Pul4, S.M. Lougheed1, S.J.A.M.
Santegoets1, R.J.C.L.M. Vuylsteke4, H.B.A.C. Stockmann4, P.A.M. van Leeuwen3, S. Meijer3, R.J. Scheper2, P. van den
Tol3, A.J.M. van den Eertwegh1, T.D. de Gruijl1
Departments of 1Surgical Oncology, 2Medical Oncology, and 3Pathology, VU University Medical Center, Amsterdam, The
Netherlands and 4Department of Surgery, Kennemergasthuis, Haarlem, The Netherlands.
Harry J. Lloyd Charitable Trust, Heelkundefonds
25. Optimalisation of immunomodulating therapies in IBD treatment
D.P. van Asseldonk1, M.L. Seinen1, K.H.N. de Boer1, C.J, Mulder1, A.A. van Bodegraven1
Department of 1Gastroenterology, VU University Medical Center
Gastrostart
26. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
C.M. Huijts1, S.J.A.M. Santegoets1, A.J.M. van den Eertwegh1, L.S. Pijpers1, J.B. Haanen2, T.D. de Gruijl1, H.M. Verheul1,
H.J. van der Vliet1
Department of 1Medical Oncology, VU University Medical Center, Amsterdam; 2 Division of Immunology, The
Netherlands Cancer Institute, Amsterdam
Improvement of treatment of head and neck cancer
27. Electrochemotherapy
D.H. Heuveling, R. de Bree
Department of Otolaryngology/Head-Neck Surgery VU University Medical Center, Amsterdam
IGEA
28. Hypothyroidism after treatment for laryngeal cancer
A.M. Lo Galbo, R. de Bree, C.R. Leemans
Department Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
29. Improvement of treatment of head and neck cancer. General aspects.
R. de Bree1, L. van der Putten1, A. Lo Galbo1, D.A. Heuveling1, S. Faraj-Hakim1, P. Doornaert2, I. van der Waal3, J. Buter4
, O.S. Hoekstra5, J.A. Castelijns5, C.R. Leemans1
Departments. of 1Otolaryngology/Head-Neck Surgery, 2Radiation Oncology, 3Oral and Maxillofacial Surgery, 4 Medical
Oncology, 5 Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam
30. Salvage treatment after (chemo)radiation
L. van der Putten, C.R. Leemans, R. de Bree
Department of Otolaryngology/Head-Neck Surgery VU University Medical Center, Amsterdam
Late effects of brain tumor therapy
31. Efficacy and toxicity of cerebral glioma treatment
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 133
I. Bosma1, M.J. Vos1,13, E. Sizoo1, M. de Groot1, F. Foklage1, T.J. Postma1, J.C. Reijneveld1,11, M.J.B. Taphoorn1,13,
W.P. Vandertop2,12, J.C. Baayen2, D. Noske2, B.J. Slotman¬3, F.J. Lagerwaard3, J. Buter4 , M. Klein5, O.S. Hoekstra6, F.
Barkhof7, E. Sanchez7, P. van der Valk8, A.A.T.P. Brink8, M.A. Blankenstein9, J. Berkhof10, J.J. Heimans1
Department of 1Neurology, 2Neurosurgery, 3Radiotherapy, 4Medical Oncology, 5Medical Psychology, 6 Nuclear
medicine, 7Radiology & Nuclear Medicine, 8Pathology, 9Clinical Chemistry, and 10Clinical Epidemiology and
Biostatistics, VU University Medical Center, Department of 11Neurology and 12Neurosurgery, Academic Medical Center,
Amsterdam, 13Department of Neurology, MC ‘Haaglanden’, Den Haag
Oncolytic adenovirus
32. Enhancement of the oncolytic potency of conditionally replicative adenoviruses
W. Dong1, K.Y. Au1, A. Gros2, J.W.G. van Ginkel1, M. Cascallo2, W.R. Gerritsen3, R. Alemany2, J.J.M. Meulenberg1, V.W.
van Beusechem1,3
1ORCA Therapeutics, Amsterdam, The Netherlands; 2Translational Research Laboratory, IDIBELL-Institut Català
d’Oncologia, Barcelona, Spain; and 3Department of Medical Oncology, VU University Medical Center, Amsterdam, The
Netherlands
33. Exploiting miRNA to enhance oncolytic adenovirus potency
J.W.H. van Ginkel1, C. Vermeulen2, J. Hodzic2, R.W.D. Kleinendorst2, A. Vermeulen3, J. Karpilow3, J.J.M. Meulenberg1,
V.W. van Beusechem1,2
1ORCA Therapeutics, Amsterdam, The Netherlands; 2Department of Medical Oncology, VU University Medical Center,
Amsterdam, The Netherlands; 3Thermo Fisher Scientific, Dharmacon RNAi Technologies, Lafayette, CO, USA
34. Virotherapy of glioblastoma multiforme using an infectivity-enhanced selectively replication-competent adenovirus
V.W. van Beusechem1, M.L.M. Lamfers2, J.M. Amado de Azevedo1, I.H. van der Meulen-Muileman1, S. Idema3, W.R.
Gerritsen1, W.P. Vandertop3, D.P. Noske3, C.M.F. Dirven2
Departments. of 1Medical Oncology and 3Neurosurgery, VU University Medical Center, Amsterdam; 2Department
Neurosurgery, Erasmus MC, Rotterdam
ZonMw Translationeel Gentherapeutisch Onderzoek 43200003
Personalized medicine
35. A randomized multicenter clinical trial for patients with multi-ORgan, Colorectal cancer metastases comparing the
combination of cHEmotherapy and maximal tumor debulking versuS chemoTheRapy Alone: ORCHESTRA.
T. Offringa, E. Gootjes, M. Neerincx, T. Buffart, D. Van der Peet, K. Verhoef, H. Verheul et al
Department of Medical Oncology, VU University Medical Center Amsterdam
36. Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer: COLOCETUX TRIAL
II.
C. Menke-van den Houven v Oordt, O.S. Hoekstra, D. Vugts, M.C. Huisman, GAMS van Dongen, H. Verheul
Department of Medical Oncology, Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam
37. Measurement of tumor kinase inhibitor concentrations using PET imaging in patients with advanced solid malignancies
1C. Menke-van den Houven v Oordt, 2OS. Hoekstra, 2M. Yaqub, 2A.A. Lammertsma, 1H. Verheul
Department of 1Medical Oncology, 2Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam
38. Pilot study on the determination of intratumoral concentrations of kinase inhibitors in patients with advanced solid
malignancies
M. Labots, M. Neerincx, J. van der Mijn, G. Peters, H. Verheul et al
Department of Medical Oncology, VU University Medical Center Amsterdam
39. Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced
renal cell cancer patients
J. van der Mijn, M. Labots, C. Jimenez, H. Verheul et al
Department of Medical Oncology, VU University Medical Center Amsterdam
40. Stereotactic ablative radiotherapy for lung cancer and comparative effectivess research
S. Senan, D.A. Palma2, W.F.A.R. Verbakel, F.J. Lagerwaard, C.J. Haasbeek, C.L. Ong, A.V. Louie, D. Rodrigues, N.E.
Verstegen, J.P. Cuijpers, A.V. Louie2, B.J. Slotman
Departments of Radiation Oncology, VU University Medical Center, Amsterdam and 2Department of Radiation Oncology,
London Regional Cancer Program, London, Ontario, Canada
41. Stereotactic ablative ratiotherapy (SABR) for oligometastases
M. Dahele, C.J.A. Haasbeek, W.F.A.R. Verbakel, D.A. Palma2, B.J. Slotman, S. Senan
Departments of Radiation Oncology, VU University Medical Center, Amsterdam, 2 1Department of Radiation Oncology,
London Regional Cancer Program, London, Ontario, Canada
42. Target identification specific for leukemic stem cells of acute myeloid leukemia
H. Verhagen1, F. Denkers1, R. Kerkhoven4, M. Terwijn1, A. Rutten1, W. Pouwels1, B. Ylstra2, R. Menezes3, G.
Ossenkoppele1, G.J. Schuurhuis1 and L. Smit1.
Department of Hematology1, Microarray Facility, Department of Pathology2, Department of Biostatistics3, VU University
Medical Center, Amsterdam, The Netherlands
Prostate Cancer
43. A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer
who progressed on or after a docetaxel containing treatment. The ReCab trial.
J. van Dodewaard-de Jong, H. Bloemendal, J. De Klerk, A. van den Eertwegh, A. ten Tije, O. Hoekstra, H. Verheul et al
Department of Medical Oncology, VU University Medical Center Amsterdam
44. A Randomised, Phase II, Study of Repeated Rhenium-188 HEDP combined with Docetaxel versus Docetaxel alone in
Castration Resistant Prostate Cancer (CRPC) Metastatic to Bone
J. van Dodewaard-de Jong, H. Bloemendal, J. De Klerk, A. van den Eertwegh, A. ten Tije, O. Hoekstra, H. Verheul et al
Department of Medical Oncology, VU University Medical Center, Amsterdam
45. Experimental therapy rationale for prostatic cancer
A.A. Geldof1,2, I.V. Bijnsdorp1, J.J.L. Jacobs1, W. Den Otter1, D. Oprea2, A. Vis1, O.S. Hoekstra2 and R.J.A. van
Moorselaar1
Departments. of 1Urology and 2Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam
Radiotherapy
46. Image-guided radiotherapy (IGRT)
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 134
S. Senan, W.F.A.R. Verbakel, M. Dahele, J.R. van Sörnsen de Koste, P. Doornaert, J.P. Cuijpers, F.J. Lagerwaard, C.L. Ong,
C.J. Haasbeek, F.O.B. Spoelstra, B.J. Slotman
Departments of Radiation Oncology, VU University Medical Center, Amsterdam
47. Innovative techniques for intracranial stereotactic radiotherapy
Lagerwaard FJ, Meijer OWM, Haasbeek CJA, Vandertop WP, Baaijen JC, van den Berg R, Postma TJ, Leemans CR, Slotman BJ
Departments. of Radiation Oncology, Neurosurgery, Radiology & Nuclear Medicine, Otolaryngology/Head and Neck
Surgery and Neurology, VU University Medical Center, Amsterdam
Varian - RapidArc
Resistance to therapy
48. A phase I study of high dose, intermittent sunitinib in patients with solid tumors
M. Rovithi, J. Voortman, H. Verheul et al
Department of Medical Oncology, VU University Medical Center Amsterdam
49. Elucidating TMZ resistance in glioma
L. Hiddingh1,2,3, G.J. Kaspers1, W.P. Vandertop2, P. Wesseling4, B.A. Tannous5, D. Noske2,3, J. Jeuken4, T.
Wurdinger2,3,5
Departments of 1Pediatric Oncology/ Hematology, 2Neurosurgery, 3Neurooncology Research Group, VU University
Medical Center, 4Pathology, RUNMC, 5Massachusetts General Hospital and Harvard Medical School, Boston, MA
Stichting www.stophersentumoren.nl
50. Molecular basis of sensitivity/resistance for folate antagonist and experimental targeted drugs
G. Jansen1, J.W. van der Heijden1, M.C. Al1, R.J. Scheper2, J. Cloos3, N.E. Franke3, S.E. Verbrugge1, M. Blits2, R. de
Jonge5, G.L. Scheffer2, G.J. Peters4, C.L. Verweij1,2, Y.G. Assaraf 6 and W.F. Lems1
Departments. of 1Rheumatology, 2Pathology, 3Pediatric Oncology and 4Medical Oncology, VU University Medical Center,
Amsterdam, The Netherlands, 5 Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands,
6Department of Biology, The Technion, Israel Institute of Technology, Haifa, Israel
51. Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma
C. Huijts, M. Labots, T. de Gruijl, J. van der Vliet, G. Peters, A. van den Eertwegh, H. Verheul et al
Department of Medical Oncology, VU University Medical Center Amsterdam
52. Targeted therapy of osteosarcoma
J. Posthuma de Boer1, M. N. Helder1, V.W. van Beusechem2, G.J.L. Kaspers3,B.J. van Royen1
1 Department of Orthopaedic Surgery, VU University Medical Center, 2 Department of Medical Oncology, VU University
Medical Center and 3 Department of Pediatric Oncology/Haematology, VU University Medical Center
The Strategic Regeneration Network, Aarhus University Hospital, Denmark; VONK and the department of Orthopaedic
Surgery, VU University Medical Center, Amsterdam
53. Targeting resistance to radio-chemotherapy by inhibition of the PI3Kinase-Akt signaling pathway
R.S. Narayan1, C.A. Fedrigo2, L.J.A. Stalpers3, B. G. Baumert4, M.E. van Linde5, N.A.P. Franken3, J. van den Berg1, J.
Theys4, G.J. Peters5, B.J. Slotman1, T. Wurdinger6, P. Sminia1
Departments. 1Radiation Oncology, 5Medical Oncology,6 Neuro-Oncology Research Group, VU University Medical Center;
2Pontificia Universidade Catolica do Rio Grande do Sul; Department 3Radiation Oncology, Academic Medical Center,
Amsterdam; 4Department Radiation Oncology Maastricht Universitair Medisch Centrum
KWF 2010-4874
RNAi
54. Identification of genes involved in resistance of lung cancer cells to cisplatin
E. Siebring-van Olst1, R.X. de Menezes2, E.F. Smit1, V.W. van Beusechem3
Departments. of 1Pulmonary Diseases, 2Epidemiology and Biostatistics, and 3Medical Oncology, VU University Medical
Center, Amsterdam
Stichting CCA / Walter Bruckerhoff Stiftung
55. Identification of genes involved in resistance of prostate cancer cells to irradiation
J. Hodzic1, B. van Triest2, A. Geldof3, R.X. de Menezes4, W.R. Gerritsen1, M. Verheij2, V.W. van Beusechem1,5
Departments of 1Medical Oncology, 3Urology, 4Epidemiology and Biostatistics and 5RNA Interference Functional
Oncogenomics Laboratory, VU University Medical Center, Amsterdam; 2Department of Radiotherapy, The Netherlands
Cancer Institute, Amsterdam
Stichting CCA
Symptoms and symptomatic treatment of cerebral glioma
56. Correlation between SV2A expression in tumour tissue and efficacy of levetiracetam in glioma patients with epilepsy
M. de Groot1, J.J. Heimans1, E. Aronica5, C.J. Vecht6, M. Klein3, C.J. Stam2, J.C. Reijneveld1,4
Departments of 1Neurology, 2Clinical Neurophysiology, and 3Medical Psychology, VU University Medical Center,
Amsterdam, Departments of 4 Neurology and 5 Pathology, Academic Medical Center, Amsterdam, and 6Department of
Neurology, Medical Center ‘Haaglanden’, The Hague
UCB Pharma Nederland BV
Other projects
57. A multicenter, randomized phase II trial of paclitaxel plus bevacizumab versus paclitaxel, bevacizumab plus capecitabine
in HER2-negative locally recurrent or metastastic breast cancer
S.W. Lam, A.H. Honkoop, S. de Groot, S v.d. Wildt, H. van Tinteren, E. Boven
Departments. of Medical Oncology, VU University Medical Center and BOOG Study Center Amsterdam
Industry
58. Absorptiometry in ICU patients
R.J.M. Strack van Schijndel1, N.J. Wierdsma2, A.A. van Bodegraven3
1Department of Intensive Care, 2Department of Nutrition and Dietetics and 3Department of Gastroenterology, Small
Bowel Disease Unit VU University medical centre, Amsterdam
59. Activity of Novel Irreversible Inhibitors of Epidermal Growth Factor Receptor in Non Small Cell Lung Cancer
E. Galvani,a,b C. Carmi,c F. Vacondio,c A. Cavazzoni,a R.R. Alfieri,a E. Giovannetti,b M. Mor,c P.G. Petronini,a G.J.
Peters.b
a University of Parma, Department of Experimental Medicine, Italy;
bVU University Medical Center, Department of Medical Oncology, Amsterdam, The Netherlands;
c University of Parma, Pharmaceutical Department, Italy
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 135
60. An miRNA-based angiostatic drug for treatment of cancer
A.W. Griffioen1, J.R. Van Beijnum1, R. Schiffelers2, R. Schaapveld3
Departments. of 1Medical Oncology, VU University Medical Center, and 2Pharmacology, UU Utrecht. 3InteRNA BV, Utrecht
TI Pharma 2010
61. Assessment and optimization of carboplatin exposure in pediatric oncology using different markers of kidney function
H.N. Blufpand1, F.C.H. Abbink1, G.J. Peters2, B. Stoffel-Wagner4, A. Bökenkamp3, G.J.L. Kaspers1
1Pediatric Oncology, 2Medical Oncology, 3Pediatric Nephrology VU University Medical Center and 4Clinical Chemistry
and Clinical Pharmacology, Bonn University Medical Center
VUmc Research on Childhood Cancer – VONK
62. Brainstem tumors: development of anti-tumor drugs for convection enhanced delivery
V. Caretti1,2,3, E. Hulleman2,3, J. Cloos2,3, W.P. Vandertop1,3, G.J.L. Kaspers2,3, D.P. Noske1,3, T. Wurdinger1,3,4
Departments. of 1Neurosurgery, 2Pediatric Oncology/ Hematology, 3Neuro-oncology Research Group ,VU University
Medical Center, Amsterdam. 4Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical
School, Boston, MA
VONK/Semmy/Stichting Egbers
63. Chemotherapy and maximal tumor debulking of multi-organ colorectal cancer metastases
T. Offringa, T. Buffart, H.M.W. Verheul
Department Of Medical Oncology, VU University Medical Center, Amsterdam
64. Chronological or random reading of radiographs in long term follow-up studies of Rheumatoid Arthritis?
L. Van Tuyl,1,2 D.M.F.M van der Heijde, 3 M. Boers (PI)1,2
1. Department of Clinical Epidemiology and Biostatistics; 2. Department of Rheumatology; VUmc; 3. Department of
Rheumatology, Leiden UMC
Reumafonds
65. Clinical evaluation of the underlying mechanisms of targeted therapy related toxicities
M. Rovithi1, H. Berkhof2, T.D. de Gruijl1, C.R. Jimenez1, M.Labots1, G.A. Meijer3, G.J. Peters1, S.Santegoets1, A.A. van
Bodegraven4, N.C.T van Grieken3, C. van Montfrans5, A.J.M van den Eertwegh1, H.M.W. Verheul1
Departments of 1Medical Oncology, 2Biostatistics, 3 Pathology, 4 Gastroenterology and 5 Dermatology of the VU
University Medical Center
66. Clonal evolution of acute myeloid leukemia stem cells
R. Wouters1,2, C. Bachas1,2, Z.J. Kwidama1,2, E. Sonneveld3, L. Smit2, G.J. Ossenkoppele2, G.J.L. Kaspers1 G.J.
Schuurhuis2, J. Cloos1,2.
Departments. of 1Pediatric Oncology/ Hematology and 2Hematology, VU University Medical Center, Amsterdam, 3Dutch
Childhood Oncology Group, The Hague
VONK
67. COBRA cohort study and patient reported remission outcomes
L. Van Tuyl,1 M. Boers 1,2,3, AE Voskuyl1, D van Schaardenburg1,3, P Kerstens 3,4, M Nurmohamed1,3 , WF Lems1
1. Department of Rheumatology; 2. Department of Clinical Epidemiology and Biostatistics; VUmc; 3. Reade/Jan van
Breemen Research Institute Amsterdam; 4. WestFries Gasthuis in Hoorn.
Pfizer
68. COBRA-light vier jaar extensieonderzoek
N.P.C. Konijn, L.H.D. van Tuyl, W.F. Lems
Department Of Reumatology, VU University Medical Center, Amsterdam
69. Combination therapy of cabazitaxel with rhenium-188-HEDP for treatment of castration-resistant prostate cancer
metastatic to bone who progressed on or after docetaxel, the ReCab study
J.M. van Dodewaard-de Jong1, J.M.H. de Klerk2, A.J.M. van den Eertwegh1, H.M.W. Verheul1, D.E. Oprea-Lager3, O.S.
Hoekstra3, H.J. Bloemendal4
Departments. of 1Medical Oncology, VU University Medical Center, 2Nuclear Medicine, Meander Medical Center,
3Radiology & Nuclear Medicine, VU University Medical Center, and 4Medical Oncology, Meander Medical Center
Sanofi Aventis
70. Combination therapy of docetaxel with rhenium-188-HEDP for treatment of castration-resistant prostate cancer
metastatic to bone, the Taxium II study
J.M. van Dodewaard-de Jong1, J.M.H. de Klerk2, A.J.M. van den Eertwegh1, H.M.W. Verheul1, D.E. Oprea-Lager3, O.S.
Hoekstra3, H.J. Bloemendal4
Departments. of 1Medical Oncology, VU University Medical Center, 2Nuclear Medicine, Meander Medical Center, 3Nuclear
Medicine & PET research, VU University Medical Center, and 4Medical Oncology, Meander Medical Center
KWF
71. Cross-talk in the brain tumor micro-environment: microRNAs and microvesicles
M. Smits1,2, S. van Rijn1,2 , P. van der Stoop1,2, J. Berenguer1,2, W.P. Vandertop1,2, D.P. Noske1,2, T Wurdinger1,2,3
Departments. of 1Neurosurgery, 2Neuro-oncology Research Group, VU University Medical Center, Amsterdam.
3Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA
NWO-VIDI, Van Reekum/van Moorselaar stichting, CCA/STR, Swedish Research Council
72. Development of immuinocompetent skin-equivalents for studies on skin inflammatory processes and novel vaccination
approaches
I. Kosten1, S.W. Spiekstra1, B.M.E. von Blomberg2, T. Rustemeyer1 , R.J. Scheper2, T.J. de Gruijl2, S. Gibbs1
Departments 1Dermatology and 2 Pathology, VU University Medical Center Amsterdam
VUmc CCA
73. Diffuse intrinsic pontine gliomas: towards new treatment strategies
V. Caretti1,2,3, D.P. Noske2,3, W.P. Vandertop2, G.J.L. Kaspers1, T. Wurdinger2,3,4
Departments of Pediatric Oncology1 and Neurosurgery2, VU University Medical Center Amsterdam, Neuro-oncology
Research Group, Cancer Center Amsterdam3, Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, MA4.
Stichting Semmy
74. Elucidation and interference of resistance to temozolomide in pediatric and adult gliomas
L. Hiddingh1,2,3, D.P. Noske1,3, W.P. Vandertop1, P. Wesseling4,5 G.J.L. Kaspers2, T. Wurdinger1,3,6
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 136
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
Departments of 1Neurosurgery and 2Pediatric oncology / 3Neuro-oncology Research Group, Cancer Center Amsterdam,
Department of 4Pathology, VU University Medical Center Amsterdam, Department of 5Pathology, Radboud University
Nijmegen Medical Center, Molecular Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School,
Boston, MA6
KiKa, Children-Cancer-free and Stichting Stophersentumoren.nl
Epstein barr virus activation and cytolytic antivirual therapy in nasopharyngeal patients
O. Ramayanti1, A.E. Greijer1, I.B. Tan2, J. Kurnianda3, J.M. Middeldorp1
1Department of Pathology, VU University Medical Center, 2Department Of Head and Neck Surgery & Medical Oncology,
NKI, Amsterdam, 3Department Medicine, Gadjah Mada University
KWF VU 2010-4809
EUROPA studie: Early Unbiased Risk-assessment Of Pediatric Asthma
M.P.C. van der Schee1, P.J. Sterk1, W.M.C. van Aalderen2, A.B Sprikkelman2 en E.G. Haarman2,3
1Department of Respiratory Medicine, Academic Medical Center, Amsterdam, 2Department of Pediatric Pulmonology,
Academic Medical Center, Amsterdam, 3Department of Pediatric Pulmonology, VU University Medical Center, Amsterdam
astmafonds
EUTOS project: (European Treatment and Outcome Study)
N. Thielen, J.J.W.M. Janssen, G.J. Ossenkoppele
Department of Hematology, VU University Medical Center
Evidence based interventional oncology: from last resort to potent alternative or additional treatment
H.J. Scheffer, M.P. van der Tol, M.R. Meijerink, C. van Kuijk
Department of Radiology & Nuclear Medicine and Surgery, VU University Medical Center, Amsterdam
EVIDENCE: European observational study on the burden of disease associated with the use of NSAIDs in rheumatology
1A. Lanas, 2M. Boers
Department of Reumatology, 1Zaragoza, Spain, 2VU University Medical Center Amsterdam
AstraZeneca international
Exploration of anti-leukemic and anti-inflammatory effects elicited by myelomonocytic cell-targeted aminopeptidase
inhibitors with an esterase-sensitive motif
M.C. Al1, K. Smid2, R. Honeywell2, S.E. Verbrugge1, E. Giovannetti2, Y.G. Assaraf 3, W.F. Lems1, G. Ossenkoppele4. G.J.
Peters2 and G. Jansen1
Departments. of 1Rheumatology, 2Medical Oncology, 4Hematology, VU University Medical Center, Amsterdam, The
Netherlands, 3Department of Biology, The Technion, Israel Institute of Technology, Haifa, Israel
VUmc CCA
Exploring the role of endothelial galectins in tumor angiogenesis
I. Schulkens1, R. Heusschen1, A.M. Dingemans2, V. Van den Boogaart2, H.M. Verheul1, A.W. Griffioen, V.L.J.L.
Thijssen1,3
Departments. of 1Medical Oncology, VU University Medical Center, 2Pulmonology, Maastricht University Medical Cencer,
Maastricht, and 3Radiotherapy, VU University Medical Center
KWF 2009-4358
Gemcitabine and PI3Kinase-Akt pathway inhibition to enhance radiotherapy in human glioblastoma multiforme (GBM)
M El-Naggar, C Fedrigo, P. Sminia, GJ Peters
Department Of Medical Oncology, VU University Medical Center, Amsterdam
Genetic and molecular mechanisms underlying Pancreatic Ductal Adenocarcinoma aggressive behaviour and
chemoresistance
A. Amir1, T. Wurdinger2, G.J. Schuurhuis3, G.J. Peters1, E. Giovannetti1
Department of 1Medical Oncology, 2Neurosurgery, 3Hematology, VU University Medical Center Amsterdam
VUmc Cancer Center Amsterdam
HOVON 51 amendment. Imatinib discontinuation in chronic phase myeloid leukemia patients in sustained complete
molecular response: a randomized trial of the Dutch HOVON study group
N. Thielen, B. van der Holt, J.J. Cornelissen, G.E.G. Verhoef, T. Gussinklo, B. Biemond, S. Daenen, R. van Marwijk Kooy, E.
Petersen, W.M. Smit, P.J.M. Valk, G.J. Ossenkoppele, J.J.W.M. Janssen
Department of Hematology, VU University Medical Center
HOVON 78 High dose imatinib versus high dose imatinib in combination with intermediate-dose cytarabine in patients
with first chronic phase myeloid leukaemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
N. Thielen, B. van der Holt, G.E.G. Verhoef, R.A.H.M. Ammerlaan, P. Sonneveld, J.J.W.M. Janssen, M.J. Kersten, J.H. F.
Falkenburg, H.A.M. Sinnige, M. Schipperus, A. Schattenberg, R. van Marwijk Kooy, W.M. Smit, I.W.T. Chu, P.J.M. Valk, Gert
J.Ossenkoppele, and Jan J. Cornelissen
Department of Hematology, VU University Medical Center
Human pharmacokinetics (PK) of selected tyrosine kinase inhibitors (TKI) in relation to transport characteristics in a
polarized gut epithelium model system
R. Honeywell; C. Fatmawati; M. Boeddha; I. Kathmann; N. Losekoot; E. Giovannetti; H.M. Verheul, E.F. Smit; G.J. Peters
Department Of Medical Oncology, VU University Medical Center, Amsterdam
Immuno-PET in non-Hodgkin’s lymphoma
Y.W.S. Jauw 1 J.M. Zijlstra1, M.C. Huisman2, O.S. Hoekstra2, G.A.M.S. van Dongen2,3, S. Zweegman1
Departments. of 1Hematology, 2Radiology & Nuclear Medicine, 3Otolaryngology, VU University Medical Center
Improvement of diagnosis and treatment of childhood leukemia in Indonesia
P.H. Widjajanto1, E. Supriyadi1, J. Cloos2,3, Y. Nency4, S. Gunawan5, S. Mostert2, M.N. Sitaresmi1, G.J.L. Kaspers2,
Sutaryo1, A.J.P. Veerman2
1Department of Pediatrics, Dr Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia; 2Departments of
Pediatric Oncology/Hematology and 3Hematology, VU University Medical Center, Amsterdam, 4Department Pediatrics, dr
Kariadi Hospital, Un. Diponegoro, Semarang, 5Department of Pediatrics dr Kandou Hospital, Un Sam Ratulangi, Manado
Dutch Cancer Society grant IN 2006-22
Improving conventional immunomodulating thiopurine and methotrexate therapy in inflammatory bowel disease
M.L. Seinen, A.A. van Bodegraven, G.J. Peters, C.J.J. Mulder
Department of Gastroenterology and Medical Oncology, VU University Medical Center
Industry: HLW bv, Helmond
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 137
90. Individualized treatment of patients with advanced colorectal cancer based on miRNA expression profiling
M. Neerincx1, T.E. Buffart1, B. Diosdado2, T. Pham1, H. Dekker1, D. Sie2, C. Verhoef3, G.A. Meijer2, H.M.W. Verheul1
1 Department of Medical Oncology VU University Medical Center Amsterdam, 2 Department of Pathology VU University
Medical Center Amsterdam, 3 Department of Surgical Oncology Erasmus Medical Center Rotterdam
91. Kinase activity of tumor-derived exosomes as a potential biomarker for response to treatment
J.C. van der Mijn1, C.R. Jimenez1, S.R. Piersma1, H. Dekker1, M. Labots1, L.M. Schutte1, E.F. Smit2, H.J. Broxterman1,
B.A. Tannous1, T. Wurdinger3, H.M.W. Verheul1
Departments. of 1Medical Oncology, 2Pulmonology 3Neurosurgery of the VU University Medical Center and
4Neurogenetics unit, Harvard Medical School, Charlestown (USA)
92. MAMMOTH; imaging of breast cancer
E. de Vries1, P. van Diest2, A.W. Griffioen3, E. Boven3
Departments. of 2. Medical Oncololgy, UMCG Groningen, 2Pathology, UMCU Utrecht, 3Medical Oncology, VU University
Medical Center.
CTMM 2010
93. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A (DZNeP) with
gemcitabine in pancreatic cancer cells
A. Avan1,* F. Crea2,* E. Paolicchi2,* N. Funel3, E. Galvani1, V.E. Marquez4, R. Honeywell1, R. Danesi2, G.J. Peters1,# E.
Giovannetti1
1Department of Medical Oncology, VU University Medical Center, Amsterdam, 2Department of Internal Medicine,
University of Pisa, Italy; 3Department of Surgery, University of Pisa, Italy; 4NIH, Frederick, MD, US
94. New Molecular and pharmacological approaches against pancreatic cancer
M. Maftouh, E. Giovannetti, G.J. Peters
Department Medical Oncology, VU University Medical Center Amsterdam
95. New therapy for Epstein-Barr virus driven tumours by targeting the virus itself
Z. Novalic1, A.E. Greijer1, I.B. Tan2, J.P. de Boer2, J.M. Middeldorp1
1Department of Pathology, VU University Medical Center, 2Department Of Head and Neck Surgery & Medical Oncology,
NKI, Amsterdam
ZonMw
96. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than coexisting leukemic stem cells
G.J. Schuurhuis, L.A. Min, H. Meel, R. Wouters, L.A. Min, N. de Jonge, M. Terwijn, A. Kelder, A.N. Snel, G.J. Ossenkoppele,
and L. Smit
Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
97. Parents’ and Health-Care Providers’ Perspectives on Side-Effects of Childhood Cancer Treatment in Manado, Indonesia
S. Gunawan1, E.E. Wolters2, J.A.P. van Dongen2, P.M. van de Ven3, M.N. Sitaresmi4, A.J.P. Veerman2, M.F.J. Mantik1,
G.J.L. Kaspers2, S. Mostert2
1Department of Pediatric Oncology-Hematology, Prof Dr RD Kandou Hospital, Manado, Indonesia, 2Department of
Pediatric Oncology-Hematology, VU University Medical Center, Amsterdam, the Netherlands, 3 Epidemiology and
Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, 4 Department of Pediatrics, Dr Sardjito
Hospital, Gadjah Mada University, Yogyakarta, Indonesia
98. PET-CT of biodistribution of rituximab in relation to therapeutic outcome and histological response of lymphoid tissue in
rheumatoid arthritis patients
S.T. Bruijnen1, A.E. Voskuyl1, G. Jansen1, G.A.M.S. van Dongen2, M.C. Huisman2, O.S. Hoekstra2, A.A. Lammertsma2,
P.P. Tak3, Boumans J.H.M., C.J. van der Laken1.
Departments of 1Rheumatology, 2Radiology & Nuclear Medicine, VU University Medical Center, Department of
Rheumatology & Immunology3, Academic Medical Center, Amsterdam
99. PHAROS project: Nationwide registration of clinical and outcome data of CML in the Netherlands
N Thielen, JJWM Janssen, GJ Ossenkoppele, P.Huijgens
Department of Hematology, VU University Medical Center
100. Preclinical screening to identify broad-range anti-glioma therapeutics
S. van Rijn1,2, J. Nilsson1,2, C. Badr3, B.A. Tannous3, W.P. Vandertop1,2, D.P. Noske1,2, T. Wurdinger1,2,3
Departments. of 1Neurosurgery, 2Neuro-oncology Research Group, VU University Medical Center, Amsterdam.3Molecular
Neurogenetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA
STOPhersentumoren.nl
101. Preclinical, translational and clinical research in pediatric oncology
G.J.L. Kaspers, F. Abbink, V. De Haas, E.G. Hulleman, W.A. Kors, R.R.L. van Litsenburg, N.A. Oeij, D.G. van Vuurden, M.A.
Veening, J. Cloos
Pediatric Oncology/Hematology, and Hematology#, VU University Medical Center, Amsterdam and *Dutch Childhood
Oncology Group, The Hague, The Netherlands
102. Prediction of achievement of deep molecular responses to combination treatment with nilotinib and pegylated interferonalpha in chronic myeloid leukemia
J.J.W.M. Janssen, M. Koppes, G.J. Schuurhuis, G.J. Ossenkoppele
Department of Hematology, VU University Medical Center
Novartis Netherlands
103. Prediction of response to radiotherapy with concomitant and adjuvant Temozolomide in glioblastoma patients with
serum proteomics
M.E. Van Linde1#, J.C. van der Mijn1#, J.C. Knol1, L.E. Wedekind3, T. Pham1, J.C. Reijneveld2, C.R. Jimenez1, H.M.W.
Verheul1
Departments. of 1Medical Oncology, 2Neurology and 3Neurosurgery of the VU University Medical Center, # contributed
equally
104. Predictive value of stem cell enumeration for the response to nilotinib in newly diagnosed CML patients
N. Thielen, A. Zevenbergen, B. van Kuijk, W. Pouwels, G.J. Schuurhuis, G.J. Ossenkoppele, J.J.W.M. Janssen
Department of Hematology, VU University Medical Center
Novartis
105. Prognostic value of CIP2A level for response to nilotinib in CML patients after failure or intolerance of imatinib
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 138
N.Thielen, K.Smolders, G.J.Ossenkoppele, J.J.W.M. Janssen
Department of Hematology, VU University Medical Center
106. Promoting antitumor immunity by specific tumor-targeting of iNKT cells
J.J. van der Vliet1, T.D. de Gruijl1, G.A.M.S. van Dongen2
1Department Of Medical Oncology and 2Otolaryngology/Head-Neck Surgery, VU University Medical Center, Amsterdam
ZonMw
107. Prospective Validation of Soluble Biomarkers as Predictors of Structural Damage in Rheumatoid Arthritis (BIODAM)
G. Wells (Canada), J. Bathon (USA), C. Bingham (USA), V. Bykerk (Canada), M. Ostergaard (Denmark), T. Kvien (Norway), M.
Boers (Netherlands), D. Aletaha (Austria), P.P. Tak (Netherlands), O. Fitzgerald (Ireland), C. Ritchlin (USA), P. Mease (USA),
H. El-Gabalawy (Canada), W. Lems (Netherlands), D.J. van Schaardenburg (Netherlands), H. Berner Hammer (Norway), M.
Backhaus (Germany), B. Combe (France), G. Ferraccioli (Italy).
OMERACT Biomarker working group
Abbott
108. Resistance to proteasome inhibitors in cancer and reumatoid arthritis
B. Dijkmans1, T.D. de Gruijl2, R.J. Scheper3, G. Jansen1
1Department Of Reumatology, 2Medical Oncology and 3Pathology, VU University Medical Center, Amsterdam
VUmc CCA
109. Resistance to receptor tyrosine kinase inhibitors
H.J. Broxterman, K.J. Gotink, M. Labots, R.R. de Haas, H. Dekker, V. van Beusechem, R.J. Honeywell, G.J. Peters, H.M.
Verheul
Department of Medical Oncology, VU University Medical Center
110. Risk and Benefit of Glucocorticoid Therapy in Rheumatoid Arthritis: A systematic review and GRADE approach to the body
of evidence from prospective studies
S. Tarp Jensen1,2, E.M. Bartels1, H. Bliddal1,3,4, M. Boers5, D.E. Furst6, J.R. Kirwan7, B. Danneskiold-Samsøe1,3,4, M.
Rasmussen2, R. Christensen1,8
1.Parker Institute (MSU), Copenhagen Univ Hosp Frederiksberg Denmark, 2. Fac Pharmaceutical Sciences, Univ
Copenhagen, Denmark, 3. Center for Sensory-Motor Interaction, Aalborg University, Denmark, 4. Fac Health & Science,
Univ of Copenhagen, Denmark, 5. Department Epidemiology and Biostatistics, VU University Medical Center, Amsterdam,
6. Univ California, Los Angeles, USA, 7. Univ Bristol, Bristol, UK,
8. Inst Sports Science and Clinical Biomechanics, Univ of Southern Denmark, Odense M, Denmark.
Mundipharma International
111. Sensitivity and resistance of tumor cells to the antiangiogenic tyrosine kinase inhibitor sunitinib
K.J. Gotink1,2, H.J. Broxterman1, R. Pili2, R.R. de Haas1, H. Dekker1, R.J. Honeywell1, A.W. Griffioen1, G.J. Peters1,
H.M.W. Verheul1
1 Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
2 Genitourinary Program, Roswell Park Cancer Institute, Buffalo, New York, USA
Pfizer Global Pharmaceuticals (research grant), AEGON (Research Fellowship Program) and KWF Dutch Cancer Foundation
(scholar internship grant)
112. Sensitization towards TRAIL-induced apoptosis in acquired bortezomib resistant A549 cells is not mediated by
downstream apoptotic signalling
L.H.A.M. de Wilt1, G.J. Peters1, S. de Jong3, G. Jansen2, F.A.E. Kruyt3
1Department of medical oncology and 2Department of Rheumatology, VU University Medical Center, Amsterdam, The
Netherlands; 3Department of medical oncology, University Medical Center Groningen, University of Groningen,
Groningen, The Netherlands
113. Specific tumor-targeting of iNKT cells and VγVδ2 T cells using nanobody technology
T.D. de Gruijl1, H. Verheul1, R.J. Scheper2, J.J. van der Vliet1
1Department Of Medical Oncology and 2Pathology, VU University Medical Center, Amsterdam
KWF fellowship
114. Stereotactic ablative radiotherapy for stage I non-small cell lung cancer
Senan S, Palma DA2, Verbakel WFAR, Lagerwaard FJ, Haasbeek CJ, Ong CL, Louie AV, Rodrigues D, Verstegen NE, Cuijpers
JP, Louie AV2 SlotmanBJ.
Departments of Radiation Oncology, VU University Medical Center, Amsterdam and 2 1Department of Radiation
Oncology, London Regional Cancer Program, London, Ontario, Canada
115. Systematic review of longitudinal studies of bone loss in RA
M. Baak, L. van Tuyl, M. Voskuyl-Lodder, W. Lems, M. Boers
Department of Epidemiology and Biostatistics
116. Targeting galectin-1 for the diagnosis and treatment of cancer
A.W. Griffioen1, R. Hartmann2, L. van der Flier3
Department of 1Medical Oncology, VU University Medical Center, and 2University Saarbruecken Germany, 3Somantix BV.
Amsterdam
EU - EuroTransBio 2011
117. The Good, the Bad and the Ugly: a Tale of MiR-101, MiR-21 and MiR-155 in Pancreatic Intraductal Papillary Mucinous
Neoplasms
Giovannetti E1, Caponi S,2 Funel N,3 Frampton AE,4 Santarpia L,6 Van der Velde A,7 L.R. Jiao,4 Falcone A,2 Kazemier G,8
Meijer GA,9 Vasile E,2 Boggi U,5 Verheul HM,1 Peters GJ1
1Department of Medical Oncology, VU University Medical Center, 2Unit Medical Oncology-2, Pisa, Italy; 3Department of
Surgical Pathology, Pisa University, Pisa, Italy; 4HPB Surgical Unit, Department of Surgery, Imperial College, London, UK;
5Department of Oncology, Division of Surgery, Pisa University Pisa, Italy; 6Department of Oncology, Translational
Research Unit, Hospital of Prato, Prato, Italy; 7Centre for Integrative Bioinformatics, VU University; 8Department of
Surgery, VU University Medical Center; 9Department of Pathology, VU University Medical Center
118. The role of epigenetics in the treatment of pediatric brain tumors
S.E. Mir1, E. Hulleman1,2, D. Biesman1, M. Smits2, S. Pons4, T. Wurdinger2, D. Noske2, G.J.L. Kaspers1, J. Cloos1,3
Departments of 1Pediatric Oncology/ Hematology, 2Neurosurgery, and 3Hematology, VU University Medical Center,
Amsterdam, 4Department of Cell Death and Proliferation, Institute for Biomedical Research of Barcelona
Mozaiek, KWF fellowship
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 139
119. The therapeutic potential of IGF1R inhibition and IGFBP7 in the specific eradication of leukemic stem cells in acute
myeloid leukemia
H. Verhagen, D. de Leeuw, A. Rutten, W. Pouwels, G. Ossenkoppele, G.J. Schuurhuis and L. Smit
Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
120. TRAIL-induced pro- and anti-apoptotic kinase activation in Non small cell lung cancer cells
K. Azijli1,2, S. Yuvaraj2, M.P. Peppelenbosch3, T. Würdinger4,5, H. Dekker1, J. Joore3, E. van Dijk6, W.J. Quax7, G.J.
Peters1, S. de Jong2, F.A.E. Kruyt2
1. Department of Medical Oncology, VU University Medical Center, Amsterdam, 2. Department of Medical Oncology ,
University of Groningen, University Medical Center Groningen, 3. Department of Gastroenterology & Hepatology, Erasmus
MC, Rotterdam 4. Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology,
VU University Medical Center, Amsterdam 5. Molecular Neurogenetics Unit, Department of Neurology, Massachusetts
General Hospital and Harvard Medical School, Charlestown, MA 02113, USA 6. Pepscan Presto BV, Lelystad 7. Department
of Pharmaceutical Biology, University of Groningen
Top Institute Pharma T3-112
121. Treatment and survival of indolent and aggressive NHL patients; population based studies in the Netherlands
D.E. Issa, M. Wondergem, O. Visser, J.M. Zijlstra, P.C. Huijgens, S. Zweegman
Department of Hematology, VU University Medical Center
122. TRILHAAR project: Towards Reliable Investigation of ciLiary beHaviour And Adequate Remedies in primary ciliary
dyskinesia
T. Paff, J. Daniels, E.G. Haarman, G. Pals, P.E. Postmus
Department of Pulmonology, Paediatrics and Clinical Genetics, VU University Medical Center Amsterdam
123. Uptake and biodistribution of 89Zirconium-labeled ipilimumab in patients with metastatic melanoma or castrationresistant prostate cancer
J.M. van Dodewaard-de Jong1, H.M.W. Verheul1, G.A.M.S. van Dongen2, O.S. Hoekstra3, D.Vugts2, D.E. Oprea-Lager3,
M.C. Huisman3, S.J.A.M. Santegoets1, T.D. de Gruijl1, A.J.M. van den Eertwegh1
Departments. of 1Medical Oncology, 2Otolaryngology/Head and Neck surgery, 3Radiology & Nuclear Medicine, VU
University Medical Center
Program 5
Late effects of tumor treatment
1. Pediatric acute lymphoblastic leukemia: quality of life and cost-effectiveness of treatment
R.R.L. van Litsenburg¹, J. Huisman², C. Verhaak³, G.J.L. Kaspers4, R.J.B.J. Gemke¹
Department of ¹Pediatrics VU University Medical Center, ²medical psychology UMC Utrecht, ³medical psychology, UMC
Nijmegen, 4Pediatric oncology-hematology VU University Medical Center
AGIKO
Patient reported outcome in head and neck cancer
2. Health related quality of life in head and neck cancer patients: survival, response shift, and care
I.M. Oskam1, R.N.P.M. Rinkel1, P. Doornaert2, I.M. Verdonck-de Leeuw1, R. de Bree1, J.A. Langendijk3, N.K. Aaronson4,
C.R. Leemans1
1Departments of Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Radiotherapy, VU University Medical
Center, 3Radiotherapy, University Medical Center Groningen, 4Division of Psychosocial Research & Epidemiology, The
Netherlands Cancer Institute Amsterdam
3. Living with cancer: innovative care programs and e-health
C.F. van Uden-Kraan, I.M. Verdonck-de Leeuw
Department Otolaryngology/Head-Neck Surgery, VU University Medical Center, VU University Medical Center, Amsterdam
KWF / Alpe d'Huzes
4. OncoCompass: Development and pilot testing of a e-health management platform to optimise disease management in
cancer patients
Lubberding S, van Uden-Kraan CF, Leemans CR. de Bree R, Gerritsen WR, van Kalken C, Kraaijenhagen RA, Cuijpers P,
Verdonck-de Leeuw IM
Department Otolaryngology/Head-Neck Surgery, VU University Medical Center, VU University Medical Center, Amsterdam
NDDO Foundation and KWF
5. OncoQuest: touch screen computer based screening of health related quality of life and distress
I.M. Verdonck-de Leeuw1, C.R. Leemans1, R.N.P.M. Rinkel1, P. Doornaert2, R. de Bree1, C.R. Leemans1
1Departments of Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Radiotherapy, VU University Medical
Center
Fonds NutsOhra 0702-118
6. Patient reported speech and swallowing outcome in head and neck cancer
R.N. Rinkel1, R. de Bree1, J.A. Langendijk2, C.R. Leemans1, I.M. Verdonck-de Leeuw1
1Department Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Department Radiotherapy, University
Medical Center Groningen, VU University Medical Center, Amsterdam
Psychosocial aspects in head and neck cancer
7. Costeffectiveness of psychological intervention via the internet in head and neck cancer patients
Krebber AMH, Leemans CR, Cuijpers P, van Straten A, Smit F, de Bree R, Becker A, Smit E, Verdonck-de Leeuw IM
Department Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
ZonMw DC 80-82305-98-09001
8. Internet-based treatment of low-grade glioma patients with depression and fatigue; randomized controlled trial
F. Boele1, M. Klein1, J.C. Reijneveld2,3, I. Verdonck4,5, J.J. Heimans2, P. Cuijpers5,
Departments of 1Medical Psychology, 2Neurology, VU University Medical Center, 3Neurology, Academic Medical Center,
4Head-Neck Surgery, VU University Medical Center, 5Clinical Psychology, VU University, Amsterdam
KWF (Alpe d'Huzes) 4615-4804
9. Stepped care to improve symptoms of anxiety and depression in cancer patients
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 140
Krebber AMH, Leemans CR, Cuijpers P, van Straten A, Smit F, de Bree R, Becker A, Smit E, Verdonck-de Leeuw IM
Department Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
ZonMW 600-82600-98-8043/300
10. Structured life review using autobiographical retrieval practice in depressed palliative head and neck cancer patients
Kleijn G. de Bree R. Leemans CR, Bohlmeijer E, Steunenberg B, Eeltink C, Slotman B, Becker A, Smit E, Cuijpers P,
Verdonck-de Leeuw IM
Department Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
ZonMw PZ 1151.0003
Retinoblastoma: Late-effects
11. Complications, functional, and cosmetic results in patients treated for retinoblastoma in the Netherlands
D.L. Mourits, D.T. Hartong, M. Bosscha, J.S. Remmers, F. Bak, H.S. Tan, A.C. Moll
Department of Ophthalmology, VU University Medical Center
ODAS
12. Early-detection of quality of life problems in children with Retinoblastoma
M.I. Bosscha1J. van Dijk2, J. A. Frankfoorder1, G. Buurmans-Kool1, , A. Kors3, E. van Dulmen-den Broeder5, M.A.
Grootenhuis4, A. Houffelaar5, I.M. Verdonck-de Leeuw5 and A.C. Moll1
Departments. of 1Ophthalmology, 2Pedriatic Psychology, 3Pediatric Oncology, 5ENT/Head and Neck, VU University
Medical Center, and 4Clinical Psychology, Free University, and Psychosocial Department, Pediatrics, University Hospital of
Amsterdam
NutsOhra 0901-072
Voice, speech, and swallowing in head and neck cancer
13. Efficacy of voice therapy in patients with voice problems after treatment for early glottic cancer
C.D.L. van Gogh1, I.M. Verdonck-de Leeuw1, R.N. Rinkel1, J.A. Langendijk2, P. Doornaert3, H.F. Mahieu1
1Department Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Department Radiotherapy, University
Medical Center Groningen, 3Department Radiotherapy, VU University Medical Center, Amsterdam
KWF Dutch Cancer Society RUG2008-3983, Fonds NutsOhra 080T-043, Eureka 2614 GGN371, VAZ/CVZ Doelmatigheid
00143 00143
14. LARINX: a web-based self-help programme for laryngectomized patients during and after treatment
Cnossen IC, Leemans CR, Rinkel RN, de Bree R, Eeerensten SE, Langendijk JA, Doornaert P Verdonck-de Leeuw IM
Department Otolarynogology'/Head-Neck Surgery, VU University Medical Center Amsterdam
Michel Keijzer Foundation
15. Objective speech assessment in head and neck cancer: acoustic-phonetic and feature analyses by a neural network
M. de Bruijn1, J.A. Langendijk2, C.R. Leemans1, R. de Bree1, I.M. Verdonck-de Leeuw1
1Department Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Department Radiotherapy, University
Medical Center Groningen
KWF Dutch Cancer Society RUG2008-3983, Fonds NutsOhra 080T-043, Eureka 2614 GGN371, VAZ/CVZ Doelmatigheid
00143 2008-3983
16. Prevention of speech, swallowing, and shoulder impairment after treatment for head and neck cancer
Cnossen IC, Leemans CR, Rinkel, RN, de Bree R, Eerenstein SE, Langendijk JA, Doornaert P, Verdonck-de Leeuw IM
Department Otolarynogology'/Head-Neck Surgery, VU University Medical Center Amsterdam
Fonds NutsOhra 080T-043 080T-043
Other projects
17. A combined physical exercise and psychosocial training program to improve physical fitness in children with cancer
K.I. Braam1, E.M. van Dijk2, E. van Dulmen-den Broeder1, M.A. Veening1, M. Bierings3, J. van der Net3, J.H.M. Merks4,
M.A. Grootenhuis4 G. Sinnema3, M. Chinapaw5, T. Takken3, J. Huisman2, G.J.L. Kaspers1
1Pediatric Oncology/ Hematology, VU University Medical Center, and 2Department of medical Psychology VU university
medical center; 3Wilhelmina Children’s Hospital, University Medical Center Utrecht; 4Academic Medical Centre,
Amsterdam; 5EMGO institute, VU University Medical Center
Alpe d’HuZes/KWF 2009-4305
18. Abandonment of childhood cancer treatment in Kenya: an analysis of causes and consequences
F Njuguna1, S Mostert2, A Slot2, S Langat1, J Skiles3, MN Sitaresmi4, PM van de Ven5, J Baliddawa1, H Jepngetich1, RC
Vreeman3 ,GJL Kaspers1
1 Department of Pediatrics, Moi Teaching and Referral Hospital, Eldoret, Kenya, 2 Department of Pediatric OncologyHematology and Doctor 2 Doctor program, VU University Medical Center, Amsterdam, the Netherlands, 3 Department of
Hematology-Oncology and USAID-Academic Model Providing Access to Healthcare (AMPATH) program, Indiana University
School of Medicine, Indianapolis, United States of America, 4 Department of Pediatrics, Dr Sardjito Hospital, Yogyakarta,
Indonesia, 5 Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands
19. Adherence of Health-Care Providers with Childhood Cancer Treatment in Western Kenya
F Njuguna1 S Mostert2, R van der Burgt2, MN Sitaresmi3, J Skiles4, GJL Kaspers2
1 Pediatrics, Moi Teaching and Referral Hospital, Eldoret, Kenya, 2 Pediatric Oncology-Hematology and Doctor2Doctor
program, VU University Medical Center, Amsterdam, the Netherlands, 3 Pediatrics, Dr Sardjito Hospital, Yogyakarta,
Indonesia, 4 Pediatrics and USAID-Academic Model Providing Access to Healthcare (AMPATH) program, Indiana University
School of Medicine, Indianapolis, United States of America
20. After completion of chemotherapy: Resistance and Endurance exercise After ChemoTherapy (REACT) study
C.S. Kampshoff, L.M. Buffart, J. Brug, W. van Mechelen
Department Public and Occupational health and Department Epidemiology and Biostatistics/EMGO+ Institute Amsterdam
Alpe d’HuZes / KWF foundation
21. After Stemcell transplantation: EXercise Intervention after Stemcell Transplantation (EXIST)
S. Persoon1, M.J.M. Chin A Paw4, M.J. Kersten2, J. Brug3, F. Nollet1
Department of 1Rehabilitation Medicine and Department of 2Hematology, Academic Medical Center, Department
3Epidemiology and Biostatistics and Department 4Public and Occupational Health, VU University Medical Center
Amsterdam
Alpe d’HuZes / KWF foundation
22. Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes
combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 141
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
E.C.W. Neefjes1, J.J. van der Vliet1, M.J.D.L. van der Vorst1, W.W.A. Zuurmond2, H.M.W. Verheul1
Departments. of 1Medical Oncology and 2Anesthesiology of the VU University Medical Center
Fonds NutsOhra 1201-038
Compliance with childhood cancer treatment in Yogyakarta, Indonesia
D Susilawati1 , MN Sitaresmi2 , S Mostert3, E Supriyadi4, IL Gamayanti1, PH Widjajanto4, GJL Kaspers3
1 Psychology, Dr Sardjito Hospital, Yogyakarta, Indonesia, 2 Social Pediatrics, Dr Sardjito Hospital, Yogyakarta, Indonesia,
3Oncology-Hematology, VU University Medical Center, Amsterdam, the Netherlands, 4 Oncology-Hematology, Dr Sardjito
Hospital, Yogyakarta, Indonesia
Distress and quality of life of patients treated with autologous stem cell transplantation following high-dose
chemotherapy: Outcome of stepped care
A. Braamse1, B. van Meijel2, O. Visser3, P.C. Huijgens3, A. Boenink1, P. Cuijpers4, P. van Oppen1 , A.T.F. Beekman1, J.
Dekker1
1 Department of Psychiatry VU University Medical Center, 2 Research Group Mental Health Nursing, Inholland University,
3 Department of Hematology VU University
VU University Medical Center and Inholland University
During chemotherapy: Physical Activity during Chemotherapy Effectiveness Study (PACES)
H. van Waart, L.M. Buffart, J. Brug, N.K. Aaronson
Dutch Center Institute
Alpe d’HuZes / KWF foundation
Early recognition and optimal treatment of delirium in patients with advanced cancer
E.C.W. Neefjes1, M.J.D.L. van der Vorst1, A.T.F. Beekman2, H. Berkhof3, H.M.W. Verheul1
Departments. of 1Medical Oncology, 2Psychiatry and 3Biostatistics of the VU University Medical Center
ZonMw 1151.0011
Enhancing quality of life in low-grade glioma patients by attacking fatigue through modafinil: a randomized
magnetoencephalography study
F.Boele1, S. Driessen1, K. Hilverda1, L. Douw2, M. de Groot2, M.J.B. Taphoorn2,4, J.J. Heimans2, J.C. Reijneveld2,3, M.
Klein1
Departments of 1Medical Psychology and 2Neurology, VU University Medical Center, Amsterdam, 3Department of
Neurology, Academic Medical Center, Amsterdam, 4Department of Neurology, MC ‘Haaglanden’, Den Haag
Fonds NutsOhra Zorgsubsidies
Epidemiology of Diagnosed Childhood Cancer in Western Kenya
S Mostert1*, F Njuguna2*, LJPA Kemps1, RM Strother3, LM Aluoch2, NG Buziba4, GJL Kaspers1
1 Department of Paediatric Oncology-Haematology and Doctor 2 Doctor program, VU University Medical Centre,
Amsterdam, the Netherlands; 2 Department of Paediatrics, Moi Teaching and Referral Hospital, Eldoret, Kenya, 3
Department of Haematology-Oncology and USAID-Academic Model Providing Access to Healthcare (AMPATH) program,
Indiana University School of Medicine, Indianapolis, United States of America, 4 Department of Pathology, Moi Teaching
and Referral Hospital, Eldoret, Kenya
European survey of oncology patients
A. Davies1, Y. Barbachano1, A. Buchanan1, M. Waghorn1, C. Griffin1, S. Andersen2, A. Damkier3, T. Vejlgaard4, F.
Nauck5, L. Radbruch6, P. Lawlor7, T. O’Brien8, K.-F. Sjolund9, M. Stenberg10, J. Zeppetella11, W. Zuurmond12
1Royal Marsden Hospital, Sutton, United Kingdom, 2Roskilde Syegus, Roskilde, Denmark, 3Odense Universitetshospital,
Nyborg, Denmark, 4Sankt Maria Hospice, Velje, Denmark, 5Georg-August-Universitat Gottingen, Germany, 6University of
Aachen, Aachen, Germany, 7St James’ Hospital, Dublin, Ireland, 8Marymount Hospice, Cork, Ireland, 9Karolinska
Universitetsjukhuset, Sweden, 10Univeristy Hosptial of Lund, Lund, Sweden, 11St. Clare Hospice, Hastingwood, United
Kingdom, 12VU university medical Center, Amsterdam, The Netherlands
Evaluation of (neuro)toxicity of systemic anti-cancer therapy and neuroprotection
T.J. Postma1, A.A. Geldof2, P.C. Huijgens3, N.K. Aaronson6, G.J. Peters4, B.J. Slotman5, J.J. Heimans1
Departments of 1Neurology, 2Endocrinology, 3Hematology, 4Medical Oncology, 5Radiotherapy, VU University Medical
Center, Amsterdam, Department of 6Psychosocial Research and Epidemiology, The Netherlands Cancer Institute,
Amsterdam
Glucocorticoid induced HPA axis suppression in childhood acute lymphoblastic leukaemia and lymphoma
M.S. Gordijn1, R.J.B.J. Gemke1, J. Rotteveel1, M.B. Bierings2, C. van den Bos3, G.J.L. Kaspers1
Departments. of 1Pediatrics and Pediatric Oncology/Hematology, VU University Medical Center, 2Pediatric Hematology,
Wilhelmina Children’s Hospital, University Medical
Center Utrecht, 3Pediatric Oncology/Hematology, Emma’s Children Hospital / Academic
Medical Center
Dutch Cancer Society, grant VU 2010-4859
Health-Care Providers’ Perspectives on Childhood Cancer Treatment in Manado, Indonesia
S Mostert1, S Gunawan2, JAP van Dongen1, PM van de Ven3 , MN Sitaresmi4 , EE Wolters1 ,AJP Veerman1, M Mantik2, GJL
Kaspers1
1 Department of Pediatric Oncology-Hematology, VU University Medical Center, Amsterdam, the Netherlands, 2
Department of Pediatric Oncology-Hematology, Prof Dr RD Kandou Hospital, Manado, Indonesia, 3 Epidemiology and
Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, 4 Department of Pediatrics, Dr Sardjito
Hospital, Gadjah Mada University, Yogyakarta, Indonesia
Health-related quality of life in high-grade glioma patients and their partners in the end-of-life phase
E. Sizoo1, J.J. Heimans1, M. Klein2, T.J. Postma1, R. Grant6, W. Grisold7, C. Marosi 8,G. Stockhammer9, H.R.W. Pasman3,
L. Deliens3 J.C. Reijneveld1,4, M.J.B. Taphoorn1,5
Departments of 1Neurology, 2Medical Psychology, and 3EMGO+, VU University Medical Center, Amsterdam, 4Department
of Neurology, Academic Medical Centre, Amsterdam, 5Department of Neurology, Medical Centre ‘Haaglanden’, Den
Haag, 6Department of Neurology, Western General Hospital, University of Edinburgh, United Kingdom, 7Ludwig Bolzman
Institute for Neuro-Oncology, Kaiser Franz Josef Hospital, Vienna, 8Department of Internal Medicine, Medical Univeristy,
Vienna, and 9Department of Neurology, Neuro-Oncology Group, Medical University of Innsbruck, Austria
Jacobus Stichting
Hypothalamic-Pituitary-Adrenal axis function in survivors of childhood acute lymphoblastic leukemia and healthy
controls
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 142
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
M.S. Gordijn1, R.R.L. van Litsenburg1, RJ.B.J. Gemke1, M.B. Bierings2, C.J. Heijnen3, P.M. Hoogerbrugge4, P.M. van de
Ven5, G.J.L. Kaspers1
Departments. of 1Pediatrics and Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, 2Pediatric
Hematology/Oncology, Wilhelmina Children’s Hospital, University Medical Center Utrecht 3Laboratory
Psychoneuroimmunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, 4Pediatric HematoOncology, Radboud University Nijmegen Medical Center, 5Epidemiology and Biostatistics, VU University Medical Center,
Amsterdam
KWF VU 2010-4859
In children with cancer: Quality of Life in Motion (QLIM)
K. Braam, E.M. van Dijk-Lokkart, G.J. Kaspers
Department Pediatrics and Department Medical Psychology, VU University Medical Center Amsterdam
Alpe d’HuZes / KWF foundation
Influence of Health Insurance Status at Diagnosis on Childhood Cancer Treatment Outcome in Kenya
S Mostert1*, F Njuguna2*, PM van de Ven3, G Obara2, LJPA Kemps1, J Baliddawa2, RM Strother4, LM Aluoch2, J Skiles4,
NG Buziba5, RC Vreeman4 ,GJL Kaspers1
1 Department of Pediatric Oncology-Hematology and Doctor 2 Doctor program, VU University Medical Center,
Amsterdam, the Netherlands, 2 Department of Pediatrics, Moi Teaching and Referral Hospital, Eldoret, Kenya, 3
Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, 4 Department of
Hematology-Oncology and USAID-Academic Model Providing Access to Healthcare (AMPATH) program, Indiana University
School of Medicine, Indianapolis, United States of America, 5 Department of Pathology, Moi Teaching and Referral
Hospital, Eldoret, Kenya
Late effects of illness and treatment and quality of life in pediatric oncology patients
E. van Dulmen-den Broeder1, M.A. Veening1, Kooter AJ2, G.J.L. Kaspers1
1Pediatric Oncology/Hematology, 2Internal Medicine, VU University Medical Center, Amsterdam
VONK
Maintaining health-related quality of life of caregivers of glioblastoma patients: a randomized, two-group, controlled trial
F.Boele1, W. Hoeben1, J.J. Heimans2, T.J. Postma2, M.J.B. Taphoorn2,3 J.C. Reijneveld2,4, M. Klein1
Departments of 1Medical Psychology and 2Neurology, VU University Medical Center, 4Department of Neurology,
Academic Medical Center, Amsterdam, 3Department of Neurology, Medical Center ‘Haaglanden’, Den Haag
Tug McGraw Foundation / National Brain Tumor Foundation
Malnutrition in patients with head and neck cancer during (chemo)radiotherapy; concepts and clinical implications
J.A.E. Langius1, C.R. Leemans2, P. Doornaert3, M.H.H. Kramer4, H.M. Kruizenga1, I.M. Verdonck-de Leeuw2, J.A.
Langendijk5, P.J.M. Weijs1
Departments. of 1Nutrition and Dietetics, Internal Medicine; 2Otolaryngology/Head and Neck Surgery; 3Radiation
Oncology, 4Internal Medicine, VU University Medical Center, Amsterdam and 5Radiation Oncology, University Medical
Center Groningen, University of Groningen, The Netherlands
CCA 2011-1-02
Metoclopramide, Dexamethasone or Aloxi for the prevention of delayed chemotherapy-induced nausea and vomiting in
moderately emetogenic non-AC-based chemotherapy: the MEDEA trial
M.J.D.L. van der Vorst1, J. Dekker2, H.M.W. Verheul1
Departments. of 1Medical Oncology, 2 Psychiatry/Rehabilitation Medicine, VU University Medical Center
Neurotoxicity of cancer treatment: Neurocognitive dysfunction and underlying mechanisms
I. Schuitema1,2, A.J.P. Veerman1, C. van den Bos3, L.M.J. de Sonneville2
1Pediatrics Oncology/Hematology, VU University Medical Center, Amsterdam; 2Department of Child and Adolescent
Studies, University of Leiden, Leiden; 3Department of Pediatrics, Division of Pediatric Hematology and Oncology,
Amsterdam Medical Center, Amsterdam
Optimalization of systemic treatment strategies in elderly patients with advanced solid malignancies
K.S. Versteeg, I.R.H.M. Konings, A.A. van der Loosdrecht, H.M.W. Verheul
Department Of Medical Oncology and Hematology, VU University Medical Center, Amsterdam
Outreach pediatric oncology
T. Israels, S. Mostert, V. de Haas, W.A. Kors, M.A. Veening, F.C.H. Abbink, G.J.L. Kaspers
Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
several organisations, including St. Baldrick’s foundation
Parental experiences of childhood cancer treatment in Western Kenya
F Njuguna1 S Mostert2, A Seijffert2, MN Sitaresmi3, J Skiles4, RC Vreeman4, GJL Kaspers2
1 Pediatrics, Moi Teaching and Referral Hospital, Eldoret, Kenya, 2 Pediatric Oncology-Hematology and Doctor2Doctor
program, VU University Medical Center, Amsterdam, the Netherlands, 3 Pediatrics, Dr Sardjito Hospital, Yogyakarta,
Indonesia, 4 Pediatrics and USAID-Academic Model Providing Access to Healthcare (AMPATH) program, Indiana University
School of Medicine, Indianapolis, United States of America
Patient reported outcome in head and neck cancer patients
I.M. Verdonck-de Leeuw1, C.F. van Uden-Kraan1, I.M. Oskam1, R.N.P.M. Rinkel1, Lubberding S1, van Nieuwenhuizen A1,
R. de Bree1, P. Doornaert2, J.A. Langendijk3, N.K. Aaronson4, C.R. Leemans1
1Departments of Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Radiotherapy, VU University Medical
Center, 3Radiotherapy, University Medical Center Groningen, 4Division of Psychosocial Research & Epidemiology, The
Netherlands Cancer Institute Amsterdam
Fonds NutsOhra 0702-118; Fonds NutsOhra 0901-072; KWF/Alpe d'HuZes 2504467
Predicting OptimaL Cancer Rehabilitation and Supportive Care (POLARIS)
J. Kalter, J. Brug, I.M. Verdonck-de Leeuw, L.M. Buffart
Department Epidemiology and Biostatistics and Department Otolaryngology, VU University Medical Center Amsterdam
Bas Mulder Award, granted to L.M. Buffart by the Alpe d’HuZes/KWF Fund (VU 2011-5045).
Prevalence and biomarkers of pre-cachexia and cachexia in advanced cancer patients scheduled for treatment with
chemotherapy
S. Blauwhoff-Buskermolen1, J.A.E. Langius1, M.A.E. van Bokhorst-de van der Schueren1, A. Becker2, H.M.W. Verheul3
1Nutrition and Dietetics, Internal Medicine, 2Pulmonology and 3Medical Oncology
VUMC: VU University Medical Center
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 143
Nuts Ohra Zorgsubsidies
48. Quality of life and neurocognitive functioning in meningioma patients
D. van Nieuwenhuizen1, S.M. Peerdeman2, L.J.A. Stalpers5, W.P. Vandertop2,6, , M. Waagemans1,3, J.J. Heimans1, M.
Klein3, J.C. Reijneveld1,4
Department of 1Neurology, 2Neurosurgery, and 3Medical Psychology, VU University Medical Center, Amsterdam,
Department of 4Neurology, 5Radiotherapy, and 6Neurosurgery, Academic Medical Center, Amsterdam
49. Quality of life in patients treated with radiotherapy for head and neck cancers
P. Doornaert, M.R. Vergeer, C.R. Leemans, B.J. Slotman
Department of Radiation Oncology, Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam
50. Reproductive function, ovarian reserve, and risk of premature menopause in female childhood cancer survivors: a
nationwide study
A. Overbeek1, M.H. van den Berg1, C.B. Lambalk2, G.J.L. Kaspers1, F.E. van Leeuwen3, E. van Dulmen-den Broeder1
Departments. of 1Pediatric Oncology/Hematology and 2Obstetrics & Gynaecology, VU University Medical Center,
3Epidemiology, Netherlands Cancer Institute, Amsterdam
KWF / Kika Foundation 2006-3622
51. Risk factors for impairments of quality of life after colorectal cancer: a feasibility study
A.M.J. Braamse1, C.J.J. Mulder 2, B Penninx1, J.H. Smit1, S.T. van Turenhout2 , J. Dekker1,3
Departments. Of 1Psychiatry, 2 Gastroenterology and Hepatology, 3 Rehabilitation Medicine, VU University Medical
Center
VU University Medical Center
52. Screening and treatment of psychological distress in colorectal cancer with metastasized disease: the TES-trial
H. Bomhof- Roordink1, A. Beekman MD1, A. Honig1, A. Hoogendoorn1, M. van der Linden2,3, B. van Meijel4 , C.J.J.
Mulder MD5, M. van Tulder6, M. van der Vorst, 3, H. Verheul3, J. Dekker1
1. Department Psychiatry 2 Department Medical Psychology, 3 Department Medical Oncology , 4 Mental Health Nursing,
Inholland University of Applied Sciences, 5 Department Gastroenterology and Hepatology, 6 Health Sciences/HTA,
VU/VUmc
Alpe d’Huzes, Dutch Cancer Society
53. Sleep, fatigue and quality of life in survivors of childhood acute lymphoblastic leukemia
M.S. Gordijn1, R.R.L. van Litsenburg1, RJ.B.J. Gemke1, J. Huisman2, M.B. Bierings3, P.M. Hoogerbrugge5, G.J.L. Kaspers1
Departments. of 1Pediatrics and Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, 2 Medical
Psychology, VU University Medical Center, Amsterdam / Pediatric Psychology & Social Work, University Medical Center
Utrecht, 3Pediatric Hematology/Oncology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, 4Pediatric
Hemato-Oncology, Radboud University Nijmegen Medical Center
KWF VU 2010-4859
54. Socio-economic status plays important role in childhood cancer treatment outcome in Manado, Indonesia
S Mostert1, S Gunawan2, EE Wolters1, PM van de Ven3 , MN Sitaresmi4 , JAP van Dongen1 ,AJP Veerman1, M Mantik2, GJL
Kaspers1
1 Department of Pediatric Oncology-Hematology, VU University Medical Center, Amsterdam, the Netherlands, 2
Department of Pediatric Oncology-Hematology, Prof Dr RD Kandou Hospital, Manado, Indonesia, 3 Epidemiology and
Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, 4 Department of Pediatrics, Dr Sardjito
Hospital, Gadjah Mada University, Yogyakarta, Indonesia
55. Supportive care needs in patients treated with autologous or allogeneic hematopoietic stem cell transplantation
A.M.J. Braamse1, O. Visser 2, B. van Meijel3, P.C. Huijgens2, A.T.F. Beekman1, J. Dekker1,4
Departments. Of 1Psychiatry, 2 Hematology, 4 Rehabilitation Medicine, VU University Medical Center, 3 Inholland
University of Applied Sciences, Amsterdam
VU University Medical Center and Inholland University of Applied Sciences
56. The development, implementation and evaluation of the meaning-centered group psychotherapy 'Living Meaningfully
with Cancer' in the Netherlands
N. van der Spek, J. Vos, R. Tollenaar, P. Cuijpers, I.M. Verdonck-de Leeuw
Departments. Otolaryngology/Head-Neck Surgery, VU University Medical Center and 12Clinical Psychology, VU University
KWF
57. The effects of enteral and parenteral fish oil on outcome in lung cancer and Graft-vs-Host Disease patients
B.S. van der Meij1, J.A.E. Langius1, M. van der Bokhorst – de van der schueren1, P.A.M. van Leeuwen2
Departments. of 1Nutrition and Dietetics and 2Surgery, VU University Medical Center
Abbott Nutrition
58. The patient perspective on remission in rheumatoid arthritis
L. Van Tuyl1, M. Boers 1,2,3, D van Schaardenburg1,3, M Scholte-Voshaar4, Wijnanda Hoogland4, Josef Smolen5, George
Wells6, John Kirwan7, Sarah Hewlett7
1. Department of Rheumatology; 2. Department of Clinical Epidemiology and Biostatistics; VUmc; 3. Reade/Jan van
Breemen Research Institute Amsterdam; 4. Patient partners, VUmc, The Netherlands; 5. Medical University of Vienna,
Austria; 6. University of Ottawa, Canada; 7. University of Bristol, United Kingdom
EULAR
59. Voice, speech, and swallowing outcome in head and neck cancer patients
I.M. Verdonck-de Leeuw1, M. de Bruijn1, I.M. Cnossen1, C.D.L. van Gogh1, R.N.P.M. Rinkel1, R. de Bree1, S.E.
Eerenstein1, J.A. Langendijk2, M. Christianen2, A. Gawryszuk2, P. Doornaert3, C.R. Leemans1
1Department Otolaryngology/Head-Neck Surgery, VU University Medical Center, 2Department Radiotherapy, Univeristy
Medical Center Groningen, 3Department Radiotherapy, VU University Medical Center, Amsterdam
KWF Dutch Cancer Society RUG2008-3983, Fonds NutsOhra 080T-043, VAZ/CVZ Doelmatigheid 00143, Michel Keizer
Foundation
Appendix Annual Report 2012 VUmc CCA – Ongoing projects - 144
Appendix 8. International collaboration
Investigator
Prominent associates
Ang CW
•
•
J. Simonsen, Statens Serum Institut, Copenhagen, Denmark
P.F. Teunis, Emory University, Atlanta, USA
Appelmelk BJ
•
•
•
C.A Bewley, NIH, Bethesda, USA
J. Nigou, CNRS, IPBS Toulouse, France
R. Appelberg, IBMC, Porto, Portugal
Avan A
•
Pancreas 2000 program, Karolinska University Hospital and European
Pancreatic Club (EPC), Malmö, Sweden
Bitter W
•
•
•
•
•
Abdallah Abdallah, Arnab Pain, KAUST, Saudi Arabia
Roland Brosch, Institut Pasteur, Paris, France
Daria Bottai, University of Pisa, Pisa, Italy
Gurdyal Besra, University of Birmingham, Birmingham, United Kingdom
Annabel Parret, EMBL, Hamburg, Germany
Boellaard R & Yaqub MM
•
Dr. Turkheimer & Dr. Tomasi, Hammersmith Hospital, London, UK
Boers M
•
•
•
•
•
•
•
•
•
•
•
•
Prof. P. Tugwell, Prof G. Wells, University of Ottawa, Canada
Prof. J. Blazeby, University of Bristol, United Kingdom
Prof. P. Brooks, University of Melbourne, Australia
Prof. D. Cella, Northwestern University, Chicago, USA
Dr. R. Christensen, University of Copenhagen, Denmark
Prof. D. Clarke, Queen’s University of Belfast, United Kingdom
Prof. J. Kirwan, University of Bristol, United Kingdom
Prof. A. Lanas, University of Zaragoza, Spain
Prof. W. Maksymovich, University of Edmonton, Canada
Prof. J. Smolen, University of Vienna, Austria
Prof. V. Strand, University of Stanford, USA.
Prof. P. Williamson, University of Liverpool, United Kingdom
Braakhuis BJM
•
•
Dr. P. Golusinsky, Poznan University of Medical Sciences, Poznan, Poland
Dr. X. Marichalar, Universidad del País Vasco, Bilbao, Spain
Buffart L
•
Prof. Rob Newton and associate prof. Daniel Galvão, Edith Cowan University,
Joondalup, West Australia
Carvalho B
•
•
Carla Oliveira, Ph.D., Associate Professor, IPATIMUP, Porto, Portugal - Visit
of 2 months of Joana Carvalho (shared PhD student).
Heike Grabsch, Phil Quirke. Leeds University, Leeds, UK
Cillessen SAGM
•
•
Dr. A. Lennard, New Castle University, New Castle, UK
Drs. M. Sieniawski, University of Cologna, Cologna, Germany
Cloos J
•
•
•
•
J. Cools, Center for the Biology of Disease, VIB, Leuven, Belgium
Y.G. Assaraf, Technion-Israel Institute of Technology, Haifa, Israel
C.J. Kirk, Onyx pharmaceuticals, Inc., San Francisco, USA
A.D. Schimmer, Ontario Cancer Institute, Princess Margaret Hospital
Toronto, Toronto, Canada
P. Kearns, School of Cancer Sciences, University of Birmingham,
Birmingham, UK
D. Reinhardt, Medical School Hannover, Hannover, Germany
J. Cools, Center for Human Genetics, Katholieke Universiteit, Leuven,
Belgium
A.D. Schimmer, Princess Margaret Hospital, Ontario Cancer Institute,
Toronto, Ontario, Canada
•
•
•
•
De Bree R
•
•
Prof.dr. SJ. Stoeckli Department of Otolaryngology / Head and Neck Surgery,
Kantonsspital St. Gallen, St. Gallen, Switzerland
SENT group (coordinator prof. dr. M. McGurk Department of Maxillofacial
Surgery, Guy’s Hospital, London, UK; European multicenter study on
sentinel node in early oral cancer.
De Rie MA
•
Dr. S.C. Chen and Dr. J.S. Fine, Merck Research USA, Kenilworth NJ, USA
De Winter JP
•
D. Schindler, University of Wuerzburg, Department of Human Genetics,
Wuerzburg, Germany
R.M. Brosh Jr., National Institute on Aging, Baltimore, USA
•
Appendix Annual Report 2012 VUmc CCA – International collaboration - 145
Investigator
Dorsman JC
Prominent associates
•
W. Wang, National Institute on Aging, Baltimore, USA
•
S-Y Cong, Shengjing Hospital of China Medical University, Department of
Neurology, Shenyang, China
S. Meyer, Royal Manchester Children’s Hospital, Young Oncology Unit,
Manchester, UK
•
Fijneman R
•
Robert Cormier, Ph.D., Associate Professor, University of Minnesota Medical
School Duluth, Duluth, MN (USA)
Gibbs S
•
•
•
•
Dr. Emanuela Corsini, Università degli Studi di Milano, Milan, Italy
Prof. Dr. J. McLoed, University of West England, Bristol, UK
Dr. E. Roggen, Novozymes BV, Bagsvaerd, Denmark
Dr. C.B. Madsen, National Food Institute, Technical University of Denmark,
Denmark
Dr. T Eitze, BASF, Berlin, Germany
•
Giovannetti E
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Gruijl, de TD
•
•
Prof. Giuseppe Giaccone, Head Medicine Oncology Branch, National Cancer
Institute, Bethesda, USA
Prof. Yehuda Assaraf, Head Pharmacology Lab, Department of Biology, The
Technion-Israel Institute of Technology, Haifa, Israel
Dr. Jih-Hsiang Lee, Department of Oncology, National Taiwan University
Hospital, Taipei, Taiwan
Dr. Heelo Sudo, Toray Industries, Inc., New Frontiers Research Laboratories,
Kanagawa, Japan
Prof. Mathias Lohr, Head Dept. Gastroenterology, Karolinska Institute,
Stockholm, Sweden
Dr. Leticia G Leon, Instituto Universitario de Bio-Organica Antonio Gonzalez
(IUBO-AG), Universidad de La Laguna, C/Astrofísico Francisco Sanchez, La
Laguna, Spain
Dr. Karl Quint, Marburg University, Marburg, Germany
Dr. Adam Frampton, Imperial College, London, UK
Dr. Hatem A Azim, Cancer Translational Research Laboratory - J.C Heuson,
Université Libre de Bruxelles Institut Jules Bordet, Brussels, Belgium
Prof. Ugo Boggi Head Division of Surgery, Pisa University, Pisa
Prof. Romano Danesi, Head Division of Pharmacology, Pisa University
Prof. Alfredo Falcone, Head Division of Oncology, Pisa University
Prof. Daniela Campani, Associate Professor of Pathology, Pisa University
Prof Filippo Minutolo, Associate Professor of Medicinal Chemistry, Pisa
University
Dr. Federico Cappuzzo, Head Department of Oncology, Livorno Civil
Hospital, Livorno
Dr. Maurizio Cantore, Head Department of Oncology, Carrara Civic Hospital,
Carrara
Prof. Andrea Ardizzoni, Head Department of Oncology, Parma University
Hospital, Parma
Dr. Armando Santoro, Head Department of Oncology and Hematology,
Humanitas Hospital, Milano
Dr. Tommaso De Pas, Unit Oncology and New Drugs, European Institute of
Oncology, Milano
Dr. Fedro Peccatori, Director, Fertility & Procreation in Oncology Unit,
Department of Medicine, European Institute of Oncology, Milano
Dr. Michele Reni, Department of Oncology, San Raffaele Hospital, Milano
Dr. Michele Milella, Regina Elena National Cancer Institute, Roma
Dr. Giovanni Codacci-Pisanelli, Roma University “La Sapienza”, Roma
Karin Jooss, Kristen Hege, Natalie Sacks, Cell Genesys Inc, South San
Francisco, CA, USA
David T. Curiel, Washington University School of Medicine, St. Louis, MO,
USA
Haarman EG
•
ERS PCD taskforce on Primary Ciliary Dyskinesia in children
Heideman DAM
•
Dr. S. Franceschi and Dr. G. Clifford, International Agency Research on
Cancer (IARC), Lyon, France.
Dr. R. Thomas, Cologne, Germany
Prof. FX Bosch, Barcelona, Spain
Prof. J. Cuzick, Centre for Epidemiology, mathematics and statistics,
Wolfson Institute, London, UK
•
•
•
Israels T
•
L. Molyneux, University of Malawi, Blantyre, Malawi
Appendix Annual Report 2012 VUmc CCA – International collaboration - 146
Investigator
Prominent associates
•
•
P. Hesseling, University of Stellenbosch, Cape Town, South Africa
S. Bailey, Northem Institute for Cancer Research, Newcastle, United
Kingdom
• Prof. Dr. E.M. Molyneux, College of Medicine, Blantyre, Malawi
• SIOP PODC, Working Group on Adapted Treatment regimens
Jansen G
•
Prof. Dr. Y.G. Assaraf, The Technion-Israel Institute of Technology, Haifa,
Israel
Kaspers GJL
•
K. London, L. Dalla-Pozza and R. Howman-Giles, The Children’s Hospital at
Westmead, Sydney, Australia
Kaspers GJL & Bokenkamp A
•
B. Stoffel-Wagner, Bonn University Medical Center, Bonn, Germany
Kaspers GJL & Cloos J
•
•
U. Creutzig and D. Reinhardt, AML-BFM group, Hannover, Germany
Y. Assaraf, Technion-Israel Institute of Technology, Haifa, Israel
Kaspers GJL & Mostert S
•
Sutaryo, P.H. Widjayanto, E. Supriyadi and M.N. Sitaresmi, Dr. Sardjito
General Hospital, UGM, Yogyakarta, Indonesia
F. Njuguna, MTRH, Eldoret, Kenya
R.M. Strother, J. Skiles, Indiana University, Indianapolis, USA
•
•
Klein M
•
Dr. M. Preusser, Department of Medicine & Comprehensive Cancer Center,
Medical University of Vienna, Vienna, Austria
Kluytmans JAJW
•
Brian D. Johnston, James R. Johnson, Veterans Affair Medical Center,
University of Minnesota, Minneapolis, USA
David Gordon, The Australian National University, Canberra, Australia
Beth J. Feingold, Ellen K. Silbergeld, Frank C. Curriero, Johns Hopkins
Bloomberg School of Public Health, Baltimore, USA
•
•
Kors WA & Veening MA
•
E. Supriyadi and P.H. Widjayanto, Dr. Sardjito General Hospital, UGM,
Yogyakarta, Indonesia
Lagerwaard FJ
•
G. Rodrigues, Dept. of Epidemiology and Biostatistics, University of Western
Ontario, London, Canada
D. Palma, Department of Radiation Oncology, London Regional Cancer
Program, London, Canada
•
Meijer CJLM
•
•
•
•
•
•
•
•
•
•
Meijer GA
•
•
•
Prof. J.G. Herman and Prof. S. Bayling, The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Prof. F Pontén, Department of Genetics and Pathology, Rudbeck Laboratory,
Uppsala University, Uppsala, Sweden
Prof. P. Quirke and H. Grabsch, PhD, Academic Unit of Pathology, University
of Leeds, United Kingdom
Prof. D. Sidransky,The Johns Hopkins School of Medicine, Baltimore,
Maryland, United States of America
R.T. Cormier, University of Minnesota Medical School, Duluth, MN, USA
Prof. G.Giaccone, Center for Cancer Research, National Cancer Institute,
Bethesda, MD, USA
K.H. Buetow PhD, Center for Biomedical Informatics and Information
Technology National Cancer Institute, Bethesda, MD, USA
Carla Oliveira, PhD, IPATIMUP, Porto, Portugal
Prof. dr. S. Tejpar, KU Leuven, Belgium
•
Prof.dr. David Thorley-Lawson, Dept. Pathology, Tufts University, Boston,
•
•
•
•
•
•
Middeldorp JM
Dr.G. Clifford, IARC, Lyon, France
Dr.S. Franceschi, IARC, Lyon France
Dr.J. Smith, Faculty Research, UNC Gillings School of Global Public Health,
University of North Carolina, Department of Epidemiology, USA
Dr.D. Kordzaia, Organisation HPV Screening, CTMA, Tbilisi, Georgia
Dr. X. Castellsagué and dr FX Bosch, dr S.de Sanjose, Servei d'Epidemiologia
i Registre del Càncer - Epidemiology and Cancer Registration Unit - Institut
Català d'Oncologia - Catalan Institute of Oncology – Barcelona -Spain
Dr.G. Ronco, Centro per la Prevezione Oncol. Piemonte, Turin, Italy
Dr. M. Arbyn, Scientific Institute of Public Health, 1050 Brussel, België
Prof dr J Cuzick, and prof dr A.Lorincz Wolffon Insitute London
Prof dr J.Dillner, Karolinska institute , Stockholm, Sweden
Dr M.Schiffman, division of of epidemiology and cancer genetics National
Cancer Institute Rockville, MD, USA
Appendix Annual Report 2012 VUmc CCA – International collaboration - 147
Investigator
Prominent associates
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Morré SA
•
•
•
Ossenkoppele GJ
•
USA
Prof.dr. Martin Allday, Dept. Medicine, Imperial College of London, London,
UK
Prof.dr. Gavin Giovannoni, Dept. Neuroscience, Barts School of Medicine,
London, UK
Prof. dr. George Tsao, Dept Microbiology and Clinical Oncology, University
of Hong Kong, Hong Kong, China
Prof.dr. Alan Chiang, Dept. Paediatrics at Queen Mary Hospital, Hong Kong
University, Hong Kong, China
Prof.dr. Sofia Haryana, Faculty of Medicine, Gadjah Mada University,
Yogyakarta, Indonesia.
Prof.dr. Allan Hildesheim, Dept. Cancer Epidemiology and Genetics,
National Cancer Institute, Rockville, USA
Prof.dr. Ingemar Ernberg, Microbiology and Tumorbiology Center,
Karolinska Institute, Stockholm, Sweden
Prof.dr. Elisabete Weiderpass, Dept. Cancer Epidemiology and Biostatistics,
Karolinska Institute, Stockholm, Sweden.
Prof.dr. Shannon Kenney, Dept. Medicine and Public Health, University of
Wisconsin, Madison, USA
Prof.Dr. Rosalyn Rochford, Dept. Medicine, SUNY University, Syracuse, USA.
Prof.dr. Lori Frappier, Dept. Molecular Genetics, University of Toronto,
Toronto,Canada
Prof.dr. Elliot Kieff. Dept. Infectious Diseases, Harvard University, Boston,
USA
Dr. Jackson Orem, School of Medicine, Makerere University, Kampala,
Uganda.
Prof.dr. Alan Rickinson, Dept. Cancer Studies, University of Birmingham,
Birmingham, UK.
Nunos Pais en Oliver Liesenfeld, Roche Molecular Systems, Pleasanton, CA,
USA
Deborah Dean, Chori and UCSF and Berkeley, SF, CA, USA
David Ojcius, UC Merced, Merced, CA, USA
•
•
W.Walter, University of Washington Medical Center, Fred Hutchinson Cancer
Research Center, Seattle, WA 98109, USA
Consortium, European Leukemianet, Mannheim Germany
R.Schlenk, Universitätsklinikum Ulm, Ulm, German
Pegtel DM
•
•
•
•
•
Prof.dr. David Thorley-Lawson, Tufts University Boston MA, USA
Prof.dr. Elliot Kieff, Harvard University, Boston MA, USA
Prof. dr. Xandra Breakefield, Harvard University Boston MA, USA
Prof. dr. Nicola Baldini, University of Bologna, Italy
Prof dr Todd Golub, Broad Institute of MIT and Harvard, Boston USA
Peters GJ
•
I. Fichtner, Max-Delbrück-Center for Molecular Medicine, Berlin-Buch,
Germany
Dr. J.M. Padron, Instituto Canario de Investigación del Cáncer (ICIC),
Tenerife, Spain
Prof. Dr. Y. Assaraf, Technion-Israel, Institute of Technology University,
Haifa, Israel
Dr. P.A. Zucali & Prof. Dr. A Santoro, Humanitas Hospital, Milan, Italy
Dr. M Fukushima, Taiho Pharmaceuticals, Tokushima, Japan
Dr. Carmelo Tibaldi
Dr. G. Giaconne, NCI, Bethesda, Maryland, USA
Dr. N. Funel, University of Pisa, Pisa, Italy
Dr. R.A. Schwendener
Prof. Dr. H Schott
Prof. Dr. J Balzarini, Rega Institute, Leuven, Belgium
Prof. Dr. O Fodstadt, Oslo, Norway
Prof. Dr. S. Eriksson, Uppsala, Sweden
Dr. C.M. Galmarini, Pharmamar, Madrid, Spain
Dr. M. Sandvold, Clavis Pharma, Oslo, Norway
Dr. F. Minutolo, University of Pisa, Pisa, Italy
Prof. Dr. K. Ichida, Jikei University, Tokyo, Japan
Prof. Dr. Y. Mayur, Center for Drug Design and Discovery, SVERI’s College of
Pharmacy, Pandharpur, India
Dr. J Hall, EORTC Tranlational research Division, Brussels, Belgium
Dr. A Hanauske, Eli Lilly &CO, European Head Quarters, Germany
Prof. Dr. A. Paradiso, National Cancer Institute, Bari, Italy
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Appendix Annual Report 2012 VUmc CCA – International collaboration - 148
Investigator
Prominent associates
•
•
•
•
•
Franco Muggia MD, New York University, New York, USA
Roger Phillips Ph.D., University of Bradford, Bradford, UK
Victor Marquez Ph.D., National Cancer Institute, Bethesda, Maryland, USA
A. Ardizzoni M.D., University of Parma, Parma, Italy
P.G. Petronini Ph.D., University of Parma, Parma, Italy
Peters GJ & Giovannetti E
•
R. Danesi, University of Pisa, Pisa, Italy
Postma TJ
•
Prof dr G Cavaletti, Universita di Milano, Bicocca, Monza, Italy
Reijneveld JC
•
Prof. Dr S.M. Chang, Brain Tumor Center University of California San
Francisco (UCSF), San Francisco, CA, USA
Dr. M. Preusser, Department of Medicine I & Comprehensive Cancer Center,
Medical University of Vienna, Vienna, Austria
•
Rustemeyer T
•
•
•
•
•
•
European consortium (30 international partners – multiple publications),
Multiple in Europe (www.sensitiv.eu), Europe
EU commission on Consumers’ Health, Multiple in Europe, EU commission
in Brussels, Belgium, Europe, organized in Brussels, Belgium
EECDRG, Multiple in Europe, EU commission in Brussels, Belgium, Europe,
several sites
EPOS, Multiple in Europe, EU commission in Brussels, Belgium, Europe,
organized in Brussels, Belgium
An Goossens, Leuven University, Leuven, Belgium
Jacob Thyssen, Danish Institute of Dermatology and Allergology
Copenhagen, Denmark
Savelkoul PHM
•
Roche Molecular Systems, Plesangton, USA
Schuurhuis GJ
•
P. Valent, Department of Internal Medicine I, Division of Hematology &
Hemostaseology, Medical University of Vienna, Vienna, Austria
S Gröschel, University Hospital Ulm, Ulm, Germany
P. Valent, Department of Internal Medicine I, Division of Hematology &
Hemostaseology, Medical University of Vienna, Vienna, Austria
S. Gröschel, University Hospital Ulm, Ulm, Germany
•
•
•
Senan S
•
•
•
•
•
•
•
Slotman BJ
•
•
•
•
•
•
Sminia P
•
•
•
•
Dr D. Palma, Department of Radiation Oncology, London Regional Cancer,
Ontario, Canada
Dr K. Huang, Department of Radiation Oncology, London Regional Cancer
Program, Ontario, Canada
Prof. G. Baumann, Department of Radiation Oncology, London Regional
Cancer Program, Ontario, Canada
Dr G. Rodrigues, Department of Epidemiology and Biostatistics, University
of Western Ontario, London, ON, Canada
Dr M. Guckenberger, Department of Radiation Oncology, University of
Würzburg, Würzburg, Germany
Dr G. Hanna, Centre for Cancer Research and Cell Biology, Queen's
University of Belfast, Belfast, Northern Ireland
Dr A. Botticella, Department of Oncology, Radiation Oncology Unit,
University of Turin, Turin, Italy
D. Palma, Department of Radiation Oncology, London Regional Cancer
Program, London, Canada
G. Rodrigues, Department of Radiation Oncology, London Regional Cancer
Program, London, Canada
J. Chang, Department of Radiation Oncology, MD Anderson Cancer Center,
Houston, USA
B. Loo Jr, Department of Radiation Oncology, Stanford University, Palo Alto,
USA
A. Sahgal, Department of Radiation Oncology, Sunnybrook Health Sciences
Center, Toronto, Canada
S. Lo, Department of Radiation Oncology, Ohio State Univ, Columbus, OH,
USA
C. A. Fedrigo, Catholic University Rio Grande do Sul, Porte Alegro, Rio
Grande do Sul, Brazil
R. Mayer, M.D., Ph.D., EBG MedAustron GmbH Ion Beam Therapy Center,
Wiener Neustadt, Austria
M. Elnaggar, M.D., Department Clinical Oncology, Assuit University Hospital,
Assuit, Egypt
B. Clavo, M.D., Ph.D. , Department of Radiation Oncology & Research Unit,
Appendix Annual Report 2012 VUmc CCA – International collaboration - 149
Investigator
Prominent associates
•
•
•
•
Snijders PJF
•
•
•
•
•
•
•
Steenbergen RDM
•
•
•
Taphoorn MJB
•
•
Dr. Negrin University Hospital, Las Palmas, Canary Islands, Spain
A. Chalmers. M.D., Ph.D. Beatson West of Scotland Cancer Center, Glasgow,
UK
S. Short, M.D., Ph. D. UCL Cancer Institute, University College London, UK
P. Enger, M.D. Ph. D. University of Bergen, Bergen, Norway
R. Bjerkvig, Ph. D. University of Bergen, Bergen, Norway
Dr.G. Clifford, Dr.S. Franceschi, Dr. H de Vuijst, Dr. M. Tommasino, IARC,
Lyon, France
Dr.J. Smith, Faculty Research, UNC Gillings School of Global Public Health,
University of North Carolina, Department of Epidemiology, USA
Dr. X. Castellsagué and dr FX Bosch, dr S.de Sanjose, Servei d'Epidemiologia
i Registre del Càncer - Epidemiology and Cancer Registration Unit - Institut
Català d'Oncologia - Catalan Institute of Oncology – Barcelona -Spain
Dr.G. Ronco, Centro per la Prevezione Oncol. Piemonte, Turin, Italy
Dr. M. Arbyn, Scientific Institute of Public Health, 1050 Brussel, België
Prof dr J Cuzick, and prof dr A.Lorincz Wolffon Insitute London
Dr. M. L. Gillison, Viral Oncology, The Ohio State University Comprehensive
Cancer Center, Columbus, OH, USA
Prof.dr. F. Rösl, Dept. Tumorvirology, DKFZ, Heidelberg, Germany
Prof.dr. T. Broker, Prof.dr. L. Chow, Biochemistry, University of Alabama,
Birmingham, USA
Prof.dr. B. Deplancke, EPFL, Lausanne, Switzerland
Prof. dr. M.J. van den Bent, on behalf of the EORTC Brain Tumour Group,
EORTC Data Center, Brussels, Belgium
Dr. A. Bottomley, on behalf of the EORTC Quality of Life Department and
PROBE project, EORTC Data Center, Brussels, Belgium
Thijssen VL
•
SM Blois, Medicine University of Berlin, Berlin, Germany
Van Beusechem VW
•
Victoria A. Meliopoulos, Lauren E. Andersen, S. Mark Tompkins, Ralph A.
Tripp, Department of Infectious Diseases, University of Georgia, Athens,
USA
Katherine F. Birrer, John Stambas, John W. Lowenthal, Andrew G. D. Bean,
Cameron R. Stewart, CSIRO Australian Animal Health Laboratory and School
of Medicine, Deakin University, Geelong, Victoria, Australia
Kaylene J. Simpson, Victorian Centre for Functional Genomics, Peter
MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Iain Fraser, Laboratory of Systems Biology, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Musa Mhlanga, Samantha Barichievy, Gene Expression & Biophysics Group,
Synthetic Biology - ERA, CSIR, Pretoria, South Africa
Queta Smith, Devin Leake, Jon Karpilow, Thermo Fisher Scientific, 2650
Crescent Drive, Lafayette, Colorado, USA
Amy Buck, Centre for Immunity, Infection & Evolution, University of
Edinburgh, Edinburgh, Scotland
Ghil Jona, Department of Biological Services, Weizmann Institute of Science,
Rehovot 76100, Israel
•
•
•
•
•
•
•
Van Bodegraven AA
•
•
S.B. Hanauer, University of Chicago, USA
Several/CERTIFI Study Group, USA/Canada/UK/Australia/France/
Sweden/Greece
Van den Elsen PJ
•
Victor E. Marquez, Center for Cancer Research, NCI-Frederick, Frederick,
MD, USA
Koichi S. Kobayashi, Department of Microbial and Molecular Pathogenesis,
College of Medicine, Texas A&M Health Science Center, 415A Reynolds
Medical Building, College Station, Texas 77843, USA
Ismail Reisli, Department of Pediatric Allergy and Immunology, Konya
University Meram Medical Faculty, Konya, Turkey
•
•
Van der Horst-Bruinsma IE
•
•
•
•
Van der Sar AM
•
Robert Plenge (VS)
Progenika (Madrid)
Executive board ASAS (Assessment of SpondyloArthritis International
Society, worldwide organisation of researchers in Ankylosing Spondylitis)
Steering committee of IGAS, International Genome wide Association Studies
(chair: Mathew Brown, Australia, Canada, US, China)
Prof. Dr. C.W. Michiels, Dr. L. Vanderkelen, Arenberg Doctoraatsschool
Appendix Annual Report 2012 VUmc CCA – International collaboration - 150
Investigator
Prominent associates
Wetenschap & Technologie, Faculteit Bio-ingenieurswetenschappen,
Departement Microbiële en Moleculaire systemen, Katholieke Universiteit
Leuven, 3001 Heverlee, België
Van Furth AM
•
•
•
•
•
Prof. dr. J. Schoeman, Tijgerberg Hospital, Cape Town, South-Africa
Prof. C.J. Reinecke, Centre for Human Metabolomics, Potchefstroom, SouthAfrica
Dr. R. Peters, ANOVA Health Institute, Limpopo, South-Africa
Prof. J. Bartlett, John Hopkins, Baltimore, USA
T. Msoka, Kilamanjaro Christian Medical Centre, Moshi, South-Africa
Van Furth AM &
Kuip, van der M
•
Prof. D. Kirschner, Department of Microbiology and Immunology, Uiversity
of Michigan, Ann Arbor, Michigan, USA
Van Grieken NCT
•
•
•
Heike Grabsch, Phil Quirke. Leeds University, Leeds, UK.
Pehr Lind. Karolinska Institute, Stockholm, Sweden
Laura Tang, Daniel Coit. Memorial Sloan-Kettering Cancer Center, New York,
USA
Van Schaardenburg D
•
•
•
•
SERA consortium in the USA (Kevin Deane, Mike Holers, Jill Norris)
Karim Raza, Birmingham, UK
Lars Klareskog, Johan Rönnelid, Sweden,
Walter Maksymowych; Anthony Marotta from Augurex, Canada
Veening MA & Kors WA
•
E. Supriyadi and P.H. Widjavanto, Dr. Sardjito General Hospital, UGM,
Yogyakarta, Indonesia
Verdonck- de Leeuw IM
•
European Organisation for Research and Treatment of Cancer (EORTC),
Quality of life Group / Head and Neck Cancer Module
European Organisation for Research and Treatment of Cancer (EORTC),
Quality of life Group / Oral Health Module
European Organisation for Research and Treatment of Cancer (EORTC),
Quality of life Group / Computerized Adaptive Testing (CAT) project
•
•
Verweij CL
•
•
Prof. dr. T.M. Aune, Div. Rheumatology, Vanderbilt University, Denver, USA
Prof. dr. Thomas Aune, Vanderbilt University School of Medicine, Division of
Rheumatology, Department of Medicine, Nashville, TN 37232, USA.
Voskuyl AE
•
•
Scleroderma Clinical Trials Consortium (SCTC), USA
DUO Registry investigators, Actelion, Switserland
Vuurden, van DG
•
M. Kool, University of Heidelberg, Heidelberg, Germany
Waisfisz Q &
Meijers-Heijboer H
•
Multiple, the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA),
broad international collaboration
Multiple, the Breast Cancer Association Consortium (BCAC), broad
international collaboration
•
Wesseling P
•
•
•
•
Ylstra B
•
•
•
•
•
•
EORTC Brain Tumor Study Group (Hegi/Stupp, Lausanne, Switzerland; Van
den Bent/Kros/French, Rotterdam, The Netherlands)
German Neuro-Oncology/Neuropathology Network (Von Deimling,
Heidelberg; Reifenberger, Dusseldorf)
eTUMOUR; European project for development of a Web accessible MR
decision support system for brain tumour diagnosis and prognosis,
incorporating in vivo and ex vivo genomic and metabolomic data (Celda,
Valencia, Spain; Arus/Julia Sape, Barcelona, Spain).
Prof. Ken Aldape, MD Anderson Cancer Center, Houston TX, USA
Prof. dr. W. Deppert Department of Clinical Chemistry/Central Laboratories,
Center for Diagnostic, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany
Dr. C. H. M. Mellink Department of Clinical Genetics, Academic Medical
Center, Amsterdam, Pro. Dr. P Tan Cancer and Stem Cell Biology, Duke-NUS
Graduate Medical School Singapore, National Cancer Centre, Singapore
Dr. H. Grabsch & Prof. dr. P. Quirke Pathology and Tumour Biology, Leeds
Institute of Molecular Medicine, University of Leeds, UK
Prof dr Schmitt IPATIMUP - Institute of Molecular Pathology and Immunology
of the University of Porto, Rua Dr Roberto Frias, s/n, 4200-465, Porto,
Portugal.
Prof. Dr. K Pantel. Institute of Tumor Biology, University Medical Center
Hamburg-Eppendorf, Martinistreet 52, 20246 Hamburg, Germany
Prof. Dr. CJ Punt CJ & dr. I Nagtegaal, Radboud University Nijmegen Medical
Appendix Annual Report 2012 VUmc CCA – International collaboration - 151
Investigator
Prominent associates
•
•
•
•
•
Centre, PO Box 9101, 6500 HB Nijmegen & Academic Medical Center,
Amsterdam, The Netherlands
Dr. K. Kok. Departmentof Genetics,UniversityMedical Center
Groningen,University Groningen
Dr. S. Tejpar, Digestive Oncology Unit,University Hospital
Gasthuisberg,Leuven,Belgium
Prof. dr. Nick Gilbert, MRC Human Genetics unit, University of Edinburg,
Edinburgh UK
Dr. Annette Byrne, Royal College of Surgeaons in Ireland, Dublin Ireland
Prof. dr. C Caldas. MRC Cancer Cell Unit, Hutchison-MRC Research Centre,
Cambridge, UK
Zijlman JM
•
Prof. dr. A. Engert / Prof. dr M. Meignan, German Hodgkin Study Group,
LYSA, Cologne, Germany / Paris
Zweegman S
•
YG Assaraf, The Fred Wyszkowski Cancer Research Laboratory, Department
of Biology, Technion-Israel Institute of Technology, Haifa, Israel
R Mesa, Division of Hematology and Oncology, Mayo Clinic, Scottsdale, USA
European Myeloma Network
Prof. dr. Y.G. Assaraf, The Fred Wyszkowski Cancer Research Laboratory,
Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel
R. Mesa, Division of Hematology and Oncology, Mayo Clinic, Scottsdale, USA
•
•
•
•
Appendix Annual Report 2012 VUmc CCA – International collaboration - 152
Appendix 9. Scientific Research Committee
CWO: Clinical protocols
Indiener
Titel
Bahce I
Can tumor uptake of [18F]afatinib in NSCLC patients be quantified, and does
[18F]afatinib uptake identify patients who will benefit from afatinib therapy?
Bakker SF
Concomitant presence of Celiac Disease in adult patients with type 1 diabetes
mellitus; investigation of the microvascular function
Bonjer HJ
De transrectale totale mesorectale excisie (TME) een hybride NOTES procedure
Boven E
Open-label multicenter expanded access onderzoek naar de behandeling van
everolimus (RAD001) in combinatie met exemestaan bij postmenopauzale
vrouwen met oestrogeenreceptor positieve lokaal gevorderde of uitgezaaide
borstkanker en ziekteprogressie na voorafgaande endocriene behandeling
Boven E
The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A phase 3 openlabel, randomized, multicenter study of NKTR-102 versus treatment of
physicians choice (TPC) in patients with locally recurrent or metastatic breast
cancer previously treated with an anthracycline, a taxane, and capecitabine
Bruynzeel AME
Extreme hypofractionated intensity modulated radiotherapy in stereotactic
conditions for cT1c-cT3a prostate cancerwith a low risk of nodal metastases
(20%, Roach index): a Novalis Circle Phase I-II prospective randomized Trial
Buter J
De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor
(cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity
Events in Human Papillomavirus-positive oropharyngeal squamous cell
carcinoma
Buter J
A phase 2 study of LY2157299 monotherapy or LY2157299 and lomustine
combination therapy compared to lomustine monotherapy in patients with
recurrent malignant glioma
Buter J
A randomised, double-blind, placebo-controlled, phase III study to evaluate the
efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients with stage III, Iva, of IVb locoregionally advanced head and neck squamous cell carcinoma
Chamuleau MED
DA-EPOCH-R study: Efficacy and feasibility of first-line treatment with riskadapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients (18 years) with
Burkitt lymphoma; a phase II clinical trial.
Chamuleau MED
Open label, multi-centre, phase 2 Study of Anti-CCR4 Monoclonal Antibody KW0761 (mogamulizumab) in Subjects with Previously Treated Peripheral T-cell
Lymphoma (PTCL)
Chamuleau MED
A randomized, controlled, double-blind Phase III trial to compare the efficacy,
safety and parmacokinetics of GP2013 plus cyclophosphamide, vincristine,
prednisone vs. Mab Thera® plus cyclophosphamide, vincristine, prednisone,
followed by GP2013 or Mab Thera® maintenance therapy in patients with
previously untreated, advanced stage follicular lymphoma
Daniels JMA
Effect of carbon dioxide enriched ambient air on pharmacokinetics and
deposition in bronchiectasis patients using tobramycin inhalation: a proof of
concept study
Daniels JMA
Een fase 3, dubbelblind, multicenter, gerandomiseerd, placebogecontroleerd
onderzoek waarin het gebruik van meerdere kuren Aztreonam oplossing voor
inhalatie/Aztreonam 75 mg poeder en oplosmiddel voor oplossing voor
verstuiving wordt geëvalueerd bij proefpersonen met non-CF-bronchiëctasieën
en gram negatieve endobronchiale infectie
de Bree R
Near-infrared fluorescence guided sentinel node detection in head and neck
cancer using Nonocoll-IRDye800CW: a feasibility study
de Meij TGJ
Microbiota profiling in pediatric infammatory bowel disease by means of IS-pro
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 153
de Meij TGJ
Microbiota profiling in Hirschsprungs disease by means of IS-pro: identification
of risk factors for enterocolitis
Dekker J
Screening and treatment of psychological distress in colorectal cancer with
metastasized disease: the TES-trial
Eekhoff EMW
In vitro Characterization of STemcells Osteogenic Potency in patients with
fibrodysplasia ossificans progressive (STOP-FOP)
Frings V
Test-retest reproducibility of whole body [18F]FDG PET-CT in patients with nonsmall cell lung cancer
Frings V
Validation of simplified quantitative methods for 3deoxy-3[18F]fluorothymidine ([18F]FLT) PET in patients with non-small cell lung cancer
treated with gefitinib
Gent Y
PET imaging of arthritis by specific macrophage targeting in Rheumatoid
Arthritis patients – clinical proof of concept studies
Gerritsen WG
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ±GM-CSF
in Men with Asymtomatic of Minimally Aymptomatic Metastatic, CastrateResistant Prostate Cancer
Gibbs S
Development of an in vitro keloid scar model for identifying and testing new
anti-scar therapies
Haasbeek CJA
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of
Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial
Hendrikse NH
[11C]Erlotinib pharmacokinetics: an in vivo study using positron emission
tomography in non-small cll lung cancer patients with and without erlotinib
therapy
Hoekstra OS
Diffusion-weighted magnetic resonance imaging (DW – MRI) as an imaging
biomarker: reproducibility of measurements in liver and lung
Hugtenburg JG
Factors influencing the outcome of first-line nilotinib treatment in patients with
chronic phase chronic myeloid leukaemia in daily practice
Huijts CM
Phase II study of sunitinib rechallenge in patients with metastatic renal cell
carcinoma
Janssen JJWM
HOVON 107: The feasibility and efficacy of subcutaneous and intravenous
Plexifor for mobilization of peripheral blood stem cells in allogeneic HLAidentical sibling donors: a randomized phase II study
Janssen JJWM
Prevalence of ESBL-producing Enterobacteriaceae in haematology patients
(versie 6-1-2012)
Janssen JJWM
EURO-SKI Trial: multicenter trial estimating the persistance of molecular
remission in chronis myeloid leukaemia after stopping TKI
Janssen JJWM
HOVON 115: Double umbilical cord blood transplantation in high-risk
haematological patients. A phase II study focussing on the mechanism of graft
predominance
Janssen JJWM
NordDutchCML009: A phase II, single arm, multicentre study of nilotinib in
combination with pegylated interferon-a2b in patients with suboptimal
molecular response or stable detectable molecular residual disease after at
least two years of imatinib treatment
Kaspers GJL
An international collaborative study to discontinue Imatinib/Glivec in
pediatric CML patients with sustained complete molecular response
(STOPIMAPED)
Kaspers GJL
ALL-11, Treatment study protocol of the Dutch Childhood Oncology Group for
childeren and adolescents (1-19 year) with newly diagnosed acute
lymphoblastic leukemia
Kaspers GJL
A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric
patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase
(CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL
Konijn NPC
Langetermijneffectiviteit van de COBRA-light en COBRA-behandeling bij vroege
reumatoïde artritis
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 154
Meijer E
Treatment guided by detection of Minimal Residual Disease after allogeneic
stem cell transplantation in Acute Myeloid Leukaemia
Menke-van der Houwen van Oordt CW
A phase II prospective imaging study evaluating the utility of pre-treatment
zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response
to identify patients with advanced HER-2 positive breast cancer unlikely to
benefit from a novel anti-HER2 therapy: T-DM1
Menko FH
Informing relatives about their cancer risk and preventive measures. A trial to
assess the effectiveness of additional counseling
Oprea-Lager DE
A study on the pharmacokinetics and repeatability of [18F]Fluoromethylcholine
in patients with Prostate Cancer
Ossenkoppele GJ
A Phase 3 Randomized, Open Label Studiy of Ponatinib versus Imatinib in Adult
Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Ossenkoppele GJ
A Phase III Randomized, double-blind, parallel Group study of the combination
of intravenous volasertib + subcutaneous LDAC vs. intravenous volasertib
placebo + subcutaneous LDAC in adult patients > 65 years with previously
untreated AML and considered ineligible for / not to benefit from intensive
remission induction
Paff T
Gene expression during cilia genesis: towards a complete candidate gene list
for Primary Ciliary Dyskinesia
Peters EJG
Micorbiological etiology of community acquired pneumonia in
immunocompromised adults (CAP extra)
Rustemeyer T
Clinical relevance of a contact allergy for cocamidopropyl betaine: clinical
studies in a group of sensitized patients
Scheffer HJ, Nielsen K
Pilot study: Non-thermal ablation using Irreversible Electroporation (IRE) to treat
colorectal liver metastases
Sie SD
Sepsis bij Neonaten: Identificatie van bacterieel DNA door middel van Real Time
– PCR (SNIP-studie) als lokaal amendement op het eerder goedgekeurde
protocol, getiteld: Effect of procalcitonim-guided decision making on duration
of antibiotic therapy in suspected early-onset neonatal sepsis: multicenter
prospective randomized intervention study (Pro 11/01)
Slotman B
ACOSOG Z4099/RTOG 1021: A randomized phase III study of sublobular
resection versus Stereotactic Body Radiation Therapy in high risk patients with
Stage I non-small cell lung cancer (NSCLC)
Smit EF
Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in
combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a
single-center single arm open-label phase II trial
Smit EF
A phase II study of gefitinib and fulvestrant in patients with advanced EGFR
mutated non-small cell lung cancer pretreated with reversible EGFR tyrosine
kinase inhibitors
Smit EF
Een fase 1-2 studie naar de veiligheid, verdraagbaarheid, farmacolkinetiek en
inleidende anti-tumowerking van de orale ALK/EGFR remmer AP 26113
Smit EF
High-dose, pulsatile erlotinib after progression on standard dose erlotinib in
EGFR-mutated NSCLC patien
Smit EF
Iressa RE-challenge in advanced NSCLC EGFR M+ pts who responded to an
EGFR-TKI used as 1st line or previous treatment – NVALT 16 IRENE trial
Smit EF
EMPHASIS-lung ETOP 3-12; A randomized phase III trial of erlotinib versus
docetaxel in patients with advanced squamous cell non-small cell lung cancer
who failed first line platinum based doublet chemotherapy stratified by
VeriStrat Good vs VeriStrat Poor
van Bodegraven AA
A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and
Immunogenicity of V212 in Adult Patients with Autoimmune Disease
van Bodegraven AA
A phase 3, randomized, double-blind, placebo-group, multicenter study to
evaluate the safety and efficacy of Ustekinumab induction therapy in subjects
with moderately to severly active Crohns disease who failed of are intolerant to
TNF Antagonist therapy CNTO1275CRD3001
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 155
van Bodegraven AA
A phase 3, randomized, double-blind, placebo-group, multicenter study to
evaluate the safety and efficacy of Ustekinumab induction therapy in subjects
with moderately to severly active Crohns disease CNTO1275CRD3002
van Bodegraven AA
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to
evaluate the safety and efficacy of Ustekinumab maintenance therapy in
subjects with moderately to severly active Crohns disease CNT)1275CRD3003
van Bodegraven AA
Randomized, single-blind, placebo controlled, multicenter, phase 3 study, to
assess the efficacy and safety of expanded autologous adipose-derived stem
cells (eASCs) CX-401, for treatment of complex perianal Crohns disease
van Bodegraven AA
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel group
study of oral CP-690,550 as an induction therapy in subjects with moderate to
severe ulcerative colitis
van Bodegraven AA
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel group
study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative
colitis
van Bodegraven AA
A multi-center, open-label study of CP-690,550 in subjects with moderate te
severe ulcerative colitis
van Bodegraven AA
A randomized, double-blind, placebo-controlled, parallel Group, Multi-centre
study to investigate the safety and efficacy of CP-690,550 for induction therapy
in subjects with moderate to severe Crohns disease (A3921083)
van Bodegraven AA
A randomized, double-blind, placebo-controlled, parallel Group, Multi-centre
study to investigate the safety and afficacy of CP-690,550 for maintenance
therapy in subjects with moderate to severe Crohns disease (A3921084)
van Brunschot S
Transluminal Endoscopic step-up approach versus minimally invasive SurgIcal
step-up approach in patients with infected pancreatic Necrosis (TENSION): a
randomized controlled parallel-group superiority multicenter trial
van de Loosdrecht AA
A non-interventional post-autorisation study to evaluate safety and efficacy in
patients receiving azacitidine in daily clinical practice in the Netherlands
(OCEAN)
van den Eertwegh AJM
The TEAM trial (Tesigna efficacy in advanced melanoma): A phase II, open label,
multi-center, single-arm study to assess the efficacy of Tasigna in the
treatment of patients with metastatic and/or inoperable melanoma herboring a
c-Kit mutation
van der Horst- Bruinsma IE
Open label phase 4 study, investigating the incidence of extra-articulair
manifestations in subjects with ankylosing spondylitis treated with golimumab
van der Horst IE
Social Participation in Ankylosing Spondylitis
(SPASS)
van der Laken J
Assessment of disease activity of ankylosing spondylitis with [18F] Fluoride PETCT
van der Peet DL
Pancreatitis of biliary origin, optimal timing of CHOlecystectomy (PONCHO): a
rondomized controlled parallel-group superiority multicenter trial
van der Vliet JJ / Derks S
Predictive markers for individualized biology-driven treatment for esophageal
cancer
van Dodewaard - de Jong JM
Uptake and biodistribution of 89*Zirconium-labeled ipilimumab in ipilimumab
treated patiens with metastatic melanoma or castration-resistant prostate
carcinoma
van Dodewaard – de Jong JM
A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with
metastatic castration resistant prostate cancer who progressed o nor after a
decetaxel containing treatment. The ReCab trial
van Dodewaard- de Jong JM
A randomised phase II study of repeated Rhenium-188-HEDP combined with
Docetaxel versus Docetaxel alone in castration resistant prostate cancer (CRPC)
metastatic to bone
van Furth AM
The genetic basis of meningococcal and other life threatening bacterial
infections of childhood
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 156
van LindeME
Phase II study of 18F fluorothymidine Positron Emission Tomography (FLT-PET)
in the follow up of glioblastoma multiforme patients treated with combined
radiotherapy and chemotherapy
van Nieuwkerk CJM
A multi-center randomized controlled study of primary prevention of
esophageal variceal bleeding in cirrhotic patients treated with HVPG-guided
therapy of standard heart rate-guided therapy: the PORTHOS trial
van Nieuwkerk CMJ
A Multi-center, Randomized, Open-label study for Induction of HbsAg decline
using an add-on treatment of peginterferon alfa-2a in HbeAg-negative chronic
hepatitis B patients treated with nucleaos(t)ide analogues
van Nieuwkerk CMJ
A Phase 3, Double Blind, Placebo Contolled Trial and Long Term Safety
Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis (747301)
van Tuyl L
Evaluatie van het stoppen van TNF-blokkerende geneesmiddelen bij patiënten
met reumatoïde artritis met lage ziekteactiviteit: de POEET studie
Vandertop WP
Ultra-early tranexamic acid after subarachnoid hemorrhage (ultra)
Veldhuijzen van Zanten SEM
Administration of therapeutic BiCNU via Convection Enhanced Delivery in
Diffuse Intrinsic Pontine Glioma (DIPG-ABC Study
Verdonck IM
Netherlands Quality of Life and Biomedical Cohort Studies In Cancer_Head and
Neck Cancer (NET-QUBIC_HNC)
Verheul HMW
Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation
induced by different opiod subtypes, combined with laboratory analysis of
immunomodulatory and antiangiogenic effects of methylnaltrexone
Verheul HMW
Therapeutic drug monitoring to individualize the dosing of pazopanib: a
randomized pharmacokinetic feasibility study
Verheul HMW
An open-label phase IIIb study of regorafenib in patients with metastatic
colorectal cancer (CRC) who have progressed after standard therapy
Verheul HMW
Measurement of tumor kinase inhibitor concentrations using PET imaging in
patients with advanced solid malignancies
Verheul HMW
A phase I study of high-dose, intermittent sunitinib in patients with solid
tumors
Verheul HWM
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating
Doses of DMOT4039A in Patients with Unresectable Pancreatic or PlatinumResistant Ovarium Cancer
Voskuyl AE
Effects of bosentan in a HOMogenEous population of SSc subjects with a
predefined restriction of blood flow in the hands (HOME)
Voskuyl AE
Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel
group study to assess the efficacy, safety and tolerability of macitentan in
patients with ischemic digital ulcers associated with systemic sclerosis (DUAL2)
Zijlstra JM
Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in
diffuse large B cell lymphoma patients
Zijlstra JM
HD 17: Treatment optimization trial in the first-line treatment of intermediate
stage Hodgkin lymphoma; treatment stratification by means of FDG-PET
Zijlstra JM
PCI 32765-MCL-3001 (RAY); A Randomized, Controlled, Open-Label, Multicenter
Phase 3 Study of the Brutons Tyrosine Kinase (Btk) Inhibitor Ibrutinib versus
Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Lymphoma
Who Have Received at Least One Prior Therapy
Zijlstra JM
A phase II study of obinutuzumab monotherapy in rituximab-fefractory
follicular lymphoma
Zweegman S
HOVON 104 Amyloidosis: A multicenter, randomized phase III study of
bortezomib and dexamethasone compared with dexamethasone alone as
induction treatment followed by high dose mephalan (HDM) and autologous
stem cell transplantation (SCT) in patients with de novo amyloid light chain (AL)
amyloidosis
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 157
Zweegman S
A phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects
Previously Treated with Ruxolitinib and with a Current Diagnosis of
Intermediate-2 of High-Risk Primary Myelofibrosis, Post-Polycythemia Vera
Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
N.B. positieve oordeel METc UMC Nijmegen volgt zodra ondertekende contract
vervangen is.
Zweegman S
A phase 3, Randomized, Controlled, Open Label, Multicenter, Safety and
Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of
Treatment Administered to Patients With Relapsed or Refractory Systemic Light
Chain (AL) Amyloidosis
Zweegman S
A randomized controlled phase 3 study of oral Pacritinib versus best available
therapy in patients with Primary Myelofibrosis, Post-Polycythemia Vera
Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis
CWO Research project / grant proposals
Grant
Principal investigator
Title
CCA
Cloos J
Identification and characterization of AML (stem) cells
responsible for development of relapse
Dana-Farber Cancer Institute
Roemer MGM
Characterizing genetic alterations in diffuse large B-cell
lymphomas occurring in immune privileged sites
GSK
Coupé VMH
A melanoma disease model to assess effects and costs of
individualized treatment strategies
KWF
Greijer A
Cytolytic virus activation (CLVA) therapy for EBV-driven gastric
carcinoma
KWF
Steenbergen R
Construction of a discriminatory, biologically relevant miRNA
marker panel for triage in hrHPV-based cervical cancer screening
KWF
Smit L
The identification of microRNAs specific for leukemic stem cells
in Acute Myeloid Leukemia
KWF
van Beijnum J
Targeting endothelial surface vimentin for angiostatic therapy
and imaging of cancer
KWF
Castelijns JA
Detection of local recurrences by PET-MRI in patients with
laryngeal carcinoma treated with chemoradiation: correlation
between PET-MRI and histopathological findings
KWF
Greijer A
New therapy for Epstein-Barr virus driven tumours by targeting
the virus itself
KWF
de Gruijl TD
Angiostasis as a means to simultaneously increase tumor
immune infiltration and eliminate cancer-associated myeloid
suppression
KWF
Braakhuis B
Mechanisms of local cancer relapse in head and neck squamous
cell carcinoma
KWF
de Winter J
Compensatory survival mechanisms in cancer cells: novel
targets for therapy?
KWF
Carvalho B
The role of AURKA and TPX2 in colorectal adenoma-tocarcinoma progression
KWF
Steenbergen R
Comprehensive analysis of the in vitro transforming properties
of the 15 high-risk human papillomavirus types (hrHPVs)
KWF
Peters GJ
Optimization of gastrointestinal and tumor uptake of tyrosine
kinase inhibitors
KWF
van Dijk M
What the placenta can teach us about cancer
KWF
den Haan J
Development of a rapid and effective prime-boost vaccination
strategy for melanoma
KWF
Dorsman JC
Molecular carcinogenesis of retinoblastoma
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 158
Grant
Principal investigator
Title
KWF
Veldhuijzen N
A case-control study to identify risk factors associated with
cervical cancer in young women
KWF
Wurdinger T
Monitoring tumour behaviour and response to treatment in
glioblastoma patients through platelet and microvesicle RNA
profiles
KWF
Voortman J
Clinical outcome prediction by next generation microRNA
sequencing of patients with locally advanced laryngeal
carcinoma treated with concurrent chemoradiation
KWF
van Egmond M /
Vidarsson G
Therapeutic potential of engineered IgG3 monoclonal antibodies
in cancer therapy
KWF
van Die IM
How galectin-4 interferes with metastasis of pancreatic cancer
cells
KWF
van Vliet SJ
Cracking carbohydrate cues in cancer
KWF
de Jong D
Clinicopathological criteria for diagnosis of nodal marginal zone
lymphoma: an emerging entity
KWF
Jordanova ES
Translating immune characteristics and genetics make-up of
metastatic tumor cells into therapeutic targets for cervical
cancer
KWF
Bleeker MCG
Vulvar carcinogenesis: a risk assessment of precursor lesions by
molecular analysis
KWF
van Egmond M
Therapeutic potential of engineered IgG3 monoclonal antibodies
in cancer therapy
KWF
Klein M
Internet-based treatment of fatigue in low-grade glioma
patients: an evidence-based randomized controlled trial
KWF
rakenhoff RH
Identification of the target genes regulated by microRNAs that
show tumor-welective lethality in head and neck cancer cells
KWF
Klein M
Evidence-based internet treatment of fatigue in low-grade
glioma patients: a randomized controlled trial
KWF
Hoekstra OS
How imaging AR expression in castrate resistant prostate cancer
(CRPC) patients may help to personalize therapy with antiandrogens
KWF
Gordijn MS & Kaspers
GJL
Sleep, fatigue and quality of life in pediatric acute lymphoblastic
leukemia
KWF
Meijerink WJHJ
Immunophotodetection in colorectal cancer
KWF
Smit L
The therapeutic potential of IGF1R inhibition and IGFBP7 in the
specific eradication of leukemic stem cells in acute myeloid
leukemia
KWF
van Egmond M /
Vidarsson G
Therapeutic potential of engineered IgG3 monoclonal antibodies
in cancer therapy
KWF
van Kooyk Y
Improving therapeutic cancer vaccines using a novel glycanpeptide-based approach
KWF
E. Giovannetti
Clinical outcome prediction in non-small cell lung cancer
(NSCLC) patients treated with novel
irreversible epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKI)
KWF
Thijssen VLJL
From bones to vessels: Targeting endothelial progenitor cell
recruitment to inhibit
tumor angiogenesis
KWF
Fijneman RJA
Validation of candidate protein biomarkers for early detection of
colorectal cancer
KWF
Snellenberg S
PRDM14, a novel apoptosis modulator in cervical cancer
KWF
de Gruijl TD
A Phase-I/II trial of local low-dose anti-CTLA4 administration
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 159
Grant
Principal investigator
Title
combined with an NY-ESO peptide vaccine in Stage 2-3
melanoma patients
KWF
Heideman DAM
Identification of sequence alterations underlying chromosomal
instability in lung
squamous carcinogenesis
KWF
van den Tol MPl &
Nielsen K
The use of PET-MRI in the follow-up of RFA treated colorectal
liver metastases
KWF
Dorsman JC
Molecular carcinogenesis of retinoblastoma
KWF
Braakhuis BJM
Molecular pathology of squamous cell carcinoma of the oral
cavity in young adults
KWF
Noordhuis P
CLEC12A antibody-drug conjugated targeted therapy of
leukemic stem cells in AML
KWF
Schuurhuis GJ
Identification of therapy surviving leukemia initiating cells in
acute myeloid leukemia in dependence of the type of leukemia
KWF
de Winter JP
Compensatory pathways in BRCA1-deficient breast tumors as
possible novel footholds for cancer therapy
KWF
de Bree R
PET–CT and near-infrared fluorescence guided sentinel node
identification in early oral
cancer using 89Zr-Nanocoll-IRDye800CW
KWF
Griffioen AW
Design of an effective anti-cancer combination therapy for
breast cancer making use of
a stochastic algorithm
KWF
van den Tol MP /
Haloua M
Ultrasound-Guided Breast Conserving Surgery for Palpable
Breast Cancer Improves
Cosmetic Outcome and Quality of Life
KWF
Jimenez CR
Multi-cellular compartment proteomics to explore aberrant
nuclear protein localization
and secretion in colorectal adenoma to carcinoma progression
KWF
Jimenez CR
Discovery and clinical evaluation of novel protein markers for
homology repair deficient
breast cancer
KWF
Brakenhoff RH
Assessment of increasing incidence rates of HPV-induced
oropharyngeal cancer in the Netherlands
KWF
Brakenhoff RH
Development of novel selective inhibitors targeting WEE1 kinase
KWF Bas Mulder Award
van Litsenburg R
The effect of sleep disorders, economic burden and physical
activity on quality of life in pediatric cancer
KWF- fellowship
Nagel R
Identification of methylation markers for prediction of treatment
outcome op patients with head and neck squamous cell
carcinoma
KWF-fellowship
Bosch LJW
Decoy Receptor 1 (DCR1), apoptosis and drug response
NWO middelgroot
Mebius R
High resolution 3D imaging of fluorescently stained large
tissues
NWO middelgroot
Boellaard R
Establishing a facility for multi-modality preclinical imaging in
drug development
NWO Veni
van der Stoop PM
Tackle the untouchables: drug target discovery for invasive
glioblastoma
NWO Veni
Poot AJ
Native radiolabeling of peptides to speed up the translational
path towards clinical
peptide imaging
NWO VICI
de Gruijl TD
Therapeutic interference in myeloid suppression in the
microenvironment of human
tumours and draining lymph nodes
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 160
Grant
Principal investigator
Title
NWO VIDI
García Vallejo JJ
Towards functional glycomics of antigen recognition
NWO VIDI
Unger WWJ
Notch controls human CD8 tumor-specific T-cells
NWO VIDI
Pegtel DM
Lockn load for discharge of tumor exosomes
ODAS stichting
Moll AC / Hartong DT
Complications, functional and cosmetic results in patients
treated for retinoblastoma in the Netherlands
ODAS stichting
de Jong MC
Multicenter implementation of MR imaging studies in childres
with retinoblastoma for assessment of response to
chemotherapy and early detection of pineoblastoma and
craniofacial second primary malignancies
Semmy Foundation
Kaspers GJ
Drug distribution and local drug delivery in diffuse intrinsic
pontine glioma
VONK
Cloos J
Improvement of prognosis of pediatric AML by identification and
characterization of (stem) cells responsible for development of
relapse
Vriendenloterij
Vis AN
De invloed van cholesterol op het biologisch gedrag van
prostaatkanker
Vriendenloterij
Dekker J
Kwaliteit van leven en zorgbehoefte na colorectale kanker: een
studie tot 5 jaar na de diagnose
Vriendenloterij
van Dongen GAMS
Moleculaire PET imaging: therapie op maat met dure
geneesmiddelen
Vriendenloterij
Heideman DAM
Verbeterde moleculaire diagnostiek die bijdraagt aan een zorg
waar therapie op maat centraal staat
Vriendenloterij
Dekker J
Zorgbehoeften van patiënten met een hematologische kanker:
een kwalitatieve studie
Vriendenloterij
Haloua M
Echogeleide borst-sparende chirurgie voor palpabel borstkanker
ter verbetering van het cosmetisch resultaat en de kwaliteit van
leven
Vriendenloterij
Huijsmans RJ
Fit ondanks Kanker: fitness voor hematologie patiënten in de
kliniek
Vriendenloterij
Smit L
De ontwikkeling van innovatieve therapie specifiek gericht tegen
leukemie cellen die terugkeer van de ziekte veroorzaken
Vriendenloterij
Verheul HMW
Optimalization of systemic treatment strategies in elderly
patients with advanced solid malignancies
Vriendenloterij
Hopmans W
De patiënt centraal: de ontwikkeling van een innovatieve
keuzehulp voor patiënten met stadium I longkanker
Vriendenloterij
Moll AC
Complicaties, functionele, en cosmetische uitkomsten bij
behandelde retinoblastoom patiënten in Nederland
Vriendenloterij
Molthoff CFM
Verbetering van de behandeling van blaaskanker
Vriendenloterij
van Kessel ECJ
Aanvraag eenmalige financiering Informatiecentrum polikliniek
VUmc Cancer Center Amsterdam
VUmc
Coupé VMH
A colorectal cancer model including molecular features:
prediction of health benefits and economic outcomes of new
generation screening test and assessment of a molecular-based
intermediate endpoint
VUmc
van Kuijk C
Evidence based interventional oncology: from last resort to
potent alternative or additional treatment
VUmc CCA PhD position
van de Loosdrecht A
Role of immune responses focussing on DC in the pathogenesis
of low risk and high risk Myelodysplastic syndromes:
Implications for immunotherapy
VUmc CCA PhD position
Brakenhoff RH
Development of personalized targeted treatments for head and
neck cancer
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 161
Grant
Principal investigator
Title
VUmc CCA PhD position
van Egmond M
The neutrophil immunoglobulin A (IgA) Fc receptor (FcaRI)
perpetuates
inflammation and tissue damage in autoimmune diseases
VUmc Hematology
Schuurhuis GJ
The role of minimal residual disease, and leukemia stem cells
herein, in clinical decision making
CWO-DEC: Animal related protocols
Indiener
Titel
Bögels M
Geeft een IgG3 antilichaam variant met verhoogde halfwaardetijd een betere
antilichaamtherapie tegen ontwikkeling van carcinoma metastases in muizen
Braakhuis B
Verbetering van radiotherapeutische behandeling van longkanker door middel van
specifieke gen inhibitie
Brakenhoff R
Behandeling van hoofd-halskanker met behulp van tumor-specifieke microRNAs
Cohen R
Evaluation of novel antibody-drug conjugates containing the highly toxic drug tubulysin for
targeted tumor treatment
den Haan J
Opzetten van depletie van CFS-1 receptor (CFS-1R) positieve macrofagen door middel van
een CFS-1R blokkerend antilichaam
den Haan J
B cel tolerantie inductie door middel van antigen gekoppeld aan antilichamen
den Haan J
Prime-boost vaccinatie door middel van antigen gekoppeld aan antilichamen die targeten
naar macrofagen of dendritische cellen
Dong W
Evaluatie van de oncolytische potentie van een nieuw conditioneel replicerend adenovirus,
ORCA-010 (AdOT-091), in een humaan prostaat kanker model in naakte muizen.
Ferrantelli E
Migration and angiogenesis in rodent peritoneal dialysis model by means intra-vital video
microscopy
Glim J
Optimalisatie operatietechnieken transplantatie humane huid op NSG-muis
Grewal S
Effecten van selectieve darm decontaminatie (SDD) op de uitgroei van tumorcellen in de
lever
Gül N
Opzetten van in vivo imaging mbv 2Photon microscoop
Gül N
Effecten van antilichaam behandeling op het uitgroei van lever metastases
Keuning E
Practicum Celbiologie cursus voor bachelor biomedische wetenschappen en
bewegingswetenschappen
Keuning E
Training protocol for intra-vital videomicroscopy in a rat and mouse model of end-stage
renal disease
Lagerweij T
Toediening van carmustine via convection enhanced delivery in de hersenstam
Lagerweij T
Het gebruik van 'intravital' microscopie in pre-klinische neuro-oncologische studies
Perdicchio M
Modification of antigens with sialic acids to dampen autoreactive immune responses
Perdicchio M
Tumor-expressed sialic acids dampen anti-tumor immune responses via dendritic cell
modulation
Reijmers RM
Identificatie van heparan sulfaat modificaties in het ontstaan van secondaire en tertiaire
lymfoïde structuren
Smit L
De invloed van microRNA expressie op leukemie initiërende capaciteit en chemotherapie
resistentie van primaire acute myeloide leukemie: identificatie van een potentiële therapie
tegen leukemie
Smit L
De identificatie van AML patiënten monsters waarbij de leukemiecellen normale en/of
maligne engraftment potentie hebben in het NOD/SCID/IL2 gamma chain (NSG) muizen
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 162
Indiener
Titel
model.
Smit L
Het bepalen van de overleving van de NOD/SCID IL2 receptor gamma chain knockout
muizen na bestraling of busulfan behandeling en injectie van acute myeloide leukemie
cellen
Ulrich M
Behandeling van wonden met Curdlan om de genezing te versnellen
Unger W
Remmen van EAE via specifieke modulatie van dendritische cellen
van der Steen L
Het blokkeren van in vivo migratie van humane Fc(RI transgene neutrofielen naar humaan
IgA antilichamen gericht tegen muis collageen type XVII
van der Stoop P
Therapeutische toepassing voor behandeling van invasieve glioma
van der Veer M
Evaluation of efficacy of whole antibody and small molecules to inhibit tumor angiogenic
vasculator formation in a syngenic and xenograft mouse model
van Dongen GAMS
Preclinical evaluation of near-infrared fluorescent nanobodies obtained through site-directed
conjugation
van Dongen GAMS
PET-imaging en biodistributie studie met 11C- en 18F-gelabeld afatinib, een HER2 en EGFR
selectieve tyrosine kinase remmer
van Dongen GAMS
Tumor targeting performance of a 89Zr-labeled anti-CEA-IL2 fusion antibody
van Dongen GAMS
Tumor targeting performance of a 89Zr-labeled anti-CD27 antibody
van Dongen GAMS
Evaluation of a novel antibody-drug conjugate (ADC) containing the antibody trastuzumab
and the highly toxic drug tubulysin for targeted tumor treatment
van Rijn S
Een in vivo screen voor tumor supressor-genen die zijn ontregeld in GBM
Veninga H
Het effect van antigen targeting naar verschillende types macrofagen op B en T cel
responsen in de afwezigheid van CD8+ dendritische cellen
Veninga H
De rol van Siglec-1 in het induceren van adaptieve immuunresponsen door metallofiele
macrofagen
Veninga H
Het effect van antigen targeting naar macrofagen op B cellen
Vos JB
Onderzoek naar de therapeutische toepassing van bi-specifieke antistoftherapie voor de
herintroductie van immunologische tolerantie tegen allergenen en auto-antigenen
Weerdenburg E
Onderzoek naar de rol van LipY in de verhoogde virulentie van ESX-5 deficiënte
Mycobacterium marinum in zebravissen
Appendix Annual Report 2012 VUmc CCA – Scientific Research Committee - 163
Appendix 10. Evening Lectures
January 17, 2012
Highlights program 1 & 3
Host: Johan de Winter
- Chantal Stoepker: A novel Fanconi anemia gene identified by exome sequencing
- Tieneke Schaaij-Visser: Novel candidate biomarkers for cisplatin response prediction and monitoring in NSCLC
February 21, 2012
Highlights program 2 & 4
Host: Frits Peters
- Victor Thijssen: Galectins in tumor angiogenesis: 1 for all, and all 4 one
- Jasper Koning: The origin of lymph node stromal cells
March 20, 2012
Highlights program 1& 5
Host: Irma Verdonck
- Joël Vos: How to continue living a meaningful life after a cancer diagnosis: psychological concerns and interventions for
cancer-patients
- Linda Bosch: Waste matters: molecular stool screening for colorectal cancer
April 17, 2012
Highlights program 2 & 3
Host: Connie Jimenez
- Sandra van Vliet: Exploring the sweet spot in colon cancer mutations
- Lotte Hiddingh: Identifying biomarkers of temozolomide resistance in glioma
May 15, 2012
Highlights program 4 & 5
Host: Irma Verdonck
- Katja Braam: Quality of Life in Motion: A combined physical exercise and psychosocial training program to improve physical
fitness in children with cancer
- Ben Slotman: Time trends in survival for elderly Dutch patients with stage I lung cancer in the past decade
June 19, 2012
Highlights program 1& 2
Host: Johan de Winter
- Berber Mol: The retinoblastoma paradigm revisited: a new subtype of retinoblastoma with normal RB1
- Nuray Gül: Surgery-induced liver metastases: how it begins and how to end it
September 18, 2012
Highlights program 3 & 4
Host: Guus van Dongen
- Derrek Heuveling: Improvement of the sentinel node procedure in head and neck cancer
- Jurjen Ruben: Expanding the Applicability of the Clinical Dendritic Cell Vaccine DCOne
October 16, 2012
Highlights program 2 & 5
- Kristiaan Lenos: Exploring the sweet spot in colon cancer mutations.
- Jacqueline Langius: Critical weight loss in patients with head and neck cancer during (chemo)radiotherapy: concepts and
implications
November 20, 2012
Highlights program 1 & 4
Host: Peter Snijders
- Denise Schütze: Human papillomavirus types on the road to (keratinocyte) eternity
- Jasmina Hodzic: Identification of candidate targets to enhance radiotherapy in prostate cancer
December 18, 2012
Highlights program 5 & 3
Host: Cor Verweij
- Kees Ruys: Unbearable suffering as measured in end-stage cancer patients in primary care
- Joyce Lubbers: Interferon and B-cell gene signatures contribute to diagnosis of pre-clinical Rheumatoid Arthritis
Appendix Annual Report 2012 VUmc CCA – Evening Lectures - 164

Similar documents

65. Annual Report 2010 20 februari 2016 — PDF bestand Page 1

65. Annual Report 2010 20 februari 2016 — PDF bestand Page 1 About 75% of all VUmc medical departments are involved in research focussed on oncology and/or immunology. Research is conducted within five well defined research themes. Furthermore, five tumour t...

More information

PDF bestand VUmc Cancer Center Amsterdam (VUmc CCA)

PDF bestand VUmc Cancer Center Amsterdam (VUmc CCA) - fundraising for cancer research, care and education Appendix Annual Report 2013 VUmc CCA – Organization - 3

More information